Sentence,class,file
Nat Commun 2015; 6:10186; PMID:26671411; http://dx.doi.org/ 10.1038/ncomms10186 © 2016 Tackhoon Kim and Dae-Sik Lim.,OADS,/arxiv_data1/oa_pdf/56/c7/kccy-15-10-1161994.PMC4916404.pdf
"10, 1311 –1312 http://dx.doi.org/10.1080/15384101.2016.1161994",Non-OADS,/arxiv_data1/oa_pdf/56/c7/kccy-15-10-1161994.PMC4916404.pdf
"Physiol Rev 2014; 94:1287-312; PMID:25287865; http://dx.doi.org/10.1152/physrev.00005.2014 [2] Cordenonsi M, et al.",Non-OADS,/arxiv_data1/oa_pdf/56/c7/kccy-15-10-1161994.PMC4916404.pdf
Nat Commun 2015; 6; PMID:26671411; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/56/c7/kccy-15-10-1161994.PMC4916404.pdf
"Genes Dev 2014; PMID:24732378; http://dx.doi.org/ 10.1101/gad.239327.114 [7] Yu O, et al.",OADS,/arxiv_data1/oa_pdf/56/c7/kccy-15-10-1161994.PMC4916404.pdf
Mol Cell Biol 2015; PMID:26459764; http://dx.doi.org/ 10.1128/mcb.00772-15 Figure 1.,OADS,/arxiv_data1/oa_pdf/56/c7/kccy-15-10-1161994.PMC4916404.pdf
"Then, a comparison criterion is per-formed at every scale kon the PPG signal for i=k+2 , …,N−k + 1 to search for local maxima as follows: m k,i=1xi−1.xi−k−1and xi−1.xi+k−1 0 otherwise/braceleftbigg (1) This operation results in a matrix M, where M=m1,1 m1,2··· m1,N m2,1 m2,2··· m2,N ............ mL,1mL,2··· mL,N⎛ ⎜⎜⎜⎝⎞ ⎟⎟⎟⎠=(m k,i) (2) 136 This is an open access article published by the IET under the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/)Healthcare Technology Letters , 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/2a/67/HTL.2016.0006.PMC4916478.pdf
136 –142 doi: 10.1049/htl.2016.0006137 This is an open access article published by the IET under the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/),Non-OADS,/arxiv_data1/oa_pdf/2a/67/HTL.2016.0006.PMC4916478.pdf
"3 Description of the algorithm design of Section 3.2 138 This is an open access article published by the IET under the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/)Healthcare Technology Letters , 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/2a/67/HTL.2016.0006.PMC4916478.pdf
136 –142 doi: 10.1049/htl.2016.0006139 This is an open access article published by the IET under the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/),Non-OADS,/arxiv_data1/oa_pdf/2a/67/HTL.2016.0006.PMC4916478.pdf
"Every graph in the ﬁgure represents posterior (i)for sample i 140 This is an open access article published by the IET under the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/)Healthcare Technology Letters , 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/2a/67/HTL.2016.0006.PMC4916478.pdf
136 –142 doi: 10.1049/htl.2016.0006141 This is an open access article published by the IET under the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/),Non-OADS,/arxiv_data1/oa_pdf/2a/67/HTL.2016.0006.PMC4916478.pdf
"1407 –1417 142 This is an open access article published by the IET under the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/)Healthcare Technology Letters , 2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/2a/67/HTL.2016.0006.PMC4916478.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/97/92/ircmj-18-04-23782.PMC4916528.pdf
Galderma S. A. http://www.dermquest.com.,Non-OADS,/arxiv_data1/oa_pdf/9a/a5/10.1177_1203475416629118.PMC4916529.pdf
"06 http://bi.tbzmed.ac.ir/ CFD simulation of blood flow inside the corkscrew collaterals of the  Buerger’s disease  Alireza Sharifi1,2*, Mohammad Charjouei Moghadam1,2 1 Department of Mechanical Engineering, Ferdowsi University of Mashhad, Mashhad, Iran 2 Research Center for Biomedical Engineering, Ferdowsi University of Mashhad, Mashhad, Iran Introduction Thromboangiitis obliterans (TAO) or Buerger’s disease is  an inflammatory, occlusive disease of small and medium- sized arteries and veins that involves distal vessels of the  extremities.1 In this disease, the arteries and veins in various  parts become inflamed and blocked.2 This condition leads  to the poor circulation of the blood to the lower organs  which is known as ischemia.",Non-OADS,/arxiv_data1/oa_pdf/77/93/BI-6-41.PMC4916545.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/77/93/BI-6-41.PMC4916545.pdf
"Jahangiri A., Adibkia K ., BioImpacts, 2016, 6(1), 1-2 doi: 10.15171/bi.2016.08 http://bi.tbzmed.ac.ir/ Applications of electrospinning/electrospraying in drug delivery Azin Jahangiri1, Khosro Adibkia2* 1Department of Pharmaceutics, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran 2Research Center for Pharmaceutical Nanotechnology and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran During recent decades, nanoscaled drug delivery  systems (DDSs) have gained much attention in  the area of pharmaceutical and biomedical appli - cations.1 Nanosized delivery systems are able to improve  the physicochemical as well as the pharmacokinetic prop - erties of either water-soluble or -insoluble drugs in the  case of both local and systemic drug deliveries.",Non-OADS,/arxiv_data1/oa_pdf/9b/9a/bi-6-1.PMC4916546.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/9b/9a/bi-6-1.PMC4916546.pdf
"Angelini et al.,  BioImpacts, 2016, 6(1), 15-24 doi: 10.15171/bi.2016.03 http://bi.tbzmed.ac.ir/ Foetal bovine serum-derived exosomes affect yield and phenotype of  human cardiac progenitor cell culture Francesco Angelini1*, Vittoria Ionta2, Fabrizio Rossi2, Fabio Miraldi3, Elisa Messina4, Alessandro Giacomello2 1 Pasteur Institute - Cenci Bolognetti Foundation, “Sapienza” University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy 2 Department of Molecular Medicine, “Sapienza” University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy 3 Department of Cardiocirculatory Pathophysiology, Anesthesiology and General Surgery, Sapienza University of Rome, Viale  Regina Elena 324, 00161 Rome, Italy 4 Department of Pediatric Cardiology, “Sapienza” University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy Introduction Myocardial infarction is still the leading cause for mortality  in the Western World.",Non-OADS,/arxiv_data1/oa_pdf/c5/01/bi-6-15.PMC4916547.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c5/01/bi-6-15.PMC4916547.pdf
"04 http://bi.tbzmed.ac.ir/ A microRNA isolation method from clinical samples Sepideh Zununi Vahed1,2,3, Abolfazl Barzegari1,3, Y alda Rahbar Saadat1, Somayeh Mohammadi4, Nasser Samadi2,3* 1 Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran 2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 3 School of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran 4 Department of Nutrition, Faculty of Nutrition Sciences, Tabriz University of Medical Sciences, Tabriz, Iran Introduction Basically, microRNAs (miRNAs) are a class of  intracellular noncoding small (20–23 nt) RNAs that post- transcriptionally regulate gene expression by binding to  the 3′ untranslated region of target mRNAs, and cause  mRNA degradation or translational inhibition.",Non-OADS,/arxiv_data1/oa_pdf/2b/b1/bi-6-25.PMC4916548.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/2b/b1/bi-6-25.PMC4916548.pdf
"Heidari et al.,  BioImpacts, 2016, 6(1), 3-8 doi: 10.15171/bi.2016.01 http://bi.tbzmed.ac.ir/ Sulfasalazine-induced renal and hepatic injury in rats and the  protective role of taurine Reza Heidari1, Maryam Rasti2, Babak Shirazi Y eganeh3, Hossein Niknahad1,2*, Arastoo Saeedi2, Asma Najibi1,2 1 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2 Pharmacology and Toxicology Department, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran 3 Department of Pathology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Introduction Sulfasalazine is widely administered against rheumatoid  arthritis and other inflammatory‑mediated disorders such  as Crohn’s  disease in the human.1 On the other hand, sev ‑ eral cases of liver injury associated with sulfasalazine ther ‑ apy have been reported.2‑4 Hepatic injury induced by sul ‑ fasalazine might lead to hepatic failure and requirement  for liver transplantation, and even patient death.5‑7 Some  investigations also indicated impairment in renal function  after sulfasalazine therapy.8,9 Sulfasalazine‑induced renal  injury might be potentially irreversible.10,11 No specific  therapeutic agent has been developed against sulfasala ‑ zine‑induced organ injury.",Non-OADS,/arxiv_data1/oa_pdf/dc/dd/bi-6-3.PMC4916549.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by‑nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/dc/dd/bi-6-3.PMC4916549.pdf
"05 http://bi.tbzmed.ac.ir/ Protective mechanisms of Cucumis sativus  in diabetes-related models  of oxidative stress and carbonyl stress Himan Heidari1,2, Mohammad Kamalinejad3, Maryam Noubarani2, Mokhtar Rahmati2, Iman Jafarian2, Hasan Adiban2,  Mohammad Reza Eskandari1,2* 1 Zanjan Metabolic Diseases Research Center, Zajan University of Medical Sciences, Zanjan, Iran 2Department of Pharmacology and Toxicology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran 3Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran  Introduction The prevalence of diabetes mellitus is growing rapidly  and represents a significant social and healthcare problem  worldwide.",Non-OADS,/arxiv_data1/oa_pdf/e0/fa/bi-6-33.PMC4916550.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/e0/fa/bi-6-33.PMC4916550.pdf
"07 http://bi.tbzmed.ac.ir/ Advanced drug delivery and targeting technologies for the ocular  diseases  Jaleh Barar, Ayuob Aghanejad, Marziyeh Fathi, Y adollah Omidi* Research Centre for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran Introduction   In the human eye, like all other mammals, non-im - age-forming photosensitive ganglion cells within the  retina function to receive the light signals and react ac - cordingly towards translation of the signals and visualiza - tion.",Non-OADS,/arxiv_data1/oa_pdf/33/b6/bi-6-49.PMC4916551.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/33/b6/bi-6-49.PMC4916551.pdf
Readers are directed to see excellent electronic sources in the following  URLs from where images were adapted: http://www.allaboutvision.com ; http://www.eyedocs.co.uk  ; http://www.bouldereyesurgeons.com   and http://www.iqlaservision.com  as well as MEMS Journal.,Non-OADS,/arxiv_data1/oa_pdf/33/b6/bi-6-49.PMC4916551.pdf
"Azandeh et al.,  BioImpacts, 2016, 6(1), 9-13 doi: 10.15171/bi.2016.02 http://bi.tbzmed.ac.ir/ Improvement of mesenchymal stem cell differentiation into the  endoderm lineage by four step sequential method in biocompatible  biomaterial Saeed Azandeh1, Anneh Mohammad Gharravi2, Mahmoud Orazizadeh1*, Ali Khodadi3, Mahmoud Hashemi Tabar1  1 Cellular and Molecular Research Center (CMRC), Department of Anatomical Science, Faculty of Medicine, Ahvaz Jundishapur  University of Medical Sciences (AJUMS), Ahvaz, Iran 2School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran 3Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Introduction   Liver disease accounts for almost 2% of all deaths.1 Many  diseases can cause liver failure and severely impaire a  person’s health and cause the need for a liver transplant.",Non-OADS,/arxiv_data1/oa_pdf/c6/6d/bi-6-9.PMC4916552.pdf
This work is published by BioImpacts as an open access article distributed under the terms of  the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c6/6d/bi-6-9.PMC4916552.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-008362).,Non-OADS,/arxiv_data1/oa_pdf/ed/94/bmjopen-2015-008362.PMC4916567.pdf
http://www.cadth.ca/en/resources/finding-evidence-is/ grey-matters.,Non-OADS,/arxiv_data1/oa_pdf/ed/94/bmjopen-2015-008362.PMC4916567.pdf
Christensen H. Beacon 2.0. https://beacon.anu.edu.au/.,OADS,/arxiv_data1/oa_pdf/ed/94/bmjopen-2015-008362.PMC4916567.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2016-011277).,Non-OADS,/arxiv_data1/oa_pdf/f7/49/bmjopen-2016-011277.PMC4916568.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/f7/49/bmjopen-2016-011277.PMC4916568.pdf
http://www.nrls.,Non-OADS,/arxiv_data1/oa_pdf/f7/49/bmjopen-2016-011277.PMC4916568.pdf
http://ec.europa.eu/health/patient_safety/policy/index_en.htm 10.,Non-OADS,/arxiv_data1/oa_pdf/f7/49/bmjopen-2016-011277.PMC4916568.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2016-012179).,Non-OADS,/arxiv_data1/oa_pdf/97/5e/bmjopen-2016-012179.PMC4916569.pdf
"Maryland: FDA, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm312210.htm (accessed 19 Nov 2015).",Non-OADS,/arxiv_data1/oa_pdf/97/5e/bmjopen-2016-012179.PMC4916569.pdf
"NSW PrEP Guidelines and clinical delivery group, 2014. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf (accessed 4 Apr 2016).",Non-OADS,/arxiv_data1/oa_pdf/97/5e/bmjopen-2016-012179.PMC4916569.pdf
2015. http://arv.ashm.org.au/images/Australian_National_PrEP_Guidelines.PDF (accessed 4 Apr 2016).,Non-OADS,/arxiv_data1/oa_pdf/97/5e/bmjopen-2016-012179.PMC4916569.pdf
Antiretroviral guidelines: US DHHS guidelines with Australian commentary- when to start antiretroviral therapy in people with HIV.http://arv.ashm.org.au/clinical-guidance.,Non-OADS,/arxiv_data1/oa_pdf/97/5e/bmjopen-2016-012179.PMC4916569.pdf
2015. http://endinghiv.org.au/nsw/ wp-content/uploads/2015/02/PrEP_Access_Options_Paper1.,Non-OADS,/arxiv_data1/oa_pdf/97/5e/bmjopen-2016-012179.PMC4916569.pdf
https://www.fcc.gov/general/local-telephone-competition- reports (accessed 21 Jan 2016).,OADS,/arxiv_data1/oa_pdf/e5/bd/bmjopen-2016-011381.PMC4916571.pdf
http://www.ghsa.org/html/stateinfo/laws/cellphone_laws.html(accessed 21 Jan 2016).,Non-OADS,/arxiv_data1/oa_pdf/e5/bd/bmjopen-2016-011381.PMC4916571.pdf
The societal cost of alcohol misuse in Scotland for 2007. http://www.scotland.gov.uk/Publications/2009/12/29122804/6 3.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
http://www.scotland.gov.uk/ Resource/0041/00410731.pdf 5.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
https://isdscotland.scot.nhs.uk/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2014-02-25/2014-02-25-ARHS2012-13-Report.pdf?13326662779 7.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
http://www.who.int/substance_abuse/terminology/ ICD10ClinicalDiagnosis.pdf 13. WHO collaborative study on Alcohol and Injuries: Final Report.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
http://www.hscic.gov.uk/catalogue/PUB10932 15.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
2012. http://www.hscic.gov.uk 16.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
http://www.isdscotland.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/214493/rrep718.pdf 23.,Non-OADS,/arxiv_data1/oa_pdf/36/07/bmjopen-2015-010005.PMC4916572.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2016-011394).,Non-OADS,/arxiv_data1/oa_pdf/f5/a0/bmjopen-2016-011394.PMC4916573.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/f5/a0/bmjopen-2016-011394.PMC4916573.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-009988).,Non-OADS,/arxiv_data1/oa_pdf/c0/41/bmjopen-2015-009988.PMC4916574.pdf
The research proto- col of this study will be registered with the ChineseClinical Trial Registry (http://www.chictr.org.cn).,Non-OADS,/arxiv_data1/oa_pdf/c0/41/bmjopen-2015-009988.PMC4916574.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-008107).,Non-OADS,/arxiv_data1/oa_pdf/a7/8e/bmjopen-2015-008107.PMC4916576.pdf
http://www.ghanahealthservice.org/region.php?dd=6&region=Brong&nbsp;Ahafo&nbsp;Region.,Non-OADS,/arxiv_data1/oa_pdf/a7/8e/bmjopen-2015-008107.PMC4916576.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2016-011224).,Non-OADS,/arxiv_data1/oa_pdf/a7/10/bmjopen-2016-011224.PMC4916577.pdf
"The programme con- sists of two essential components: (1) over- dose prevention, recognition and responsetraining that participants are required to complete in order to be eligible to obtain a kit, and (2) receiving a kit containing twoampoules of naloxone, an opioid antagonist which reverses the effects of an opioid-related overdose, two retractable syringes and othersupplies (a full description is available at http://www.towardtheheart.com/naloxone).",Non-OADS,/arxiv_data1/oa_pdf/a7/10/bmjopen-2016-011224.PMC4916577.pdf
http://www.bccdc.ca/about/news-stories/news-releases/2015/fentanyl-campaign-launches-to-raise-awareness-about-the-dangers-of-the-drug 9.,Non-OADS,/arxiv_data1/oa_pdf/a7/10/bmjopen-2016-011224.PMC4916577.pdf
"http://www.bccdc.ca/resource-gallery/Documents/EducationalMaterials/Epid/Other/UpdatedBCHarmReductionDocumentAug2012JAB_final.pdf Ambrose G, et al.BMJ Open 2016; 6:e011224.",Non-OADS,/arxiv_data1/oa_pdf/a7/10/bmjopen-2016-011224.PMC4916577.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010847).,Non-OADS,/arxiv_data1/oa_pdf/f0/dd/bmjopen-2015-010847.PMC4916578.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011066).,Non-OADS,/arxiv_data1/oa_pdf/f0/d7/bmjopen-2016-011066.PMC4916579.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010866).,Non-OADS,/arxiv_data1/oa_pdf/7a/56/bmjopen-2015-010866.PMC4916580.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011280).,Non-OADS,/arxiv_data1/oa_pdf/4f/e9/bmjopen-2016-011280.PMC4916582.pdf
http://www.who.int/nutrition/topics/ida/en/ 3.,Non-OADS,/arxiv_data1/oa_pdf/4f/e9/bmjopen-2016-011280.PMC4916582.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2016-011474).,Non-OADS,/arxiv_data1/oa_pdf/41/50/bmjopen-2016-011474.PMC4916584.pdf
Lancet 2009;374:976 –7; author reply 77. http://dx.doi.org/10.1016/S0140-6736(09)61659-7 14.,Non-OADS,/arxiv_data1/oa_pdf/41/50/bmjopen-2016-011474.PMC4916584.pdf
http://www.farrinstitute.org15.,Non-OADS,/arxiv_data1/oa_pdf/41/50/bmjopen-2016-011474.PMC4916584.pdf
"Edinburgh, 2012. http://www.scot-ship.ac.uk/sites/default/files/Reports/SHIP_BLUEPRINT_DOCUMENT_final_100712.pdf 20. von Elm E, Altman DG, Egger M, et al.",Non-OADS,/arxiv_data1/oa_pdf/41/50/bmjopen-2016-011474.PMC4916584.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2015-010786).,Non-OADS,/arxiv_data1/oa_pdf/35/79/bmjopen-2015-010786.PMC4916586.pdf
2013. https://www.eatforhealth.gov.au/sites/default/files/files/the_guidelines/n55_australian_dietary_guidelines.pdf 6.,Non-OADS,/arxiv_data1/oa_pdf/35/79/bmjopen-2015-010786.PMC4916586.pdf
2012. http://www.abs.gov.au/ websitedbs/censushome.nsf/home/communityprofiles?opendocument&navpos=230 25.,OADS,/arxiv_data1/oa_pdf/35/79/bmjopen-2015-010786.PMC4916586.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011462).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
"Such interventions must include anoverhaul of the current inadequate reporting andTable 2 Duration of bullying and undermining experience Duration Percentage Over the last 12 months 9.3 Over the last couple of years 26.1Over the last 3 –5 years 29.3 Longer than 5 years 35.3Table 4 Outcome of reporting bullying and undermining behaviour Outcome Percentage Issue resolved and behaviour stopped 4 Issues resolved but behaviour recurred 7Issue addressed but not resolved andbehaviour continued32 Issue not resolved 57 Table 3 Effects of bullying and undermining on consultants Impact on professional and personal life Category Percentage Major 22 Moderate 44Minor 27Coping 7Table 1 Individual perpetrators of bullying and undermining behaviour Perpetrator Frequency Senior consultant 57 Junior consultant 25Manager 2Medical director 5Others 20Undeclared 3Total 112 iihttps://www.rcog.org.uk/globalassets/documents/careers-and- training/workplace-and-workforce-issues/rcog-rcm-statement-undermining-behaviours-oct-15.pdf 4 Shabazz T, et al.BMJ Open 2016; 6:e011462.",Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
The final draft was formally approved for publication without change by RCOG officers.Competing interests All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare two potential conflicting interests: TS was employed by the RCOG and received some financial support for the submitted work.,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
June 2014. http://www.gmcuk.org/National_training_survey_2014_key_findings_report_1114.pdf_58504492.pdf (accessed 14 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
June 2013. http://www.gmcuk.org/National_training_survey_key_findings_report_2013.pdf_52299037.pdf (accessed 14 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
March 2014. http://www.mddus.com/resources/resource-type/ publications/gpst/gpst-issue-08/undermining-patient-safety/(accessed 12 Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
February 2015. https://freedomtospeakup.org.uk/the-report/ (accessed: 15 Feb 2015).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
February 2013. http://www.midstaffspublicinquiry.com/ report (accessed 25 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
http://dro.dur.ac.uk/10533/1/10533.pdf?DDD45+DDC42 +clfc44 (20 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
2013. http://www.gov.scot/Resource/0044/ 00440163.pdf (accessed Jan 2016).,Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
"24. https://www.rcog.org.uk/en/careers-training/workplace-workforce- issues/improving-workplace-behaviours-dealing-with undermining/development/ 6 Shabazz T, et al.BMJ Open 2016; 6:e011462.",Non-OADS,/arxiv_data1/oa_pdf/8b/31/bmjopen-2016-011462.PMC4916587.pdf
doi:10.1136/bmjopen-2015- 010154 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010154).,Non-OADS,/arxiv_data1/oa_pdf/ac/3e/bmjopen-2015-010154.PMC4916588.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2016-011315).,Non-OADS,/arxiv_data1/oa_pdf/05/24/bmjopen-2016-011315.PMC4916590.pdf
It can be found atthe following web address: http://www.crd.york.ac.uk/ PROSPERO/display_record.asp?ID=CRD42015016266#.,Non-OADS,/arxiv_data1/oa_pdf/05/24/bmjopen-2016-011315.PMC4916590.pdf
"The Cochrane Database of Systematic Reviews (The Cochrane Library, issue 4, 2016) B. MEDLINE (via OVID) (from January 1980 until 27 April 2016) C. EMBASE (via OVID) (from January 1980 until 27 April 2016) D. The NCBI PubMed database http://www.ncbi.nlm.",OADS,/arxiv_data1/oa_pdf/05/24/bmjopen-2016-011315.PMC4916590.pdf
"nih.gov/pubmed — searched 27 April 2016 E. Centre for Reviews and Dissemination (CRD) http://www.crd.york.ac.uk/CRDWeb/ including the databases Database of Abstracts of Reviews of Effects(DARE), Health T echnology Assessments (HTA) and NHS Economic Evaluation Database (NHS EED) Note: At the time of searching and write-up, the fol- lowing information was made available by DARE: ‘Bibliographic records will be published on DARE and NHS EED until 31st March 2015.",Non-OADS,/arxiv_data1/oa_pdf/05/24/bmjopen-2016-011315.PMC4916590.pdf
http://www.medicines.org.uk/emc/medicine/3637/SPC/ 6.,Non-OADS,/arxiv_data1/oa_pdf/05/24/bmjopen-2016-011315.PMC4916590.pdf
http://www.medicinescomplete.com 7.,Non-OADS,/arxiv_data1/oa_pdf/05/24/bmjopen-2016-011315.PMC4916590.pdf
https://www.crn.nihr.ac.uk/can-help/funders-academics/nihrcrn-portfolio/ (accessed 17 Feb 2015).,Non-OADS,/arxiv_data1/oa_pdf/05/24/bmjopen-2016-011315.PMC4916590.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2016-011975).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
A video of the system in action is openly available to the public and can be found at: https://www.rnoh.nhs.uk/clinical-services/foot-ankle-lower-limb.,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2008. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicy AndGuidance/DH_092647 (accessed 1 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2015. https://www.engage.england.nhs.uk/consultation/proms-programme (accessed 10 Mar2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2015. http://www.aomrc.org.uk/doc_download/9825-collecting-clinical-information-in-outpatients.html(accessed 10 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2013. https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2013/10/proms-meth-prim-revis.pdf(accessed 10 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2013. http://www.nhsiq.nhs.uk/media/2594793/ilg_-_technology_to_improve_service.pdf (accessed 10Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2008. http://www.iata.org/pressroom/pr/Pages/2008-31-05-01.aspx (accessed 1 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2015. http://searchengineland.com/its-official-google- says-more-searches-now-on-mobile-than-on-desktop-220369(accessed 4 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2013. https://www.gov.uk/government/news/jeremy-hunt-challenges-nhs-to-go-paperless-by-2018-2(accessed 1 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
2015. https://www.healthcareers.nhs.uk/about/careers-nhs/nhs-pay-and- benefits/agenda-change-pay-rates (accessed 1 Mar 2016).28.,Non-OADS,/arxiv_data1/oa_pdf/0d/bb/bmjopen-2016-011975.PMC4916591.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 010811).,Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
2008. http://digitalarchive.maastrichtuniversity.nl/fedora/get/guid:33a72da3-d773-4f20-9873-c6321b89b99a/ASSET1.,Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Sydney, Australia: National Health Performance Authority, 2015.http://www.myhospitals.gov.au/.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
http://www.health.qld.gov.au/hsu/default.asp.,Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Canberra: ABS, 2006. http://www.abs.gov.au/ausstats/ abs@.nsf/mf/2039.0/.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
http://www.abs.gov.au/ausstats/abs@.nsf/mf/1216.0.,Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Melbourne: Baker IDI Heart & Diabetes Institute, 2011. https://www.nhmrc.gov.au/guidelines-publications/di21.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Leeds, UK: Health & Social Care Information Centre, 2014. http://www.hscic.gov.uk/searchcatalogue?productid=14305.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Canberra, Australia: Diabetes Australia, 2015. https://www.ndss.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Brussels, Belgium: IDF, 2013. https://www.ndss.com.au/diabetes-map (accessed 15 Apr 2016).",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Sydney, Australia: NSW Government, 2010. http://www.bhi.nsw.gov.au/.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
http://www.aihw.gov.au/publication-detail/?id=60129551442.,Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Canberra: AIHW, 2013. http://www.aihw.gov.au/ publication-detail/?id=60129543133.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
"Ottawa, Canada: Canadian Institute for Health Information, 2013. https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC2320&lang=en.",Non-OADS,/arxiv_data1/oa_pdf/09/88/bmjopen-2015-010811.PMC4916592.pdf
http://www.kennisinstituutbier.nl/glazenstandaard.,Non-OADS,/arxiv_data1/oa_pdf/e2/48/bmjopen-2015-010437.PMC4916604.pdf
See: http://creativecommons.org/licenses/by-nc/2.0/ http://creativecommons.org/licenses/by-nc/2.0/legalcode REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/a0/6d/bmjqir-u210329-w4679.PMC4916605.pdf
Private Performance Feedback Reporting for Physicians http://www.ahrq.gov/ professionals/clinicians-providers/resources/privfeedbackgdrpt/index.html.,Non-OADS,/arxiv_data1/oa_pdf/a0/6d/bmjqir-u210329-w4679.PMC4916605.pdf
Available at: http://www.primece.com/downloads/new-patient-centered-models-2014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a0/6d/bmjqir-u210329-w4679.PMC4916605.pdf
Available at: http://www.himss.org.,Non-OADS,/arxiv_data1/oa_pdf/a0/6d/bmjqir-u210329-w4679.PMC4916605.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2016-011157).,Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
"30 Alongside GAS-eous, ULIS-III will record patient engage- ment in goal setting and their satisfaction with the goals using six-point Likert scales designed speci ﬁcally for this purpose.21 Further information about the GAS-eous and associated tools may be found at the following websites: http://www.kcl.ac.uk/lsm/research/divisions/cicelysaunders/resources/tools/gas-eous.aspx; http:// www.kcl.ac.uk/lsm/research /divisions/cicelysaunders/ resources/tools/gas.aspx.",Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
Ethics approval See Health Authorities list here: https://clinicaltrials.gov/ct2/ show/study/NCT02454803.,Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
"London, UK: RCP, 2009. https://www.rcplondon.ac.uk/sites/default/files/documents/spasticity-in-adults-management-botulinum-toxin.pdf(accessed Feb 2015).",Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
http://www.sign.ac.uk/pdf/sign118.pdf (accessed Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
October 2013.http://www.euroqol.org (accessed Feb 2015).,Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
https://clinicaltrials.gov/ct2/show/study/NCT02454803?,Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
2007. http://www.pharmacoepi.org/resources/guidelines_08027.cfm (accessed Nov2015).,Non-OADS,/arxiv_data1/oa_pdf/f1/df/bmjopen-2016-011157.PMC4916608.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010963).,Non-OADS,/arxiv_data1/oa_pdf/8b/c3/bmjopen-2015-010963.PMC4916610.pdf
2014. http://apps.who.int/iris/bitstream/10665/112682/2/9789241507226_eng.pdf (accessed 13 Dec 2015).,OADS,/arxiv_data1/oa_pdf/8b/c3/bmjopen-2015-010963.PMC4916610.pdf
2014. http://www.unicef.org/ media/files/Levels_and_Trends_in_Child_Mortality_2014.pdf(accessed 13 Dec 2015).,Non-OADS,/arxiv_data1/oa_pdf/8b/c3/bmjopen-2015-010963.PMC4916610.pdf
2014. http://www.countdown2015mnch.,Non-OADS,/arxiv_data1/oa_pdf/8b/c3/bmjopen-2015-010963.PMC4916610.pdf
"http://ctep.cancer.gov, Publish Date: 9 August 2006.",Non-OADS,/arxiv_data1/oa_pdf/6a/65/bmjopen-2016-011565.PMC4916612.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2016-011369).,Non-OADS,/arxiv_data1/oa_pdf/b4/69/bmjopen-2016-011369.PMC4916614.pdf
https://www.destatis.de/DE/Publikationen/ Qualitaetsberichte/Gesundheitswesen/Grunddatenkrankenhaueser.pdf?__blob=publicationFile 38.,Non-OADS,/arxiv_data1/oa_pdf/b4/69/bmjopen-2016-011369.PMC4916614.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-010534).,Non-OADS,/arxiv_data1/oa_pdf/0d/55/bmjopen-2015-010534.PMC4916615.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/0d/55/bmjopen-2015-010534.PMC4916615.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2016-011100).,Non-OADS,/arxiv_data1/oa_pdf/1b/a9/bmjopen-2016-011100.PMC4916616.pdf
"Compend Contin Educ Dent 2002;23:261 –6, 268, 270 passim; quiz 274. http://www.ncbi.nlm.nih.",Non-OADS,/arxiv_data1/oa_pdf/1b/a9/bmjopen-2016-011100.PMC4916616.pdf
Institute for Clinical SystemsImprovement website November 2013: https://www.icsi.org/_asset/bw798b/chronicpain.pdf 48.,Non-OADS,/arxiv_data1/oa_pdf/1b/a9/bmjopen-2016-011100.PMC4916616.pdf
"Horsham, PA: ISMP, 2004. http://www.ismp.",Non-OADS,/arxiv_data1/oa_pdf/85/d5/bmjopen-2016-011401.PMC4916617.pdf
http://www.nccmerp.org/councilRec.html 27.,Non-OADS,/arxiv_data1/oa_pdf/85/d5/bmjopen-2016-011401.PMC4916617.pdf
"Canberra, 2004:80. http://www.aihw.gov.au/publication-detail/?id=6442467670 (accessed 20 Dec 2015).",Non-OADS,/arxiv_data1/oa_pdf/67/ca/bmjopen-2015-010446.PMC4916620.pdf
The analysis and reporting of the results of the clinical outcomes will follow the CONSORT guidelines (http://www.consort-statement.org).,Non-OADS,/arxiv_data1/oa_pdf/e4/85/bmjopen-2015-010676.PMC4916621.pdf
See: http://creativecommons.org/licenses/by-nc/2.0/ http://creativecommons.org/licenses/by-nc/2.0/legalcode REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
Available from:http://www.nhs.uk/NHSEngland/bruce-keogh-review/Documents/ outcomes/keogh-review-final-report.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
Available from: http://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/ patient-centred-leadership-rediscovering-our-purpose-may13.pdf 3.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
Available from: at https://www.england.nhs.uk/wp-content/uploads/2013/07/fft-imp-guid.pdf 4.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
Available from http://www.institute.nhs.uk/quality_and_service_improvement_tools/quality_and_service_improvement_tools/patient_perspectives.html 5.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
Available from: http://www.nhssurveys.org/Filestore/documents/QIFull.pdf 6.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
Available from: https://www.england.nhs.uk/wp-content/uploads/2015/07/fft-guidance-160615.pdf 7.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
Available from: http://www.institute.nhs.uk/images/Patient_Experience/Final%20Project%20Report%20pdf%20doc%20january%202012.pdf 4 Cooper D. BMJ Quality Improvement Reports 2016; 5:u210384.w4457.,Non-OADS,/arxiv_data1/oa_pdf/e6/30/bmjqir-u210384-w4457.PMC4916622.pdf
2012. http://eating-veggies.com (accessed 27 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2012. http://www.acidalkalinediet.com/ alkaline-diet-for-cancer (accessed 27 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2012. http://www.youtube.com/watch?,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2012. http://www.youtube.,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
http://www.americanaci.org/13.,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2012. http://www.alkalinephdiet.com/ alkaline-diet-for-cancer-patients/ (accessed 27 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2012. http://www.aicr.org/press/health-features/ nutrition-wise/nw-questions-about-body-ph-and-cancer-mets-stevia.,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2012. http://www.cancer.ca/en/ prevention-and-screening/be-aware/cancer-myths-and-controversies/an-alkaline-diet-and-cancer/?region=on (accessed 27 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2000. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 15 May 2016).,Non-OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
2011. http://www.cochrane-handbook.,OADS,/arxiv_data1/oa_pdf/ed/eb/bmjopen-2015-010438.PMC4916623.pdf
See: http://creativecommons.org/licenses/by-nc/2.0/ http://creativecommons.org/licenses/by-nc/2.0/legalcode REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/4f/87/bmjqir-u210035-w4128.PMC4916624.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010694).,Non-OADS,/arxiv_data1/oa_pdf/50/31/bmjopen-2015-010694.PMC4916625.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/50/31/bmjopen-2015-010694.PMC4916625.pdf
https://www.umcg.nl/NL/Zorg/Professionals/tarieven_onderlinge_dienstverlening/Paginas/default.aspx (accessed 17 Aug 2015).,Non-OADS,/arxiv_data1/oa_pdf/50/31/bmjopen-2015-010694.PMC4916625.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011384).,Non-OADS,/arxiv_data1/oa_pdf/de/3a/bmjopen-2016-011384.PMC4916627.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2016-011947).,Non-OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
http://www.ncbi.nlm.nih.gov/pubmed/ 15173288 (accessed 9 Oct 2013).,OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
"2013. http://www.nhs.uk/NHSEngland/bruce-keogh-review/Pages/published-reports.aspx 6 Zaidi R, et al.BMJ Open 2016; 6:e011947.",Non-OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
2013. http://www.hscic.gov.uk/article/2021/ Website-Search?productid=13264&q=title:+ ‘Admitted+Patient+Care +England ’&sort=Relevance&size=10&page=1&area=both#top (accessed 5 Jan 2014).,Non-OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
http://www.ncbi.nlm.nih.gov/pubmed/12141621 (accessed 23 Oct 2013).,Non-OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
http://www.njrcentre.org.uk/njrcentre/Portals/0/ Documents/England/MDSv4.0 A1.pdf 21.,Non-OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
http://www.njrcentre.org.uk/njrcentre/Portals/0/ Documents/England/Data collection forms/MDSv6.0_A2_V004.pdf 22.,Non-OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
"Statistical Bulletin Deaths Registered in England and Office of National Statistics, 2014. http://www.ons.gov.uk.",Non-OADS,/arxiv_data1/oa_pdf/5a/1e/bmjopen-2016-011947.PMC4916628.pdf
To view please visit the journal online (http://dx.doi.org/10.1136/openhrt- 2016-000441).,Non-OADS,/arxiv_data1/oa_pdf/df/5f/openhrt-2016-000441.PMC4916629.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/df/5f/openhrt-2016-000441.PMC4916629.pdf
"Agency for Healthcare Research and Quality (US), January 2014. http://www.effectivehealthcare.ahrq.gov 40.",Non-OADS,/arxiv_data1/oa_pdf/df/5f/openhrt-2016-000441.PMC4916629.pdf
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 14 Oct 2015).,Non-OADS,/arxiv_data1/oa_pdf/df/5f/openhrt-2016-000441.PMC4916629.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/openhrt-2016-000451).,Non-OADS,/arxiv_data1/oa_pdf/63/81/openhrt-2016-000451.PMC4916631.pdf
http://www.gov.scot/Topics/ Health/Policy/2020-Vision/Strategic-Narrative (accessed 19 Jun2015).,Non-OADS,/arxiv_data1/oa_pdf/fd/24/bmjopen-2015-010101.PMC4916633.pdf
"WHO, 2012. http://apps.who.int/ iris/bitstream/10665/70840/1/WHO_DCO_WHD_2012.1_eng.pdf (accessed 26 Aug 2015).",OADS,/arxiv_data1/oa_pdf/fd/24/bmjopen-2015-010101.PMC4916633.pdf
http://www.scotland.gov.uk/ Publications/2012/08/5616/0.,Non-OADS,/arxiv_data1/oa_pdf/fd/24/bmjopen-2015-010101.PMC4916633.pdf
"KnowledgeCenter Measurement Instruments, 2011:13. http://www.cosmin.nl/images/upload/files/Protocol%20klinimetrische%20review%20version%20nov%202011.pdf 49.",OADS,/arxiv_data1/oa_pdf/fd/24/bmjopen-2015-010101.PMC4916633.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011505).,Non-OADS,/arxiv_data1/oa_pdf/f8/44/bmjopen-2016-011505.PMC4916634.pdf
"55With initiation of the ENGAGES study, we launched a training moduleon a non-pro ﬁt international educational website, International Consortium for Electroencephalograph Training of Anesthesia Practitioners (http://www.icetap.org), titled ‘EEG Waveforms and Depth of Anesthesia ’.",Non-OADS,/arxiv_data1/oa_pdf/f8/44/bmjopen-2016-011505.PMC4916634.pdf
http://www.aoa.,Non-OADS,/arxiv_data1/oa_pdf/f8/44/bmjopen-2016-011505.PMC4916634.pdf
http://www.cdc.gov/nchs/fastats/insurg.htm (accessed 18 Jan 2014).,OADS,/arxiv_data1/oa_pdf/f8/44/bmjopen-2016-011505.PMC4916634.pdf
http://www.hospitalelderlifeprogram.org/for-family-members/what-you-can-do/ (accessed 31 Oct 2014).,Non-OADS,/arxiv_data1/oa_pdf/f8/44/bmjopen-2016-011505.PMC4916634.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2016- 011072).,Non-OADS,/arxiv_data1/oa_pdf/ff/1c/bmjopen-2016-011072.PMC4916635.pdf
http://www.ncbi.nlm.nih.gov/pubmed/14517510 (accessed 3 Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/90/7a/bmjopen-2016-011173.PMC4916638.pdf
http://www.ncbi.nlm.nih.gov/ pubmed/10419909 (accessed 2 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/90/7a/bmjopen-2016-011173.PMC4916638.pdf
25. http://www.gso.gov.vn/.,Non-OADS,/arxiv_data1/oa_pdf/90/7a/bmjopen-2016-011173.PMC4916638.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 010938).,Non-OADS,/arxiv_data1/oa_pdf/aa/95/bmjopen-2015-010938.PMC4916640.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1. de Boo HA, Harding JE.",Non-OADS,/arxiv_data1/oa_pdf/cf/48/bmjopen-2015-008916.PMC4916642.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/48/73/bmjopen-2016-011113.PMC4916700.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowEpilepsy is a neurological disorder that can cause unusual  activities such as loss of consciousness or seizures.",Non-OADS,/arxiv_data1/oa_pdf/45/41/SNI-7-65.PMC4916737.pdf
Surg Neurol Int 2016;7:65. http://surgicalneurologyint.com/Never-giving-up/,Non-OADS,/arxiv_data1/oa_pdf/45/41/SNI-7-65.PMC4916737.pdf
"Editor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com © 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowSir, I read with great interest the paper by Kochanski et al .",Non-OADS,/arxiv_data1/oa_pdf/d3/47/SNI-7-64.PMC4916738.pdf
Surg Neurol Int 2016;7:64. http://surgicalneurologyint.com/A-rare-intracranial-tumor-consisting-of-malignant- anaplastic-and-papillary-meningioma-subtypes/,Non-OADS,/arxiv_data1/oa_pdf/d3/47/SNI-7-64.PMC4916738.pdf
Graphical abstract This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8f/c4/nihms790263.PMC4916766.pdf
SUPPLEMENTAL INFORMATION Supplemental Information includes six figures and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.,OADS,/arxiv_data1/oa_pdf/8f/c4/nihms790263.PMC4916766.pdf
Available from http://www.hscic.,Non-OADS,/arxiv_data1/oa_pdf/2e/c9/JISPCD-6-183.PMC4916789.pdf
Available from: https://www.gov.,Non-OADS,/arxiv_data1/oa_pdf/2e/c9/JISPCD-6-183.PMC4916789.pdf
Available from:  http://www.noo.org.uk/NOO_about_obesity/inequalities.,Non-OADS,/arxiv_data1/oa_pdf/2e/c9/JISPCD-6-183.PMC4916789.pdf
Available from: https://www.nice.org.uk/ guidance/ph55.,Non-OADS,/arxiv_data1/oa_pdf/2e/c9/JISPCD-6-183.PMC4916789.pdf
Available from: http://www.socialstyrelsen.se/ publikationer2010/2010‑6‑7 [Last accessed on 2013 Aug 19].,Non-OADS,/arxiv_data1/oa_pdf/48/da/JISPCD-6-224.PMC4916796.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/11/e1/SJA-10-255.PMC4916806.pdf
Available from: http://www.stat.uiowa.edu/~rlenth/Power.,OADS,/arxiv_data1/oa_pdf/04/b9/SJA-10-288.PMC4916812.pdf
Web address of trial: http://www.ANZCTR.org.au/A CTRN12614000994684.aspx.,OADS,/arxiv_data1/oa_pdf/2b/54/SJA-10-295.PMC4916813.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/63/ff/SJA-10-332.PMC4916820.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/63/ff/SJA-10-332.PMC4916820.pdf
"Published with license by Taylor & Francis This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which per- mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
"2, 243 /C0250 http://dx.doi.org/10.1080/21623945.2015.1082015",Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Annu Rev Physiol 2010;72:517-49; PMID:20148687; http://dx.doi.org/10.1146/annurev-physiol-021909-135821 2.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Nature 2002; 418:935-41; PMID:12198538;http://dx.doi.org/10.1038/nature00965 3.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Cell 2002; 111:919-22; PMID:12507418; http://dx.doi.org/10.1016/S0092-8674(02)01225-4 4.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
PLoS Biol 2011; 9:e1000595; PMID:21364973; http://dx.doi.org/10.1371/journal.pbio.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Cell 2002; 110:251-60; PMID:12150932; http://dx.doi.org/10.1016/S0092-8674(02)00825-5 7.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J Clin Invest 2013; 123:3404-8; PMID:23867622; http://dx.doi.org/ 10.1172/JCI67803 9.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J ClinInvest 2013; 123:215-23; PMID:23221344; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Nat Med 2011; 17:200-5; PMID:21258337;http://dx.doi.org/10.1038/nm.2297 11.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Science 2010; 330:1349-54;PMID:21127246; http://dx.do i.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Cell 2002; 109:307-20; PMID:12015981; http://dx.doi.org/10.1016/S0092-8674(02)00722-5 13.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Proc Natl Acad Sci US A 2012; 109:5541-6; PMID:22431615; http://dx.doi.org/ 10.1073/pnas.1118726109 14.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Science 2005; 308:1043-5; PMID:15845877;http://dx.doi.org/10.1126/science.1108750 15.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Proc Natl Acad Sci U SA 2011; 108:1657-62; PMID:21220317; http://dx.doi.org/ 10.1073/pnas.1018375108 16.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Cell Metab 2010; 12:509-20;PMID:21035761; http://dx.doi.org/10.1016/j.cmet.2010.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
PLoS Med 2011; 8:e1001141; PMID:22162955; http://dx.doi.org/10.1371/journal.pmed.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Scand J Work Environ Health 2002; 28:64-71; PMID:11871855; http://dx.doi.org/10.5271/sjweh.648 19.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Proc Natl Acad Sci U S A 2008; 105:15172-7; PMID:18779586; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
FASEB J 2012; 26:3453-63; PMID:22611086; http://dx.doi.org/10.1096/fj.12-205781 22.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Islets 2011; 3:381-8; PMID:22045262; http://dx.doi.org/ 10.4161/isl.3.6.18157 23.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Int J Obes (Lond) 2014; 37:666-72; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
PMID:22578422; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
FASEB J 2013; 27:1721-32; PMID:23303208; http://dx.doi.org/10.1096/ fj.12-210898 27.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J Biol Rhythms 2013; 28:262-71; PMID:23929553; http://dx.doi.org/10.1177/0748730413493862 28.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
PLoS One 2015; 10:e0122570; PMID:25837425; http://dx.doi.org/10.1371/journal.pone.0122570 30.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J Exp Bot 2004; 55:277-83; PMID:14695902; http://dx.doi.org/10.1093/jxb/erh034 31.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Sci-ence 2010; 330:379-85; PMID:20947768; http://dx.doi.org/10.1126/science.1195262 32.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Am J Physiol Regul Integr Comp Physiol 2007; 292:R37-46; PMID:17008453; http://dx.doi.org/10.1152/ ajpregu.00668.2006 33.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
"Front Biosci (Landmark Ed) 2010; 15:564-94; PMID:20036834; http://dx.doi.org/10.2741/3634 34. van der Veen DR, Shao J, Chapman S, Leevy WM, Duf- ﬁeld GE.",OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J Biol Rhythms 2001; 16:196-204; PMID:11407779; http://dx.doi.org/10.1177/074873040101600302 36.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
BrainRes 1989; 503:163-6; PMID:2611651; http://dx.doi.org/ 10.1016/0006-8993(89)91720-4 37.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Diabetes 2006; 55:962-70; PMID:16567517; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
PLoS One 2013; 8:e70109; PMID:23990898; http://dx.doi.org/10.1371/ journal.pone.0070109 39.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Mol Metab 2013; 2:184-93; PMID:24049733; http://dx.doi.org/10.1016/j.molmet.2013.05.002 40.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J Insect Physiol2012; 58:704-9; PMID:22360999; http://dx.doi.org/ 10.1016/j.jinsphys.2012.02.004 41.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Diabetes 2009; 58:2583-7; PMID:19696186;http://dx.doi.org/10.2337/db09-0833 43.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Nature 2013; 503:410-3; PMID:24162845; http://dx.doi.org/10.1038/nature12642 44.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J Cell Sci 2015; 128:1835-47; PMID:25749863; http://dx.doi.org/10.1242/jcs.167643 45.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Sci Rep 2015; 5:11239; PMID:26058812; http://dx.doi.org/10.1038/srep11239 46.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Trends Endo- crinol Metab 2015; 26:231-7; PMID:25843910; http://dx.doi.org/10.1016/j.tem.2015.03.002 47.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Nature 2010; 466:627-31; PMID:20562852; http://dx.doi.org/10.1038/ nature09253 48.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
J Cell Sci 2013;126:2213-24; PMID:23525013; http://dx.doi.org/10.1242/ jcs.120519 49.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Endocrinology 2012; 153:3133-46;PMID:22549226; http://dx.doi.org/10.1210/en.2012- 1016 50.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
PMID:21723505; http://dx.doi.org/10.1016/j.cmet.2011.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Exp Cell Res 2015;331:200-10; PMID:25218946; http://dx.doi.org/10.1016/j.yexcr.2014.08.041 53.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Cell Rep 2013; 3:996-1004; PMID:23583176; http://dx.do i.org/10.1016/j.celrep.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Proc Natl Acad Sci U S A 2013; 110:E2106-15; PMID:23690597; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
Nature 2012; 485:62-8;PMID:22460951; http://dx.doi.org/10.1038/nature11030 56.,Non-OADS,/arxiv_data1/oa_pdf/11/e8/kadi-05-02-1082015.PMC4916866.pdf
"1, 20 –26 http://dx.doi.org/10.1080/19491034.2016.1149666",Non-OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Nature 1997; 389:251-60;PMID:9305837; http://dx.doi.org/10.1038/38444 [4] van Holde KE, Lohr DE, Robert C. What happens to nucleosomes during transcription?",Non-OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Cell 1976; 9:409-17; PMID:991271; http://dx.doi.org/10.1016/0092-8674(76)90085-4 [6] Lee MS, Garrard WT.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Biochemis-try 1979; 18:2871-80; PMID:476061; http://dx.doi.org/10.1021/bi00580a031 [8] Furuyama T, Codomo CA, Henikoff S. Reconstitution of hemisomes on budding yeast centromeric DNA.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
Nucleic Acids Res 2013; 41:5769-83; PMID:23620291; http://dx.doi.org/10.1093/nar/gkt314 [9] Annunziato AT.,Non-OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"J Biol Chem 2005;280:12065-8; PMID:15664979; http://dx.doi.org/10.1074/jbc.R400039200 [10] Xu M, Long C, Chen X, Huang C, Chen S, Zhu B. Parti- tioning of histone H3-H4 tetramers during DNA replica- tion-dependent chromatin assembly.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Science 2010;328:94-8; PMID:20360108; http://dx.doi.org/10.1126/science.1178994 [11] Huang C, Zhang Z, Xu M, Li Y, Li Z, Ma Y, Cai T, Zhu B. H3.3-H4 tetramer splitting events feature cell-type speci ﬁc enhancers.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"PLoS Genetics 2013; 9:e1003558; PMID:23754967;http://dx.doi.org/10.1371/journal.pgen.1003558 [12] Katan-Khaykovich Y, Struhl K. Splitting of H3-H4 tet- ramers at transcriptionally active genes undergoingdynamic histone exchange.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
Cell 2009; 138:104-13; PMID:19596238; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"eLife 2014; 3:e01861; PMID:24737863; http://dx.doi.org/10.7554/eLife.01861 [17] Brogaard K, Xi L, Wang JP, Widom J.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Genome Res 2015; 25:381-90; PMID:25491770;http://dx.doi.org/10.1101/gr.182618.114 [19] Mizuguchi G, Xiao H, Wisniewski J, Smith MM, Wu C. Nonhistone Scm3 and histones CenH3-H4 assemble the core of centromere-speci ﬁc nucleosomes.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"129:1153-64; PMID:17574026; http://dx.doi.org/10.1016/ j.cell.2007.04.026 [20] Rhee HS, Bataille AR, Zhang L, Pugh BF.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Cell 2014; 159:1377-88; PMID:25480300; http://dx.doi.org/10.1016/j.cell.2014.10.054 [21] Leschziner AE, Saha A, Wittmeyer J, Zhang Y, Bustamante C, Cairns BR, Nogales E. Conformational ﬂexibility in the chromatin remodeler RSC observed by electron micros-copy and the orthogonal tilt reconstruction method.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Nat Struct Mol Biol 2008; 15:1272-7; PMID:19029894; http://dx.doi.org/10.1038/nsmb.1524 [23] Saha A, Wittmeyer J, Cairns BR.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Nat Struct Mol Biol 2005; 12:747-55;PMID:16086025; http://dx.doi.org/10.1038/nsmb973 [24] Lorch Y, Maier-Davis B, Kornberg RD.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Proc Natl Acad Sci U S A 2010; 107:3458-62; PMID:20142505; http://dx.doi.org/10.1073/ pnas.1000398107 [25] Hsu JM, Huang J, Meluh PB, Laurent BC.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Mol Cell Biol2003; 23:3202-15; PMID:12697820; http://dx.doi.org/ 10.1128/MCB.23.9.3202-3215.2003 [26] Kruger W, Peterson CL, Sil A, Coburn C, Arents G, Mou- drianakis EN, Herskowitz I. Amino acid substitutions inthe structured domains of histones H3 and H4 partiallyrelieve the requirement of the yeast SWI/SNF complexfor transcription.",Non-OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Genes Dev 1995; 9:2770-9; PMID:7590252; http://dx.doi.org/10.1101/gad.9.22.2770 [27] Muthurajan UM, Bao Y, Forsberg LJ, Edayathumanga- l a mR S ,D y e rP N ,W h i t eC L ,L u g e rK .C r y s t a ls t r u c -tures of histone Sin mutant nucleosomes revealaltered protein-DNA interactions.",Non-OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"EMBO J 2004; 23:343-53; PMID:14726954;http://dx.doi.org/10.1038/sj.emboj.7600047 [29] Kadoch C, Crabtree GR.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"Sci Adv 2015; 1:e1500447; PMID:26601204; http://dx.doi.org/10.1126/sciadv.1500447 [30] Henikoff JG, Belsky JA, Krassovsky K, MacAlpine DM, Henikoff S. Epigenome characterization at singlebase-pair resolution.",OADS,/arxiv_data1/oa_pdf/9b/18/kncl-07-01-1149666.PMC4916871.pdf
"2, 175 –185 http://dx.doi.org/10.1080/21623945.2015.1111972",Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
J Clin Invest 2015; 125:478-86; PMID:25642708; http://dx.doi.org/10.1172/JCI78362 2.,Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Cell 2014; 156:20-44; PMID:24439368; http://dx.doi.org/10.1016/j.cell.2013.12.012 3.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Nat Med 2013; 19:1252-63; PMID:24100998; http://dx.doi.org/10.1038/ nm.3361 4.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Cell Metabol 2010; 11:268-72; PMID:20374959; http://dx.doi.org/10.1016/j.cmet.2010.03.007 5.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Diabetologia 2015; 58:1704-7; PMID:25957230; http://dx.doi.org/10.1007/s00125-015- 3611-y 6.,Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Diabetes 2015; 64:2352-60; PMID:26050667; http://dx.doi.org/10.2337/db15-0146 7.,Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Mol Ther 2004; 9:209-17; PMID:14759805; http://dx.doi.org/10.1016/j.ymthe.2003.11.021 9.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Methods Cell Biol2013; 116:83-105; PMID:24099289; http://dx.doi.org/ 10.1016/B978-0-12-408051-5.00006-1 10.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
J Lipid Res 2007; 48:465-71;PMID:17093294; http://dx.do i.org/10.1194/ jlr.D600033- JLR200 11.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Cell Metabol 2013; 17:562-74; PMID:23499423; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
PloS One 2009; 4:e6940; PMID:19759827; http://dx.doi.org/10.1371/ journal.pone.0006940184 M. S. ISIDOR ET AL.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Endocrinology 2012; 153:5629-36; PMID:23008513; http://dx.doi.org/10.1210/en.2012-1456 15.,Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
"StemCells (Dayton, Ohio) 2009; 27:2753-60; PMID:19697348; http://dx.doi.org/10.1002/stem.200 17.",OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
Cell Metabol2012; 15:395-404; PMID:22405074; http://dx.doi.org/ 10.1016/j.cmet.2012.01.019 19.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
EMBO Rep2014; 15:1069-76; PMID:25135951; http://dx.doi.org/10.15252/embr.201438775 20.,Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
J Biol Chem 2000; 275:25073-81; PMID:10825155;http://dx.doi.org/10.1074/jbc.M000547200 21.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
J Biol Chem 2000; 275:25494-501; PMID:10829031; http://dx.doi.org/10.1074/jbc.M004046200 22.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
J Exp Med 2005; 201:1397-405; PMID:15867092; http://dx.doi.org/10.1084/jem.20042224 24.,Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
J Biol Chem 1999; 274:2386-93; PMID:9891007; http://dx.doi.org/ 10.1074/jbc.274.4.2386 26.,OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
PloS One 2009; 4:e8458; PMID:20107496; http://dx.doi.org/ 10.1371/journal.pone.0008458ADIPOCYTE 185,Non-OADS,/arxiv_data1/oa_pdf/a1/5d/kadi-05-02-1111972.PMC4916873.pdf
"2, 146 –154 http://dx.doi.org/10.1080/19491034.2016.1174800",Non-OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Principles and con- cepts of DNA replication in bacteria, archaea, and eukarya.Cold Spring Harb Perspect Biol 2013; 5:a010108; PMID:23818497; http://dx.doi.org/10.1101/cshperspect.a010108 [2] MacNeill S. The Eukaryotic Replisome: A Guide to Pro- tein Structure and Function.",Non-OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"EMBO Mol Med 2016; 8:77-9; PMID:26787652; http://dx.doi.org/10.15252/emmm.201505965 [4] Sun J, Fernandez-Cid A, Riera A, Tognetti S, Yuan Z, Still- man B, Speck C, Li H. Structural and mechanistic insightsinto Mcm2-7 double-hexamer assembly and function.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"GenesDev 2014; 28:2291-303; PMID:25319829; http://dx.doi.org/ 10.1101/gad.242313.114[5] Evrin C, Clarke P, Zech J, Lurz R, Sun J, Uhle S, Li H, Stillman B, Speck C. A double-hexameric MCM2-7 com-plex is loaded onto origin DNA during licensing ofeukaryotic DNA replication.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Cell 2009; 139:719-30; PMID:19896182; http://dx.doi.org/10.1016/j.cell.2009.10.015 [7] Ticau S, Friedman LJ, Ivica NA, Gelles J, Bell SP.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
Cell 2015;161:513-25; PMID:25892223; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Genes Dev 2014; 28:1653-66;PMID:25085418; http://dx.doi.org/10.1101/gad.242404.114 [9] Costa A, Ilves I, Tamberg N, Petojevic T, Nogales E, Botchan MR, Berger JM.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nat Struct Mol Biol 2011; 18:471-7; PMID:21378962; http://dx.doi.org/10.1038/nsmb.2004 [10] Bochman ML, Schwacha A.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Mol Cell 2008; 31:287-93;PMID:18657510; http://dx.doi.org/10.1016/j.molcel.2008.05.020 [11] Moyer SE, Lewis PW, Botchan MR.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Elife 2015; 4:e04988; PMID:25871847; http://dx.doi.org/ 10.7554/eLife.04988 [13] Ilves I, Petojevic T, Pesavento JJ, Botchan MR. Activation of the MCM2-7 helicase by association with Cdc45 and GINSproteins.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Mol Cell 2010; 37:247-58; PMID:20122406; http://dx.doi.org/10.1016/j.molcel.2009.12.030 [14] Kang YH, Galal WC, Farina A, Tappin I, Hurwitz J.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
Nat Cell Biol 2006; 8:358-66; PMID:16531994; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"EMBO J 2009; 28:2992-3004; PMID:19661920; http://dx.doi.org/10.1038/emboj.2009.226 [17] Georgescu RE, Langston L, Yao NY, Yurieva O, Zhang D, Finkelstein J, Agarwal T, O ’Donnell ME.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nat Struct Mol Biol 2015; 22:185-91; PMID:25622295; http://dx.doi.org/10.1038/nsmb.2957 [20] Kunkel TA, Burgers PM.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Trends Cell Biol 2008;18:521-7; PMID:18824354; http://dx.doi.org/10.1016/j.tcb.2008.08.005 [21] Miyabe I, Kunkel TA, Carr AM.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"PLoS Genet 2011; 7:e1002407; PMID:22144917; http://dx.doi.org/10.1371/ journal.pgen.1002407 [22] Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA.",Non-OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Mol Cell 2008; 30:137-44; PMID:18439893;http://dx.doi.org/10.1016/j.molcel.2008.02.022 [23] Pursell ZF, Isoz I, Lundstrom EB, Johansson E, Kunkel TA.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"S cience 2007; 317:127-30; PMID:17615360; http://dx.doi.org/10.1126/science.1144067 [24] Yu C, Gan H, Han J, Zhou ZX, Jia S, Chabes A, Farrugia G, Ordog T, Zhang Z. Strand-speci ﬁc analysis shows pro- tein binding at replication forks and PCNA unloadingfrom lagging strands when forks stall.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Mol Cell 2014;56:551-63; PMID:25449133; http://dx.doi.org/10.1016/j.molcel.2014.09.017 [25] Johnson RE, Klassen R, Prakash L, Prakash S. A Major Role of DNA Polymerase delta in Replication of Both theLeading and Lagging DNA Strands.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Mol Cell 2015;59:163-75; PMID:26145172; http://dx.doi.org/10.1016/j.molcel.2015.05.038 [26] Yuan Z, Bai L, Sun J, Georgescu R, Liu J, O ’Donnell ME, Li H. Structure of the eukaryotic replicative CMG heli-case suggests a pumpjack motion for translocation.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nat Struct Mol Biol 2015; 22:976-82;PMID:26524492; http://dx.doi.org/10.1038/nsmb.3113 [28] Enemark EJ, Joshua-Tor L. On helicases and other motor proteins.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Curr Opin Struct Biol 2008; 18:243-57;PMID:18329872; http://dx.doi.org/10.1016/j.sbi.2008.01.007 [29] Lyubimov AY, Strycharska M, Berger JM.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"CurrOpin Struct Biol 2011; 21:240-8; PMID:21282052; http://dx.doi.org/10.1016/j.sbi.2011.01.002 [30] Patel SS, Picha KM.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Annu Rev Biochem 2000; 69:651-97; PMID:10966472; http://dx.doi.org/10.1146/annurev.biochem.69.1.651 [31] Abid Ali F, Renault L, Gannon J, Gahlon HL, Kotecha A, Zhou JC, Rueda D, Costa A. Cryo-EM structures of theeukaryotic replicative helicase bound to a translocationsubstrate.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nat Commun 2016; 7:10708; PMID:26888060;http://dx.doi.org/10.1038/ncomms10708 [32] Kelch BA, Makino DL, O ’Donnell M, Kuriyan J.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"The mechanism of ATP-dependentprimer-template recognition by a clamp loader complex.Cell 2009; 137:659-71; PMID:19450514; http://dx.doi.org/10.1016/j.cell.2009.03.044 [34] Enemark EJ, Joshua-Tor L. Mechanism of DNA translo- cation in a replicative hexameric helicase.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nature 2006; 442:270-5; PMID:16855583; http://dx.doi.org/10.1038/nature04943 [35] Froelich CA, Kang S, Epling LB, Bell SP, Enemark EJ.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Elife 2014; 3:e01993;PMID:24692448; http://dx.doi.org/10.7554/eLife.01993 [36] Lee JY, Yang W. UvrD helicase unwinds DNA one base pair at a time by a two-part power stroke.",Non-OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Cell 2006; 127:1349-60; PMID:17190599; http://dx.doi.org/10.1016/j.cell.2006.10.049 [37] Velankar SS, Soultanas P, Dillingham MS, Subramanya HS, Wigley DB.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Cell 1999; 97:75-84; PMID:10199404;http://dx.doi.org/10.1016/S0092-8674(00)80716-3 [38] Itsathitphaisarn O, Wing RA, Eliason WK, Wang J, Steitz TA.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Cell 2012; 151:267-77;PMID:23022319; http://dx.doi.org/10.1016/j.cell.2012.09.014 [39] Bochman ML, Bell SP, Schwacha A. Subunit organization of Mcm2-7 and the unequal role of active sites in ATP hydroly-sis and viability.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Mol Cell Biol 2008; 28:5865-73;PMID:18662997; http://dx.doi.org/10.1128/MCB.00161-08 [40] Bochman ML, Schwacha A.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nucleic Acids Res 2010; 38:6078-88; PMID:20484375; http://dx.doi.org/10.1093/nar/gkq422 [41] Johansson E, Dixon N. Replicative DNA polymerases.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Biol Direct 2009; 4:11; PMID:19296856; http://dx.doi.org/10.1186/1745-6150-4-11 [43] Dua R, Edwards S, Levy DL, Campbell JL.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Curr Biol 2013; 23:543-52; PMID:23499531;http://dx.doi.org/10.1016/j.cub.2013.02.011 [45] Dua R, Levy DL, Campbell JL.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"J Biol Chem 1999; 274:22283-8; PMID:10428796; http://dx.doi.org/10.1074/jbc.274.32.22283 [46] Kesti T, Flick K, Keranen S, Syvaoja JE, Wittenberg C. DNA polymerase epsilon catalytic domains are dispens-able for DNA replication, DNA repair, and cell viability.Mol Cell 1999; 3:679-85; PMID:10360184; http://dx.doi.org/10.1016/S1097-2765(00)80361-5 [47] Niwa O, Bryan SK, Moses RE.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nature 2014; 510:293-7; PMID:24805245; http://dx.doi.org/10.1038/nature13234 [50] Costa A, Renault L, Swuec P, Petojevic T, Pesavento J, Ilves I, MacLellan-Gibson K, Fleck RA, Botchan MR,Berger JM.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"J Biol Chem 2007; 282:34229-34; PMID:17884823; http://dx.doi.org/10.1074/jbc.M706300200 [52] Singleton MR, Dillingham MS, Wigley DB.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"AnnuRev Biochem 2007; 76:23-50; PMID:17506634; http://dx.doi.org/10.1146/annurev.biochem.76.052305.115300 [53] Iida T, Araki H. Noncompetitive counteractions of DNA polymerase epsilon and ISW2/yCHRAC for epigeneticinheritance of telomere position effect in Saccharomycescerevisiae.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
Mol Cell Biol 2004; 24:217-27; PMID: 14673157; http://dx.doi.org/10.1128/MCB.24.1.217-227.,OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"JCell Biol 2005; 169:35-47; PMID:15824130; http://dx.doi.org/10.1083/jcb.200502104 [55] Fu YV, Yardimci H, Long DT, Ho TV, Guainazzi A, Bermu- d e zV P ,H u r w i t zJ ,v a nO i j e nA ,S c h a r e rO D ,W a l t e rJ C .",Non-OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Cell 2011; 146:931-41;PMID:21925316; http://dx.doi.org/10.1016/j.cell.2011.07.045 [56] Huang H, Stromme CB, Saredi G, Hodl M, Strandsby A, Gonzalez-Aguilera C, Chen S, Groth A, Patel DJ.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nat Struct Mol Biol 2015; 22:618-26; PMID:26167883; http://dx.doi.org/10.1038/ nsmb.3055 [57] Wang H, Wang M, Yang N, Xu RM.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Protein Cell 2015; 6:693-7; PMID:26186914;http://dx.doi.org/10.1007/s13238-015-0190-0 [58] Sun J, Shi Y, Georgescu RE, Yuan Z, Chait BT, Li H, O’Donnell ME.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"Nat Struct Mol Biol 2015; 22:976-82;PMID:26524492; http://dx.doi.org/10.1038/nsmb.3113 [59] Yuan Z, Bai L, Sun J, Georgescu R, Liu J, O ’Donnell ME, Li H. Structure of the eukaryotic replicative CMG heli-case suggests a pumpjack motion for translocation.",OADS,/arxiv_data1/oa_pdf/ed/86/kncl-07-02-1174800.PMC4916876.pdf
"2, 187 –202 http://dx.doi.org/10.1080/19491034.2016.1179409",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
Nat Rev Mol Cell Biol 2003; 4:948-59; PMID:14685173; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nat Struct Mol Biol 2015; 22:848-52;PMID:26581518; http://dx.doi.org/10.1038/nsmb.3083 [3] Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM, Terns MP.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell cycle-regulated traf ﬁcking of human telo- m e r a s et ot e l o m e r e s .M o lB i o lC e l l2 0 0 6 ;1 7 : 9 5 5 - 6 5 ;P M I D : 16339074; http://dx.doi.org/10.1091/mbc.E05-09-0903 [4] Hiyama E, Hiyama K. Telomere and telomerase in stem cells.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Br J Cancer 2007; 96:1020-4; PMID:17353922;http://dx.doi.org/10.1038/sj.bjc.6603671 [5] Novo CL, Londono-Vallejo JA .",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Semin Cancer Biol 2013; 23:116-24; PMID:22330096;http://dx.doi.org/10.1016/j.semcancer.2012.02.001 [6] Cristofari G, Lingner J. Telomere length homeostasis requires that telomerase levels are limiting.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"EMBO J2006; 25:565-74; PMID:16424902; http://dx.doi.org/ 10.1038/sj.emboj.7600952 [7] Venteicher AS, Abreu EB, Meng Z, McCann KE, Terns RM, Veenstra TD, Terns MP, Artandi SE.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Science 2009;323:644-8; PMID:19179534; http://dx.doi.org/10.1126/ science.1165357 [8] Zhong F, Savage SA, Shkreli M, Giri N, Jessop L, Myers T, Chen R, Alter BP, Artandi SE.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
Genes Dev 2011; 25:11-6; PMID:21205863;http://dx.doi.org/10.1101/gad.2006411 [9] de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres.,OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Genes Dev 2005; 19:2100-10; PMID:16166375; http://dx.doi.org/10.1101/ gad.1346005 [10] Palm W, de Lange T. How shelterin protects mamma- lian telomeres.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Ann Rev Genet 2008; 42:301-34;PMID:18680434; http://dx.doi.org/10.1146/annurev.genet.41.110306.130350 [11] Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
Sci- ence 1998; 282:1484-7; PMID:9822378; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell Death Differ 2012; 19:321-32; PMID:21818122;http://dx.doi.org/10.1038/cdd.2011.101 [13] Sfeir A, Kosiyatrakul ST, Hockemeyer D, MacRae SL, Karl- seder J, Schildkraut CL, de Lange T. Mammalian telomeres resemble fragile sites and require TRF1 for ef ﬁcient replica- tion.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell 2009; 138:90-103; PMID:19596237; http://dx.doi.org/10.1016/j.cell.2009.06.021 [14] Drosopoulos WC, Kosiyatrakul ST, Schildkraut CL.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Biol 2015; 210:191-208; PMID:26195664; http://dx.doi.org/10.1083/jcb.201410061 [15] Vannier JB, Sandhu S, Petalcorin MI, Wu X, Nabi Z, Ding H, Boulton SJ.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Science 2013; 342:239-42; PMID:24115439;http://dx.doi.org/10.1126/science.1241779 [16] Mason JM, Frydrychova RC, Biessmann H. Drosophila telomeres: an exception providing new insights.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Bioes-says 2008; 30:25-37; PMID:18081009; http://dx.doi.org/ 10.1002/bies.20688 [17] Raffa GD, Cenci G, Ciapponi L, Gatti M. Organization and evolution of drosophila terminin: Similarities anddifferences between drosophila and human telomeres.Front Oncol 2013; 3:112; PMID:23675571; http://dx.doi.org/10.3389/fonc.2013.00112 [18] Burla R, Carcuro M, Raffa GD, Galati A, Raimondo D, Rizzo A, La Torre M, Micheli E, Ciapponi L, Cenci G, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
PMID:26110528; http://dx.doi.org/10.1371/journal.pgen.,OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"doi.org/10.1371/journal.pgen.1005260 [20] van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions.Cell 1998; 6:401-13; PMID:9476899; http://dx.doi.org/10.1016/S0092-8674(00)80932-0 [21] Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Curr Biol 2003; 13:6533-41;http://dx.doi.org/10.1016/S0960-9822(03)00542-6 [22] Smogorzewska A, Karlseder J, Holtgreve-Grez H, Jauch A, de Lange T. DNA ligase IV-dependent NHEJ ofdeprotected mammalian telomeres in G1 and G2.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"CurrBiol 2002; 12:1635-44; PMID:12361565; http://dx.doi.org/10.1016/S0960-9822(02)01179-X [23] Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lack-ing TRF2.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Science 1999; 283:1321-5; PMID:10037601; http://dx.doi.org/10.1126/science.283.5406.1321 [24] Arnoult N, Karlseder J.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Complex interactions between the DNA-damage response and mammalian telomeres.Nat Struct Mol Biol 2015; 22:859-66; PMID:26581520;http://dx.doi.org/10.1038/nsmb.3092 [25] Denchi E, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 andPOT1.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nature 2007; 448:1068-71; PMID:17687332; http://dx.doi.org/10.1038/nature06065 [26] Bandaria JN, Qin P, Berk V, Chu S, Yildiz A. Shelterin protects chromosome ends by compacting telomericchromatin.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell 2016; 164:735-46; PMID:26871633;http://dx.doi.org/10.1016/j.cell.2016.01.036 [27] Badie S, Escandell JM, Bouwman P, Carlos AR, Thanasoula M, Gallardo MM, Suram A, Jaco I, Benitez J, Herbig U,et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nat Struct Mol Biol 2010; 17:1461- 9; PMID:21076401; http://dx.do i.org/10.1038/nsmb.1943 [28] Rippe K, Luke B. TERRA and the state of the telomere.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nat Struct Mol Biol 2015; 22:853-8; PMID:26581519;http://dx.doi.org/10.1038/nsmb.3078 [29] Dechat T, P ﬂeghaar K, Sengupta K, Shimi T, Shumaker D, Solimando L, Goldman R. Nuclear lamins: major fac-tors in the structural organization and function of the nucleus and chromatin.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Genes Dev 2008; 22:832-53; PMID:18381888; http://dx.doi.org/10.1101/gad.1652708 [30] Shumaker D, Solimando L, Sengupta K, Shimi T, Adam S, Grunwald A, Strelkov S, Aebi U, Cardoso M, Gold-man R. The highly conserved nuclear lamin Ig-foldbinds to PCNA: its role in DNA replication.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Biol2008; 181:269-80; PMID:18426975; http://dx.doi.org/10.1083/jcb.200708155 [31] Butin-Israeli V, Adam SA, Goldman AE, Goldman RD.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Trends Genet2012; 28:464-71; PMID:22795640; http://dx.doi.org/ 10.1016/j.tig.2012.06.001 [32] Vergnes L, Peterfy M, Bergo MO, Young SG, Reue K. Lamin B1 is required for mouse development andnuclear integrity.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nucleus2011; 2:562-9; PMID:22127257; http://dx.doi.org/10.4161/nucl.2.6.18085 [34] Shimi T, Butin-Israeli V, Adam SA, Hamanaka RB, Goldman AE, Lucas CA, Shumaker DK, Kosak ST,Chandel NS, Goldman RD.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Genes Dev 2011; 25:2579-93; PMID:22155925; http://dx.doi.org/10.1101/ gad.179515.111 [35] Eriksson JE, Dechat T, Grin B, Helfand B, Mendez M, Pal- lari HM, Goldman RD.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Clin Invest 2009; 119:1763-71;PMID:19587451; http://dx.doi.org/10.1172/JCI38339 [36] Moir RD, Yoon M, Khuon S, Goldman RD.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Biol 2000; 151:1155-68; PMID:11121432; http://dx.doi.org/10.1083/jcb.151.6.1155 [37] Schellhaus AK, De Magistris P, Antonin W. Nuclear Reformation at the End of Mitosis.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell Rep 2012; 2:1521-9; PMID:23260663; http://dx.doi.org/10.1016/j.celrep.2012.11.019 [39] Kind J, Pagie L, de Vries SS, Nahidiazar L, Dey SS, Bienko M, Zhan Y, Lajoie B, de Graaf CA, Amendola M, et al.Genome-wide Maps of Nuclear Lamina Interactions in Sin-gle Human Cells.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell 2015; 163:134-47; PMID:26365489;http://dx.doi.org/10.1016/j.cell.2015.08.040 [40] Melcer S, Hezroni H, Rand E, Nissim-Ra ﬁnia M, Skoultchi A, Stewart CL, Bustin M, Meshorer E. Histonemodi ﬁcations and lamin A regulate chromatin protein dynamics in early embryonic stem cell differentiation.Nat Commun 2012; 3:910; PMID:22713752; http://dx.doi.org/10.1038/ncomms1915 [41] Gilson E, Laroche T, Gasser SM.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Trends Cell Biol 1993; 3:128-34; PMID:14731767; http://dx.doi.org/ 10.1016/0962-8924(93)90175-Z [42] Taddei A, Hediger F, Neumann FR, Gasser SM.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"The function of nuclear architecture: a genetic approach.Annu Rev Genet 2004; 38:305-45; PMID:15568979;http://dx.doi.org/10.1146/annurev.genet.37.110801.142705 [43] Scherthan H, Jerratsch M, Li B, Smith S, Hulten M, Lock T, de Lange T. Mammalian meiotic telomeres: protein com- position and redistribution in relation to nuclear pores.198 R. BURLA ET AL.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Proc Natl Acad Sci U S A 2007;104:7426-31; PMID:17452644; http://dx.doi.org/ 10.1073/pnas.0609198104 [45] Link J, Jahn D, Schmitt J, Gob E, Baar J, Ortega S, Bena- vente R, Alsheimer M. The meiotic nuclear lamina regu-lates chromosome dynamics and promotes ef ﬁcient homologous recombination in the mouse.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Biol 1996; 135:867-81; PMID:Can ’t; http://dx.doi.org/10.1083/jcb.135.4.867 [48] Dechat T, Gajewski A, Korbei B, Gerlich D, Daigle N, Haraguchi T, Furukawa K, Ellenberg J, Foisner R. LAP2alpha and BAF transiently localize to telomeres and speci ﬁc regions on chromatin during nuclear assembly.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Sci 2004; 117:6117-28; PMID:15546916;http://dx.doi.org/10.1242/jcs.01529 [49] Chojnowski A, Ong PF, Wong ES, Lim JS, Mutalif RA, Navasankari R, Dutta B, Yang H, Liow YY, Sze SK, et al.Progerin reduces LAP2alpha-telomere association inHutchinson-Gilford progeria.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell Cycle 2009; 8:931-9; PMID:19229133; http://dx.doi.org/10.4161/cc.8.6.7941 [52] Wood AM, Laster K, Rice EL, Kosak ST. A beginning of the end: new insights into the functional organization oftelomeres.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nucleus 2015; 6:172-8; PMID:25961132;http://dx.doi.org/10.1080/19491034.2015.1048407 [53] Ottaviani A, Schluth-Bolard C, Rival-Gervier S, Bous- souar A, Rondier D, Foerster AM, Morere J, Bauwens S,Gazzo S, Callet-Bauchu E, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"EMBO J 2009;28:2428-36; PMID:19644448; http://dx.doi.org/10.1038/emboj.2009.201 [54] Bronshtein I, Kepten E, Kanter I, Berezin S, Lindner M, Redwood AB, Mai S, Gonzalo S, Foisner R, Shav-Tal Y,et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nat Commun 2015; 6:8044; PMID:26299252; http://dx.doi.org/10.1038/ ncomms9044[55] Gonzalez-Suarez I, Redwood A, Gonzalo S. Loss of A- type lamins and genomic instability.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell Cycle 2009;8:3860-5; PMID:19901537; http://dx.doi.org/10.4161/cc.8.23.10092 [56] Gonzalez-Suarez I, Redwood A, Perkins S, Vermolen B, Lichtensztejin D, Grotsky D, Morgado-Palacin L, Gapud E,Sleckman B, Sullivan T, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"EMBO J 2009; 28:2414-27; PMID:19629036; http://dx.doi.org/10.1038/emboj.2009.196 [57] Lottersberger F, Karssemeijer RA, Dimitrova N, de Lange T. 53BP1 and the LINC Complex PromoteMicrotubule-Dependent DSB Mobility and DNARepair.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell 2015; 163:880-93; PMID:26544937; http://dx.doi.org/10.1016/j.cell.2015.09.057 [58] Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, WrightWE.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Science 1998; 279:349-52;PMID:9454332; http://dx.doi.org/10.1126/science.279.5349.349 [59] Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Biol 2011; 192:547-56; PMID:21321098; http://dx.doi.org/10.1083/jcb.201009094 [61] Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Sci- ence 2002; 295:2446-9; PMID:11923537; http://dx.doi.org/10.1126/science.1069523 [62] McClintock D, Gordon LB, Djabali K. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascularcells as detected by an anti-Lamin A G608G antibody.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nucleus 2013; 4:410-9; PMID:24153156; http://dx.doi.org/10.4161/nucl.26873 [65] Scaf ﬁdi P, Misteli T. Lamin A-dependent nuclear defects in human aging.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Science 2006; 312:1059-63; PMID:16645051;http://dx.doi.org/10.1126/science.1127168 [66] Kudlow BA, Stanfel MN, Burtner CR, Johnston ED, Kennedy BK.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Mol Biol Cell 2008;19:5238-48; PMID:18843043; http://dx.doi.org/10.1091/mbc.E08-05-0492 [67] Wang C, Jurk D, Maddick M, Nelson G, Martin-Ruiz C, von Zglinicki T. DNA damage response and cellularsenescence in tissues of aging mice.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Aging cell 2009; 8:311-23; PMID:19627270; http://dx.doi.org/10.1111/ j.1474-9726.2009.00481.x [68] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell 2013;153:1194-217; PMID:23746838; http://dx.doi.org/10.1016/j.cell.2013.05.039 [69] Holohan B, Wright WE, Shay JW.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Am J HumGenet 2009; 85:823-32; PMID:19944403; http://dx.doi.org/10.1016/j.ajhg.2009.10.028 [71] Townsley DM, Dumitriu B, Young NS.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Blood 2014; 124:2775- 83; PMID:25237198; http://dx.doi.org/10.1182/blood-2014-05-526285 [72] Balakumaran A, Mishra PJ, Pawelczyk E, Yoshizawa S, Sworder BJ, Cherman N, Kuznetsov SA, Bianco P, GiriN, Savage SA, et al.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Blood 2015; 125:793-802; PMID:25499762; http://dx.doi.org/10.1182/blood-2014- 06-566810 [73] Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wie- mann S, Mason PJ, Poustka A, Dokal I. X-linked dys-keratosis congenita is caused by mutations in a highlyconserved gene with putative nucleolar functions.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
NatGenet 1998; 19:32-8; PMID:9590285; http://dx.doi.org/10.1038/ng0598-32 [74] Dokal I. Dyskeratosis congenita.,OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Hematol Am Soc Hematol Educ Program 2011; 2011:480-6; PMID:22160078; http://dx.doi.org/10.1182/ash education-2011.1.480 [75] Walne AJ, Vulliamy T, Kirwan M, Plagnol V, Dokal I. Con- stitutional mutations in RTEL1 cause severe dyskeratosiscongenita.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Am J Hum Genet 2013; 92:448-53; PMID:23453664; http://dx.doi.org/10.1016/j.ajhg.2013.02.001 [76] Liao CY, Kennedy BK.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Curr Top Dev Biol 2014; 109:249- 85; PMID:24947239; http://dx.doi.org/10.1016/B978-0-12-397920-9.00003-2 [77] Lee HW, Blasco MA, Gottlieb GJ, Horner JW, 2nd, Greider CW, DePinho RA.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nature 1998;392:569-74; PMID:9560153; http://dx.doi.org/10.1038/33345 [78] Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, Sahin E, Kost-Alimova M, Protopopov A,Cadinanos J, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nature 2011; 469:102-6; PMID:21113150; http://dx.doi.org/10.1038/nature09603 [79] Bernardes de Jesus B, Vera E, Schneeberger K, Tejera AM, Ayuso E, Bosch F, Blasco MA.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"EMBO Mol Med 2012; 4:691-704; PMID:22585399; http://dx.doi.org/10.1002/emmm.201200245 [80] Mart /C19ınez P, Thanasoula M, Mu ~noz P, Liao C, Tejera A, McNees C, Flores J, Fern /C19andez-Capetillo O, Tarsounas M, Blasco M. Increased telomere fragility and fusionsresulting from TRF1 de ﬁciency lead to degenerative pathologies and increased cancer in mice.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Genes Dev 2009; 23:2060-75; PMID:Can ’t; http://dx.doi.org/ 10.1101/gad.543509 [81] Worman H, Fong L, Muchir A, Young S. Laminopathies and the long strange trip from basic cell biology to ther-apy.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Clin Invest 2009; 119:1825-36; PMID:19587457;http://dx.doi.org/10.1172/JCI37679 [82] Camozzi D, Capanni C, Cenni V, Mattioli E, Colum- baro M, Squarzoni S, Lattanzi G. Diverse lamin-depen- dent mechanisms interact to control chromatin dynamics.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nucleus 2014;5:427-40; PMID:25482195; http://dx.doi.org/10.4161/nucl.36289 [83] De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, A m i e lJ ,B o c c a c c i oI ,L y o n n e tS ,S t e w a r tC L ,M u n n i c hA ,Le Merrer M, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Science 2003; 300:2055; PMID:12702809; http://dx.doi.org/10.1126/science.1084125 [84] Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY,Berglund P, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Recurrent de novo point mutations inlamin A cause Hutchinson-Gilford progeria syndrome.Nature 2003; 423:293-8; PMID:12714972; http://dx.doi.org/10.1038/nature01629 [85] Decker ML, Chavez E, Vulto I, Lansdorp PM.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Mech Ageing Dev 2009; 130:377-83; PMID:19428457; http://dx.doi.org/10.1016/j.mad.2009.03.001 [86] Benson E, Lee S, Aaronson S. Role of progerin-induced telomere dysfunction in HGPS premature cellularsenescence.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Sci 2010; 123:2605-12; PMID:20605919; http://dx.doi.org/10.1242/jcs.067306 [87] Barrowman J, Wiley PA, Hudon-Miller SE, Hrycyna CA, Michaelis S. Human ZMPSTE24 disease muta- tions: residual proteolytic activity correlates with dis-ease severity.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"2011; 155A:2617-25; PMID:21932319; http://dx.doi.org/ 10.1002/ajmg.a.34249 [89] Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Ken- d a l lL V ,M o h rA ,M e t aM ,G e n a n tH ,J i a n gY ,e ta l .Zmpste24 de ﬁciency in mice causes spontaneous bone frac- tures, muscle weakness, and a prelamin A processing defect.Proc Natl Acad Sci U S A 2002; 99:13049-54; PMID: 12235369; http://dx.doi.org/10.1073/pnas.192460799 [90] Varela I, Cadinanos J, Pendas AM, Gutierrez-Fernandez A, Folgueras AR, Sanchez LM, Zhou Z, Rodriguez FJ,Stewart CL, Vega JA, et al.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nature 2005; 437:564-8; PMID:16079796; http://dx.doi.org/10.1038/nature04019 [91] Liu B, Wang Z, Zhang L, Ghosh S, Zheng H, Zhou Z.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nat Commun 2013; 4:1868; PMID:23695662;http://dx.doi.org/10.1038/ncomms2885 [92] Scaf ﬁdi P, Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing.Nat Cell Biol 2008; 10:452-9; PMID:18311132; http://dx.doi.org/10.1038/ncb1708 [93] Espada J, Varela I, Flores I, Ugalde AP, Cadinanos J, Pendas AM, Stewart CL, Tryggvason K, Blasco MA, Freije JM, et al.Nuclear envelope defects cause stem cell dysfunction in pre-mature-aging mice.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Biol 2008; 181:27-35;PMID:18378773; http://dx.doi.org/10.1083/jcb.200801096 [94] Rosengardten Y, McKenna T, Grochova D, Eriksson M. Stem cell depletion in Hutchinson-Gilford progeria syn-drome.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Aging Cell 2011; 10:1011-20; PMID:21902803; http://dx.doi.org/10.1111/j.1474-9726.2011.00743.x [95] Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, DePinho RA.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell 1999; 96:701-12; PMID:10089885; http://dx.doi.org/10.1016/S0092-8674(00)80580-2 [96] Martinez P, Thanasoula M, Munoz P, Liao C, Tejera A, McNees C, Flores JM, Fernandez-Capetillo O, Tarsou- nas M, Blasco MA.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"GenesDev 2009; 23:2060-75; PMID:19679647; http://dx.doi.org/10.1101/gad.543509 [97] Mason PJ, Bessler M. The genetics of dyskeratosis conge- nita.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cancer Genet 2011; 204:635-45; PMID:22285015;http://dx.doi.org/10.1016/j.cancergen.2011.11.002 [98] Mounkes LC, Kozlov S, Hernandez L, Sullivan T, Stewart CL.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Am J Med Genet A 2006; 140:2603-24; PMID:16838330; http://dx.doi.org/10.1002/ajmg.a.31346 [102] Pereira S, Bourgeois P, Navarro C, Esteves-Vieira V, Cau P, De Sandre-Giovannoli A, Levy N. HGPS andrelated premature aging disorders: from genomic identi-ﬁcation to the ﬁrst therapeutic approaches.",Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Bone Miner Res 2011; 26:1494-505; PMID:21308778; http://dx.doi.org/10.1002/jbmr.349 [104] Chen CY, Chi YH, Mutalif RA, Starost MF, Myers TG, Anderson SA, Stewart CL, Jeang KT.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell 2012;149:565-77; PMID:22541428; http://dx.doi.org/10.1016/j.cell.2012.01.059 [105] Zhang J, Lian Q, Zhu G, Zhou F, Sui L, Tan C, Mutalif RA, Navasankari R, Zhang Y, Tse HF, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Cell Stem Cell 2011; 8:31-45; PMID:21185252;http://dx.doi.org/10.1016/j.stem.2010.12.002 [106] Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, Greider CW.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
Cell 1997; 91:25-34; PMID:9335332; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nature 2010;464:292-6; PMID:20164838; http://dx.doi.org/10.1038/nature08792 [108] Hernandez L, Roux KJ, Wong ES, Mounkes LC, Mutalif R, Navasankari R, Rai B, Cool S, Jeong JW, Wang H, et al.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Functional coupling between the extracellularmatrix and nuclear lamina by Wnt signaling in progeria.Dev Cell 2010; 19:413-25; PMID:20833363; http://dx.doi.org/10.1016/j.devcel.2010.08.013 [109] Cao K, Blair CD, Faddah DA, Kieckhaefer JE, Olive M, Erdos MR, Nabel EG, Collins FS.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
J Clin Invest 2011; 121:2833-44; PMID:21670498; http://dx.doi.org/10.1172/JCI43578NUCLEUS 201,Non-OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nat Rev MolCell Biol 2007; 8:692-702; PMID:17700626; http://dx.doi.org/10.1038/nrm2238 [111] Vulliamy T, Marrone A, Goldman F, Dearlove A, Bess- ler M, Mason PJ, Dokal I.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Nature 2001; 413:432-5; PMID: 11574891; http://dx.doi.org/10.1038/35096585 [112] Vulliamy TJ, Knight SW, Mason PJ, Dokal I.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"BloodCells Mol Dis 2001; 27:353-7; PMID:11259155; http://dx.doi.org/10.1006/bcmd.2001.0389 [113] Hande MP, Samper E, Lansdorp P, Blasco MA.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J Cell Biol1999; 144:589-601; PMID:10037783; http://dx.doi.org/10.1083/jcb.144.4.589[114] Burgdorf W, Kurvink K, Cervenka J.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"J MedGenet 1977; 14:256-7; PMID:926136; http://dx.doi.org/10.1136/jmg.14.4.256 [115] Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang JD,LiKM,ChauPY,ChenDJ,etal.Genomicinstabilityinlam-inopathy-based premature aging.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"Br J Haematol 2011; 153:634-43; PMID:21477209;http://dx.doi.org/10.1111/j.1365-2141.2011.08679.x [117] Espejel S, Klatt P, Menissier-de Murcia J, Martin-Cabal- lero J, Flores JM, Taccioli G, de Murcia G, Blasco MA.Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs.",OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
J CellBiol 2004; 167:627-38; PMID:15545322; http://dx.doi.org/10.1083/jcb.200407178202 R. BURLA ET AL.,OADS,/arxiv_data1/oa_pdf/7a/b7/kncl-07-02-1179409.PMC4916877.pdf
"1, 27 –33 http://dx.doi.org/10.1080/19491034.2016.1139272",Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
NatRev Genet 2001;2:292-301; PMID:11283701; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Science 2009; 326:289-93; PMID:19815776;http://dx.doi.org/10.1126/science.1181369 3.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Cell 2013; 152:1270-84; PMID:23498936; http://dx.doi.org/10.1016/j.cell.2013.02.001 4.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
CurrOpin Chem Biol 2014; 20:112-9; PMID:24981829; http://dx.doi.org/10.1016/j.cbpa.2014.05.009 5.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Curr Opin Cell Biol 2007; 19:31-316; PMID:17184986; http://dx.doi.org/10.1016/j.ceb.2006.12.009 6.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
J Cell Biol 1996; 135:1195-205; PMID:8947544;http://dx.doi.org/10.1083/jcb.135.5.1195 7.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Curr Biol 1997; 7:930-9;PMID:9382846; http://dx.doi.org/10.1016/S0960-9822(06)00412-X 8.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Nature 2015; 518:331-6; PMID:25693564;http://dx.doi.org/10.1038/nature14222 9.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Curr OpinGenet Dev 2007; 17:435-42; PMID:17905579; http://dx.doi.org/10.1016/j.gde.2007.08.004 10.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Nat Commun 2015; 6:8044;PMID:26299252; http://dx.doi.org/10.1038/ncomms9044 11.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Phys Rev E 2013; 87:052713; http://dx.doi.org/10.1103/PhysRevE.87.052713 12.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
A case of telomere subdiffusion.Biophys J 2012; 103:1839-47; PMID:23199912; http://dx.doi.org/10.1016/j.bpj.2012.09.040 13.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Phys Today 2012; 65:29-35;http://dx.doi.org/10.1063/PT.3.1677 14.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Biophys J 2002; 82:2775-83; PMID:11964263; http://dx.doi.org/10.1016/S0006-3495(02)75618-X 15.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Phys Chem Chem Phys 2014; 16:24128-64;PMID:25297814; http://dx.doi.org/10.1039/C4CP03465A 17.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Genes Dev 2008; 22:832-53;PMID:18381888; http://dx.doi.org/10.1101/gad.1652708 19.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
J Cell Sci 2012; 125:2087-93; PMID:22669459; http://dx.doi.org/10.1242/jcs.087288 20.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Annu Rev Biochem2015; 84:131-64; PMID:25747401; http://dx.doi.org/10.1146/annurev-biochem-060614-034115 21.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Trends Cell Biol 2013;24:247-56; PMID:24309562; http://dx.doi.org/10.1016/j.tcb.2013.11.004 24.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
EMBO J 2009; 28:2414-27; PMID:19629036;http://dx.doi.org/10.1038/emboj.2009.196 25.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
J Clin Pathol 1992; 45:416- 9; PMID:1350788; http://dx.doi.org/10.1136/jcp.45.5.416 26.,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Cell 2008;132:487-98; PMID:18267078; http://dx.doi.org/10.1016/j.cell.2007.12.033 27.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Nat Cell Biol 2002; 4:502-8; PMID:12068306;http://dx.doi.org/10.1038/ncb809 28.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Science 2004; 304:1797-800; PMID:15205532;http://dx.doi.org/10.1126/science.1099754 29.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Nat Cell Biol 2010; 12:543-52; PMID:20453848; http://dx.doi.org/10.1038/ncb2056 31.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
Cell Biochem Biophys 2007; 49:141-64;PMID:17952641; http://dx.doi.org/10.1007/s12013-007-9000-5 32.,OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
J Cell Biol 2009; 187:481-96; http://dx.doi.org/10.1083/jcb.200907029NUCLEUS 33,Non-OADS,/arxiv_data1/oa_pdf/99/2e/kncl-07-01-1139272.PMC4916879.pdf
"21 1(3):533-51; http://dx.doi.org/10.1083/jcb.201504035 © 2016 F. Marullo, E. Cesarini, L. Antonelli, F. Gregoretti, G. Oliva, and C. Lanzuolo.",Non-OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"2, 103 –111 http://dx.doi.org/10.1080/19491034.2016.1157675",Non-OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Annu Rev Biochem2015; 84:131-64; PMID:25747401; http://dx.doi.org/10.1146/annurev-biochem-060614-034115 [2] Bianchi A, Lanzuolo C. Into the chromatin world: Role of nuclear architecture in epigenome regulation.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"AIMS Bio-physics 2015; 2:585-612; http://dx.doi.org/10.3934/ biophy.2015.4.585 [3] Collas P, Lund EG, Oldenburg AR.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Bioessays2014; 36:75-83; PMID:24272858; http://dx.doi.org/10.1002/bies.201300138 [4] Meuleman W, Peric-Hupkes D, Kind J, Beaudry JB, Pagie L, Kellis M, Reinders M, Wessels L, van Steensel B. Con- stitutive nuclear lamina-genome interactions are highly conserved and associated with A/T-rich sequence.Genome Res 2013; 23:270-80; PMID:23124521; http://dx.doi.org/10.1101/gr.141028.112 [5] Kind J, Pagie L, Ortabozkoyun H, Boyle S, de Vries SS, Janssen H, Amendola M, Nolen LD, Bickmore WA, vanSteensel B. Single-cell dynamics of genome-nuclear lam-ina interactions.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Cell 2013; 153:178-92; PMID:23523135; http://dx.doi.org/10.1016/j.cell.2013.02.028 [6] Kind J, van Steensel B. Genome-nuclear lamina interac- tions and gene regulation.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Curr Opin Cell Biol 2010;22:320-5; PMID:20444586; http://dx.doi.org/10.1016/j.ceb.2010.04.002 [7] Lund E, Oldenburg A, Delbarre E, Freberg C, Duband-Goulet I, Eskeland R, Buendia B, Collas P.Lamin A/C-promoter interactions specify chromatin state-dependent transcription outcomes.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Genome Res 2013; 23(10):1580-9; PMID:23861385; http://dx.doi.org/10.1101/gr.159400.113 [8] Pickersgill H, Kalverda B, de Wit E, Talhout W, Fornerod M, van Steensel B.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Nat Genet2006; 38:1005-14; PMID:16878134; http://dx.doi.org/10.1038/ng1852 [9] Kubben N, Voncken JW, Konings G, van Weeghel M, van den Hoogenhof MM, Gijbels M, van Erk A, Schoon-derwoerd K, van den Bosch B, Dahlmans V, et al.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Post-natal myogenic and adipogenic developmental: defectsand metabolic impairment upon loss of A-type lamins.Nucleus 2011; 2:195-207; PMID:21818413; http://dx.doi.org/10.4161/nucl.2.3.15731 [10] Stewart C, Burke B. Teratocarcinoma stem cells and early mouse embryos contain only a single major lamin poly- peptide closely resembling lamin B.",Non-OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Cell 1987; 51:383-92;PMID:3311384; http://dx.doi.org/10.1016/0092-8674(87)90634-9 [11] Swift J, Ivanovska IL, Buxboim A, Harada T, Dingal PC, Pinter J, Pajerowski JD, Spinler KR, Shin JW, Tewari M,et al.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Science 2013; 341:1240104; PMID:23990565; http://dx.doi.org/10.1126/science.1240104 [12] Haque F, Lloyd DJ, Smallwood DT, Dent CL, Shana- han CM, Fry AM, Trembath RC, Shackleton S. SUN1interacts with nuclear lamin A and cytoplasmicnesprins to provide a physical connection between the nuclear lamina and the cytoskeleton.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Mol Cell Biol 2006; 26:3738-51; PMID:16648470; http://dx.doi.org/10.1128/MCB.26.10.3738-3751.2006 [13] Hozak P, Sasseville AM, Raymond Y, Cook PR.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"J Cell Sci 1995; 108(Pt 2):635-44; PMID:7769007 [14] Kolb T, Maass K, Hergt M, Aebi U, Herrmann H. Lamin A and lamin C form homodimers and coexist in higher complex forms both in the nucleoplasmicfraction and in the lamina of cultured human cells.Nucleus 2011; 2:425-33; PMID:22033280; http://dx.doi.org/10.4161/nucl.2.5.17765 [15] Naetar N, Foisner R. Lamin complexes in the nuclear interior control progenitor cell proliferation and tissuehomeostasis.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Cell Cycle 2009; 8:1488-93; PMID:19377295; http://dx.doi.org/10.4161/cc.8.10.8499 [16] Lehner CF, Furstenberger G, Eppenberger HM, Nigg EA.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"J Cell Biol 2000; 151:1155-68; PMID:11121432; http://dx.doi.org/10.1083/jcb.151.6.1155 [18] Dechat T, Vlcek S, Foisner R. Review: lamina-associated polypeptide 2 isoforms and related proteins in cell cycle-dependent nuclear structure dynamics.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"J Struct Biol2000; 129:335-45; PMID:10806084; http://dx.doi.org/10.1006/jsbi.2000.4212 [19] Dechat T, Korbei B, Vaughan OA, Vlcek S, Hutchison CJ, Foisner R. Lamina-associated polypeptide 2alpha bindsintranuclear A-type lamins.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Circ Res 2010;106:346-53; PMID:19926876; http://dx.doi.org/10.1161/CIRCRESAHA.109.205724 [22] Gotic I, Schmidt WM, Biadasiewicz K, Leschnik M, Spilka R, Braun J, Stewart CL, Foisner R. Loss of LAP2alpha delays satellite cell differentiation and affects post- natal ﬁber-type determination.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Stem Cells 2010; 28:480- 8; PMID:20039368; http://dx.doi.org/10.1002/stem.292 [23] Markiewicz E, Ledran M, Hutchison CJ.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"J Cell Sci 2005;118:409-20; PMID:15654018; http://dx.doi.org/10.1242/ jcs.01630 [24] Gesson K, Vidak S, Foisner R. Lamina-associated poly- peptide (LAP)2alpha and nucleoplasmic lamins in adultstem cell regulation and disease.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Semin Cell Dev Biol2014; 29:116-24; PMID:24374133; http://dx.doi.org/10.1016/j.semcdb.2013.12.009 [25] Kind J, van Steensel B. Stochastic genome-nuclear lamina interactions: Modulating roles of Lamin A and BAF.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
Nucleus 2014; 5:124-30; PMID:24717229; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Annu Rev Genet 2012; 46:561-89;PMID:22994356; http://dx.doi.org/10.1146/annurev-genet-110711-155603 [27] Luis NM, Morey L, Di Croce L, Benitah SA.",Non-OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
Cell Stem Cell 2012; 11:16-21; PMID:22770239; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Nature 2011; 469:343-9;PMID:21248841; http://dx.doi.org/10.1038/nature09784 [29] Cheutin T, Cavalli G. Polycomb silencing: from linear chromatin domains to 3D chromosome folding.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"PLoS Genet2012; 8:e1002465; PMID:22275876; http://dx.doi.org/10.1371/journal.pgen.1002465 [31] Bantignies F, Roure V, Comet I, Leblanc B, Schuetten- gruber B, Bonnet J, Tixier V, Mas A, Cavalli G. Polycomb- Dependent Regulatory Contacts between Distant Hox Loci in Drosophila.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Cell 2011; 144:214-26; PMID:21241892;http://dx.doi.org/10.1016/j.cell.2010.12.026 [32] Lanzuolo C, Lo Sardo F, Orlando V. Concerted epigenetic signatures inheritance at PcG targets through replication.Cell Cycle 2012; 11:1296-300; PMID:22421150; http://dx.doi.org/10.4161/cc.19710 [33] Lanzuolo C, Roure V, Dekker J, Bantignies F, Orlando V. Polycomb response elements mediate the formation of chromosome higher-order structures in the bithoraxcomplex.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Nat Cell Biol 2007; 9:1167-74; PMID:17828248;http://dx.doi.org/10.1038/ncb1637 [34] Lo Sardo F, Lanzuolo C, Comoglio F, De Bardi M, Paro R, Orlando V. PcG-mediated higher-orderchromatin structures modulate replication programsat the drosophila BX-C. PLoS Genet 2013; 9: e1003283; PMID:23437006; http://dx.doi.org/10.1371/ journal.pgen.1003283110 F. MARULLO ET AL.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Nat Genet 2015; 47:1179-86; PMID:26323060; http://dx.doi.org/10.1038/ng.3393 [36] Tolhuis B, Blom M, Kerkhoven RM, Pagie L, Teunissen H, Nieuwland M, Simonis M, de Laat W, van Lohuizen M, van Steensel B. Interactions among Polycombdomains are guided by chromosome architecture.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"PLoSGenet 2011; 7:e1001343; PMID:21455484; http://dx.doi.org/10.1371/journal.pgen.1001343 [37] Wani AH, Boettiger AN, Schorderet P, Ergun A, Munger C, Sadreyev RI, Zhuang X, Kingston RE, Francis NJ.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Nat Commun 2016; 7:10291; PMID:26759081; http://dx.doi.org/10.1038/ncomms10291 [38] Cesarini E, Mozzetta C, Marullo F, Gregoretti F, Gargiulo A, Columbaro M, Cortesi A, Antonelli L, Di Pelino S,Squarzoni S, et al.",Non-OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"J Cell Biol 2015; 211:533-51; PMID:26553927;http://dx.doi.org/10.1083/jcb.201504035 [39] Gesson K, Rescheneder P, Skoruppa MP, von Haeseler A, Dechat T, Foisner R. A-type lamins bind both hetero-and euchromatin, the latter being regulated by lamina-associated polypeptide 2alpha.",Non-OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Genes Dev 2004; 18:2627-38; PMID:15520282;http://dx.doi.org/10.1101/gad.1241904 [41] Capanni C, Del Coco R, Squarzoni S, Columbaro M, Mattioli E, Camozzi D, Rocchi A, Scotlandi K, Mar-aldi N, Foisner R, et al.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Exp Cell Res 2008; 314:3628-37; PMID:18951892; http://dx.doi.org/ 10.1016/j.yexcr.2008.09.026 [42] Boettiger AN, Bintu B, Mof ﬁtt JR, Wang S, Beliveau BJ, Fudenberg G, Imakaev M, Mirny LA, Wu CT,Zhuang X. Super-resolution imaging reveals distinctchromatin folding for different epigenetic states.Nature 2016; 529(7586):418-22; PMID:26760202;http://dx.doi.org/ 10.1038/nature16496 [43] Lanzuolo C. Epigenetic alterations in muscular disorders.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Comp Funct Genomics 2012; 2012:256892;PMID:22761545; http://dx.doi.org/10.1155/2012/256892 [44] McCord RP, Nazario-Toole A, Zhang H, Chines PS, Z h a nY ,E r d o sM R ,C o l l i n sF S ,D e k k e rJ ,C a oK .C o r -related alterations in genome organization, histonemethylation, and DNA-lamin A/C interactions inHutchinson-Gilford progeria syndrome.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"Genome Res 2013; 23:260-9; PMID:23152449; http://dx.doi.org/ 10.1101/gr.138032.112 [45] Ostlund C, Bonne G, Schwartz K, Worman HJ.",OADS,/arxiv_data1/oa_pdf/68/ef/kncl-07-02-1157675.PMC4916880.pdf
"2, 224 –231 http://dx.doi.org/10.1080/21623945.2016.1148834",Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Cell 2014; 156:20-44; PMID:24439368;http://dx.doi.org/10.1016/j.cell.2013.12.012 2.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Genes Dev 2013;27:234-50; PMID:23388824; http://dx.doi.org/10.1101/ gad.211649.1123.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Cell Metab 2012; 15:222-9; PMID:22326223; http://dx.doi.org/10.1016/j.cmet.2012.01.008 5.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
FEBS Lett 1984; 167:10- 4; PMID:6698197; http://dx.doi.org/10.1016/0014-5793(84)80822-4 6.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Cell Metab 2012; 15:395-404; PMID:22405074; http://dx.doi.org/ 10.1016/j.cmet.2012.01.019 7.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Nature 2012;481:463-8; PMID:22237023; http://dx.doi.org/10.1038/ nature10777 8.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Cell Rep2013; 5:1196-203; PMID:24290753; http://dx.doi.org/ 10.1016/j.celrep.2013.10.044 10.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
"Lo KA, Sun L. Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes.Biosci Rep 2013; 33:711-9; http://dx.doi.org/10.1042/BSR20130046 12.",Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Cell Metab 2015; 21:262-72; PMID:25651180; http://dx.doi.org/10.1016/j.cmet.2015.01.009 15.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Nat Med 2013; 19:1338-44; PMID:23995282; http://dx.doi.org/10.1038/nm.3324 16.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Trends Endocrinol Metab 2015; 20:16-24; http://dx.doi.org/10.1016/j.tem.2008.09.002 18.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Dev Biol 2005; 288:276-83; PMID:16256976; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Sci- ence (80-) 2000; 289:950-3; http://dx.doi.org/10.1126/ science.289.5481.950 20.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Effects of Wnt Signaling on Brown Adipocyte Differentiation and Metab- olism Mediated by PGC-1 a. Mol Cell Biol 2005; 25:1272- 82; PMID:15684380; http://dx.doi.org/10.1128/MCB.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Cancer Res 2013;73:502-7; PMID:23188502; http://dx.doi.org/10.1158/0008-5472.CAN-12-2258 22.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Differentiation 2012; 84:203- 13; PMID:22784633; http://dx.doi.org/10.1016/j.diff.2012.06.004 23.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
J BiolChem 2012; 287:34167-78; PMID:22888000; http://dx.doi.org/10.1074/jbc.M112.381970 24.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Development 2013; 140:2961-71; PMID:23760955; http://dx.doi.org/10.1242/dev.094458 25.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Development 2014; 141:2206-15; PMID:24821987;http://dx.doi.org/10.1242/dev.104976 26.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Wnts are dispensable for differentiation andself-renewal of adult murine hematopoietic stem cells.Blood 2015; 2402:1086-95; http://dx.doi.org/10.1182/ blood-2014-09-598540 27.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Nature 2009; 461:614-20; PMID:19759537; http://dx.doi.org/10.1038/nature 08356 28.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Circ Res 2007; 101:581-9; PMID:17673669; http://dx.doi.org/10.1161/CIRCRESAHA.107.156372 30.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Nature 2011; 480:104-8; PMID:22101429; http://dx.doi.org/10.1038/nature10653 31.,Non-OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
Cell 2014; 157:1292-308; PMID:24906148; http://dx.doi.org/ 10.1016/j.cell.2014.03.066 32.,OADS,/arxiv_data1/oa_pdf/bf/57/kadi-05-02-1148834.PMC4916886.pdf
"2, 98 –118 http://dx.doi.org/10.1080/21623945.2015.1122857",Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Available from: http://www.who.int/mediacentre/fact sheets/fs311/en/ (accessed 1 October 2015) 2.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2013; 17:851-9; PMID:23747244; http://dx.doi.org/10.1016/j.cmet.2013.05.008 3.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell 2012; 148:852-71; PMID:22385956; http://dx.doi.org/10.1016/j.cell.2012.02.017 4.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Gastroenterology 2007; 132:2169-80; PMID:17498510; http://dx.doi.org/10.1053/j.gastro.2007.03.059 5.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell 2010; 140:900-17; PMID:20303879; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabetes 2007; 56:901-11; PMID:17395738; http://dx.doi.org/10.2337/db06-0911 7.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Endocr Rev 2010;31:364-95; PMID:20156986; http://dx.doi.org/10.1210/er.2009-0027 8.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochim Biophys Acta 2010; 1801:338-49; PMID:20056169; http://dx.do i.org/10.1016/j.bbalip.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Clin Invest 2011; 121: 2094-101; PMID:21633177; http://dx.doi.org/10.1172/JCI45887 1 0 .,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Proc Natl Acad Sci U S A 2012; 109:5874-9; PMID:22451920; http://dx.doi.org/ 10.1073/pnas.1200447109 11.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Eur J Nucl Med 2002; 29:1393-8; PMID:12271425; http://dx.doi.org/10.1007/s00259-002- 0902-6ADIPOCYTE 109,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
N Engl J Med 2009;360:1509-17; PMID:19357406; http://dx.doi.org/10.1056/NEJMoa0810780 14.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
N Engl J Med 2009; 360:1518-25; PMID:19357407; http://dx.doi.org/10.1056/NEJMoa0808949 15.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Faseb J 2009; 23:3113-20; PMID: 19417078; http://dx.doi.org/10.1096/fj.09-133546 16.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabetes 2009; 58:1526-31; PMID:19401428; http://dx.doi.org/ 10.2337/db09-0530 17.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
N Engl J Med 2009; 360:1500-8; PMID:19357405;http://dx.doi.org/10.1056/NEJMoa0808718 18.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Free Radic Biol Med 2011; 51:1106-15; PMID:21762777; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2010; 11:253-6; PMID:20374956;http://dx.doi.org/10.1016/j.cmet.2010.03.004 20.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Med 2013; 19:635-9; PMID:23603815; http://dx.doi.org/10.1038/nm.3112 21.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Ann Med 2011; 43:104-15; PMID:21254898; http://dx.doi.org/10.3109/07853890.2010.535557 22.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Rev Drug Discov2010; 9:465-82; PMID:20514071; http://dx.doi.org/10.1038/nrd3138 23.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Med 2015; 21:760-8; PMID:26076036; http://dx.doi.org/10.1038/nm.3881 24.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2013; 17:798-805; PMID:23663743; http://dx.doi.org/10.1016/j.cmet.2013.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Med 2013; 19:631-4;PMID:23603813; http://dx.doi.org/10.1038/nm.3017 26.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
PLoS One 2012; 7:e49452; PMID:23166672; http://dx.doi.org/10.1371/journal.pone.0049452 27.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell 2012; 150:366-76; PMID:22796012; http://dx.doi.org/ 10.1016/j.cell.2012.05.016 28.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell 2007;131:242-56; PMID:17956727; http://dx.doi.org/10.1016/j.cell.2007.10.004 30.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Int J Obes 2011; 36:320-4; PMID:21610697; http://dx.doi.org/10.1038/ijo.2011.101 31.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nature 2014; 510:76-83; PMID:24899307; http://dx.doi.org/10.1038/nature13477 32.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Rev Endocrinol 2014; 10: 24-36; PMID:24146030; http://dx.doi.org/10.1038/ nrendo.2013.204 34.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Adipo- cyte 2014; 3:4-9; PMID:24575363; http://dx.doi.org/10.4161/adip.26232 35.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
U S A 2007; 104:4401-6; PMID:17360536; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab2012; 16:348-62; PMID:2294019 8; http://dx.doi.org/ 10.1016/j.cmet.2012.08.003 37.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Rev Drug Discov2010; 9:465-82; PMID:20514071; http://dx.doi.org/ 10.1038/nrd3138 38.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2015; 22:546-59; PMID:26445512; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Stem Cell 2008; 3:382-8; PMID:18940730; http://dx.doi.org/10.1016/j.stem.2008.09.015 40.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Exp Cell Res 1993; 208:226-31; PMID:8359217; http://dx.doi.org/ 10.1006/excr.1993.1241 42.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2012; 15:480-91; PMID:22482730; http://dx.doi.org/10.1016/j.cmet.2012.03.009] 45.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nature 2013; 495:379-83; PMID:23485971; http://dx.doi.org/ 10.1038/nature11943 46.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cancer Res 2012; 72:4372-82; PMID:22719069; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Toxi- col Appl Pharmacol 2013; 273:456-63; PMID:24141031;http://dx.doi.org/10.1016/j.taap.2013.10.011 49.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2014;20:396-407; PMID:25127354; http://dx.doi.org/10.1016/j.cmet.2014.07.005 50.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nature 2012; 481:463-8; PMID:22237023; http://dx.doi.org/10.1038/nature10777 51.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Clin Invest 2012; 122:1022-36; PMID:22307324; http://dx.doi.org/10.1172/JCI59701 52.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
PLoS One 2013; 8: e74083; PMID:24066098; http://dx.doi.org/10.1371/journal.pone.0074083 53.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2013; 17:638-43; PMID:23583169; http://dx.doi.org/10.1016/j.cmet.2013.02.020 55.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell 2014; 157:1279-91; PMID:24906147; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nature 2006; 439:484-9; PMID:16400329; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2015; 21:33- 8; PMID:25565203; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Genes Dev 2013;27:234-50; PMID:23388824; http://dx.doi.org/10.1101/ gad.211649.112 61.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochim Biophys Acta - Mol Cell Biol Lipids 2013; 1831:969-85; PMID:23246573; http://dx.doi.org/10.1016/j.bbalip.2012.12.002 62.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell 2012; 151:400-13; PMID:23063128; http://dx.doi.org/10.1016/j.cell.2012.09.010 64.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Mol Med (Berl) 2012; 90:887-93; PMID:22231746; http://dx.doi.org/10.1007/s00109-012-0858-3 65.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Med 2011; 17:200-5; PMID:21258337; http://dx.doi.org/10.1038/nm.2297 66.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Am J Physiol Regul Integr Comp Physiol 2009; 296:R1327-35; PMID:19211718; http://dx.doi.org/10.1152/ajpregu.91012.2008 68.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabetes 2005; 54:664-71; PMID:15734841; http://dx.doi.org/10.2337/diabetes.54.3.664 69.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochim Biophys Acta 2013; 1831:934-42; PMID:23228690; http://dx.doi.org/ 10.1016/j.bbalip.2012.11.011 70.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2010; 12:42-52; PMID:20620994; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Involvement of adipose tissues in the early hypolipidemic action of PPARgamma agonism in the rat.Am J Physiol Regul Integr Comp Physiol 2007; 292: R1408-17; PMID:17170230; http://dx.doi.org/10.1152/ ajpregu.00761.2006 73.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Physiol Rev 2010; 90:367-417; PMID:20086080; http://dx.doi.org/10.1152/physrev.00003.2009 74.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochim Biophys Acta 1995; 1259:65-72; PMID:7492617; http://dx.doi.org/10.1016/0005-2760(95) 00147-5 78.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Obesity (Silver Spring) 2010; 18:1398-403; PMID:19893500; http://dx.doi.org/10.1038/oby.2009.412 80.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Curr Opin Lipidol 2007; 18:271-6; PMID:17495600; http://dx.doi.org/10.1097/MOL.0b013e3281338558 81.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nature 2010; 464:917-21; PMID:20228789; http://dx.doi.org/10.1038/ nature08945 82.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
57:1505-16; PMID:24795087; http://dx.doi.org/10.1007/ s00125-014-3255-3 83.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Signal 2006; 18:1360-5; PMID:16716567; http://dx.doi.org/10.1016/j.cellsig.2006.03.011 85.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biotechnol Lett 2009; 31:1695-701;PMID:19565192; http://dx.doi.org/10.1007/s10529-009- 0065-7 89.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
FASEB J 2013; 27:277-87; PMID:23047894; http://dx.doi.org/10.1096/ fj.12-211516 90.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Bio- chem Biophys Res Commun 2013; 441:42-6; PMID:24129192; http://dx.doi.org/10.1016/j.bbrc.2013.10.014 91.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Metabolism 2014; 63:895-902; PMID:24814684; http://dx.doi.org/10.1016/j.metabol.2014.04.003 93.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter.Trends Endocrinol Metab 2011; 22:1-8; PMID:20889351;http://dx.doi.org/10.1016/j.tem.2010.09.002 94.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nature 2012; 484:333-8; PMID:22466288; http://dx.doi.org/10.1038/nature1098695.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Commun 2013; 4:1528; PMID:23443556; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2012;16:189-201; PMID:22863804; http://dx.doi.org/ 10.1016/j.cmet.2012.06.013 100.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biochem 2012; 152:387-95; PMID:22984005; http://dx.doi.org/10.1093/jb/mvs105 101.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Cell Biol 2000; 149:707-18; PMID:10791983; http://dx.doi.org/10.1083/jcb.149.3.707 102.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 1997; 272:31738-46; PMID:9395518; http://dx.doi.org/ 10.1074/jbc.272.50.31738 104.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
FASEB J 2010; 24:4366-77; PMID:20605947; http://dx.doi.org/10.1096/fj.09-152298 105.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2007; 6:484-96; PMID:18054317; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Proc Natl Acad Sci U S A 2002; 99:11482-6; PMID:12177411; http://dx.doi.org/10.1073/ pnas.132384699 107.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Trends Endocrinol Metab 2014; 25:168-77; PMID:24389130; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2012; 287:42921-35; PMID:23124204; http://dx.doi.org/10.1074/jbc.M112.397828 110.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Physiol Rev 2004; 84:277- 359; PMID:14715917; http://dx.doi.org/10.1152/physrev.00015.2003 111.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
P ﬂugers Arch 2005; 449:463-9; PMID:15688247; http://dx.doi.org/10.1007/s00424-004-1353-7 112.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2012; 287:2273-9; PMID:22090029; http://dx.doi.org/10.1074/jbc.R111.309088 113.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Annu Rev Biochem 2012; 81:687-714;PMID:22524315; http://dx.doi.org/10.1146/annurev-biochem-061009-102430 114.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
FEBS Lett 2010;584:2176-82; PMID:20303960; http://dx.doi.org/10.1016/ j.febslet.2010.03.022 115.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem2014; 289:9560-72; PMID:24519944; http://dx.doi.org/10.1074/jbc.M114.547687 116.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Curr Opin Lipidol 2009; 20:121-6; PMID:19276890;http://dx.doi.org/10.1097/MOL.0b013e328328d0bb 117.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Am J Physiol Endocrinol Metab 2009;297(5):E977-86; PMID:19458063; http://dx.doi.org/ 10.1152/ajpendo.00183.2009 118.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nat Genet 2003; 35:49-56; PMID:12910269; http://dx.doi.org/10.1038/ng1225 119.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Mech Ageing Dev 2004; 125:337-8; PMID:15063110; http://dx.doi.org/ 10.1016/j.mad.2004.01.002 120.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
EMBO J 2008; 27:1537-48; PMID:18480843; http://dx.doi.org/10.1038/ emboj.2008.92 121.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochem Biophys Res Commun 2009; 387:294-9; PMID:19577538; http://dx.doi.org/10.1016/j.bbrc.2009.06.147 122.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2014; 289:12029-39; PMID:24627478; http://dx.doi.org/10.1074/jbc.M113.539890 123.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2007; 282:34213-8; PMID:17884815; http://dx.doi.org/10.1074/jbc.M707404200 124.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Prog Lipid Res 2009; 48:275-97; PMID:19464318; http://dx.doi.org/10.1016/ j.plipres.2009.05.001 126.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase.Science 2004; 306:1383-6; PMID:15550674; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2004; 279:47066-75; PMID:15337759; http://dx.doi.org/ 10.1074/jbc.M403855200 128.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Lipid Res 2009;50:3-21; PMID:18952573; http://dx.doi.org/10.1194/jlr.R800031-JLR200 130.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Prog Lipid Res 2011; 50:14-27; PMID:21087632; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2006; 3:309-19; PMID:16679289; http://dx.doi.org/10.1016/j.cmet.2006.03.005 132.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2010; 11:194- 205; PMID:20197052; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Science 2006; 312:734-7; PMID:16675698; http://dx.doi.org/ 10.1126/science.1123965 134.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Genomics 2008; 92:26-32; PMID:18572100; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2011; 13:739-48; PMID:21641555; http://dx.doi.org/10.1016/j.cmet.2011.05.002 137.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2012; 287:25038-48; PMID:22685301; http://dx.doi.org/10.1074/jbc.M112.374041 138.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Annu Rev Nutr 2000; 20:365-93; PMID:10940339; http://dx.doi.org/10.1146/annurev.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biosci Rep 1987; 7:897-904;PMID:3329536; http://dx.doi.org/10.1007/BF01119481 141.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2009;284:32116-25; PMID:19717842; http://dx.doi.org/10.1074/jbc.M109.006726 144.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochem Soc Trans 2003;31:1120; PMID:14641008; http://dx.doi.org/10.1042/ bst0311120 145.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
PLoS One 2008; 3:e1793; PMID:18335062; http://dx.doi.org/10.1371/journal.pone.0001793 147.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2000; 275:5011-5; PMID:10671541;http://dx.doi.org/10.1074/jbc.275.7.5011 151.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2007; 282:5726-35; PMID:17189257; http://dx.doi.org/ 10.1074/jbc.M610580200 152.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
L ife Sci 2005; 77:435-43; PMID:15894012; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2009; 9:203-9; PMID:19187776; http://dx.doi.org/10.1016/j.cmet.2008.12.014 154.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Endocrinol 2012; 214:359-65; PMID:22728333; http://dx.doi.org/10.1530/JOE-12-0155 155.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Nature 1979; 281:31-5;PMID:551265; http://dx.doi.org/10.1038/281031a0 156.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2010; 12:53-64; PMID:20620995; http://dx.doi.org/10.1016/j.cmet.2010.05.012 160.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Annu Rev Bio-chem 1980; 49:395-420; PMID:6157353; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabetes Metab Rev 1989; 5:271-84; PMID:2656156; http://dx.doi.org/10.1002/ dmr.5610050305 162.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
FEBS Lett 1995;363:41-5; PMID:7729550; http://dx.doi.org/10.1016/ 0014-5793(95)00277-G 165.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochem J 1997; 327 ( Pt1):225-31; PMID:9355756; http://dx.doi.org/10.1042/ bj3270225 167.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2008; 283:6878-85; PMID:18192268; http://dx.doi.org/10.1074/jbc.M707965200 168.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Proc Natl Acad Sci U S A 2011;108:9691-6; PMID:21593415; http://dx.doi.org/ 10.1073/pnas.1103267108 169.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabetes 2013; 62:2329- 37; PMID:23493572; http://dx.doi.org/10.2337/db12-1451 170.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
BiochimBiophys Acta - Protein Struct Mol Enzymol 2001; 1546:21-43; PMID:11257506; http://dx.doi.org/10.1016/ S0167-4838(01)00147-9 171.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Biochem J 1998; 241:233-41; PMID:9693125; http://dx.doi.org/10.1042/bj3340233 172.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2003; 278:9058-63; PMID:12499375; http://dx.doi.org/10.1074/jbc.M209999200 174.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Mol Genet Metab 2008; 93:314-22; PMID:18023382; http://dx.doi.org/10.1016/j.ymgme.2007.10.006 175.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Bio-chem J 1988; 252:293-6; PMID:3421907; http://dx.doi.org/10.1042/bj2520293 176.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Rep 2015; 10:266- 79; PMID:25578732; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabe- tes 2009; 58:550-8; PMID:19073774; http://dx.doi.org/ 10.2337/db08-1078 179.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Biol Chem 2004; 279:27177-86; PMID:15105415;http://dx.doi.org/10.1074/jbc.M403566200 180.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Hepatology 2011; 53:821-32; PMID:21319201; http://dx.doi.org/10.1002/hep.24140 182.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Hepatol 2012; 56:632-9; PMID:22037024; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabetologia 2014; 57:1067-77; PMID:24488024; http://dx.doi.org/10.1007/s00125-014-3173-4 185.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Bio- chem J 2011; 435:723-32; PMID:21348853; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Am J Physiol Endocrinol Metab 2015; 308:E756-69; PMID:25714670; http://dx.doi.org/10.1152/ ajpendo.00362.2014 187.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Dia-betes 2005; 54:462-71; PMID:15677504; http://dx.doi.org/10.2337/diabetes.54.2.462 188.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
PLoS One 2014; 9:e97195; PMID:24819600; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Proc Natl Acad Sci U S A 1984; 81:4203-7; PMID:6588384; http://dx.doi.org/ 10.1073/pnas.81.13.4203 191.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
J Histochem Cytochem 1971; 19:670-5; PMID:4107748; http://dx.doi.org/10.1177/19.11.670 193.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2014;19:380-92; PMID:24508507; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Diabetes Care 2005; 28:475-80; PMID:15677820;http://dx.doi.org/10.2337/diacare.28.2.475 195.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Neurogastroen- terol Motil 2013; 25:e70-9; PMID:23095091; http://dx.doi.org/10.1111/nmo.12034 196.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2015; 22:228-38; PMID:26244932;http://dx.doi.org/10.1016/j.cmet.2015.07.009 197.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Expert Opin Investig Drugs 2014; 23:1055- 66; PMID:25000213; http://dx.doi.org/10.1517/ 13543784.2014.918952 199.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Expert Opin Drug Saf 2012; 11:459-71; PMID:22439841; http://dx.doi.org/10.1517/14740338.2012.675326 201.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Obes (Silver Spring) 2012; 20:1426-36; PMID:22421927; http://dx.doi.org/10.1038/oby.2012.66 202.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Recent Pat Endocr Metab Immune DrugDiscov 2012; 6:117-28; PMID:22435392; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Available from: http://www.ema.europa.eu/docs/en_GB/documen t_library/Medicine_QA/2013/05/WC500143811.pdf 204.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ ucm413318.pdf 205.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Press_release/2015/01/WC500180857.pdf 206.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
"Endocrinol Metab (Seoul, Korea) 2014; 29:410-7; PMID:25559569; http://dx.doi.org/10.3803/ EnM.2014.29.4.410 207.",Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Drug Des Devel Ther 2014; 8:1419-27; PMID:25258511; http://dx.doi.org/10.2147/DDDT.S55587 208.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Medscape 2015; Available from: http://emedicine.medscape.com/article/123702-medication 209.,Non-OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab2013; 18:118-29; PMID:23823482; http://dx.doi.org/ 10.1016/j.cmet.2013.06.003 211.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
NatCommun 2015; 6:6356; PMID:25754609; http://dx.doi.org/10.1038/ncomms7356 212.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
Cell Metab 2012;15:595-605; PMID:22560212; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/62/kadi-05-02-1122857.PMC4916887.pdf
"1, 50 –67 http://dx.doi.org/10.1080/19491034.2016.1150392",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Oncotarget 2015; 6:10697- 711; PMID:25986923; http://dx.doi.org/10.18632/ oncotarget.4037 [2] Ajani JA, Song S, Hochster HS, Steinberg IB.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Semin Oncol 2015;42 Suppl 1:S3-17; PMID:25839664; http://dx.doi.org/10.1053/j.seminoncol.2015.01.001 [3] Ailles LE, Weissman IL.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Curr Opin Biotechnol 2007; 18:460-6; PMID:18023337; http://dx.do i.org/10.1016/j.copbio.,OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Breast Cancer Res Treat 2013;142:237-55; PMID:24162158; http://dx.doi.org/10.1007/ s10549-013-2743-364 K. HARDY ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"[5] Visvader JE, Stingl J. Mammary stem cells and the differ- entiation hierarchy: current status and perspectives.Genes Dev 2014; 28:1143-58; PMID:24888586; http://dx.doi.org/10.1101/gad.242511.114 [6] Maruyama R, Choudhury S, Kowalczyk A, Bessarabova M, Beresford-Smith B, Conway T, Kaspi A, Wu Z, NikolskayaT, Merino VF, et al.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"PLoS Genet 2011; 7:e1001369; PMID:21533021;http://dx.doi.org/10.1371/journal.pgen.1001369 [7] Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, PolyakK, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Proc Natl Acad Sci US A 2011; 108:7950-5; PMID:21498687; http://dx.doi.org/ 10.1073/pnas.1102454108 [8] Nieto MA.,OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Ann Rev CellDev Biol 2011; 27:347-76; PMID:21740232; http://dx.doi.org/10.1146/annurev-cellbio-092910-154036 [9] Thiery JP, Acloque H, Huang RY, Nieto MA.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Epithelial- mesenchymal transitions in development and disease.Cell 2009; 139:871-90; PMID:19945376; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"PloS One2008; 3:e2888; PMID:18682804; http://dx.doi.org/10.1371/journal.pone.0002888 [11] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Nat Rev Mol Cell Biol 2014; 15:178-96; PMID:24556840; http://dx.doi.org/ 10.1038/nrm3758 [12] Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3 0 kinase/AKT pathways.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Oncogene 2005; 24:7443-54;PMID:16288291; http://dx.doi.org/10.1038/sj.onc.1209091 [13] Weber CE, Li NY, Wai PY, Kuo PC.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"J Burn Care Res: Off Pub Am Burn Assoc 2012; 33:311-8; PMID:22561306;http://dx.doi.org/10.1097/BCR.0b013e318240541e [14] Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Put- ney JW Jr., Goodhill GJ, Thompson EW, Roberts-Thom-son SJ, Monteith GR.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Oncogene 2014; 33:2307-16; PMID:23686305; http://dx.doi.org/10.1038/onc.2013.187 [15] Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H,Grunert S. Autocrine PDGFR signaling promotes mam-mary cancer metastasis.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"J Clin Investigat 2006; 116:1561-70; PMID:16741576; http://dx.doi.org/10.1172/JCI24652 [16] Malaguarnera R, Bel ﬁore A.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Front Endocrinol 2014; 5:10; PMID:24550888; http://dx.doi.org/10.3389/fendo.2014.00010[17] Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progres-sion.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Curr Opin Oncol 2013; 25:76-84; PMID:23197193;http://dx.doi.org/10.1097/CCO.0b013e32835b6371 [18] Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells.,Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"J Clin Investigat 2009; 119:1417-9; PMID:19487817; http://dx.doi.org/10.1172/JCI39675 [19] Chaffer CL, Weinberg RA.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Science (New Yo rk, NY) 2011; 331:1559-64; PMID:21436443; http://dx.doi.org/10.1126/science.1203543 [20] Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Mol Cell Biol 2014; 34:2961-80; PMID:24891615;http://dx.doi.org/10 .1128/MCB.01693-13 [22] Waki H, Nakamura M, Yamauchi T, Wakabayashi K, Yu J, Hirose-Yotsuya L, Take K, Sun W, Iwabu M, Okada- Iwabu M, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"PLoS Genet2011; 7:e1002311; PMID:22028663; http://dx.doi.org/10.1371/journal.pgen.1002311 [23] Murtha M, Strino F, Tokcaer-Keskin Z, Sumru Bayin N, Shalabi D, Xi X, Kluger Y, Dailey L. Comparative FAIRE- seq analysis reveals distinguishing features of the chro- matin structure of ground state- and primed-pluripotentcells.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Stem Cells (Dayton, Ohio) 2015; 33:378-91;PMID:25335464; http://dx.doi.org/10.1002/stem.1871 [24] Davie K, Jacobs J, Atkins M, Potier D, Christiaens V, Halder G, Aerts S. Discovery of transcription factors andregulatory regions driving in vivo tumor development byATAC-seq and FAIRE-seq open chromatin pro ﬁling.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"GenomicsData 2015; 3:28-32; PMID:26484144; http://dx.doi.org/10.1016/j.gdata.2014.11.002 [26] Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Nature 2011; 473:43-9;PMID:21441907; http://dx.doi.org/10.1038/nature09906 [27] Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. Recon ﬁguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation ofenhancers and insulators in cancer.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Genome Res 2014; 24:1421-32; PMID:24916973; http://dx.doi.org/10.1101/ gr.163485.113NUCLEUS 65,OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Curr Opin Genet Dev2014; 24:8-15; PMID:24657531; http://dx.doi.org/10.1016/j.gde.2013.10.011 [29] Witte S, O ’Shea JJ, Vahedi G. Super-enhancers: Asset management in immune cell genomes.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Trends Immunol2015; 36:519-26; PMID:26277449; http://dx.doi.org/ 10.1016/j.it.2015.07.005 [30] Romanoski CE, Link VM, Heinz S, Glass CK.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Cancer Res 2011; 71:3076-86; PMID:21346143; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Cell 2013; 152:327-39; PMID:23332764; http://dx.doi.org/10.1016/j.cell.2012.12.009 [35] Poletti V, Delli Carri A, Malagoli Tagliazucchi G, Faedo A, Petiti L, Mazza EM, Peano C, De Bellis G, Bicciato S, MiccioA, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Nature 2009; 459:108-12; PMID:19295514; http://dx.doi.org/10.1038/nature07829 [37] Rhie SK, Hazelett DJ, Coetzee SG, Yan C, Noushmehr H, Coetzee GA. Nucleosome positioning and histone modi-ﬁcations de ﬁne relationships between regulatory ele- ments and nearby gene expression in breast epithelialcells.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"BMC Genomics 2014; 15:331; PMID:24885402;http://dx.doi.org/10.1186/1471-2164-15-331 [38] Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"PloS One2014; 9:e88950; PMID:24658684; http://dx.doi.org/ 10.1371/journal.pone.0088950 [39] Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, Smit MA, Geiger TR, Laoukili J, Iskit S,et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Proc Natl Acad Sci U S A 2013; 110:5139-44; PMID:23483055; http://dx.doi.org/ 10.1073/pnas.1222085110 [40] Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Rein- hardt F, Wu ZJ, Krall JA, Bierie B, Guo W, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"CancerCell 2013; 24:347-64; PMID:24029232; http://dx.doi.org/10.1016/j.ccr.2013.08.005 [41] Biddie SC, John S, Sabo PJ, Thurman RE, Johnson TA, Schiltz RL, Miranda TB, Sung MH, Trump S, LightmanSL, et al.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"MolCell 2011; 43:145-55; PMID:21726817; http://dx.doi.org/10.1016/j.molcel.2011.06.016 [42] Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"J Sci 2004; 117:5965-73; PMID:15564374; http://dx.doi.org/10.1242/ jcs.01589 [43] Kim M, Kim T, Johnson RL, Lim DS.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Cell Rep 2015; 11:270-82; PMID:25843714; http://dx.doi.org/10.1016/j .celrep.2015.03.015 [44] Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A ,F r a s s o nC ,I n u iM ,M o n t a g n e rM ,P a r e n t iA R ,P o l e t t iA , et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Cell 2011; 147:759-72;PMID:22078877; http://dx.doi.org/10.1016/j.cell.2011.09.048 [45] Hiemer SE, Szymaniak AD, Varelas X.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"The transcriptional regulators TAZ and YAP direct transforming growth factorbeta-induced tumorigenic phenotypes in breast cancer cells.J Biol Chem 2014; 289:13461-74; PMID:24648515; http://dx.doi.org/10.1074/jbc.M113.529115 [46] Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M, Imamura T, Miyazono K,Aburatani H. Chromatin immunoprecipitation on micro-array analysis of Smad2/3 binding sites reveals roles ofETS1 and TFAP2A in transforming growth factor betasignaling.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Mol Cell Biol 2009; 29:172-86; PMID:18955504;http://dx.doi.org/10.1128/MCB.01038-08 [47] Cyr AR, Kulak MV, Park JM, Bogachek MV, Spanheimer PM, Wood ﬁeld GW, White-Baer LS, O ’Malley YQ, Sugg SL, Olivier AK, et al.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Forkhead factors regu- late epithelial plasticity: impact on cancer progression.Cell Cycle 2011; 10:2454-60; PMID:21685726; http://dx.doi.org/10.4161/cc.10.15.16306 [49] Zaret KS, Carroll JS.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"25:2227-41; PMID:22056668; http://dx.doi.org/10.1101/ gad.176826.111 [50] Vernimmen D, Bickmore WA.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"The hierarchy of tran- scriptional activation: from enhancer to promoter.Trends Genet: TIG 2015; 31:696-708; PMID:26599498;http://dx.doi.org/10.1016/j.tig.2015.10.004 [51] Myatt SS, Lam EW.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Nat Rev Cancer 2007; 7:847-59; PMID:17943136; http://dx.doi.org/10.1038/nrc2223 [52] Saunders LR, McClay DR. Sub-circuits of a gene regula- tory network control a developmental epithelial-mesen-chymal transition.",Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Development (Cambridge, England)2014; 141:1503-13; PMID:24598159; http://dx.doi.org/10.1242/dev.101436 [53] Simon JM, Giresi PG, Davis IJ, Lieb JD.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Mol Cell Biol2009; 29:1972-86; PMID:19158270; http://dx.doi.org/ 10.1128/MCB.01590-08[55] Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.,Non-OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Nat Methods 2012; 9:357-9;PMID:22388286; http://dx.doi.org/10.1038/nmeth.1923 [57] Zang C, Schones DE, Zeng C, Cui K, Zhao K, Peng W. A clustering approach for identi ﬁcation of enriched domains from histone modi ﬁcation ChIP-Seq data.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Bio- informatics 2009; 25:1952-8; PMID:19505939; http://dx.doi.org/10.1093/bioinformatics/btp340 [58] Anders S, Pyl PT, Huber W. HTSeq –a Python framework to work with high-throughput sequencing data.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Bioinfor-matics 2015; 31:166-9; PMID:25260700; http://dx.doi.org/10.1093/bioinformatics/btu638 [59] Frith MC, Fu Y, Yu L, Chen JF, Hansen U, Weng Z.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"Nucleic Acids Res 2004; 32:1372-81;PMID:14988425; http://dx.doi.org/10.1093/nar/gkh299 [60] Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukary-otic transcription factor binding pro ﬁles.",OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
Nucleic Acids Res 2004; 32:D91-4; PMID:14681366; http://dx.doi.org/ 10.1093/nar/gkh012NUCLEUS 67,OADS,/arxiv_data1/oa_pdf/a7/74/kncl-07-01-1150392.PMC4916893.pdf
"2, 232 –237 http://dx.doi.org/10.1080/21623945.2015.1120913",Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Nat Rev Mol Cell Biol 2006; 7:885-96; PMID:17139329; http://dx.doi.org/10.1038/nrm2066 3.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Nat Med 2013; 19:1252-63; PMID:24100998; http://dx.doi.org/10.1038/ nm.3361 4.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Nat Rev Mol Cell Biol 2008; 9:367-77;PMID:18401346; http://dx.doi.org/10.1038/nrm2391 6.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Sci- ence 2009; 326:1220-4; PMID:19965465; http://dx.doi.org/ 10.1126/science.1175668 7.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
EMBO J 2012; 31:3991-4004; PMID:22940692; http://dx.doi.org/10.1038/emboj.2012.244 8.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
J Biol Chem 2011; 286:28403-13; PMID:21700709; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Nat Med 2011; 17:179-88; PMID:21217695; http://dx.doi.org/10.1038/ nm.2279 10.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Trends Cell Biol 2009; 19:16-23; PMID:19027299; http://dx.doi.org/10.1016/j.tcb.2008.10.003 11.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Mol Diagn Ther 2009; 13:225-44; PMID:19712003; http://dx.doi.org/10.1007/BF03256329 12.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Expert Opin Ther Targets 2010; 14:1343-54; PMID:21058923; http://dx.doi.org/10.1517/14728222.2010.531011 13.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Cell 1997; 91:961-71; PMID:9428519; http://dx.doi.org/ 10.1016/S0092-8674(00)80487-0 14.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Annu Rev Pharmacol Toxicol 2000; 40:617-47; PMID:10836149; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
PloS one 2013; 8:e54491; PMID:23359526; http://dx.doi.org/ 10.1371/journal.pone.0054491 16.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Diabetologia 2013; 56:825-37; PMID:23354124; http://dx.doi.org/10.1007/s00125-012-2820-x 17.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Autophagy 2011; 7:240-2; PMID:21135576; http://dx.doi.org/10.4161/auto.7.2.14286 18.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
J Neurosci 2014;34:12168-81; PMID:25186760; http://dx.doi.org/ 10.1523/JNEUROSCI.2513-13.2014 22.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Genes Dev 2010; 24:1614-9; PMID:20679397; http://dx.doi.org/10.1101/gad.1942810 23.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Science 2005; 309:1074-8; PMID:16099986; http://dx.doi.org/10.1126/ science.1110955 24.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Nat Med 2013; 19:1338-44;PMID:23995282; http://dx.doi.org/10.1038/nm.3324 25.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Cell 2008; 135:240-9; PMID:18835024; http://dx.doi.org/10.1016/j.cell.2008.09.036 26.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Nat Cell Biol 2014; 16:367-75; PMID:24609269; http://dx.doi.org/ 10.1038/ncb2922 27.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Nat Cell Biol 2015; 17:1099-111; PMID:26280538; http://dx.doi.org/10.1038/ncb3217 28.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Cell Rep 2014;7:1443-55; PMID:24857652; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Cell Metab 2012; 16:723-37; PMID:23217255; http://dx.doi.org/10.1016/j.cmet.2012.10.019 3 0 .,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
N Engl J Med 2015; 373:895-907; PMID:262877 46; http://dx.doi.org/ 10.1056/NEJMoa1502214 3 1 .,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Biochemistry 1999; 38:15673-80;PMID:10569954; http://dx.doi.org/10.1021/bi9914255 33.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
J Biol Chem 2013; 288:16403-15;PMID:23615913; http://dx.doi.org/10.1074/jbc.M113.474593 34.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
J Biol Chem 1997; 272:25267-74; PMID:9312143; http://dx.doi.org/10.1074/jbc.272.40.25267 35.,Non-OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Cell Metab 2011; 13:68-79; PMID:21195350; http://dx.doi.org/10.1016/j.cmet.2010.12.005 36.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
J BiolChem 2006; 281:29174-80; PMID:16880201; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Cell 1999; 96:857-68; PMID:10102273; http://dx.doi.org/10.1016/S0092-8674 (00)80595-4 38.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Dev cell 2003; 4:119-29;PMID:12530968; http://dx.doi.org/10.1016/S1534-5807(02)00401-X 39.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Hum Mol Genet 2014; 23:502- 13; PMID:24026679; http://dx.doi.org/10.1093/hmg/ ddt444 40.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
Cell Metab 2011;13:739-48; PMID:21641555; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
J Biol Chem 2009; 284:13296-300; PMID:19297333; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/a3/13/kadi-05-02-1120913.PMC4916895.pdf
"2, 136 –152 http://dx.doi.org/10.1080/21623945.2016.1187345",Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Eur J Bio- chem FEBS 1978; 82:515-21; http://dx.doi.org/10.1111/ j.1432-1033.1978.tb12045.x 3.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem Biophys ResCommun 1976; 73:577-83; PMID:1008874; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2014; 20:433-47; PMID:25043816; http://dx.doi.org/10.1016/j.cmet.2014.06.011 6.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Tissue Res 1991; 266:149-61; PMID:1747909; http://dx.doi.org/ 10.1007/BF00678721 8.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2010; 285:7153- 64; PMID:20028987; http://dx.doi.org/10.1074/jbc.M109.053942 9.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Am J Physiol Endocrinol Metab 2012; 302:E19-31; http://dx.doi.org/ 10.1152/ajpendo.00249.2011 10.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell 2012; 150:366-76;PMID:22796012; http://dx.doi.org/10.1016/j.cell.2012.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Obes Rev Off J Int Assoc Study Obes2012; 13 Suppl 2:83-96; http://dx.doi.org/10.1111/j.1467- 789X.2012.01039.x 12.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nat Rev Endocrinol 2014; 10:24-36; PMID:24146030; http://dx.do i.org/10.1038/nrendo.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
NatMed 2015; 21:389-94; PMID:25774848; http://dx.doi.org/ 10.1038/nm.3819 14.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2007; 6:38-54; PMID:17618855; http://dx.doi.org/10.1016/j.cmet.2007.06.001 16.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2003;278:33370-6; PMID:12807871; http://dx.doi.org/10.1074/ jbc.M305235200 17.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
FEBS J 2015; 282:647-72; PMID: 25495651; http://dx.doi.org/10.1111/febs.13175 18.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Ablation of PRDM16 and beige adipose causes metabolicdysfunction and a subcutaneous to visceral fat switch.Cell 2014; 156:304-16; PMID:24439384; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2011; 14:658-70;PMID:21982742; http://dx.doi.org/10.1016/j.cmet.2011.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol Cell 2015; 57:235-46; PMID:25578880;http://dx.doi.org/10.1016/j.molcel.2014.12.005 21.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol Endocrinol Baltim Md 2014; 28:344-56;http://dx.doi.org/10.1210/me.2013-1254 22.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
NatCommun 2013; 4:1769; PMID:23612310; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Stem Cells Dayt Ohio 2014; 32:1578-90; http://dx.doi.org/10.1002/ stem.1603 24.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Endocrinology 2013; 154:3141-51; PMID:23751871; http://dx.doi.org/10.1210/en.2012-1873 25.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
N Engl J Med 2015;373:895-907; PMID:26287746; http://dx.doi.org/10.1056/ NEJMoa1502214 26.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Clin Invest 2016; 126(5):1897-910[cited2016 Apr 26]; PMID:27064284; http://dx.doi.org/10.1172/JCI85526 27.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell 2015; 163:1360-74; PMID:26638070; http://dx.doi.org/10.1016/ j.cell.2015.11.004 31.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Microbiota depletion promotesbrowning of white adipose tissue and reduces obesity.Nat Med 2015; 21:1497-501; http://dx.doi.org/10.1038/ nm.3994 32.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Life Sci 2015; 139:153-9; PMID:26281919; http://dx.doi.org/10.1016/j.lfs.2015.07.030 33.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Rep 2015; 13:1538-44; PMID:26586436; http://dx.doi.org/10.1016/j.celrep.2015.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
"Am J Physiol Regul Integr Comp Physiol 2011; 300:R1115-1125; PMID:21368268; http://dx.doi.org/10.1152/ajpregu.00806.2010 3 6 .C a oL ,C h o iE Y ,L i uX ,M a r t i nA ,W a n gC ,X uX , During MJ.",Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2011; 14:324-38; PMID:21907139; http://dx.doi.org/10.1016/ j.cmet.2011.06.020 37.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Genes Dev2012; 26:271-81; PMID:22302939; http://dx.doi.org/ 10.1101/gad.177857.111 39.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem J 2016; 473(6):685-92; PMID:26769382; http://dx.doi.org/10.1042/ BJ20150808 40.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2015; 21:731-8; http://dx.doi.org/ 10.1016/j.cmet.2015.04.019 41.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol Metab 2016; 5:79-90; PMID:26909316; http://dx.doi.org/ 10.1016/j.molmet.2015.11.002 42.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
PloS One 2014; 9:e84910; PMID:24416310; http://dx.doi.org/10.1371/journal.pone.0084910 43.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nature2012; 481:463-8; PMID:22237023; http://dx.doi.org/ 10.1038/nature10777 44.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2015; 22:734-40; PMID:26278051; http://dx.doi.org/10.1016/j.cmet.2015.08.001 45.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell 2014; 157:1279-91; PMID:24906147; http://dx.doi.org/10.1016/j.cell.2014.03.065 46.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nature 2011; 480:104-8; PMID:22101429; http://dx.doi.org/10.1038/nature10653 47.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nature 2015; 519:242-6; PMID:25533952; http://dx.doi.org/10.1038/ nature14115 48.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2014; 19:96-108; PMID:24411942; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Endocri- nology 2012; 153:3133-46; PMID:22549226; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
New role of bone morphogenetic pro- tein 7 in brown adipogenesis and energy expenditure.Nature 2008; 454:1000-4; PMID:18719589; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
AntioxidRedox Signal 2013; 19:243-57; PMID:22938691; http://dx.doi.org/10.1089/ars.2012.4536 53.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Dia- betes 2014; 63:162-75; PMID:24062245; http://dx.doi.org/10.2337/db13-0808 54.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2015; 290:14679-91; PMID:25931124; http://dx.doi.org/ 10.1074/jbc.M115.643817 55.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Endocrinology 2005; 146:1764-71;PMID:15677759; http://dx.doi.org/10.1210/en.2004-1427 56.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Rep 2016; 14:1621-31;PMID:26876182; http://dx.doi.org/10.1016/j.celrep.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell 2015; 160:88-104; PMID:25594176; http://dx.doi.org/10.1016/j.cell.2014.12.022 59.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Endocrinology 2006; 147:2468-80; PMID:16469807; http://dx.doi.org/10.1210/ en.2005-1216 6 0 .,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2015; 22:279-90; PMID:26166748; http://dx.doi.org/10.1016/j.cmet.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Eur J Biochem FEBS 2003;270:699-705; http://dx.doi.org/10.1046/j.1432-1033.2003.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nature 2014; 516:395-9; PMID:25317558; http://dx.doi.org/10.1038/nature13816 65.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol Metab 2016; 5(4):271- 82; PMID:27069867; http://dx.doi.org/10.1016/j.molmet.2016.01.008 66.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
BiochimBiophys Acta 2013; 1831:969-85; PMID:23246573; http://dx.doi.org/10.1016/j.bbalip.2012.12.002 67.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
PMID:26586443; http://dx.doi.org/10.1016/j.celrep.2015.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2011; 14:478-90; PMID:21982708; http://dx.doi.org/10.1016/j.cmet.2011.08.010 69.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Front Neurosci 2014; 8:1-14; PMID:24478622; http://dx.doi.org/10.3389/ fnins.2014.00014 70.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nat Commun 2015; 6:6794; PMID:25864946;http://dx.doi.org/10.1038/ncomms7794 71.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nat Med 2015; 21:166-72; PMID:25485911; http://dx.doi.org/10.1038/nm.3766 72.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem Biophys Res Com-mun 2015; 464:724-9; PMID:26164229; http://dx.doi.org/ 10.1016/j.bbrc.2015.07.015 73.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Diabetes 2015; 64:393-404; PMID:25187367; http://dx.doi.org/10.2337/db14-0395 75.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Diabetes 2014; 63:3346-58; PMID:24917578; http://dx.doi.org/10.2337/db14-030278.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Clin Invest 2012; 122:1022-36; PMID: 22307324; http://dx.doi.org/10.1172/JCI59701 79.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 1999; 274:21920-5; PMID:10419513; http://dx.doi.org/10.1074/jbc.274.31.21920 81.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Nature1990; 347:645-50; PMID:2129546; http://dx.doi.org/10.1038/347645a0 82.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol Cell Biol 1993; 13:4753-9; PMID:8336713; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem Pharma- col 1996; 52:693-701; PMID:8765467; http://dx.doi.org/ 10.1016/0006-2952(96)00345-0 84.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2001;276:1486-93; PMID:11050084; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2000; 275:31722-32; PMID:10921912; http://dx.doi.org/10.1074/jbc.M001678200 87.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab 2013;17:562-74; PMID:23499423; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Genes Dev 2015; 29:7-22; PMID:25504365; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell 1998; 92:829-39; PMID:9529258; http://dx.doi.org/10.1016/S0092-8674(00)81410-5 90.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Diabetes 2015; 64:471-84; PMID:25249574; http://dx.doi.org/ 10.2337/db14-0496 91.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Hypertension 2010; 56:274-81; PMID: 20585108; http://dx.doi.or g/10.1161/HYPERTENSIO NAHA.110.153536 92.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Int J Obes 2005; 39:967-76http://dx.doi.org/ 10.1038/ijo.2015.23 94.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Nutr Biochem 2016; 27:193-202; PMID:26456563; http://dx.doi.org/10.1016/j.jnutbio.2015.09.006 95.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem Biophys Res Commun 2015; 466:530-5; PMID:26381176; http://dx.doi.org/10.1016/j.bbrc.2015.09.064 96.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem Biophys Res Commun 2015; 466:247-53; PMID:26362189; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Int J Obes Relat Metab Disord J Int Assoc Study Obes 1997; 21:955-62; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochim Biophys Acta 2013; 1831:986-1003; PMID:23454373; http://dx.doi.org/10.1016/j.bbalip.2013.02.003 99.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochim Biophys Acta 2016; 1861:285-93; http://dx.doi.org/10.1016/j.bbalip.2016.01.007 101.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol Metab 2014; 3:834-47; PMID:25506549; http://dx.doi.org/10.1016/j.molmet.2014.09.003 102.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Nutr Biochem 2015; 26:616-25; PMID:25801353; http://dx.doi.org/10.1016/j.jnutbio.2014.12.016 103.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Lipids 2009; 44:975-82; PMID:19779754; http://dx.doi.org/10.1007/s11745-009- 3348-9 104.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
"Cheng Y, Meng Q, Wang C, Li H, Huang Z, Chen S, Xiao F, Guo F. Leucine deprivation decreases fat mass by stimu- lation of lipolysis in white adipose tissue and upregulation of uncoupling protein 1 (UCP1) in brown adipose tissue.Diabetes 2010; 59:17-25; PMID:19833890; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Am J Physiol Regul Integr Comp Physiol 2010; 299:R728-739; PMID:20538896; http://dx.do i.org/10.1152/ajpregu.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Curr Opin Clin Nutr Metab Care 2012; 15:529-38; PMID:23075933; http://dx.doi.org/10.1097/MCO.0b013e3283595cff 113.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Amino Acids 2012; 43:1265-75; PMID: 22200933; http://dx.doi.org/10.1007/s00726-011-1199-1 114.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Metab2016; 23:165-78; PMID:26549485; http://dx.doi.org/ 10.1016/j.cmet.2015.10.003 115.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Br J Nutr 2012; 108Suppl 2:S139-148; http://dx.doi.org/10.1017/ S0007114512002358 116.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
MedSport Sci 2012; 59:18-28; PMID:23075551; http://dx.doi.org/10.1159/000341937 119.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Nutr 2015;145:1429-37; PMID:26019250; http://dx.doi.org/10.3945/ jn.114.200626 120.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol NutrFood Res 2014; 58:2320-30; PMID:25271764; http://dx.doi.org/10.1002/mnfr.201400507 121.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Mol Nutr Food Res 2014; 58:1765-75; PMID:24913603; http://dx.doi.org/10.1002/ mnfr.201400053 122.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Adipocyte 2015; 4:129-34;PMID:26167416; http://dx.doi.org/10.4161/21623945.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem J 1967;105:529-36; PMID:5583995; http://dx.doi.org/10.1042/ bj1050529 127.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem2009; 284:27025-9; PMID:19636077; http://dx.doi.org/10.1074/jbc.R109.040543 129.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
BiosciRep 1983; 3:263-7; PMID:6860784; http://dx.doi.org/10.1007/BF01122458 131.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Can J Physiol Pharmacol 2008; 86:416-23;PMID:18641690; http://dx.doi.org/10.1139/Y08-052 132.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
R1536-1541; PMID:12736183; http://dx.doi.org/10.1152/ ajpregu.00764.2002 134.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
P ﬂ€ug Arch Eur J Physiol 2005; 449:463- 9; http://dx.doi.org/10.1007/s00424-004-1353-7 135.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem J1972; 127:809-18; PMID:4342497; http://dx.doi.org/10.1042/ bj1270809 136.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem J 1995; 305 (Pt 1):65-71; PMID:7826355; http://dx.doi.org/10.1042/bj3050065 137.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Trends Endocrinol Metab TEM 2004; 15:129-35; PMID:15046742; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochimie 2001; 83:933-43; PMID:11728630; http://dx.doi.org/10.1016/S0300-9084 (01)01343-8 140.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2006;281:13141-9; PMID:16524879; http://dx.doi.org/; http:// dx.doi.org/10.1074/jbc.M512943200 141.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2003; 278:18785-90; PMID:12644461; http://dx.doi.org/10.1074/jbc.M206999200 142.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Obes Silver Spring Md 2009; 17:196-8; http://dx.doi.org/10.1038/oby.2008.467 143.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Diabetes 2002; 51:624-30; PMID:11872659; http://dx.doi.org/10.2337/diabetes.51.3.624 144.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell Biochem Biophys 2007; 48:89-95; PMID:17709878; http://dx.doi.org/10.1007/s12013-007-0025-6 146.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Diabetolo-gia 2007; 50:666-75; PMID:17242918; http://dx.doi.org/10.1007/s00125-006-0560-5 147.,Non-OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2004; 279:48941-9; PMID:15347677; http://dx.doi.org/10.1074/jbc.M407120200 148.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
JBiol Chem 2002; 277:30409-12; PMID:12087111; http://dx.doi.org/10.1074/jbc.R200006200 149.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell 2014; 156:343-58; PMID:24439387; http://dx.doi.org/10.1016/j.cell.2013.10.058 150.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Eur J Biochem FEBS 1995; 234:390-6; http://dx.doi.org/ 10.1111/j.1432-1033.1995.390_b.x 151.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Biochem Pharma- col 2002; 64:893-901; PMID:12213584; http://dx.doi.org/ 10.1016/S0006-2952(02)01157-7 152.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2008; 283:27688-97; PMID:18678870; http://dx.doi.org/ 10.1074/jbc.M804268200 153.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
J Biol Chem 2006; 281:31894-908; PMID:16914547; http://dx.doi.org/10.1074/jbc.M606114200 154.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
Cell 2015; 163:643-55; PMID:26496606; http://dx.doi.org/10.1016/j.cell.2015.09.035 155.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
PloS One 2013; 8:e52879; PMID:23326362; http://dx.doi.org/10.1371/ journal.pone.0052879152 C. FOREST ET AL.,OADS,/arxiv_data1/oa_pdf/1e/58/kadi-05-02-1187345.PMC4916896.pdf
"Notes and references 1 Centers for Disease Control and Prevention, National Diabetes Statistics Report: Estimates of Diabetes and ItsBurden in the United States, 2014 , Dept of Health and Human Services, Atlanta, GA, U.S., 2014, accessed http://www.cdc.gov/diabetes/pubs/factsheet11.htm on 20 August2014.",Non-OADS,/arxiv_data1/oa_pdf/6b/52/SC-007-C5SC03718B.PMC4916918.pdf
"4 Facts about Type 2 diabetes: American Diabetes Association, 2014, http://www.diabetes.org/diabetes-basics.",Non-OADS,/arxiv_data1/oa_pdf/6b/52/SC-007-C5SC03718B.PMC4916918.pdf
http://www.ircwash.org/ projects/life-cycle-costing-tools.,Non-OADS,/arxiv_data1/oa_pdf/2b/9c/CD012199-0001.PMC4916930.pdf
http://www.wateraid.org/us/~/media/ Publications/WASH-the-silent-weapon-against-NTDs.pdf?,Non-OADS,/arxiv_data1/oa_pdf/2b/9c/CD012199-0001.PMC4916930.pdf
2002. http://apps.who.int/iris/bitstream/ 10665/42588/1/WHO_TRS_912.pdf.,OADS,/arxiv_data1/oa_pdf/2b/9c/CD012199-0001.PMC4916930.pdf
Progress report 2001-2010 and strategic plan 2011-2020. http://apps.who.int/iris/ bitstream/10665/44804/1/9789241503129_eng.pdf.,Non-OADS,/arxiv_data1/oa_pdf/2b/9c/CD012199-0001.PMC4916930.pdf
http://www.who.int/neglected_ diseases/NTD_RoadMap_2012_Fullversion.pdf (accessed 3 February 2016).,Non-OADS,/arxiv_data1/oa_pdf/2b/9c/CD012199-0001.PMC4916930.pdf
http://www.who.int/neglected_diseases/ preventive_chemotherapy/databank/en/ (accessed 3 February 2016).,Non-OADS,/arxiv_data1/oa_pdf/2b/9c/CD012199-0001.PMC4916930.pdf
https://clinicaltrials.gov/ct2/show/NCT01570504 (access ed 24 August 2015).,Non-OADS,/arxiv_data1/oa_pdf/b8/30/CD007745.PMC4916931.pdf
http://www.cdc.gov/parasites/strongyloide s/ health professionals/ (accessed 24 August 2015).,Non-OADS,/arxiv_data1/oa_pdf/b8/30/CD007745.PMC4916931.pdf
http://www.cidrz.org/past-studies/ (accessed 4 September 2015).,Non-OADS,/arxiv_data1/oa_pdf/57/6f/CD011420.PMC4916932.pdf
http://www.google.com/url?sa=t&rct=j& q=&esrc=s&source=web&cd=10&ved=0ahUKEwj5tLmS- JvMAhUKRCYKHRClA2sQFghBMAk&url= http%3A%2F%2Fwww.auruminstitute.org%2Findex.php%3Foptio n%3Dcom k2%26view%3D usg=AFQjCNF7uy6NicdwmPpa-FbGGDfjEmMpvQ (accessed 4 April 2016).,OADS,/arxiv_data1/oa_pdf/57/6f/CD011420.PMC4916932.pdf
http://www.alere.com/ww/en/product-details/ determine-tb-lam.html (accessed 16 November 2014).,Non-OADS,/arxiv_data1/oa_pdf/57/6f/CD011420.PMC4916932.pdf
Available from http://srdta.cochrane.org/.,OADS,/arxiv_data1/oa_pdf/57/6f/CD011420.PMC4916932.pdf
Available from http://gdt.guidelinedevelopment.org/central prod/ design/ client/handbook/handbook.html (accessed 12 April 2016).,Non-OADS,/arxiv_data1/oa_pdf/57/6f/CD011420.PMC4916932.pdf
http://www.who.int/ tb/publications/ISTC 3rdEd.pdf?ua=1 (accessed 16 Nov 2014):1–87.,Non-OADS,/arxiv_data1/oa_pdf/57/6f/CD011420.PMC4916932.pdf
http://www.controlled-trials.com/ ISRCTN85737357 (accessed 25 August 2011).,Non-OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
http://www.controlled- trials.com/ISRCTN88523834.,Non-OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
"http://clinicaltrials.gov/show/ NCT00301054 (accessed 25 August 2011).Nguyen 2002 {published data only} Nguyen/uni00A0XN, Berger/uni00A0J, Dao/uni00A0TQ, Nguyen/uni00A0CK, Traissac/uni00A0P, Ha/uni00A0HK.",OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
2004. http://users.ox.ac.uk/˜hay/058.pdf (accessed 20 March 2007).,Non-OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
The Africa Malaria Report 2003. http://www.rollbackmalaria.org/ amd2003/amr2003/pdf/amr2003.pdf (accessed 25 August 2011).,Non-OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
http://www.who.int/vmnis/indicators/ serum_ferritin.pdf (accessed 9 August 2011).,OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
http://apps.who.int/iris/ bitstream/10665/44651/1/9789241502047_  eng.pdf 2011. WHO GMP 2010 World Health Organization Global Malaria Programme.,Non-OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
World Malaria Report 2010. http://www.who.int/malaria/world_  malaria_   report_   2010/en/index.html (accessed 31 August 2011).,Non-OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
http://www.who.int/nutrition/publications/ micronutrients/anaemia_   iron_   deficiency/9789241596107/en/ index.html (accessed 25 August 2011).,Non-OADS,/arxiv_data1/oa_pdf/23/3f/CD006589.PMC4916933.pdf
http://www.controlled- trials.com/ISRCTN95204603 (accessed 14 July 2014).,Non-OADS,/arxiv_data1/oa_pdf/33/1e/CD009913.PMC4916937.pdf
http://apps.who.int/medicinedocs/en/d/Js4872e/ (accessed 13 March 2016).,OADS,/arxiv_data1/oa_pdf/33/1e/CD009913.PMC4916937.pdf
September 2009. http://www.who.int/tb/challenges/ interim_   paediatric_   fdc_  dosing_   instructions_   sept09.pdf (accessed 13 March 2016).WHO 2010 World Health Organization.,Non-OADS,/arxiv_data1/oa_pdf/33/1e/CD009913.PMC4916937.pdf
http://apps.who.int/iris/ bitstream/10665/79199/1/9789241505345_   eng.pdf (accessed 9 March 2016).,OADS,/arxiv_data1/oa_pdf/33/1e/CD009913.PMC4916937.pdf
2We performed all calculations using: http://www.sealedenvelope.com/power/binary-noninferior/.,OADS,/arxiv_data1/oa_pdf/33/1e/CD009913.PMC4916937.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/ © B Reinhart et al.",Non-OADS,/arxiv_data1/oa_pdf/71/9c/mtm201640.PMC4916946.pdf
(2016) Supplementary Information accompanies this paper on the Molecular Therapy— Oncolytics  website (http://www.nature.com/mto),Non-OADS,/arxiv_data1/oa_pdf/fa/cb/mto201617.PMC4916948.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/  © A Bhatia et al.",Non-OADS,/arxiv_data1/oa_pdf/1c/36/mtm201641.PMC4916949.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/90/eb/main.PMC4916950.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2016.04.005,OADS,/arxiv_data1/oa_pdf/90/eb/main.PMC4916950.pdf
"According to the Catalogue of Somatic Mutations in Cancer database ( http://cancer.sanger.ac.uk/cosmic , accessed in October 2015), ccRCC is the only tumor type that SETD2 ranks into the top five mutated genes.",Non-OADS,/arxiv_data1/oa_pdf/90/eb/main.PMC4916950.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9e/ca/gzw015.PMC4917058.pdf
"This is an Open Access article distributed under the terms of the CreativeCommons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5e/ea/gfv093.PMC4917060.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 1936-5233/16http://dx.doi.org/10.1016/j.tranon.2016.03.007,Non-OADS,/arxiv_data1/oa_pdf/a5/96/main.PMC4917080.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/44/b7/rjw104.PMC4917175.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3d/db/rjw106.PMC4917179.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/61/22/rjw111.PMC4917280.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.016,Non-OADS,/arxiv_data1/oa_pdf/e9/36/main.PMC4917392.pdf
MALDI-TOF MS Spectrum The MALDI-TOF MS spectrum of N. timonensis is available at http://www.mediterranee-infection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/e9/36/main.PMC4917392.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,1 3 –14 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/e9/36/main.PMC4917392.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Cerebrovascular ReactivityBOLD signalwhite matter hyperintensityDynamic responseCarbon dioxide 1.,Non-OADS,/arxiv_data1/oa_pdf/54/63/main.PMC4917393.pdf
http://dx.doi.org/10.1016/j.nicl.2016.05.0082213-1582/© 2016 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/54/63/main.PMC4917393.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/54/63/main.PMC4917393.pdf
This  is  an  open access article under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/25/48/main.PMC4917394.pdf
Fine  needle  aspi- http://dx.doi.org/10.1016/j.ijscr.2016.06.008 2210-2612/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/25/48/main.PMC4917394.pdf
"Araujo,  S.  Cheng,  O.  Mete,  S.  Serra,  E.  Morin,  Sylvia  L.  Asa,  et  al.,  Evaluation of  the  WHO  2010  grading  and  AJCC/UICC  staging  systems  in  prognosticbehavior  of  intestinal  neuroendocrine  tumors,  PLoS  One  8  (2013)  e61538 http://dx.doi.org/10.1371%2Fjournal.pone.0061538 .",Non-OADS,/arxiv_data1/oa_pdf/25/48/main.PMC4917394.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/63/79/main.PMC4917395.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.05.016 2210-2612/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/63/79/main.PMC4917395.pdf
"http://immunenetwork.org 147pISSN 1598-2629 · eISSN 2092-6685 The Immune Landscape in Nonalcoholic Steatohepatitis Sowmya Narayanan1,2, Fionna A. Surette1 and Young S. Hahn1,2* 1Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia 22908, United States of America,  2Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia 22908, United States of  Americahttp://dx.doi.org/10.4110/in.2016.16.3.147REVIEW ARTICLE INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is a formi- dable health problem as it is the third leading cause of  liver transplants in the United States and is predicted  to surpass viral hepatitis and alcoholic cirrhosis as the  leading cause in the next decade (1).",Non-OADS,/arxiv_data1/oa_pdf/93/57/in-16-147.PMC4917398.pdf
Hepatic Immune Responses in NASH http://immunenetwork.org 149of monocytes and macrophages to injured hepatocytes  in NASH is a multifactorial process that can be targeted for therapeutic intervention.,Non-OADS,/arxiv_data1/oa_pdf/93/57/in-16-147.PMC4917398.pdf
Hepatic Immune Responses in NASH http://immunenetwork.org 151genes (65).,Non-OADS,/arxiv_data1/oa_pdf/93/57/in-16-147.PMC4917398.pdf
"Hepatic Immune Responses in NASH http://immunenetwork.org 153transfer of Tregs into high-fat diet mice decreases  hepatic inflammation and serum levels of liver enzymes, indicating that Tregs may regulate the transition from  NAFLD to NASH (89).",Non-OADS,/arxiv_data1/oa_pdf/93/57/in-16-147.PMC4917398.pdf
Hepatic Immune Responses in NASH http://immunenetwork.org 155Hepatocytes release ceramide-enriched pro-inflammatory  extracellular vesicles in an IRE1alpha-dependent manner.,Non-OADS,/arxiv_data1/oa_pdf/93/57/in-16-147.PMC4917398.pdf
Hepatic Immune Responses in NASH http://immunenetwork.org 15763.,Non-OADS,/arxiv_data1/oa_pdf/93/57/in-16-147.PMC4917398.pdf
"http://immunenetwork.org 159pISSN 1598-2629 · eISSN 2092-6685 Roles of IL-33 in Resistance and Tolerance to Systemic  Candida albicans  Infections Sang Jun Park1,2, Hong Rae Cho1,2 and Byungsuk Kwon2,3* 1Department of Surgery and 2Biomedical Research Center, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan  44033, 3School of Biological Sciences, University of Ulsan, Ulsan 44610, Koreahttp://dx.doi.org/10.4110/in.2016.16.3.159REVIEW ARTICLE INTRODUCTION Candida albicans  is a major commensal fungus residing  in the mucosal surfaces of our bodies.",Non-OADS,/arxiv_data1/oa_pdf/55/ad/in-16-159.PMC4917399.pdf
"IL-33 in C. albicans  Infections http://immunenetwork.org 161gency granulopoiesis to supply sufficient numbers of  granulocytes to the site of infection, thus, indirectly increasing host resistance to  C. albicans  infections.",Non-OADS,/arxiv_data1/oa_pdf/55/ad/in-16-159.PMC4917399.pdf
IL-33 in C. albicans  Infections http://immunenetwork.org 163interleukin-33 drives protective antiviral CD8+ T cell  responses.,Non-OADS,/arxiv_data1/oa_pdf/55/ad/in-16-159.PMC4917399.pdf
"http://immunenetwork.org 165pISSN 1598-2629 · eISSN 2092-6685 Immunomodulatory Effects of Ambroxol on Airway  Hyperresponsiveness and Inflammation Ambroxol is used in COPD and asthma to increase mucociliary clearance and regulate surfactant levels, perhaps  through anti-oxidant and anti-inflammatory activities.",Non-OADS,/arxiv_data1/oa_pdf/c2/a4/in-16-165.PMC4917400.pdf
"[Immune Network 2016;16(3):165-175] Keywords: Ambroxol, Airway hyperresponsiveness, Neutrophils, Eosinophilshttp://dx.doi.org/10.4110/in.2016.16.3.165ORIGINAL ARTICLE Received on February 12, 2016.",Non-OADS,/arxiv_data1/oa_pdf/c2/a4/in-16-165.PMC4917400.pdf
"Ambroxol and Airway Hyperresponsiveness http://immunenetwork.org 167resistance (RL) was continuously computed (Labview,  National Instruments, Austin, TX, USA) by fitting flow,  volume, and pressure to an equation of motion, using a  recessive least squares algorithm.",OADS,/arxiv_data1/oa_pdf/c2/a4/in-16-165.PMC4917400.pdf
"Ambroxol and Airway Hyperresponsiveness http://immunenetwork.org 169challenge, histological analysis revealed that ambroxol  treatment initiated following OV A challenge did not alter  inflammatory cell infiltration or goblet cell metaplasia in the airways of OV A-sensitized and challenged mice (Fig.",Non-OADS,/arxiv_data1/oa_pdf/c2/a4/in-16-165.PMC4917400.pdf
Ambroxol and Airway Hyperresponsiveness http://immunenetwork.org 171to determine the degree of oxidative damage in the  airways.,Non-OADS,/arxiv_data1/oa_pdf/c2/a4/in-16-165.PMC4917400.pdf
Ambroxol and Airway Hyperresponsiveness http://immunenetwork.org 173that the anti-oxidant effects of ambroxol were transient  and decreased levels of protein carbonyls in BAL fluid were not observed 2 days after cessation of ambroxol  treatment.,Non-OADS,/arxiv_data1/oa_pdf/c2/a4/in-16-165.PMC4917400.pdf
Ambroxol and Airway Hyperresponsiveness http://immunenetwork.org 175Physiol .,Non-OADS,/arxiv_data1/oa_pdf/c2/a4/in-16-165.PMC4917400.pdf
"3: 176-182, June, 2016 176pISSN 1598-2629 · eISSN 2092-6685 Roles of RUNX1 and PU.1 in CCR3  Transcription  Su-Kang Kong1, Byung Soo Kim1, Sae Mi Hwang1, Hyune Hwan Lee3 and Il Yup Chung1,2* 1Department of Bionano Technology, Hanyang University, Ansan 15588, 2Division of Molecular and Life Sciences, College of Science  and Technology, Hanyang University, Ansan 15588, 3Department of Bioscience and Biotechnology and Protein Research Center of  GRRC, College of Natural Sciences, Hankuk University of Foreign Studies, Yongin 17035, Koreahttp://dx.doi.org/10.4110/in.2016.16.3.176ORIGINAL ARTICLE INTRODUCTION The CC chemokine receptor CCR3 plays a major role  in the development of allergic diseases by mediating  the recruitment of allergic cells to inflamed sites (1).",Non-OADS,/arxiv_data1/oa_pdf/ff/5e/in-16-176.PMC4917401.pdf
Roles of RUNX1 and PU.1 in CCR3  Transcription http://immunenetwork.org 177regulatory sequence of the CCR3  gene contains two  cis-acting elements of the transcription factors Runt- related transcription factor 1 (RUNX1) and PU.1.,Non-OADS,/arxiv_data1/oa_pdf/ff/5e/in-16-176.PMC4917401.pdf
Roles of RUNX1 and PU.1 in CCR3  Transcription http://immunenetwork.org 179PU.1 transcription factors (Fig.,Non-OADS,/arxiv_data1/oa_pdf/ff/5e/in-16-176.PMC4917401.pdf
"Roles of RUNX1 and PU.1 in CCR3  Transcription http://immunenetwork.org 181was observed, although the effect was not synergistic, as  evidenced by additive decreases upon elimination of both  PU.1 and GATA sites (construct 8 in Fig.",OADS,/arxiv_data1/oa_pdf/ff/5e/in-16-176.PMC4917401.pdf
"http://immunenetwork.org 183pISSN 1598-2629 · eISSN 2092-6685 Induction of Nuclear Enlargement and Senescence by  Sirtuin Inhibitors in Glioblastoma Cells Kyoung B. Yoon1, Kyeong R. Park1, Soo Y .",Non-OADS,/arxiv_data1/oa_pdf/5b/92/in-16-183.PMC4917402.pdf
"Kim2 and Sun-Young Han1* 1College of Pharmacy and Research Institute of Life Sciences, Gyeongs ang National University, Jinju 52828, 2Division of Basic Science,  Research Institute, National Cancer Center, Goyang 10408, Koreahttp://dx.doi.org/10.4110/in.2016.16.3.183ORIGINAL ARTICLE INTRODUCTION The mammalian sirtuin family comprises seven enzymes  (SIRT1–SIRT7).",Non-OADS,/arxiv_data1/oa_pdf/5b/92/in-16-183.PMC4917402.pdf
Effects of Sirtuin Inhibitors on Cellular Senescence http://immunenetwork.org 185ResUl Ts Treatment with sirtuin inhibitors increased the nuclear size  in glioblastoma cells Small-molecule inhibitors of sirtuin activity were  employed to investigate the role of sirtuin in glioblastoma  cells.,Non-OADS,/arxiv_data1/oa_pdf/5b/92/in-16-183.PMC4917402.pdf
Effects of Sirtuin Inhibitors on Cellular Senescence http://immunenetwork.org 187an important function in aging (8).,Non-OADS,/arxiv_data1/oa_pdf/5b/92/in-16-183.PMC4917402.pdf
"http://immunenetwork.org 189pISSN 1598-2629 · eISSN 2092-6685 Differential Chemokine Signature between Human  Preadipocytes and Adipocyteshttp://dx.doi.org/10.4110/in.2016.16.3.189BRIEF COMMUNICATION Rosa Mistica C. Ignacio1, Carla R. Gibbs1, Eun-Sook Lee2 and Deok-Soo Son1* 1Department of Biochemistry and Cancer Biology, 2Department of Physiology, Meharry Medical College, Nashville, Tennessee 37208  USA INTRODUCTION Adipose tissue is composed of adipocytes, stromal  vascular fraction such as preadipocytes at various stage  of differentiation, fibroblasts, vascular endothelial cells  and heterogeneous population of immune cells (1).",OADS,/arxiv_data1/oa_pdf/1a/e6/in-16-189.PMC4917403.pdf
"Obesity-related Chemokine Network http://immunenetwork.org 191instructions, a real-time PCR was performed using a  Bio-Rad CFX96 under the following two-step cycling program: 1 cycle at 95 oC for 10 min, 40 cycles at 95oC  for 15 sec and at 60oC for 1 min.",Non-OADS,/arxiv_data1/oa_pdf/1a/e6/in-16-189.PMC4917403.pdf
Data analysis was  performed using PCR Array Data Analysis Software (http://www.sabiosciences.com/RTPCR.php) provided  by SABiosciences/Qiagen.,OADS,/arxiv_data1/oa_pdf/1a/e6/in-16-189.PMC4917403.pdf
"Data analysis from geO dataset Data analysis was performed using microarray data sets deposited in the NCBI Gene Expression Omnibus  (GEO, http://www.ncbi.nlm.nih.gov/geo/) database  under accession number GSE44000.",OADS,/arxiv_data1/oa_pdf/1a/e6/in-16-189.PMC4917403.pdf
"We employed Gitools 2.2.3 (http://www.gitools.org)  based on Oracle Java 7, an open-source tool to perform  Genomic Data Analysis and Visualization as interactive  heat-maps (14).",OADS,/arxiv_data1/oa_pdf/1a/e6/in-16-189.PMC4917403.pdf
Obesity-related Chemokine Network http://immunenetwork.org 193while the matured human adipocytes had lipid accu- mulation in spherical form (Fig.,Non-OADS,/arxiv_data1/oa_pdf/1a/e6/in-16-189.PMC4917403.pdf
"http://immunenetwork.org 195pISSN 1598-2629 · eISSN 2092-6685 Cross-Reactivity of Porcine Immunoglobulin A Antibodies  with Fecal Immunoglobulins of Wild Boar ( Sus scrofa ) and  Other Animal Species Sang won Seo1#, Sung J. Yoo1#, Sunyoung Sunwoo1†, Bang hun Hyun2 and Young S. Lyoo1* 1Department of Pathology, College of Veterinary Medicine, Konkuk University, Seoul 05029, 2Animal and Plant Quarantine Agency,  Gimcheon 39660, Koreahttp://dx.doi.org/10.4110/in.2016.16.3.195CASE REPORT INTRODUCTION Wild boars can be a reservoir of agents that are infectious  to domestic pigs and other livestock (1).",Non-OADS,/arxiv_data1/oa_pdf/9c/bb/in-16-195.PMC4917404.pdf
"Cross-Reactivity of Porcine IgA Antibodies in Animals http://immunenetwork.org 197other animal species had low reactivity with porcine IgA  antibodies, showing statistically significant difference  with that of wild boar in all age groups (p<0.001).",Non-OADS,/arxiv_data1/oa_pdf/9c/bb/in-16-195.PMC4917404.pdf
Cross-Reactivity of Porcine IgA Antibodies in Animals http://immunenetwork.org 199immunosorbent assay.,Non-OADS,/arxiv_data1/oa_pdf/9c/bb/in-16-195.PMC4917404.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Febrile infection-related epilepsy syndrome FIRES Status epilepticusLidocaineMgSO 4 1.,Non-OADS,/arxiv_data1/oa_pdf/51/12/main.PMC4917485.pdf
http://dx.doi.org/10.1016/j.ebcr.2016.05.002 2213-3232/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/51/12/main.PMC4917485.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/12/main.PMC4917485.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.015,Non-OADS,/arxiv_data1/oa_pdf/ff/da/main.PMC4917486.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,1 5 –16 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/ff/da/main.PMC4917486.pdf
We then attempted to elucidate the molecular features of CA-MRSA and gain novel New Microbe and New Infect 2016; 13:17–21 © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.011,Non-OADS,/arxiv_data1/oa_pdf/97/7f/main.PMC4917487.pdf
"Arrow 1 indicates an inﬁltrative shadow overlapping the second arch in the middle to lower ﬁeld of the right lung, while arrow 2 indicates consolidation with air bronchograms on the lateral side of the left middle lung ﬁeld.18 New Microbes and New Infections , Volume 13 Number C, September 2016 NMNI © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,1 7 –21 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/97/7f/main.PMC4917487.pdf
"Inﬂuenza, ST121/ agr4 MRSA CAP and fatal aspiration pneumonia 19 © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,1 7 –21 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/97/7f/main.PMC4917487.pdf
"Severe community-acquired pneumonia due to20 New Microbes and New Infections , Volume 13 Number C, September 2016 NMNI © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,1 7 –21 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/97/7f/main.PMC4917487.pdf
"Inﬂuenza, ST121/ agr4 MRSA CAP and fatal aspiration pneumonia 21 © 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,1 7 –21 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/97/7f/main.PMC4917487.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/a2/main.PMC4917488.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.05.012 2049-0801/ ©2016 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/f1/a2/main.PMC4917488.pdf
"Rizvi, S. Ejaz, Measuring thewell-being of health care professionals in the Punjab: a psychometric evalu- ation of the Warwick-Edinburgh Mental Well-being Scale in a Pakistani population, PeerJ 3 (2015 Oct 1) e1264, http://dx.doi.org/10.7717/peerj.1264 eCollection 2015.",Non-OADS,/arxiv_data1/oa_pdf/f1/a2/main.PMC4917488.pdf
"41 (2007) 788 e800, http://dx.doi.org/10.1111/j.1365- 2923.2007.02797.x .",Non-OADS,/arxiv_data1/oa_pdf/f1/a2/main.PMC4917488.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.003,Non-OADS,/arxiv_data1/oa_pdf/67/60/main.PMC4917496.pdf
MALDI-TOF MS spectrum accession number The MALDI-TOF MS spectrum of M. timonensis is available at http://www.mediterranee-infection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/67/60/main.PMC4917496.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,2 5 –26 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/67/60/main.PMC4917496.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious DiseasesThis is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.017,Non-OADS,/arxiv_data1/oa_pdf/67/a2/main.PMC4917497.pdf
nov. MALDI-TOF MS Spectrum Accession Number The MALDI-TOF MS spectrum of ‘Lascolabacter vaginalis ’is available at http://www.mediterranee-infection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/67/a2/main.PMC4917497.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,2 2 –24 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/67/a2/main.PMC4917497.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,2 2 –24 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/67/a2/main.PMC4917497.pdf
This  is  an  open access article under the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0f/7b/main.PMC4917498.pdf
"In  addition,  there  was  a  questionable  thrombus at  the  conﬂuence  of  the  superior  mesenteric  vein  and  portal  vein http://dx.doi.org/10.1016/j.ijscr.2016.06.002 2210-2612/© 2016  The  Author(s).",Non-OADS,/arxiv_data1/oa_pdf/0f/7b/main.PMC4917498.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medi-um, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/58/03/520_2016_Article_3148.PMC4917571.pdf
http://ganjoho.jp/ professional/index.html .A c c e s s e d2 2J u l y2 0 1 5 5.,Non-OADS,/arxiv_data1/oa_pdf/df/fb/520_2016_Article_3156.PMC4917580.pdf
"Appendix 3 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by -nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium,provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/1f/ef/520_2016_Article_3131.PMC4917584.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Predictors of Heartburn/Reﬂux-Related Sleep Disturbance Resolution 537",Non-OADS,/arxiv_data1/oa_pdf/3e/40/40261_2016_Article_398.PMC4917592.pdf
"In 2013, an estimated 9 million people developed TB worldwide, and 1.5 million patients died from the disease.1In Japan in 2013, the incidence of TB per 100,000 people was 18(http://www.who.int/tb/country/data/pro ﬁles/en/).",Non-OADS,/arxiv_data1/oa_pdf/0d/9e/hgv201614.PMC4917605.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ © The Author(s) 2016 Supplementary Information for this article can be found on the Human Genome Variation website (http://www.nature.com/hgv).Antituberculosis drug-induced liver injury T Mushiroda et al 4 Human Genome Variation (2016) 16014 Of ﬁcial journal of the Japan Society of Human Genetics",Non-OADS,/arxiv_data1/oa_pdf/0d/9e/hgv201614.PMC4917605.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org /licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/ac/main.PMC4917640.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/ac/main.PMC4917640.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.12.006 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/ef/ac/main.PMC4917640.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/9e/main.PMC4917641.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/9e/main.PMC4917641.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.07.001 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/13/9e/main.PMC4917641.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.12.009 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
Available from: < https://www.unodc.,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
Available from: < https://www.unodc.org/documents/ southeastasiaandpaciﬁc//Publi cations/2015/incb/INCB_ Annual_Report_2014_EN.pdf >.,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
Available from: <http://www.indexmundi.com/s audi_arabia/demographics_ proﬁle.html >.,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
Available from: < http://ijptsud.sljol.info/articles/abstract/10.4038/ ijptsud.v1i1.5907/ >.,OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
Availablefrom < http://www.nationaldrugstrategy.gov.au/internet/ drugstrategy/Publishing.nsf/content/2D1717263A2129CA CA2574C50010A827/$File/ats-strategy08.pdf >.,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
Available from:<http://register.consilium.europa.eu/doc/srv?l=EN&f=ST %2015181%202013%20INIT .,Non-OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
Available from: < https://www.osac.gov/pages/ ContentReportDetails.aspx?cid=13573 >.,OADS,/arxiv_data1/oa_pdf/1f/6c/main.PMC4917642.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fa/19/main.PMC4917643.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fa/19/main.PMC4917643.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.12.007 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/fa/19/main.PMC4917643.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cc/a6/main.PMC4917644.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.12.004 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/cc/a6/main.PMC4917644.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ec/b8/main.PMC4917645.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ec/b8/main.PMC4917645.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.12.001 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/ec/b8/main.PMC4917645.pdf
[3] International Diabetes Federation < https://www.idf.org/ webdata/docs/IDF_Meta_def_ﬁnal.pdf > [Accessed 2006].,Non-OADS,/arxiv_data1/oa_pdf/ec/b8/main.PMC4917645.pdf
"The IDF consensus worldwide deﬁnition of the metabolic syndrome, 2006; <http://www.idf.org/webdata/docs/MetS_def_update2006.",Non-OADS,/arxiv_data1/oa_pdf/ec/b8/main.PMC4917645.pdf
Mice carrying this floxed allele were donatedto The Jackson Laboratory Mouse Repository (http://jaxmice.jax.org/ strain/027495.html); the official strain designation is B6.Cg- Tnfrsf11atm1.1Irw/J.,Non-OADS,/arxiv_data1/oa_pdf/85/66/mi2015121a.PMC4917673.pdf
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi ACKNOWLEDGMENTS We thank Dr Tim Denning for valuable suggestions and advice.,Non-OADS,/arxiv_data1/oa_pdf/85/66/mi2015121a.PMC4917673.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ARTICLES 916 VOLUME 9 NUMBER 4 |JULY 2016 |www.nature.com/mi",Non-OADS,/arxiv_data1/oa_pdf/85/66/mi2015121a.PMC4917673.pdf
Data were analyzed using R (version 3.1.0) (Published Online First: 2014.http://www.r-project.org/).,OADS,/arxiv_data1/oa_pdf/71/2d/mi2015108a.PMC4917674.pdf
"SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi ACKNOWLEDGMENTS This work was supported by grants BFU2012-35999/BFI,MC1_TV3_122931, and the Helmsley Trust.",Non-OADS,/arxiv_data1/oa_pdf/71/2d/mi2015108a.PMC4917674.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ARTICLES Mucosal Immunology |VOLUME 9 NUMBER 4 |JULY 2016 959",Non-OADS,/arxiv_data1/oa_pdf/71/2d/mi2015108a.PMC4917674.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6b/c1/main.PMC4917708.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6b/c1/main.PMC4917708.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.06.002 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/6b/c1/main.PMC4917708.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/79/2c/main.PMC4917710.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.10.001 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/79/2c/main.PMC4917710.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org /licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/49/0d/main.PMC4917711.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/49/0d/main.PMC4917711.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.11.005 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/49/0d/main.PMC4917711.pdf
Eur J Hum Genet 2011;19. http://dx.doi.org/ 10.1038/ejhg.2011.68 .,OADS,/arxiv_data1/oa_pdf/49/0d/main.PMC4917711.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/44/b4/main.PMC4917712.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/44/b4/main.PMC4917712.pdf
URL: www.ksu.edu.sahttp://dx.doi.org/10.1016/j.jsha.2015.11.004 Production and hosting by Elsevier,Non-OADS,/arxiv_data1/oa_pdf/44/b4/main.PMC4917712.pdf
Available online at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com ejc supplements 14 (2016) 1 e20 http://dx.doi.org/10.1016/j.ejcsup.2016.01.001 1359-6349/ ©2016 Published by Elsevier Ltd.,Non-OADS,/arxiv_data1/oa_pdf/86/20/main.PMC4917740.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/86/20/main.PMC4917740.pdf
Available from: http://www.un.org/esa/population/ publications/worldageing19502050/ (accessed April 2015).,Non-OADS,/arxiv_data1/oa_pdf/86/20/main.PMC4917740.pdf
Available from: http://www.nccn.org/professionals/physician_gls/f_ guidelines.asp ea g e( a c c e s s e d9N o v e m b e r2 0 1 5 ) .,Non-OADS,/arxiv_data1/oa_pdf/86/20/main.PMC4917740.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a5/9f/dmw014.PMC4917743.pdf
"It was suggested that centersmust perform arti ﬁcial oocyte activation only in selected patients, such as those with PLC ζdeﬁciency, and that the rationale for using calcium ionophore for individual cases should be documented,ensuring that patients are fully informed about the ef ﬁcacy and potential risks ( http://www.hfea.gov.uk/139.html ).",Non-OADS,/arxiv_data1/oa_pdf/a5/9f/dmw014.PMC4917743.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/eb/2a/ehw179.PMC4917748.pdf
"Keywords:  Fibrosis; Interferon beta-1a; Laminectomy  Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b8/5a/asj-10-407.PMC4917756.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 17, 2015; Accepted Oct 9, 2015 Corresponding author: Mevlüt Özgür Taşkapılıoğlu Department of Neurosurgery, Uludag University Medical Schoo,l Görükle, 16059 Nilüfer/Bursa, Turkey Tel: +90-224-295-2740, Fax: +90-224-295-0019, E-mail: ozgurt@uludag.edu.tr    ASJBasic Study Asian Spine J 2016;10(3):407-413  •  http://dx.doi.org/10.4184/asj.2016.10.3.407 Asian Spine Journal Introduction Failed-back syndrome develops in 20% of the surgically  treated lumbar disc herniation patients [1].",Non-OADS,/arxiv_data1/oa_pdf/b8/5a/asj-10-407.PMC4917756.pdf
"Keywords:  Pedicle screw; Pullout test; Osteoporosis; Spine fusion; Screw fixation Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2b/12/asj-10-414.PMC4917757.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 26, 2015; Revised Oct 27, 2015; Accepted Oct 27, 2015 Corresponding author: Venkatesh Krishnan  Spinal Disorder Sugery Unit, Department of Orthopaedics, Christian Medical College,  Vellore, Tamil Nadu 632004, India Tel: +91-416-2282731, Fax:+91-416-2232103, E-mail: venketeshortho1@cmcvellore.ac.in    ASJBasic Study Asian Spine J 2016;10(3):414-421  •  http://dx.doi.org/10.4184/asj.2016.10.3.414 Asian Spine Journal Introduction Despite advancements in pedicle screw instrumentation, failures including screw breakage and loosening due to  fatigue loading and bending continue to be reported [1].",Non-OADS,/arxiv_data1/oa_pdf/2b/12/asj-10-414.PMC4917757.pdf
"Keywords:  Scoliosis; Spine; Congenital abnormalities; Kyphosis; Spinal curvatures Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/33/e4/asj-10-422.PMC4917758.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Aug 23, 2015; Revised Oct 7, 2015; Accepted Oct 9, 2015 Corresponding author: Agnivesh Tikoo Department of Neurosciences, Park Clinic, 4 Gorky Terrace, Minto Park, Kolkata 700017 India Tel: +91-33-4019-9000, Fax: +91-33-2280-1807, E-mail: agniveshtikoo@gmail.com    ASJClinical Study Asian Spine J 2016;10(3):422-429  •  http://dx.doi.org/10.4184/asj.2016.10.3.422 Asian Spine Journal Introduction Congenital defects usually have serious consequences in  spinal growth.",Non-OADS,/arxiv_data1/oa_pdf/33/e4/asj-10-422.PMC4917758.pdf
"Keywords:  Atlantoaxial dislocation; High cervical disc prolapse; Transarticular fixation Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/06/78/asj-10-430.PMC4917759.pdf
"Medical College, Parel, Mumbai-400012, India Tel: +91-22-24129884, Fax: +91-22-24143435, E-mail: atulgoel62@hotmail.com     ASJClinical Study Asian Spine J 2016;10(3):430-435  •  http://dx.doi.org/10.4184/asj.2016.10.3.430 Asian Spine Journal Introduction The author presents clinical details of four patients who  had C2–3 vertebral body fusion and cord compression opposite the C3–4 disc space.",Non-OADS,/arxiv_data1/oa_pdf/06/78/asj-10-430.PMC4917759.pdf
"Keywords:  Non acute spinal fractures; Osteoporotic vertebral fractures; Bone marrow edema; Percutaneous vertebroplasty Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/11/ad/asj-10-436.PMC4917760.pdf
ASJClinical Study Asian Spine J 2016;10(3):436-442  •  http://dx.doi.org/10.4184/asj.2016.10.3.436 Asian Spine Journal Introduction Many clinical entities can cause painful vertebral collapse.,Non-OADS,/arxiv_data1/oa_pdf/11/ad/asj-10-436.PMC4917760.pdf
"Keywords:  Posterior fusion; Lumbar; Laminoplasty; Isthmic spondylolisthesis; Long term; Follow up studies Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/64/asj-10-443.PMC4917761.pdf
"Istanbul Arel University, Türkoba Mahallesi Erguvan Sokak No:26/K, Tepekent,  34537 Tepekent, Büyükçekmece, İstanbul, Turkey  Tel: +0216-360-12-26, Fax: +0216-302-03-91, E-mail: kadirkotil@gmail.com    ASJClinical Study Asian Spine J 2016;10(3):443-449  •  http://dx.doi.org/10.4184/asj.2016.10.3.443 Asian Spine Journal Introduction The technique for the surgical treatment of isthmic spon - dylolisthesis (ISL) is still controversial.",Non-OADS,/arxiv_data1/oa_pdf/60/64/asj-10-443.PMC4917761.pdf
"Keywords: Chronic low back pain; Multifidus retraining; Segmental stabilization; Back exercises; Multifidus exercises Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cd/a8/asj-10-450.PMC4917762.pdf
ASJClinical Study Asian Spine J 2016;10(3):450-456  •  http://dx.doi.org/10.4184/asj.2016.10.3.450 Asian Spine Journal Introduction A well aligned and flexible spine is important for an active  and healthy life.,Non-OADS,/arxiv_data1/oa_pdf/cd/a8/asj-10-450.PMC4917762.pdf
Available from:   http://www.irishhealth.com/article.html?id=577&ss=  Lumbago.,Non-OADS,/arxiv_data1/oa_pdf/cd/a8/asj-10-450.PMC4917762.pdf
"Keywords:  Posterolateral lumbar fusion; Non-union; Complication; Recombinant human bone morphogenetic protein 2 Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/28/39/asj-10-457.PMC4917763.pdf
ASJClinical Study Asian Spine J 2016;10(3):457-464  •  http://dx.doi.org/10.4184/asj.2016.10.3.457 Asian Spine Journal,Non-OADS,/arxiv_data1/oa_pdf/28/39/asj-10-457.PMC4917763.pdf
"Keywords:  Pyogenic; Infection; Discitis; Posterior surgery; Titanium pedicle screws Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f8/f8/asj-10-465.PMC4917764.pdf
": +39 0715964567, Fax: +39 0715964575, E-mail: dobran@libero.it    ASJClinical Study Asian Spine J 2016;10(3):465-471  •  http://dx.doi.org/10.4184/asj.2016.10.3.465 Asian Spine Journal",Non-OADS,/arxiv_data1/oa_pdf/f8/f8/asj-10-465.PMC4917764.pdf
"Keywords:  Cerebrospinal fluid leakage; Thoracic decompression; Incidence; Risk factors Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/d1/asj-10-472.PMC4917765.pdf
"ASJClinical Study Asian Spine J 2016;10(3):472-479  •  http://dx.doi.org/10.4184/asj.2016.10.3.472 Asian Spine Journal Introduction Surgery on the thoracic spine is a great challenge for  spinal surgeons, and frequently complicated by undesir - able events, such as cerebrospinal fluid leakage (CSFL).",Non-OADS,/arxiv_data1/oa_pdf/be/d1/asj-10-472.PMC4917765.pdf
"Keywords:  Iran; Pain Sensitivity Questionnaire; Validity; Lumbar disc herniation Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e0/0b/asj-10-480.PMC4917766.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 9, 2015; Revised Sep 30, 2015; Accepted Oct 1, 2015 Corresponding author: Parisa Azimi Department of Neurosurgery, Shohada Tajrish Hospital, Functional Neurosurgery Research Center of Shohada Tajrish Hospital,  Shahid Beheshti University of Medical Sciences, Tehran, Iran Tel: +98-212-274-9204, Fax: +98-218-826-5188, E-mail: parisa.azimi@gmail.com    ASJClinical Study Asian Spine J 2016;10(3):480-487  •  http://dx.doi.org/10.4184/asj.2016.10.3.480 Asian Spine Journal Introduction Lumbar disc herniation (LDH) is a displacement of disc  material (annulus fibrosis or nucleus pulposus) beyond  the intervertebral disc space.",Non-OADS,/arxiv_data1/oa_pdf/e0/0b/asj-10-480.PMC4917766.pdf
Available from: http://www.who.int/substance_ abuse/research_tools/translation/en/.,Non-OADS,/arxiv_data1/oa_pdf/e0/0b/asj-10-480.PMC4917766.pdf
"Keywords:  Copenhagen Neck Functional Disability Scale; Modified Japanese orthopedic association; Cervical spondylotic myelopathy;  Clinical outcome Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/00/82/asj-10-488.PMC4917767.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 19, 2015; Revised Oct 25, 2015; Accepted Oct 25, 2015 Corresponding author: Parisa Azimi Shohada Tajrish Hospital, Functional Neurosurgery Research Center of Shohada Tajrish Hospital,  Shahid Beheshti University of Medical Sciences, Tehran, Iran Tel: +98-2122749204 Fax: +98-2188265188, E-mail: parisa.azimi@gmail.com    ASJClinical Study Asian Spine J 2016;10(3):488-494  •  http://dx.doi.org/10.4184/asj.2016.10.3.488 Asian Spine Journal Introduction Cervical spondylotic myelopathy (CSM) refers to the im -paired function of the spinal cord caused by degenerative  changes of the discs and facet joints in the cervical spine.",Non-OADS,/arxiv_data1/oa_pdf/00/82/asj-10-488.PMC4917767.pdf
"Keywords:  Information technology professionals; Lumbar lordosis; Lumbar core strength; Flexicurve  Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/69/da/asj-10-495.PMC4917768.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 3, 2015; Revised Dec 28, 2015; Accepted Jan 8, 2016 Corresponding author: Sanket Nagrale Sancheti Institute College of Physiotherapy, Thube Park, Shivajinagar, Pune 411005, India Tel: +91-20-2553-9393, Fax: +91-20-2553-9494, E-mail: nagralesanket@gmail.com ASJClinical Study Asian Spine J 2016;10(3):495-500  •  http://dx.doi.org/10.4184/asj.2016.10.3.495 Asian Spine Journal Introduction Back pain is one of the great human afflictions [1].",Non-OADS,/arxiv_data1/oa_pdf/69/da/asj-10-495.PMC4917768.pdf
"Keywords:  Work-related low back pain; Patient-care workers; Social cognitive theory; Multidisciplinary; Questionnaire development  Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7a/07/asj-10-501.PMC4917769.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Oct 7, 2015; Revised Nov 5, 2015; Accepted Nov 5, 2015 Corresponding author: Tavaian Sedigheh Sadat Department of Health Education, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran  E-mail:tavafian@modares.ac.ir     ASJClinical Study Asian Spine J 2016;10(3):501-508  •  http://dx.doi.org/10.4184/asj.2016.10.3.501 Asian Spine Journal Introduction Musculoskeletal disorders (MSD) make up a significant portion of occupational-related injuries and disabilities  within the nursing profession [1].",Non-OADS,/arxiv_data1/oa_pdf/7a/07/asj-10-501.PMC4917769.pdf
"Keywords:  Lumbar; Intervertebral disc; Surgery; Pain Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/63/be/asj-10-509.PMC4917770.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 1, 2015; Accepted Oct 4, 2015 Corresponding author: Seiji Ohtori Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University,  1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan Tel: +81-43-226-2117, Fax: +81-43-226-2116 , E-mail: sohtori@faculty.chiba-u.jp    ASJClinical Study Asian Spine J 2016;10(3):509-515  •  http://dx.doi.org/10.4184/asj.2016.10.3.509 Asian Spine Journal Introduction Human intervertebral disc degeneration is a cause of back  pain.",Non-OADS,/arxiv_data1/oa_pdf/63/be/asj-10-509.PMC4917770.pdf
"Keywords:  Lumbar; Muscle; Injury; Surgery; Pain Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b3/e6/asj-10-516.PMC4917771.pdf
": +81-43-226-2117, Fax: +81-43-226-2116, E-mail: sohtori@faculty.chiba-u.jp    ASJClinical Study Asian Spine J 2016;10(3):516-521  •  http://dx.doi.org/10.4184/asj.2016.10.3.516 Asian Spine Journal Introduction In Sweden, up to 25% of patients report unimproved or worse pain and up to 40% are not happy with the outcome  of lumbar fusion [1].",Non-OADS,/arxiv_data1/oa_pdf/b3/e6/asj-10-516.PMC4917771.pdf
"Keywords:  Total en bloc  spondylectomy; Learning curve Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/17/2f/asj-10-522.PMC4917772.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Oct 25, 2015; Revised Dec 5, 2015; Accepted Dec 6, 2015 Corresponding author: Takayoshi Ishii Department of Orthopaedic Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan Tel: +81-76-265-2374, Fax: +81-76-234-4261, E-mail: taka_ishii55@yahoo.co.jp  ASJClinical Study Asian Spine J 2016;10(3):522-527  •  http://dx.doi.org/10.4184/asj.2016.10.3.522 Asian Spine Journal Introduction Patients with spinal metastasis are generally considered  to be in the terminal stage of disease.",Non-OADS,/arxiv_data1/oa_pdf/17/2f/asj-10-522.PMC4917772.pdf
"Keywords:  Disc degeneration; Ligamentum flavum; Lumbar spine; Spinal canal stenosis Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d6/c5/asj-10-528.PMC4917773.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 8, 2015; Revised Oct 15, 2015; Accepted Oct 16, 2015 Corresponding author: Masashi Miyazaki Department of Orthopaedic Surgery, Oita University Faculty of Medicine,  1-1 Idaigaoka, Hsama-machi, Yufu 879-5593, Japan Tel: +81-97-586-5872, Fax: +81-97-586-6647, E-mail: masashim@oita-u.ac.jp    ASJClinical Study Asian Spine J 2016;10(3):528-535  •  http://dx.doi.org/10.4184/asj.2016.10.3.528 Asian Spine Journal Introduction Posterior spinal conditions including hypertrophy of the  ligamentum flavum (LF) play a major role in the patho - genesis of lumbar spinal canal stenosis (LSCS) [1-3].",Non-OADS,/arxiv_data1/oa_pdf/d6/c5/asj-10-528.PMC4917773.pdf
"Keywords:  Cervical spinal canal stenosis; Cervical spinal cord injury without major fracture or dislocation; Magnetic resonance im - aging; Neurological outcome Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/asj-10-536.PMC4917774.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 13, 2015; Revised Oct 25, 2015; Accepted Oct 26, 2015 Corresponding author: Tsuneaki Takao Department of Orthopaedic Surgery, Spinal Injuries Center, 550-4 Igisu, Iizuka 820-8508, Japan Tel: +81-948-24-7500, Fax: +81-948-29-1065, E-mail: tsuneaki@iris.ocn.ne.jp  ASJClinical Study Asian Spine J 2016;10(3):536-542  •  http://dx.doi.org/10.4184/asj.2016.10.3.536 Asian Spine Journal Introduction Numerous previous studies have been published concern -ing adult traumatic cervical spinal cord injuries (CSCI)  without major bony injury or dislocation, using various  nomenclature, such as hyperextension dislocation [1],",Non-OADS,/arxiv_data1/oa_pdf/b1/ce/asj-10-536.PMC4917774.pdf
"Keywords:  Spinal tuberculosis; Debridement; Surgical decompression; Spinal fusion; Pedicle screws  Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4d/8c/asj-10-543.PMC4917775.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 21, 2015; Revised Nov 9, 2015; Accepted Nov 14, 2015 Corresponding author: Weera Sudprasert  Department of Orthopedic Surgery, Maharat Nakhon Ratchasima Hospital,  Mueang, Nakhon Ratchasima, 30000, Thailand  Tel: +6644235529, Fax: +6644259677, E-mail: weespine@gmail.com ASJClinical Study Asian Spine J 2016;10(3):543-552  •  http://dx.doi.org/10.4184/asj.2016.10.3.543 Asian Spine Journal Introduction Spinal tuberculosis accounts for approximately 50% to 66% of all cases of osteoarticular tuberculosis and imag - ing is important for characterizing lesions, as osteolytic  patterns and destructive behaviors likely to produce ky -",Non-OADS,/arxiv_data1/oa_pdf/4d/8c/asj-10-543.PMC4917775.pdf
"Keywords:  Cervical vertebrae; Giant cell tumor of bone; Recurrence; Denosumab Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5e/7c/asj-10-553.PMC4917776.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Nov 24, 2015; Revised Jan 6, 2016; Accepted Jan 11, 2016 Corresponding author: Hiroto Kamoda Department of Orthopedic Surgery, Chiba Cancer Center, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan Tel: +81-43-264-5431, Fax: +81-43-262-8680, E-mail: kamodahiroto@gmail.com ASJCase Report Asian Spine J 2016;10(3):553-557  •  http://dx.doi.org/10.4184/asj.2016.10.3.553 Asian Spine Journal Introduction Giant cell tumor (GCT) of bone is a primary tumor that  commonly occurs in the epiphyses of long bones, and  most frequently in the distal end of the femur [1].",Non-OADS,/arxiv_data1/oa_pdf/5e/7c/asj-10-553.PMC4917776.pdf
"Keywords:  Sacral insufficiency fractures; Osteoporosis; Lumbar pathology Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ed/c1/asj-10-558.PMC4917777.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 2, 2015; Revised Sep 27, 2015; Accepted Oct 1, 2015 Corresponding author: G. Sudhir Ortho Spine Department, Sir GangaRam Hospital, Old Rajinder Nagar, New Delhi–110060, India Tel: +91-99-6227-7126, Fax: +91-011-4225-1947, E-mail: sudhir_axon@yahoo.co.in    ASJCase Report Asian Spine J 2016;10(3):558-564  •  http://dx.doi.org/10.4184/asj.2016.10.3.558 Asian Spine Journal Introduction  Sacral insufficiency fractures (SIFs) are a common cause  of debilitating back pain in the elderly.",Non-OADS,/arxiv_data1/oa_pdf/ed/c1/asj-10-558.PMC4917777.pdf
"Keywords:  Axis; Cervical vertebra; Spondylolysis; Spinal cord compression  Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ec/3a/asj-10-565.PMC4917778.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Nov 3, 2015; Revised Dec 1, 2015; Accepted Dec 1, 2015 Corresponding author: Toshinori Sakai Department of Orthopedics, Institute of Health Biosciences, The University of Tokushima Graduate School,  3-18-15 Kuramoto, 770-8503 Tokushima, Japan Tel: +81-88-633-7240, Fax: +81-88-633-0178, E-mail: norinoridowluck@yahoo.co.jp    ASJCase Report Asian Spine J 2016;10(3):565-569  •  http://dx.doi.org/10.4184/asj.2016.10.3.565 Asian Spine Journal Introduction Spondylolysis is a condition defined as a bony defect at  the pars interarticularis in the spine [1,2].",Non-OADS,/arxiv_data1/oa_pdf/ec/3a/asj-10-565.PMC4917778.pdf
"Keywords:  Scoliosis; Physiotherapy; Rehabilitation; Treatment Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c0/3f/asj-10-570.PMC4917779.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Aug 11, 2015; Revised Oct 11, 2015; Accepted Oct 12, 2015 Corresponding author: Shu Yan Ng Wanchai Chiropractic Centre, 11/fl China Hong Kong Tower, 8 Hennessy Road, Wanchai, Hong Kong Tel: +852-3998-3208, Fax: +852-3998-3222, E-mail: ngshuyanhcc@gmail.com  ASJReview Article Asian Spine J 2016;10(3):570-581  •  http://dx.doi.org/10.4184/asj.2016.10.3.570 Asian Spine Journal Introduction Adolescent idiopathic scoliosis (AIS) is defined as a three  dimensional spinal deformity [1-4] with no identifiable  causes [5,6] in a growing child who is otherwise healthy.",Non-OADS,/arxiv_data1/oa_pdf/c0/3f/asj-10-570.PMC4917779.pdf
Internet J Rehabil  2009;1. http://dx.doi.org/10.5580/e71.,OADS,/arxiv_data1/oa_pdf/c0/3f/asj-10-570.PMC4917779.pdf
"Keywords:  Cervical vertebrae/surgery; Spinal fusion; Complications; Adjacent segment pathology; Risk factors; Reoperation  Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/28/a5/asj-10-582.PMC4917780.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 30, 2015; Accepted Oct 22, 2015 Corresponding author: Sung Kyu Kim Department of Orthopedics, Chonnam National University Hospital, Chonnam National University Medical School,  42 Jebong-ro, Dong-gu, Gwangju 61469, Korea Tel: +82-62-227-1640, Fax: +82-62-225-7794, E-mail: bonjourksk@hanmail.net   ASJReview Article Asian Spine J 2016;10(3):582-592  •  http://dx.doi.org/10.4184/asj.2016.10.3.582 Asian Spine Journal Introduction Anterior cervical discectomy and fusion (ACDF) was first  reported in 1955 [1].",Non-OADS,/arxiv_data1/oa_pdf/28/a5/asj-10-582.PMC4917780.pdf
"Keywords:  Proximal junctional kyphosis; Spinal deformity; Epidemiology; Treatment; Risk factor Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/97/21/asj-10-593.PMC4917781.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Sep 20, 2015; Revised Sep 30, 2015; Accepted Oct 1, 2015 Corresponding author: Ye-Soo Park Department of Orthopaedic Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine,  153 Gyeongchun-ro, Guri 11923, Korea Tel: +82-31-560-2317, Fax: +82-31-560-8781, E-mail: hyparkys@hanyang.ac.kr    ASJReview Article Asian Spine J 2016;10(3):593-600  •  http://dx.doi.org/10.4184/asj.2016.10.3.593 Asian Spine Journal Introduction Proximal junctional kyphosis (PJK) has become the great - est challenge in surgery for spinal deformity.",Non-OADS,/arxiv_data1/oa_pdf/97/21/asj-10-593.PMC4917781.pdf
"Keywords:  Vertebral column resection; Three column osteotomy; Pedicle subtraction osteotomy; Spine deformity; Complications;  Neurologic complications Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/34/c1/asj-10-601.PMC4917782.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Aug 26, 2015; Revised Oct 4, 2015; Accepted Oct 5, 2015 Corresponding author: Han Jo Kim Department of Orthopaedic Surgery, Hospital for Special Surgery, 535 E 70th St., New York, NY 10021, USA Tel: +1-212-774-2837, Fax: +1-646-797-8428, E-mail: hanjokimmd@gmail.com    ASJReview Article Asian Spine J 2016;10(3):601-609  •  http://dx.doi.org/10.4184/asj.2016.10.3.601 Asian Spine Journal Introduction The correction of rigid spinal deformity in adult patients  can require the use of three-column osteotomies (3COs),  specifically pedicle subtraction osteotomies (PSO) and  vertebral column resection (VCR).",Non-OADS,/arxiv_data1/oa_pdf/34/c1/asj-10-601.PMC4917782.pdf
"610 Asian Spine J 2016;10(3):610-610 Comment on “The Surgical Management of  T raumatic Lower Cervical Spondylolisthesis with  Posterior Percutaneous Pedicle Screw Fixation”  Arjun RHH, Vijay Goni, Sarvadeep Dhatt, Vishal Kumar, Rakesh John, Uday Guled, Harsha Vardhan    Department of Orthopaedics, Post Graduate Institute of Medical Education and Research, Chandigarh, India Copyright Ⓒ 2016 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/f6/asj-10-610.PMC4917783.pdf
"Asian Spine Journal • pISSN 1976-1902 eISSN 1976-7846 • www.asianspinejournal.orgReceived Oct 17, 2015; Accepted Oct 17, 2015 Corresponding author: Arjun RHH  Department of Orthopaedics, Post Graduate Institute of Medical Education and Research (PGIMER), Sector-12, Chandigarh, India-160012  Tel: +918872523222, Fax: +01722756740, E-mail: arjunrhh@yahoo.co.in    ASJLetter to the Editor Asian Spine J 2016;10(3):610-610  •  http://dx.doi.org/10.4184/asj.2016.10.3.610 Asian Spine Journal Dear Colleagues, Y our published technique evoked a great interest in us as  it was discussed in one of the journal clubs at our institute.",Non-OADS,/arxiv_data1/oa_pdf/f3/f6/asj-10-610.PMC4917783.pdf
Available athttp://www.aemps.gob.es/informa/ notasInformativaUsoHumano/ seguridad/2002/NI_2002- 03_nimesulida.htm (last accessed 16 April 2015).,OADS,/arxiv_data1/oa_pdf/f4/6d/BCP-82-238.PMC4917796.pdf
Available at http://www.ema.europa.eu/doc s/en_GB/document_library/ Referrals_document/Nimesulid e_31/WC500013818.pdf (last accessed 16 April 2015).,Non-OADS,/arxiv_data1/oa_pdf/f4/6d/BCP-82-238.PMC4917796.pdf
Availa ble at https://www.hpra.ie/ homepage/medicines/safety-notices/item?t=/nimesulide- suspension&id=7d69f825-9782-6eee-9b55-ff00008c97d0 (last accessed 16 April 2015).,Non-OADS,/arxiv_data1/oa_pdf/f4/6d/BCP-82-238.PMC4917796.pdf
Available at http://www.whocc.no/atc_ddd_index/(last accessed 21 July 2015).,OADS,/arxiv_data1/oa_pdf/f4/6d/BCP-82-238.PMC4917796.pdf
"Based onthe results of the data in healthy male subjects and RA patients,SB4 has been approved as the ﬁrst ETN biosimilar in the EU Competing Interests All of the authors have completed the Uni ﬁed Competing Interest form at http://www.icmje.org/coi_disclosure.pdf(available on request from the corresponding author) anddeclare that this study was funded by Samsung Bioepis Co.,Ltd., Incheon, Republic of Korea.",Non-OADS,/arxiv_data1/oa_pdf/f7/13/BCP-82-064.PMC4917797.pdf
http://www.ema.europa.eu/ docs/en_GB/document_library/Scienti ﬁc_guideline/2012/06/ WC500128686.pdf 10Committee for Medicinal Products for Human Use (CHMP).,Non-OADS,/arxiv_data1/oa_pdf/f7/13/BCP-82-064.PMC4917797.pdf
"European Medicines Agency, 2005. http://www.ema.europa.eu/docs/ en_GB/document_library/Scienti ﬁc_guideline/2009/09/ WC500003517.pdf 11Food and Drug Administration Center for Drug Evaluation and Research.",Non-OADS,/arxiv_data1/oa_pdf/f7/13/BCP-82-064.PMC4917797.pdf
"EuropeanMedicines Agency, 2010. http://www.ema.europa.eu/docs/ en_GB/document_library/Scienti ﬁc_guideline/2010/01/ WC500070039.pdf 15Food and Drug Administration Center for Drug Evaluation and Research.",Non-OADS,/arxiv_data1/oa_pdf/f7/13/BCP-82-064.PMC4917797.pdf
"US Department of Health and Human Service, 2014. http://www.fda.",Non-OADS,/arxiv_data1/oa_pdf/f7/13/BCP-82-064.PMC4917797.pdf
Supporting Information Additional Supporting Information may be found in the online version of this article at the publisher ’s web-site: http://onlinelibrary.wiley.com/doi/10.1111/bcp.,Non-OADS,/arxiv_data1/oa_pdf/f7/13/BCP-82-064.PMC4917797.pdf
"Competing Interests All authors have completed the Uni ﬁed Competing Inter- est form at http://www.icmje .org/coi_disclosure.pdf (http://www.icmje.org/coi_dis closure.pdf) (available on re- quest from the corresponding author) and declare the fol-lowing ﬁnancial relationships with organizations that m i g h th a v ea ni n t e r e s ti nt h es u b m i t t e dw o r ki nt h ep r e -vious 3 years: SC has been a consultant and investigatorfor P ﬁzer Inc. PE has undertaken clinical trials and pro- vided expert advice to Abbott/Abbvie, Bristol MyersSquibb, P ﬁzer, UCB, MSD, Roche, Novartis, Samsung, Takeda and Lilly.",Non-OADS,/arxiv_data1/oa_pdf/cb/b6/BCP-82-129.PMC4917800.pdf
Available at http://www.ema.europa.eu/docs/en_GB/ document_library/Scienti ﬁc_guideline/2013/06/WC500144124.,Non-OADS,/arxiv_data1/oa_pdf/cb/b6/BCP-82-129.PMC4917800.pdf
Available at http://www.hc-sc .gc.ca/dhp-mps/alt_formats/ pdf/brgtherap/applic-demande /guides/seb-pbu/seb-pbu-2010- eng.pdf (last accessed 16 September 2015).,Non-OADS,/arxiv_data1/oa_pdf/cb/b6/BCP-82-129.PMC4917800.pdf
Available at http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf (last accessed 16 September 2015).,Non-OADS,/arxiv_data1/oa_pdf/cb/b6/BCP-82-129.PMC4917800.pdf
Available at http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/cb/b6/BCP-82-129.PMC4917800.pdf
Available at http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/000165/WC500025821.pdf (last accessed 7 October 2014).7Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arth ritis.,Non-OADS,/arxiv_data1/oa_pdf/cb/b6/BCP-82-129.PMC4917800.pdf
Supporting Information Additional Supporting Information may be found in the online version of this article at the publisher ’s web-site: http://onlinelibrary.wiley.com/doi/10.1111/bcp.,Non-OADS,/arxiv_data1/oa_pdf/cb/b6/BCP-82-129.PMC4917800.pdf
For Review Only /g4/g9/g22/g19/g16/g10/g11/g13/g6/g14/g9/g15/g21 /g5/g23/g15/g6/g17/g21/g11/g7/g1/g14/g6/g19/g12/g9/g19 /g2/g13/g21/g9/g19/g9/g8/g1/g21/g6/g22 /g3/g9/g15/g8/g19/g11/g21/g9/g20 /g2/g24/g1/g17/g13/g6/g18/g22/g9Page 18 of 35 https://mc04.manuscriptcentral.com/caresCurrent Alzheimer Research 1 2 34 5 67 8 910 11 1213 14 1516 17 1819 20 2122 23 2425 26 2728 29 3031 32 3334 35 3637 38 3940 41 4243 44 45 46 4748 49 5051 52 5354 55 5657 58 5960,Non-OADS,/arxiv_data1/oa_pdf/2a/a1/CAR-13-281.PMC4917817.pdf
"10, 1526–1536 http://dx.doi.org/10.1080/00032719.2015.1118484  ELECTROCHEMISTRY  Voltammetric Determination of Dinonyl Diphenylamine and  Butylated Hydroxytoluene in Mineral and Synthetic Oil  Yaling Xianga, Xuzheng Qiana, Meng Huab, Bingxue Chenga, Wu Chena, and Jian Lia  aWuhan Research Institute of Materials Protection, State Key Laboratory of Special Surface Protection Materials  and Application Technology, Wuhan, Hubei, China; bMBE Department, City University of Hong Kong, Kowloon,  Hong Kong   ABSTRACT  A method is reported for the determination of diphenylamine and  butylated hydroxytoluene in mineral and synthetic oil.",Non-OADS,/arxiv_data1/oa_pdf/57/36/lanl-49-1526.PMC4917899.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/ licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is prope rly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/63/aa/yppc-24-147.PMC4917901.pdf
Johnston http://orcid.org /0000-0001-8201- 629X References 1 Canadian Cancer Society ’s Advisory Committee on Cancer Statistics.,Non-OADS,/arxiv_data1/oa_pdf/63/aa/yppc-24-147.PMC4917901.pdf
Online at http://www.rrh.org.au .,Non-OADS,/arxiv_data1/oa_pdf/63/aa/yppc-24-147.PMC4917901.pdf
"6, 1072 –1079 http://dx.doi.org/10.1080/19440049.2016.1184493 © 2016 European Union.",Non-OADS,/arxiv_data1/oa_pdf/c0/af/tfac-33-1072.PMC4917902.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc- nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/c0/af/tfac-33-1072.PMC4917902.pdf
"http://www.bfr.bund.de/cm/349/pri mary-aromatic-amines-from-printed-food-contact-materi als-such-as-napkins-or-bakery-bags.pdf Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y.",Non-OADS,/arxiv_data1/oa_pdf/c0/af/tfac-33-1072.PMC4917902.pdf
"https://standards.cen.eu/dyn/www/f?p= 204:110:0::::FSP_PROJECT,F SP_ORG_ID:7621,6153&cs= 149DB105508C3B355EB305A0DB7DFEE06 EC.2006 .",Non-OADS,/arxiv_data1/oa_pdf/c0/af/tfac-33-1072.PMC4917902.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.CONTACT Christine L. Gray clgray@email.unc.edu Department of Epidemiology, Gillings School of Global Public Health, CB #7435, University of North Carolina, Chapel Hill 27599-7435, NC, USAAIDS CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/a9/29/caic-28-857.PMC4917905.pdf
"7, 857 –865 http://dx.doi.org/10.1080/09540121.2016.1147013",Non-OADS,/arxiv_data1/oa_pdf/a9/29/caic-28-857.PMC4917905.pdf
"Retrieved Feburary 12, 2015, from http://www.unaids.org/sites/default/ ﬁles/en/media/ unaids/contentassets/documents/data-and-analysis/tools/spectrum/India2012report.pdf UNICEF.",Non-OADS,/arxiv_data1/oa_pdf/a9/29/caic-28-857.PMC4917905.pdf
"Retrieved April 25, 2014, from, http://www.unicef.org/sowc2012/pdfs/SOWC202012- Main20Report_EN_13Mar2012.pdf .",Non-OADS,/arxiv_data1/oa_pdf/a9/29/caic-28-857.PMC4917905.pdf
"5, 717–728 http://dx.doi.org/10.1080/00140139.2015.1084051 Slip resistance of winter footwear on snow and ice measured using maximum  achievable incline Jennifer Hsua,b, Robert Shawc, Alison Novaka, Yue Lia, Marcus Ormerodd, Rita Newtond, Tilak Duttaa,b and  Geoff Ferniea,b aiDAPT, Toronto rehabilitation i nstitute – University Health network, Toronto, c anada; bDepartment of m echanical and i ndustrial Engineering,  University of Toronto, Toronto, canada; cHealth and s afety Laboratory, Buxton, UK; dsUrFA cE i nclusive Design research c entre, University of  salford, Lancashire, UK ABSTRACT Protective footwear is necessary for preventing injurious slips and falls in winter conditions.",Non-OADS,/arxiv_data1/oa_pdf/ec/f3/terg-59-717.PMC4917907.pdf
"© 2015 The Author(s) Published by i nforma UK Limited, trading as Taylor & Francis group This is an open Access article distributed under the terms of the creative c ommons Attribution-nonc ommercial-noDerivatives License (http://creativecommons.org/licenses/by-nc- nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in  any way.KEYWORDS slips and falls; gait  kinematics; product safety; user testing; winter footwearARTICLE HISTORY received 30 July 2014 Accepted 27 July 2015 CONTACT Jennifer Hsu  jen.hsu@mail.utoronto.ca 1.",Non-OADS,/arxiv_data1/oa_pdf/ec/f3/terg-59-717.PMC4917907.pdf
"Accessed March 3, 2015, from http://www.canadapost.ca/cpo/mc/assets/pdf/aboutus/csr/2007_csrreport_en.pdf Canada Post Corporation.",Non-OADS,/arxiv_data1/oa_pdf/ec/f3/terg-59-717.PMC4917907.pdf
"Accessed March 3, 2015, from https://www.canadapost.ca/cpo/mr/assets/pdf/aboutus/csr/2008_csrreport_en.pdf Cham, R., and M. S. Redfern.",Non-OADS,/arxiv_data1/oa_pdf/ec/f3/terg-59-717.PMC4917907.pdf
"” Safety Science  Monitor 16 (1): 1–10, Article 5. http://ssmon.chb.kth.se/ volumes/vol16/5_Rolfsman_Bylund.pdf .",Non-OADS,/arxiv_data1/oa_pdf/ec/f3/terg-59-717.PMC4917907.pdf
"3, 344–367 http://dx.doi.org/10.1080/00140139.2015.1081412 Multi-modal assessment of on-road demand of voice and manual phone calling and  voice navigation entry across two embedded vehicle systems Bruce Mehlera, David Kiddb, Bryan Reimera, Ian Reaganb, Jonathan Dobresa and Anne McCarttb amiT AgeLab, new England University Transportation c enter, c ambridge, m A, UsA; binsurance i nstitute for Highway s afety, Arlington, VA, UsA ABSTRACT One purpose of integrating voice interfaces into embedded vehicle systems is to reduce drivers’ visual and  manual distractions with ‘infotainment’ technologies.",Non-OADS,/arxiv_data1/oa_pdf/c2/be/terg-59-344.PMC4917911.pdf
"This is an open Access article distributed under the terms of the creative c ommons Attribution-nonc ommercial-noDerivatives License (http://creativecommons.org/Licenses/by-nc-nd/4.0/),  which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.KEYWORDS Voice interface; visual  demand; distraction; workload; human–machine interfaceARTICLE HISTORY received 20 December 2014 Accepted 17 June 2015 CONTACT Bruce m ehler  bmehler@mit.edu The Appendix was originally published with errors.",Non-OADS,/arxiv_data1/oa_pdf/c2/be/terg-59-344.PMC4917911.pdf
See Corrigendum (http://dx.doi.org/10.1080/00140139.2016.1179501).1.,Non-OADS,/arxiv_data1/oa_pdf/c2/be/terg-59-344.PMC4917911.pdf
https://bitbucket.org/agelab/ annotator .,Non-OADS,/arxiv_data1/oa_pdf/c2/be/terg-59-344.PMC4917911.pdf
http://web.mit.,Non-OADS,/arxiv_data1/oa_pdf/c2/be/terg-59-344.PMC4917911.pdf
"16, 1564 –1580 http://dx.doi.org/10.1080/02640414.2015.1123284 © 2015 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/42/71/rjsp-34-1564.PMC4917912.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/42/71/rjsp-34-1564.PMC4917912.pdf
"ORCID Hideki Takagi http://orcid.org/0000-0001-8797-7014 Motomu Nakashima http://orcid.org/0000-0002-1349-8763 Yohei Sato http://orcid.org/0000-0001-5313-5767 Kazuo Matsuuchi http://orcid.org/0000-0002-7565-1858 Ross H. Sanders http://orcid.org/0000-0003-0489-3048 References Adams, M. ( 2000 ).",Non-OADS,/arxiv_data1/oa_pdf/42/71/rjsp-34-1564.PMC4917912.pdf
"8, 422–427 http://dx.doi.org/10.1080/10826076.2016.1169429  Simultaneous quantitative analysis of main components in linderae reflexae radix  with one single marker  Li-li Wanga,b, Yun-bin Zhangc, Xiao-ya Suna, and Sui-qing Chena,b  aSchool of Pharmacy, Henan University of Traditional Chinese Medicine, Jinshui District, ZhengZhou, China; bCollaborative Innovation Center for  Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Jinshui District, ZhengZhou, China; cHenan  Province Hospital of Traditional Chinese Medicine, Jinshui District, ZhengZhou, China   ABSTRACT  Establish a quantitative analysis of multi-components by the single marker (QAMS) method for quality  evaluation and validate its feasibilities by the simultaneous quantitative assay of four main components  in Linderae Reflexae Radix.",Non-OADS,/arxiv_data1/oa_pdf/fe/21/ljlc-39-422.PMC4917913.pdf
"https://github.com/anvc/scalar/graphs/ contributors .TRUSTING OTHERS TO ‘DO THE MATH ’ 383 INTERDISCIPLINARY SCIENCE REVIEWS, Vol.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Accessed February 2. http://mith.umd.edu/topicmodeling/about/ About Scalar.,OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Accessed May 17. http://scalar.usc.edu/scalar/ About Southern Spaces.,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"Accessed May 17. http://southernspaces.org/about Alexander, Marc.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Accessed May 18. http://scalar.usc.edu/scalar/ showcase/ Belfast Group Poetry|Networks.,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"Belfast Group Poetry|Networks .http://belfastgroup.digitalscholarship .emory.edu/ Chang, Geoffrey, Christopher B. Roth, Christopher L. Reyes, Owen Pornillos, Yen-Ju Chen, and Andy P. Chen.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"Accessed April 4. http://journalofdigitalhumanities.org/2– 1/ review-papermachines-by-adam-crymble/ Fertig, Scott, Eric Freeman, and David Gelernter.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"http://www.sigchi.org/chi96/proceedings/videos/Fertig/etf.htm Goble, Carole.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"Accessed April 4. http://journalofdigitalhumanities.org/2-1/ review-mallet-by-ian-milligan-and-shawn-graham/ Hettrick, Simon.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Software Sustainability Institut e. Accessed December 4. http://www.software.ac.uk/blog/ 2014-12-04-its-impossible-conduct-research-without-software-say-7-out-10-uk-researchers .,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
http://dhcommons.org/journal/issue-1 .,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Belfast Group Poetry| Networks .http://belfastgroup.digitalscholarship.emory.edu/network/about/ .,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"Accessed April 9. http://journalofdigitalhumanities.org/2-1/dh-contribution-to-topic-modeling/ Miller, Greg.",OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"presented at the Topic Modeling for Humanities Research, Maryland Institute for Technology in the Humanities, College Park, Maryland, Accessed November 3. https://vimeo.com/53080123 Nelson, Robert.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Accessed September 7. http://dsl.richmond.,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Genius-annotated version of ‘http://ejohn.org/files/jquery-Original.html.,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"http://tools.ietf.org/html/rfc1321 Schloen, David, and Sandra Schloen.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"http://www.digitalhumanities.org/dhq/vol/8/4/ 000196/000196.html Spool, Jared.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Accessed September 14. https://www.uie.com/brainsparks/2011/09/14/do-users-change-their-settings/ The Heartbleed Bug.,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"Accessed May 8. http://heartbleed.com/ Underwood, Ted, and Jordan Sellers.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
Accessed June 26. http://journalofdigitalhumanities.org/1-2/ the-emergence-of-literary-diction-by-ted-underwood-and-jordan-sellers/ “Vectors Journal: Introduction.,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"Accessed May 17. http://vectors.usc.edu/journal/index.php?page= Introduction Visconti, Amanda.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
http://dissertation.amandavis conti.com/ .,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
In KDD .http://www.cs.umass.edu/mimno/papers/fast-topic-model.,Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"edu; http://rlskoeser.github.io/392 REBECCA SUTTON KOESER INTERDISCIPLINARY SCIENCE REVIEWS, Vol.",Non-OADS,/arxiv_data1/oa_pdf/8a/b5/yisr-40-376.PMC4917914.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, trans- formed, or built upon in any way.DOI 10.1080/03080188.2016.1165456",Non-OADS,/arxiv_data1/oa_pdf/8c/2a/yisr-40-342.PMC4917915.pdf
"ORCID Tara Andrews http://orcid.org/0000-0001-6930-3470 References Bogost, Ian.",Non-OADS,/arxiv_data1/oa_pdf/8c/2a/yisr-40-342.PMC4917915.pdf
http://www.digitalhumanities.org/dhq/vol/5/1/000091/000091.html .,Non-OADS,/arxiv_data1/oa_pdf/8c/2a/yisr-40-342.PMC4917915.pdf
http://www.press.uchicago.,Non-OADS,/arxiv_data1/oa_pdf/8c/2a/yisr-40-342.PMC4917915.pdf
"1, 11 –24 http://dx.doi.org/10.1080/01621424.2016.1145166 © Sytske Van Bruggen, Jacobijn Gussekloo, Christina Bode, Dorothea P. Touwen, Dick P. Engberts, and Jeanet W. Blom.",Non-OADS,/arxiv_data1/oa_pdf/51/0e/whhc-35-011.PMC4917916.pdf
"Published with license by Taylor & Francis This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/51/0e/whhc-35-011.PMC4917916.pdf
"S1, S1 /C0S11 http://dx.doi.org/10.1080/17458080.2015.1102343",Non-OADS,/arxiv_data1/oa_pdf/f0/7a/tjen-11-S01.PMC4917917.pdf
This article makes reference to supplementary material available on the publisher ’s website at http://dx.doi.org/10.1080/17437199.,Non-OADS,/arxiv_data1/oa_pdf/09/d2/rhpr-10-187.PMC4917920.pdf
"2, 187 –203 http://dx.doi.org/10.1080/17437199.2016.1138871",Non-OADS,/arxiv_data1/oa_pdf/09/d2/rhpr-10-187.PMC4917920.pdf
"To do so, we entered the abstracts of the articles that met our inclusion criteria into Wordle ( http://www.wordle.net ) to identify the most commonly used words.",Non-OADS,/arxiv_data1/oa_pdf/09/d2/rhpr-10-187.PMC4917920.pdf
Retrieved from http://www.weightwatchers.co.uk/templates/marketing/Landing_1col_nonav.,Non-OADS,/arxiv_data1/oa_pdf/09/d2/rhpr-10-187.PMC4917920.pdf
"Retrieved January 15, 2015, from http://mason.gmu.edu/~ dwilsonb/ma.html Wing, R. R., Gorin, A.",Non-OADS,/arxiv_data1/oa_pdf/09/d2/rhpr-10-187.PMC4917920.pdf
"6, 1053 –1062 http://dx.doi.org/10.1080/19440049.2016.1188436 © 2016 European Union.",Non-OADS,/arxiv_data1/oa_pdf/f8/01/tfac-33-1053.PMC4917924.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc- nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/f8/01/tfac-33-1053.PMC4917924.pdf
"ORCID Carlos Gonçalves http://orcid.org/0000-0002-2569-7452 References Baumgartner S, Führer M, Krska R. 2010.",Non-OADS,/arxiv_data1/oa_pdf/f8/01/tfac-33-1053.PMC4917924.pdf
Available from: http://ec.europa.eu/food/fs/ scoop/task3210.pdf European Commission.,Non-OADS,/arxiv_data1/oa_pdf/f8/01/tfac-33-1053.PMC4917924.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.CONTACT Kevin Schluter kevin.schluter@nyu.edu Supplemental data for this article can be accessed at http://dx.doi.org/10.1080/23273798.2016.1151058 .LANGUAGE, COGNITION AND NEUROSCIENCE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/13/66/plcp-31-728.PMC4917926.pdf
"6, 728 –740 http://dx.doi.org/10.1080/23273798.2016.1151058",Non-OADS,/arxiv_data1/oa_pdf/13/66/plcp-31-728.PMC4917926.pdf
"ORCID Kevin Schluter http://orcid.org/0000-0003-2721-9400 Stephen Politzer-Ahles http://orcid.org/0000-0002- 5474-7930 Diogo Almeida http://orcid.org/0000-0003-4674-8092 References Abdi, H., Williams, L. J., Valentin, D., & Bennani-Dosse, M. ( 2012 ).",Non-OADS,/arxiv_data1/oa_pdf/13/66/plcp-31-728.PMC4917926.pdf
"Retrieved from http://www.iphod.com Walter, M. A., & Hacquard, V. ( 2004 ).MEG evidence for phonolo- gical underspeci ﬁcation .",OADS,/arxiv_data1/oa_pdf/13/66/plcp-31-728.PMC4917926.pdf
"2, 196 –207 http://dx.doi.org/10.1080/14427591.2016.1162191",Non-OADS,/arxiv_data1/oa_pdf/0a/e5/rocc-23-196.PMC4917970.pdf
ORCID Ana L. Borges da Costa http://orcid.org/0000-0003-1124-0694 Diane L. Cox http://orcid.org/0000-0003-2691-6423JOURNAL OF OCCUPATIONAL SCIENCE 205,Non-OADS,/arxiv_data1/oa_pdf/0a/e5/rocc-23-196.PMC4917970.pdf
http://www.statystyka.medstat.waw.pl/ wyniki/wyniki.htm [Access: 9.05.2016].,Non-OADS,/arxiv_data1/oa_pdf/50/62/RU-54-27667.PMC4918044.pdf
"Zakład Ubezpieczeń Społecznych, Departament Statystyki i Pro-   gnoz Aktuarialnych Wydatki na świadczenia z ubezpieczeń społecznych związane z niezdolnością do pracy w 2014 r. http://www.zus.pl/files/Wydatki%20na%20%C5%9Bwiadcze-nia%20z%20ubezpiecze%C5%84%20spo%C5%82ecznych%20zwi%C4%85zane%20z%20niezdolno%C5%9Bci%C4%85%20do%20pracy%20w%202014%20r.pdf pp.",Non-OADS,/arxiv_data1/oa_pdf/50/62/RU-54-27667.PMC4918044.pdf
http://www.statystyka.medstat.waw.pl/wyniki/Tabe- laEurostat2014szac.htm [Access: 15.01.2016].,Non-OADS,/arxiv_data1/oa_pdf/3f/2e/RU-54-27670.PMC4918047.pdf
World Health Organization http://www.who.int/en/ [Access:  7.04.2016].,Non-OADS,/arxiv_data1/oa_pdf/3f/2e/RU-54-27670.PMC4918047.pdf
Available form: http://hypertextbook.com/facts/2003/VietTran.shtml  [Last accessed on 2013 May 11].,Non-OADS,/arxiv_data1/oa_pdf/1a/fd/ABR-5-101.PMC4918210.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/59/89/itt-3-001.PMC4918229.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 1–8ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S3082 1emerging treatments in management of prostate  cancer: biomarker validation and endpoints   for immunotherapy clinical trial design Susan F Slovin Genitourinary Oncology Service,   Sidney Kimmel Center for Prostate  and Urologic Cancers, Memorial  Sloan-Kettering Cancer Center,   New Y ork, NY, USA Correspondence: Susan F Slovin   Sidney Kimmel Center for Prostate   and Urologic Cancers, Memorial   Sloan-Kettering Cancer Center,   1275 York Avenue, New York,   NY 10065, USA   Fax +1 212 988 0701   Tel +1 646 422 4470   email slovins@mskcc.or gAbstract:  The rapidly emerging field of immunotherapy and the development of novel   immunologic agents that have been approved in melanoma and successfully studied in lung  cancer, kidney cancer, and prostate cancer have mandated that there be uniformity in clinical  trial analysis beyond conventional survival endpoints and imaging.",Non-OADS,/arxiv_data1/oa_pdf/59/89/itt-3-001.PMC4918229.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/59/89/itt-3-001.PMC4918229.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/38/d1/itt-3-009.PMC4918230.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 9–18ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  9RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S3204 9Implications of chemokine receptors   and inflammatory lipids in cancer Johannes Rolin Azzam A Maghazachi Department of Physiology, Institute   of Basic Medical Sciences, Faculty   of Medicine, University of Oslo,    Oslo, Norway Correspondence: Johannes Rolin   Department of Physiology, Institute   of Basic Medical Sciences, Faculty of   Medicine, University of Oslo, POB 1105   Blindern N-0317, Oslo, Norway   email johannes.rolin@medisin.uio.n oAbstract:  Inflammatory lipids receive much attention due to their important biological activities.",Non-OADS,/arxiv_data1/oa_pdf/38/d1/itt-3-009.PMC4918230.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/38/d1/itt-3-009.PMC4918230.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/03/54/itt-3-019.PMC4918231.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 19–28ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  19RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S4013 1Immunotherapy for the treatment of Alzheimer’s  disease: amyloid- β or tau, which is the right target?",Non-OADS,/arxiv_data1/oa_pdf/03/54/itt-3-019.PMC4918231.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/03/54/itt-3-019.PMC4918231.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 29–38ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  29RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S37419B cell receptor pathway in chronic lymphocytic  leukemia: specific role of CC-292 Jon e Arnason1 Jennifer R Brown2 1Beth Israel Deaconess Medical  Center, 2CLL Center, Department  of Medical Oncology, Dana-Farber  Cancer Institute, Harvard Medical  School, Boston, MA, USA Correspondence: Jon E Arnason   Beth Israel Deaconess Medical   Center, KS121, 330 Brookline Ave,   Boston, MA, 02215, USA   email jarnason@bidmc.harvard.ed uAbstract:  Chronic lymphocytic leukemia (CLL) is the most common adult leukemia.",Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
Available from: http://clinicaltrials.gov/show/NCT01520519.,Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
Available from: http://clinicaltrials.gov/ show/NCT01611090.,Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
Available  from: http://clinicaltrials.gov/show/NCT01569295.,Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
Available from: http://clinicaltrials.gov/show/ NCT01732861.,Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
Available from: http://clinicaltrials.gov/show/NCT01744626.,Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/38/d6/itt-3-029.PMC4918232.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e0/69/itt-3-039.PMC4918233.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 39–54ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  39REVIEWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S5652 9Interleukin-17 and type 17 helper T cells   in cancer management and research Nicolas J Llosa1 Abby L Geis2 Erik Thiele Orberg2 Franck Housseau2 1Department of Pediatric Oncology,   2Department of Oncology , Sidney  Kimmel Comprehensive Cancer  Center, Johns Hopkins University,   Baltimore, MD, USA Correspondence : Franck Housseau   Johns Hopkins University, Department  of Oncology, Cancer Research Building  1, Room 4m59, 1650 Orleans Street,  Baltimore, MD, USA, 21287   Tel +1 410 502 984 6  Fax +1 410 955 4905   Email fhousse1@jhmi.ed uAbstract:  Since their recent discovery, T helper 17 (Th17)  cells have been frequently detected  in the tumor microenvironment of many malignancies, but their clinical implications remain  largely unknown.",Non-OADS,/arxiv_data1/oa_pdf/e0/69/itt-3-039.PMC4918233.pdf
Available  from: http://clinicaltrials.gov/show/NCT01010581.,Non-OADS,/arxiv_data1/oa_pdf/e0/69/itt-3-039.PMC4918233.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/e0/69/itt-3-039.PMC4918233.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a1/27/itt-3-055.PMC4918234.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 55–66ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  55RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S4012 1Dendritic cell vaccination for glioblastoma  multiforme: review with focus on predictive  factors for treatment response Joost Dejaegher¹ Stefaan van Gool² Steven De vleeschouwer¹ ¹Department of Neurosciences,   ²Department of Microbiology and  Immunology, KU Leuven, Leuven,   Belgium Correspondence: Steven De  vleeschouwer   Department of Neurosciences,   O&N II Herestraat 49 – Box 7003,   3000 Leuven, Belgium   Tel +32 16 34 4290   Fax +32 16 34 4285   email steven.devleeschouwer@uzleuven.b eAbstract:  Glioblastoma multiforme (GBM) is the most common and most aggressive type of  primary brain cancer.",Non-OADS,/arxiv_data1/oa_pdf/a1/27/itt-3-055.PMC4918234.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/a1/27/itt-3-055.PMC4918234.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4a/30/itt-3-079.PMC4918236.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 79–89ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  79RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S3729 2Antigen-based immunotherapy for the treatment  of acute lymphoblastic leukemia: the emerging  role of blinatumomab Mark R Litzow Mayo Clinic, Rochester, MN, USA Correspondence: Mark R Litzow   Division of Hematology, Mayo Clinic,   200 First Street, Sw, Rochester,   MN 55905, USA   Tel +1 507 284 5362   Fax +1 507 266 4972   email litzow.mark@mayo.ed uAbstract:  Acute lymphoblastic leukemia (ALL) arises from immature B and T lymphoblasts.",Non-OADS,/arxiv_data1/oa_pdf/4a/30/itt-3-079.PMC4918236.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/4a/30/itt-3-079.PMC4918236.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c4/b0/itt-3-091.PMC4918237.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 91–96ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  91RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S4019 9Clinical potential of apremilast   in the treatment of psoriatic arthritis Alberto Cauli Giovanni Porru Matteo Piga Alessandra vacca Grazia Dessole Alessandro Mathieu Rheumatology Unit, Department  of Medical Sciences, Policlinico of  University of Cagliari, Monserrato,   Italy Correspondence: Alberto Cauli   Department of Medical Sciences,   Rheumatology Unit, Policlinico   of University of Cagliari, ss  554,   Monserrato, Cagliari, Italy   Tel/Fax +39 070 5109 6383  Mob +39 348 410 9449  email cauli@medicina.unica.i tAbstract:  Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by  joint and skin involvement, and by typical extra-articular manifestations.",Non-OADS,/arxiv_data1/oa_pdf/c4/b0/itt-3-091.PMC4918237.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/c4/b0/itt-3-091.PMC4918237.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/77/a0/itt-3-107.PMC4918239.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 107–120ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  107RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/ITT .S3142 5Hairy cell leukemia – immunotargets   and therapies Faisal Basheer David M Bloxham Mike A Scott George A Follows Department of Haematology,   Addenbrookes Hospital, University   of Cambridge, Cambridge, UK Correspondence: George A Follows;   Faisal Basheer   Department of Haematology,   Addenbrookes Hospital,   University of Cambridge, Hills Road,   Cambridge, CB2  0XY, UK   email george.follows@addenbrookes.nhs.",Non-OADS,/arxiv_data1/oa_pdf/77/a0/itt-3-107.PMC4918239.pdf
Available  from: http://clinicaltrials.gov/show/NCT0032155 5.,Non-OADS,/arxiv_data1/oa_pdf/77/a0/itt-3-107.PMC4918239.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/77/a0/itt-3-107.PMC4918239.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3a/ca/itt-3-121.PMC4918240.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 121–134ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  121RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/ITT .S6247 1Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/3a/ca/itt-3-121.PMC4918240.pdf
"Or use: http://dvpr.es/1lGZdg gNanocarrier-based immunotherapy in cancer  management and research Manu Smriti Singh1 Sangeeta Bhaskar2 1Laboratory of Pharmaceutical  T echnology and Biopharmaceutics,   University of Bonn, Bonn, Germany;   2Product Development Cell, National  Institute of Immunology, New Delhi,   India Correspondence: Sangeeta Bhaskar   Product Development Cell, National   Institute of Immunology, Aruna Asaf   Ali Marg, New Delhi 110067, India   Tel +91 11 2670 3670   Fax +91 11 2616 2125   email sangeeta@nii.ac.i nAbstract:  Research in cancer immunotherapy has gained momentum in the last two decades,  with many studies and clinical trials showing positive therapeutic outcomes.",Non-OADS,/arxiv_data1/oa_pdf/3a/ca/itt-3-121.PMC4918240.pdf
Available from: http://clinicaltrials.gov/show/NCT0039507 0.,Non-OADS,/arxiv_data1/oa_pdf/3a/ca/itt-3-121.PMC4918240.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/3a/ca/itt-3-121.PMC4918240.pdf
Available  from: http://news.harvard.edu/gazette/story/2013/09/cancer-vaccine- begins-phase-i-clinical-trials /.,Non-OADS,/arxiv_data1/oa_pdf/3a/ca/itt-3-121.PMC4918240.pdf
Available  from: http://www.cytimmune.com/go.cfm?do =page.viewandpid =26.,Non-OADS,/arxiv_data1/oa_pdf/3a/ca/itt-3-121.PMC4918240.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/89/31/itt-3-135.PMC4918241.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpImmunoTargets and Therapy 2014:3 135–150ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  135RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S4026 4Therapeutic cancer vaccines and combination  immunotherapies involving vaccination Trang Nguyen1 Julie Urban1 Pawel Kalinski1–5 1Department of Surgery, 2Department  of Immunology, 3Department of  Microbiology and Infectious Disease,   4Department of Bioengineering,   University of Pittsburgh, 5University  of Pittsburgh Cancer Institute,   Pittsburgh, PA, USA Correspondence: Pawel Kalinski   University of Pittsburgh and the   University of Pittsburgh Cancer   Institute, Hillman Cancer Center,   UPCI Research Pavilion, Suite 1.46,   5117 Center Ave, Pittsburgh,   PA 15213-1863, USA   Tel +1 412 623 7712   Fax +1 412 623 7709   email kalinskip@upmc.ed uAbstract:  Recent US Food and Drug Administration approvals of Provenge® (sipuleucel-T) as  the first cell-based cancer therapeutic factor and ipilimumab (Y ervoy®/anticytotoxic T - lymphocyte  antigen-4) as the first “checkpoint blocker” highlight recent advances in cancer immunotherapy.",Non-OADS,/arxiv_data1/oa_pdf/89/31/itt-3-135.PMC4918241.pdf
Available from: http://eccamsterdam2013.ecco- org.eu/Scientific-Programme/Abstract-search.aspx?abstractid =8961.,Non-OADS,/arxiv_data1/oa_pdf/89/31/itt-3-135.PMC4918241.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/89/31/itt-3-135.PMC4918241.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/02/ee/itt-3-151.PMC4918242.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2014:3 151–165ImmunoTargets and Therapy Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/02/ee/itt-3-151.PMC4918242.pdf
"Or use: http://dvpr.es/1E3Ds2 CDove press submit your manuscript | www.dovepress.co m Dove press  151RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S3779 0Harnessing immunosurveillance: current  developments and future directions   in cancer immunotherapy Maureen L Drakes Patrick J Stiff Department of Medicine, Division of  Hematology and Oncology, Stritch  School of Medicine, Loyola University  Chicago, Maywood, IL, USA Correspondence: Maureen L Drakes   Loyola University Chicago, Cardinal  Bernardin Cancer Center, Oncology  Institute – room  232, 2160 South First  Avenue, Maywood, IL  60153, USA   Tel +1 708 327 3125  Fax +1 708 327 3219  email mdrakes@luc.ed uAbstract:  Despite improved methods of cancer detection and disease management over the  last few decades, cancer remains a major public health problem in many societies.",Non-OADS,/arxiv_data1/oa_pdf/02/ee/itt-3-151.PMC4918242.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/02/ee/itt-3-151.PMC4918242.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 1–11ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1REVIEWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/ITT .S4965 6Antigen-based immunotherapy for autoimmune  disease: current status Darren Lowell Hirsch Punita Ponda Division of Allergy and Immunology,   North Shore-Long Island Jewish  Health System/Hofstra North Shore- LIJ School of Medicine, New Hyde  Park, NY, USA Correspondence: Darren Hirsch   North Shore-Long Island Jewish Health  System/Hofstra North Shore-LIJ School  of Medicine, Division of Allergy and  Immunology,  865 Northern   Boulevard – Suite  101, Great Neck,   NY 11021, USA   Tel +1 516 622 5192  Fax +1 516 622 5060  Email dhirsch12@nshs.ed uAbstract:  Autoimmune diseases are common chronic disorders that not only have a major  impact on the quality of life but are also potentially life-threatening.",Non-OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
Available from: http://www.aarda.org/autoimmune-information/ autoimmune-statistics /.,OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
Available from: http://www.diamyd.com/docs/trials - Diabetes.aspx?section =trials.,Non-OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
"Available from: http://www.immupharma.org/lupuzo r.  Accessed May  12, 2014.",Non-OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
Available from: http://www.immusant.com/clinical-trial /.,Non-OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
Available from http://www.di.uq.edu.au/clinicaltri - alra.,Non-OADS,/arxiv_data1/oa_pdf/09/34/itt-4-001.PMC4918244.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/6d/c8/itt-4-027.PMC4918245.pdf
Information on how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 27–34ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  27RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S4992 3Alzheimer’s disease and immunotherapy:   what is wrong with clinical trials?,Non-OADS,/arxiv_data1/oa_pdf/6d/c8/itt-4-027.PMC4918245.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/6d/c8/itt-4-027.PMC4918245.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d4/88/itt-4-013.PMC4918246.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 13–26ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  13RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S7672 0The role of autophagy in microbial   infection and immunity Mayura Desai1 Rong Fang2 Jiaren Sun1 1Department of Microbiology   and Immunology,  2Department   of Pathology, University of T exas  Medical Branch at Galveston,   Galveston, TX, USA Correspondence: Mayura Desai   Department of Microbiology and  Immunology, University of Texas Medical  Branch,  301 University Boulevard,  Galveston, TX  77555-1070, USA   Tel +1 409 772 4911  Fax +1 409 747 6869  email madesai@utmb.ed uAbstract:  The autophagy pathway represents an evolutionarily conserved cell recycling process  that is activated in response to nutrient deprivation and other stress signals.",Non-OADS,/arxiv_data1/oa_pdf/d4/88/itt-4-013.PMC4918246.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/d4/88/itt-4-013.PMC4918246.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ff/d2/itt-4-035.PMC4918247.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 35–44ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  35RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S3740 9Development of antibody-based c-Met   inhibitors for targeted cancer therapy Dongheon Lee eun-Sil Sung Jin-Hyung Ahn Sungwon An Jiwon Huh weon-Kyoo Y ou Hanwha Chemical R&D Center,   Biologics Business Unit, Daejeon,   Republic of Korea Correspondence: weon-Kyoo You   Hanwha Chemical R&D Center, Biologics  Business Unit, 76 Gajeong-Ro,   Yuseong-Gu, Daejeon 305-804,   Republic of Korea   Tel +82 42 865 6980   Fax +82 42 865 6744   email weonkyoo.you@hanwha.co mAbstract:  Signaling pathways mediated by receptor tyrosine kinases (RTKs) and their ligands  play important roles in the development and progression of human cancers, which makes   RTK-mediated signaling pathways promising therapeutic targets in the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/ff/d2/itt-4-035.PMC4918247.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/ff/d2/itt-4-035.PMC4918247.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d7/d9/itt-4-045.PMC4918248.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 45–53ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  45RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S6149 8Current perspectives on natural killer cell  education and tolerance: emerging roles   for inhibitory receptors L Michael Thomas Laboratory of Immunogenetics,   National Institute of Allergy and  Infectious Diseases, National  Institutes of Health, Rockville, MD,   USA Correspondence: L Michael Thomas   Laboratory of Immunogenetics, National  Institute of Allergy and Infectious  Diseases, National Institutes of Health,   12441 Parklawn Drive, Rockville, MD   20852, USA   Tel +1 301 496 2951  Fax +1 301 402 0259  email louis.thomas@nih.go vAbstract:  Natural killer (NK) cells are regulated through the coordinated functions of activat - ing and inhibitory receptors.",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/itt-4-045.PMC4918248.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/d7/d9/itt-4-045.PMC4918248.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/11/6f/itt-4-091.PMC4918249.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 91–100ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  91RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S6129 2Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/11/6f/itt-4-091.PMC4918249.pdf
"Or use: http://youtu.be/pvRLCYOOR7 senhancement of antibody-dependent cell  mediated cytotoxicity: a new era in cancer  treatment Narendiran Rajasekaran1,* Cariad Chester1,* Atsushi Y onezawa1,2 Xing Zhao1,3 Holbrook e Kohrt1 1Division of Oncology, Stanford  School of Medicine, Stanford  University, Stanford, CA, USA;   2Department of Clinical Pharmacology  and Therapeutics, Kyoto University  Hospital, Kyoto, Japan; 3Tissue  engineering and Stem Cells Research  Center, Department of Immunology,   Guiyang Medical University, Guiyang,   Guizhou Province, People’s Republic  of China *These authors contributed equally to  this work Correspondence: Holbrook e Kohrt   Division of Oncology, Stanford School  of Medicine, 269 Campus Drive, CCSR  1105, Stanford University Medical  Center, Stanford, CA 94305-5151, USA   Tel +1 650 725 6452   Fax +1 650 736 1454   email k ohrt@stanford.ed uAbstract:  The therapeutic efficacy of some anti-tumor monoclonal antibodies (mAbs) depends  on the capacity of the mAb to recognize the tumor-associated antigen and induce cytotoxic - ity via a network of immune effector cells.",Non-OADS,/arxiv_data1/oa_pdf/11/6f/itt-4-091.PMC4918249.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/11/6f/itt-4-091.PMC4918249.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e6/8b/itt-4-101.PMC4918250.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 101–109ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  101RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S5806 4emerging roles for HMGB1 protein in immunity,  inflammation, and cancer Simona Martinotti Mauro Patrone elia Ranzato DiSIT – Dipartimento di Scienze e  Innovazione Tecnologica, University of  Piemonte Orientale, Alessandria, Italy Correspondence: elia Ranzato   DiSIT – Dipartimento di Scienze e  Innovazione Tecnologica, University of  Piemonte Orientale, viale Teresa Michel   11, 15121 Alessandria, Italy   Tel +39 0131 3602 60   Fax +39 0131 3602 43   email elia.ranzato@uniupo.i tAbstract:  High-mobility group box  1 (HMGB1) protein is a member of the highly conserved  non-histone DNA binding protein family.",Non-OADS,/arxiv_data1/oa_pdf/e6/8b/itt-4-101.PMC4918250.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/e6/8b/itt-4-101.PMC4918250.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/23/c6/itt-4-111.PMC4918251.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 111–122ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  111RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S6164 7CD28 co-stimulation in T -cell homeostasis:   a recent perspective Niklas Beyersdorf Thomas Kerkau Thomas Hünig Institute for virology and  Immunobiology, University of  würzburg, würzburg, Germany Correspondence: Thomas Hünig   Institute for virology and Immunobiology,  University of würzburg, versbacher  Strasse  7, D-97079 würzburg, Germany   Tel +49 931 31 89796  Fax +49 931 31 81619  email huenig@vim.uni-wuerzburg.d eAbstract:  T -cells play a key role within the adaptive immune system mediating cellular  immunity and orchestrating the immune response as a whole.",Non-OADS,/arxiv_data1/oa_pdf/23/c6/itt-4-111.PMC4918251.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/23/c6/itt-4-111.PMC4918251.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9c/22/itt-4-123.PMC4918252.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 123–130ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  123RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S6039 8Anti-ghrelin antibodies in appetite suppression:  recent advances in obesity pharmacotherapy velimir Altabas Vanja Zjačić-Rotkvić Department of endocrinology,   Diabetes and Metabolic Diseases,   “Mladen Sekso”, Clinic for Internal  Medicine, University Hospital Center  “Sestre milosrdnice”, Zagreb, Croatia Correspondence: Velimir Altabas   Department of endocrinology, Diabetes  and Metabolic Diseases “Mladen Sekso”,  Clinic for Internal Medicine, University  Hospital Center “Sestre milosrdnice”,  Vinogradska cesta 29, 1000 Zagreb,  Croatia   Tel +385 98 741 218   Fax +385 1 3787 692   email velimir.altabas@ gmail.co mAbstract:  Obesity is a medical condition caused by accumulated excess body fat with negative  impact on patients’ health, including decreased life expectancy.",Non-OADS,/arxiv_data1/oa_pdf/9c/22/itt-4-123.PMC4918252.pdf
Available from: http://www.who.int/mediacentre/factsheets/fs311/en /.,Non-OADS,/arxiv_data1/oa_pdf/9c/22/itt-4-123.PMC4918252.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/9c/22/itt-4-123.PMC4918252.pdf
"Available from: http://www.cytos.ch/news/180/15/ Phase-I-IIa-clinical-trial-with-obese-individuals-shows-no-effect-of- CYT009-GhrQb-on-weight-loss.htm l. Accessed January 3, 2015.",Non-OADS,/arxiv_data1/oa_pdf/9c/22/itt-4-123.PMC4918252.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7a/3f/itt-4-131.PMC4918253.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 131–141ImmunoTargets and Therapy Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/7a/3f/itt-4-131.PMC4918253.pdf
"Or use: http://youtu.be/3X9ePtKva2 MDove press submit your manuscript | www.dovepress.co m Dove press  131RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S5797 6Novel perspectives on non-canonical inflammasome  activation Catherine emma  Diamond1,2 Hanif Javanmard Khameneh1 David Brough2 Alessandra Mortellaro1 1Singapore Immunology Network  (SIgN), Agency for Science, Technology  and Research (A*STAR), Singapore;   2Faculty of Life Sciences, University of  Manchester, Manchester, UK Correspondence: Alessandra Mortellaro   Singapore Immunology Network (SIgN),  Agency for Science, Technology and  Research (A*STAR),  8A Biomedical  Grove, #04-06 Immunos, Singapore   138648   Tel +65 6407 0065  Fax +65 6464 2057  email alessandra_mortellaro@immunol.a- star.edu.s gAbstract:  Inflammasomes are cytosolic multi-protein complexes that regulate the secretion of  the proinflammatory cytokines, IL-1 β and IL-18, and induce pyroptosis, an inflammatory form  of cell death.",Non-OADS,/arxiv_data1/oa_pdf/7a/3f/itt-4-131.PMC4918253.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/7a/3f/itt-4-131.PMC4918253.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cb/04/itt-4-143.PMC4918254.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 143–157ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  143RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S6152 8The hygiene hypothesis: current perspectives and  future therapies Leah T Stiemsma1,2 Lisa A Reynolds3 Stuart e T urvey1,2,4 B Brett Finlay1,3,5 1Department of Microbiology &  Immunology, University of British  Columbia, 2The Child and Family  Research Institute, 3Michael Smith  Laboratories, University of British  Columbia, 4Department of Pediatrics,   University of British Columbia,   5Department of Biochemistry and  Molecular Biology, University of  British Columbia, vancouver, BC,   Canada Correspondence: B Brett Finlay   Michael Smith Laboratories,  2329 west  Mall, University of British Columbia,  vancouver, BC, v6T  1Z4, Canada   email bfinlay@msl.ubc.c aAbstract:  Developed countries have experienced a steady increase in atopic disease and  disorders of immune dysregulation since the  1980s.",Non-OADS,/arxiv_data1/oa_pdf/cb/04/itt-4-143.PMC4918254.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/cb/04/itt-4-143.PMC4918254.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0f/fd/itt-4-159.PMC4918255.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 159–171ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  159RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S5541 5The role of regulatory T cells in cancer immunology Theresa L whiteside University of Pittsburgh Cancer  Institute, Pittsburgh, PA, USA Correspondence: Theresa L whiteside   University of Pittsburgh Cancer Institute,   5117 Centre Avenue, Suite  1.32,  Pittsburgh, PA  15213, USA   Tel +1 412 624 0096  Fax +1 412 624 0264  email whitesidetl@upmc.ed uAbstract:  Regulatory T cells (Treg) are generally considered to be significant contributors  to tumor escape from the host immune system.",Non-OADS,/arxiv_data1/oa_pdf/0f/fd/itt-4-159.PMC4918255.pdf
The table   lists clinical trials posted online at http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/0f/fd/itt-4-159.PMC4918255.pdf
"ImmunoTargets and Therapy 2015:4submit your manuscript | www.dovepress.co m Dove press Dove press 167Treg in human cancer immunology Table  2 Immunotherapy clinical trials incorporating strategies for Treg depletion in patients with solid or hematologic malignancies Cancer Clinical trial   gov numberTreg-targeting   agentImmunotherapy Trial status AML relapsed NCT  01106950 Cyclophosphamide Haploidentical NK cells Terminated121 Phase II Denileukin diftitox Fludarabine Colorectal metastatic   to liver/lungNCT  00986518 ex vivo sorting to   deplete TregAdoptive transfer of   autologous lymphocytesCompleteda Phase I/II Cyclophosphamide Fludarabine Relapsed hematologic cancers NCT  00675831 Anti-CD25 Ab using   CliniMACsDepleted donor   lymphocyte infusionCompleteda Phase I Renal cell cancer metastatic NCT  01462214 Metronomic low-dose   cyclophosphamideeverolimus Recruiting122 Phase I/II Melanoma stages IIIc–IV NCT  022009384 Denileukin diftitox Ipilimumab Recruiting Phase II Melanoma NCT  00847106 Daclizumab DC-based antitumor   vaccineCompleteda Phase I/II Melanoma recurrent stage IV NCT  01307618 Daclizumab Peptide-based antitumor   vaccineActive, not  recruiting Phase II Metastatic breast, lung,   colorectal, pancreatic cancersNCT  00128622 Denileukin diftitox TRICOM DC-based   vaccineCompleteda Phase I Solid tumors (advanced,   recurrent)NCT  01929486 Mogamulizumab None Recruiting Phase I Melanoma stage IV NCT  00056134 Denileukin diftitox Tumor peptide-loaded   autologous DCCompleteda Phase I/II Melanoma metastatic NCT  00515528 Denileukin diftitox 4-Peptide antitumor   vaccineActive, not  recruiting Phase II Mesothelioma NCT  01241682 Low-dose   cyclophosphamidevaccine with tumor-lysate   pulsed DCCompleteda Phase I Notes:  The above list of clinical trials includes  12/20 that can be found on the http://www.clinicaltrials.go v site.",Non-OADS,/arxiv_data1/oa_pdf/0f/fd/itt-4-159.PMC4918255.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/0f/fd/itt-4-159.PMC4918255.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cf/de/itt-4-173.PMC4918256.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 173–183ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  173RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S5551 6Place in therapy of rituximab in the treatment of  granulomatosis with polyangiitis and microscopic  polyangiitis Shivani Shah Duvuru Geetha Department of Medicine, Division of  Nephrology, Johns Hopkins University  School of Medicine, Baltimore,    MD, USA Correspondence: Duvuru Geetha   Department of Medicine, Division of  Nephrology, Johns Hopkins University  School of Medicine, 301 Mason Lord  Drive, Baltimore, MD 21224, USA   Tel +1 410 550 2820   Fax +1 410 955 0485   email gduvura@jhmi.ed uAbstract:  Granulomatosis with polyangiitis and microscopic polyangiitis are small vessel  vasculitides characterized by circulating antineutrophil circulating antibodies.",Non-OADS,/arxiv_data1/oa_pdf/cf/de/itt-4-173.PMC4918256.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/cf/de/itt-4-173.PMC4918256.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/dd/46/itt-4-055.PMC4918257.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 55–63ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  55RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S3138 9Management of patients with non-Hodgkin’s  lymphoma: focus on adoptive T -cell therapy Serena Kimi Perna1 Leslie e Huye1,† Barbara Savoldo1,2 1Center for Cell and Gene Therapy,   Baylor College of Medicine, Houston  Methodist Hospital, Houston, TX,   2Department of Pediatrics, Texas  Children’s Hospital, Houston, TX, USA †Leslie e Huye passed away on January  1st, 2015 Correspondence: Barbara Savoldo   Center for Cell and Gene Therapy,  Baylor College of Medicine,  6621 Fannin  Street – MC  3-3320, Houston,   TX 77030, USA   Tel +1 832 824 4725  Fax +1 832 825 4732  email bsavoldo@bcm.ed uAbstract:  Non-Hodgkin’ s lymphoma (NHL) represents a heterogeneous group of malignancies  with high diversity in terms of biology, clinical responses, and prognosis.",Non-OADS,/arxiv_data1/oa_pdf/dd/46/itt-4-055.PMC4918257.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/dd/46/itt-4-055.PMC4918257.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/87/be/itt-4-185.PMC4918258.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 185–190ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  185RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S6287 0Current perspective on the role of the  interleukin-23/interleukin-17 axis in inflammation  and disease (chronic arthritis and psoriasis) Alberto Cauli Matteo Piga Alberto Floris Alessandro Mathieu Rheumatology Unit, Department of  Medical Sciences, Policlinico of the  University of Cagliari, Monserrato,   Cagliari, Italy Correspondence: Alberto Cauli   Rheumatology Unit, Department of  Medical Sciences, Policlinico of the  University of Cagliari, ss554, Monserrato,  090142 Cagliari, Italy   Tel +39 070 6754 229   Fax +39 070 6754 229   email cauli@medicina.unica.i tAbstract:  TH17 is a lymphocyte subset, which is characterized by its polarization to secrete  interleukin (IL)-17.",Non-OADS,/arxiv_data1/oa_pdf/87/be/itt-4-185.PMC4918258.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/87/be/itt-4-185.PMC4918258.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2e/13/itt-4-065.PMC4918259.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 65–77ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  65RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S5554 9emerging role of Natural killer cells in oncolytic  virotherapy Rauf Bhat Jean Rommelaere Division of T umor virology, German  Cancer Research Center, Heidelberg,   Germany Correspondence: Rauf Bhat   Deutsches Krebsforschungszentrum,  Tumor virology, F010, Im Neuenheimer  Feld 242, D-69120, Heidelberg, Germany   Tel +49 622 142 4961  Fax +49 622 142 4962  email rauf012@yahoo.co mAbstract:  Natural killer (NK) cells constitute a subtype of lymphocytes that initiate innate  immune responses against tumors and virus-infected cells.",Non-OADS,/arxiv_data1/oa_pdf/2e/13/itt-4-065.PMC4918259.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/2e/13/itt-4-065.PMC4918259.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/58/21/itt-4-079.PMC4918260.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pImmunoTargets and Therapy 2015:4 79–89ImmunoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  79RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/ITT .S6159 0Update on use of aldesleukin for treatment   of high-risk metastatic melanoma Rodabe N Amaria1 Alexandre Reuben2 Zachary A Cooper2,3 Jennifer A wargo2,3 1Department of Melanoma Medical  Oncology,  2Department of Surgical  Oncology,  3Department of Genomic  Medicine, University of Texas MD  Anderson Cancer Center, Houston,  TX, USA Correspondence: Jennifer A wargo   Department of Surgical Oncology,  University of Texas MD Anderson  Cancer Center,  1515 Holcombe Blvd,  Houston, TX  77030, USA   email jwargo@mdanderson.or gAbstract:  High-dose interleukin-2 has been used for the treatment of metastatic melanoma since   1998 based on data proving durable complete responses in up to  10% of treated patients.",Non-OADS,/arxiv_data1/oa_pdf/58/21/itt-4-079.PMC4918260.pdf
"ImmunoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/immunotargets-and-therapy-journa lImmunoTargets and Therapy is an international, peer-reviewed open access journal  focusing on the immunological basis of diseases, potential targets for immune  based therapy and treatment protocols employed to improve patient management.",Non-OADS,/arxiv_data1/oa_pdf/58/21/itt-4-079.PMC4918260.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/08/36/jhc-1-001.PMC4918262.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 1–7Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  1Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4453 7A review on the diagnosis and treatment of  hepatocellular carcinoma with a focus on the role  of wnts and the dickkopf family of wnt inhibitors Junlin Shi1,2 Jill M Keller3 Jian Zhang1,2 evan T Keller1–3 1Key Laboratory of Longevity and  Ageing-Related Diseases, Ministry  of education, Nanning, Guangxi,   People’s Republic of China; 2Center  for Translational Medicine, Guangxi  Medical University, Nanning,   Guangxi, People’s Republic of China;   3Department of Urology, School of  Medicine, University of Michigan, Ann  Arbor, M i, USA Correspondence : evan T Keller   University of Michigan, Room 5308  Cancer Center, 1500 east Medical  Center Dr, Ann Arbor, Mi 48105, USA   email etkeller@umich.ed uAbstract:  Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide.",Non-OADS,/arxiv_data1/oa_pdf/08/36/jhc-1-001.PMC4918262.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/08/36/jhc-1-001.PMC4918262.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/08/36/jhc-1-001.PMC4918262.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d9/05/jhc-1-009.PMC4918263.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 9–19Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  9Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4446 0emerging role of insulin-like growth factor-binding  protein 7 in hepatocellular carcinoma Maaged Akiel Devaraja Rajasekaran Rachel Gredler Ayesha Siddiq Jyoti Srivastava Chadia Robertson Nidhi Himanshu Jariwala Paul B Fisher Devanand Sarkar Department of Human and Molecular  Genetics, Massey Cancer Center,  vCU institute of Molecular Medicine,  virginia Commonwealth University,  Richmond, virginia, USA Correspondence: Devanand Sarkar   1220 e Broad St, PO Box 980035,  Richmond, vA 23298, USA   Tel +1 804 827 2339   Fax +1 804 628 1176   email dsarkar@vcu.ed uAbstract:  Hepatocellular carcinoma (HCC) is a vicious and highly vascular cancer with a  dismal prognosis.",Non-OADS,/arxiv_data1/oa_pdf/d9/05/jhc-1-009.PMC4918263.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/d9/05/jhc-1-009.PMC4918263.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d9/05/jhc-1-009.PMC4918263.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/48/51/jhc-1-021.PMC4918264.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 21–33Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  21Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4446 3Micro-ribonucleic acids: potential noninvasive   biomarkers for hepatocellular carcinoma Limin Li wenli Diao Ke Zen Jiangsu engineering Research   Center for MicroRNA Biology   and Biotechnology, State Key   Laboratory of Pharmaceutical  Biotechnology, School of Life   Sciences, Nanjing University,    Nanjing, People’s Republic of China Correspondence: Ke Zen   Jiangsu engineering Research   Center for MicroRNA Biology and   Biotechnology, State Key Laboratory   of Pharmaceutical Biotechnology,   School of Life Sciences, Nanjing   University,  22 Hankou Road,   Nanjing, Jiangsu  210093,   People’s Republic of China   email kzen@nju.edu.c nAbstract:  Hepatocellular carcinoma (HCC) is one of the most common malignancies globally.",Non-OADS,/arxiv_data1/oa_pdf/48/51/jhc-1-021.PMC4918264.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/48/51/jhc-1-021.PMC4918264.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/48/51/jhc-1-021.PMC4918264.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e8/1e/jhc-1-035.PMC4918265.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 35–42Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  35Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4851 7Critical analysis of the potential of targeting  GPC3 in hepatocellular carcinoma Kazuya Ofuji Keigo Saito T oshiaki Y oshikawa T etsuya Nakatsura Division of Cancer immunotherapy,   exploratory Oncology Research and  Clinical Trial Center, National Cancer  Center, Kashiwa, Japan Correspondence: Tetsuya Nakatsura   Division of Cancer immunotherapy,  exploratory Oncology Research and  Clinical Trial Center, National Cancer  Center,  6-5-1 Kashiwanoha,   Kashiwa  277-8577, Japan   Tel +81 4 7131 5490  Fax +81 4 7133 6606  email tnakatsu@east.ncc.go.j pAbstract:  Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths   worldwide.",Non-OADS,/arxiv_data1/oa_pdf/e8/1e/jhc-1-035.PMC4918265.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/e8/1e/jhc-1-035.PMC4918265.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/1e/jhc-1-035.PMC4918265.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/66/42/jhc-1-043.PMC4918266.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 43–54Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  43Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4895 8Fibroblast growth factor family as a potential  target in the treatment of hepatocellular  carcinoma Stacey J Coleman1 Richard P Grose1 Hemant M Kocher1,2 1Centre for Tumour Biology, Barts  Cancer institute – a CRUK Centre of  excellence, Queen Mary University of  London, 2Barts and the London HPB  Centre, The Royal London Hospital,   Barts Health NHS Trust, London, UK Correspondence: Hemant M Kocher   Queen Mary University of London,  Centre for Tumour Biology, Barts   Cancer institute – a CRUK Centre   of excellence, Charterhouse Square,   London eC1M  6BQ, UK   Tel +44 20 7882 3579  Fax +44 20 7882 3884  email h.kocher@qmul.ac.u kAbstract:  Hepatocellular cancer (HCC) is currently the third leading cause of cancer death  worldwide.",Non-OADS,/arxiv_data1/oa_pdf/66/42/jhc-1-043.PMC4918266.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/66/42/jhc-1-043.PMC4918266.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/66/42/jhc-1-043.PMC4918266.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f6/c0/jhc-1-085.PMC4918267.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 85–99Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  85Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4504 0Sorafenib in advanced hepatocellular carcinoma:   current status and future perspectives Chih-Hung Hsu1,4 Ying-Chun Shen1,2 Yu-Yun Shao1,4 Chiun Hsu1,4 Ann-Lii Cheng1,3,4 1Department of Oncology,   2Department of Medical Research,   3Department of internal Medicine,   National Taiwan University Hospital,   4Graduate institute of Oncology,   College of Medicine, National Taiwan  University, Taipei, Taiwan Correspondence: Ann-Lii Cheng   Department of internal Medicine,   National Taiwan University Hospital,   7 Chung-Shan South Road,   Taipei  10002, Taiwan   Tel +886 2 2312 3456 ext  67251  Fax +886 2 2371 1174  email alcheng@ntu.edu.t wAbstract:  The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase  and the vascular endothelial growth factor receptor, in  2007 for treating advanced hepatocel - lular carcinoma (HCC) has generated considerable enthusiasm in drug development for this  difficult-to-treat disease.",Non-OADS,/arxiv_data1/oa_pdf/f6/c0/jhc-1-085.PMC4918267.pdf
"http://globocan.iarc.f r. Accessed October  4, 2013.",Non-OADS,/arxiv_data1/oa_pdf/f6/c0/jhc-1-085.PMC4918267.pdf
Available from: http://pharma.bayer.,Non-OADS,/arxiv_data1/oa_pdf/f6/c0/jhc-1-085.PMC4918267.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/f6/c0/jhc-1-085.PMC4918267.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f6/c0/jhc-1-085.PMC4918267.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ae/55/jhc-1-101.PMC4918268.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 101–108Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  101Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4860 2Clinical utility of imaging for evaluation   of hepatocellular carcinoma Takamichi Murakami1 Masakatsu Tsurusaki1 T omoko Hyodo1 Yasuharu imai2 1Department of Radiology, Kinki  University Faculty of Medicine,   2Department of Hepatology and  Gastroenterology, ikeda Municipal  Hospital, Osaka, Japan Correspondence: Takamichi Murakami   Department of Radiology, Kinki   University Faculty of Medicine,   377-2 Ohno-Higashi, Osaka-Sayama,   Osaka  589-8511, Japan   Tel +817 2366 0221  Fax +817 2367 1685  email murakami@med.kindai.ac.j pAbstract:  The hemodynamics of a hepatocellular nodule is the most important imaging  para meter used to characterize various hepatocellular nodules in liver cirrhosis, because sequen - tial changes occur in the feeding vessels and hemodynamic status during hepatocarcinogenesis.",Non-OADS,/arxiv_data1/oa_pdf/ae/55/jhc-1-101.PMC4918268.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/ae/55/jhc-1-101.PMC4918268.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ae/55/jhc-1-101.PMC4918268.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d3/d0/jhc-1-109.PMC4918269.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 109–114Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  109Case seriesopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JHC.S6086 7T elaprevir-containing regimen for treatment   of hepatitis C virus infection in patients   with hepatocellular carcinoma awaiting   liver transplantation: a case series Harrys a T orres1 ahmed Kaseb2 Parag Mahale1 ethan Miller3 Catherine Frenette4 1Department of infectious  Diseases, infection Control and  employee Health, 2Department of  Gastrointestinal Medical Oncology,   3Department of Gastroenterology,   Hepatology and Nutrition,    The University of Texas MD anderson  Cancer Center, Houston, TX, Usa;   4Department of Liver Transplantation,   Weill Cornell Medical College,    The Methodist Hospital, Houston,    TX, Usa Correspondence: Harrys a Torres   Department of infectious Diseases,   infection Control and employee Health,   The University of Texas MD anderson,   Cancer Center, Houston, TX, Usa   Tel +1 713 792 6503   Fax +1 713 745 6839   email htorres@mdanderson.or gAbstract:  In patients who undergo liver transplantation (LT), allograft failure secondary to hepatitis  C virus (HCV) recurrence after LT accounts for two-thirds of graft failures and deaths.",Non-OADS,/arxiv_data1/oa_pdf/d3/d0/jhc-1-109.PMC4918269.pdf
"Available from: http://hcvguidelines.or g. Accessed  February 10, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d3/d0/jhc-1-109.PMC4918269.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/d3/d0/jhc-1-109.PMC4918269.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d3/d0/jhc-1-109.PMC4918269.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ef/23/jhc-1-055.PMC4918270.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 55–63Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  55Original researCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JHC.S5601 2Potential immunotherapeutic role of interleukin-2   and interleukin-12 combination in patients   with hepatocellular carcinoma abdulwahab ali gabeen1 Fatma Farag abdel-Hamid1 Motawa eisa el-Houseini2 shadia abdel-Hamid Fathy1 1Biochemistry Department, Faculty   of science, ain shams University,    Cairo, egypt;  2Cancer Biology   Department, national Cancer   institute (n Ci), Cairo University,    Cairo, egypt Correspondence: abdulwahab ali gabeen,   Department of Biochemistry, Faculty of  science, ain shams University, 7 Basus,  al-Qanater al-Khayriya st, Qalyubia  governorate, 13751, egypt   Tel +20 122 515 0309  email a bdulwahabgabeen@yahoo.co mBackground:  Many recent therapeutic interventions are necessary to improve the treatment  of hepatocellular carcinoma (HCC), including immunotherapy, which seems to offer one of the  new realistic therapeutic modalities.",Non-OADS,/arxiv_data1/oa_pdf/ef/23/jhc-1-055.PMC4918270.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/ef/23/jhc-1-055.PMC4918270.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ef/23/jhc-1-055.PMC4918270.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4d/84/jhc-1-115.PMC4918271.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 115–125Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  115Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4438 1Hepatocellular carcinoma: epidemiology   and risk factors Michael C Kew Department of Medicine, Groote  Schuur Hospital and University of  Cape T own, Cape T own, South Africa Correspondence: Michael C Kew   Department of Medicine, Groote Schuur  Hospital and University of Cape Town,  Main Street, Observatory, Cape Town,  South AfricaAbstract:  Hepatocellular carcinoma is one of the major malignant tumors in the world today.",Non-OADS,/arxiv_data1/oa_pdf/4d/84/jhc-1-115.PMC4918271.pdf
Available from: http://www-dep.iarc.f r. Accessed.,Non-OADS,/arxiv_data1/oa_pdf/4d/84/jhc-1-115.PMC4918271.pdf
Available from: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/4d/84/jhc-1-115.PMC4918271.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/4d/84/jhc-1-115.PMC4918271.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4d/84/jhc-1-115.PMC4918271.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/6a/80/jhc-1-065.PMC4918272.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 65–83Journal of Hepatocellular Carcinoma Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/6a/80/jhc-1-065.PMC4918272.pdf
"Or use: http://dvpr.es/1ja86k mDove press submit your manuscript | www.dovepress.co m Dove press  65Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4450 6New insights on the role of epigenetic alterations  in hepatocellular carcinoma Maddalena Frau1 Claudio F Feo2 Francesco Feo1 Rosa M Pascale1 1Department of Clinical and   experimental Medicine, Division   of experimental Pathology and   Oncology,  2Department of Clinical   and experimental Medicine,    Division of Surgery, University of  Sassari, Sassari, italy Correspondence: Francesco Feo   Department of Clinical and experimental   Medicine, University of Sassari, Division  of experimental Pathology and Oncology,  via P Manzella  4, 07100 Sassary, italy   Tel +35 079 228307   Fax +35 079 228305   email feo@uniss.i tAbstract:  Emerging evidence assigns to epigenetic mechanisms heri table  differences in gene  function that come into being during cell development or via the effect of environmental factors.",Non-OADS,/arxiv_data1/oa_pdf/6a/80/jhc-1-065.PMC4918272.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/6a/80/jhc-1-065.PMC4918272.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/6a/80/jhc-1-065.PMC4918272.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e5/f4/jhc-1-127.PMC4918273.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Hepatocellular Carcinoma 2014:1 127–135Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  127Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4851 2emerging role of the peroxisome   proliferator-activated receptor-gamma   in hepatocellular carcinoma Hui-Tzu Hsu1 Chin-w en Chi1,2 1Department and institute of  Pharmacology, School of Medicine,   National Yang-Ming University, Taipei,   Taiwan;  2Department of Medical  Research, Taipei veterans General  Hospital, Taipei, Taiwan Correspondence: Chin-wen Chi   Department of Medical Research, Taipei  veterans General Hospital, No  322,   Sec 2, Shipai Road, Taipei  112, Taiwan   Tel +886 2 2875 7627  Fax +886 2 2875 1562  email cwchi@vghtpe.gov.t wAbstract:  Hepatocellular carcinoma (HCC) is the major leading cause of cancer death  worldwide.",Non-OADS,/arxiv_data1/oa_pdf/e5/f4/jhc-1-127.PMC4918273.pdf
Or use: http://dvpr.es/1BrTGE 6,Non-OADS,/arxiv_data1/oa_pdf/e5/f4/jhc-1-127.PMC4918273.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/e5/f4/jhc-1-127.PMC4918273.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e5/f4/jhc-1-127.PMC4918273.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1b/ec/jhc-1-137.PMC4918274.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 137–148Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  137Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4437 9Radiological diagnosis of hepatocellular carcinoma irene Bargellini valentina Battaglia elena Bozzi Dario Luca Lauretti Giulia Lorenzoni Carlo Bartolozzi Department of Diagnostic and  interventional Radiology, Pisa  University Hospital, Pisa, italy Correspondence: irene Bargellini   Diagnostic and interventional   Radiology, University of Pisa,   via Paradisa 2, 56100 Pisa, italy   T el +39 050 996 961   Fax +39 050 995 545   email irenebargellini@hotmail.co mAbstract:  Diagnosis of hepatocellular carcinoma (HCC) still remains a challenging issue.",Non-OADS,/arxiv_data1/oa_pdf/1b/ec/jhc-1-137.PMC4918274.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/1b/ec/jhc-1-137.PMC4918274.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1b/ec/jhc-1-137.PMC4918274.pdf
Available from: http://www.acr.org/Quality- Safety/Resources/LIRADS /.,Non-OADS,/arxiv_data1/oa_pdf/1b/ec/jhc-1-137.PMC4918274.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4b/3c/jhc-1-149.PMC4918275.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 149–161Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  149Original researCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JHC.S7101 9Potent efficacy signals from systemically  administered oncolytic herpes simplex virus  (HSV1716) in hepatocellular carcinoma   xenograft models Lynne Braidwood Kirsty Learmonth Alex Graham Joe Conner Virttu Biologics Ltd, Department  of Neurology, Southern General  Hospital, Glasgow, UK Correspondence: Joe Conner   Virttu Biologics Ltd, Department   of Neurology, Southern General Hospital,   1345 Govan Rd, Glasgow G51 4TF , UK   T el +141 445 1716   Fax +141 445 1715   email joe.conner@virttu.co mAbstract:  Oncolytic herpes simplex virus (HSV1716), lacking the neurovirulence factor ICP34.5,  has highly selective replication competence for cancer cells and has been used in clinical studies  of glioma, melanoma, head and neck squamous cell carcinoma, pediatric non-central nervous  system solid tumors, and malignant pleural mesothelioma.",Non-OADS,/arxiv_data1/oa_pdf/4b/3c/jhc-1-149.PMC4918275.pdf
gov/NCT0093193 1) and a Phase I/IIa study in malignant pleu - ral mesothelioma ( http://clinicaltrials.gov/NCT0172101 8) are  currently ongoing.,Non-OADS,/arxiv_data1/oa_pdf/4b/3c/jhc-1-149.PMC4918275.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/4b/3c/jhc-1-149.PMC4918275.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4b/3c/jhc-1-149.PMC4918275.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e8/cf/jhc-1-183.PMC4918276.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 183–186Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  183Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4876 3emerging role of dual antiplatelet therapy   in the prevention of hepatitis B virus-associated  hepatocellular carcinoma Roberto Aiolfi Giovanni Sitia Division of immunology,   Transplantation and infectious  Diseases, San Raffaele Scientific  institute, Milan, italy Correspondence: Giovanni Sitia   San Raffaele Scientific Institute,   Division of immunology,   Transplantation and infectious Diseases,  via Olgettina 58, 20132 Milan, italy   Tel +39 02 2643 4956   Fax +39 02 2643 6822   email sitia.giovanni@hsr.i tAbstract:  Platelets, the chief effectors of vascular homeostasis, have been identified as impor - tant players in the pathogenesis of both acute and chronic liver disease in preclinical models of  hepatitis B viral infection.",Non-OADS,/arxiv_data1/oa_pdf/e8/cf/jhc-1-183.PMC4918276.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/e8/cf/jhc-1-183.PMC4918276.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/cf/jhc-1-183.PMC4918276.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1c/79/jhc-1-163.PMC4918277.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 163–182Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  163Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S5047 2Transarterial radioembolization using yttrium-90  microspheres in the treatment of hepatocellular  carcinoma: a review on clinical utility   and developments Alberta Cappelli1 Cinzia Pettinato2 Rita Golfieri1 1Radiology Unit, 2Medical Physics Unit,   Department of Medical and Surgical  Sciences, Alma Mater Studiorum –   University of Bologna, S Orsola- Malpighi Hospital, Bologna, italy Correspondence: Alberta Cappelli   Radiology Unit, Department of Medical  and Surgical Sciences, Alma Mater  Studiorum – University of Bologna,   S Orsola-Malpighi Hospital, via   Albertoni, 15, 40138 Bologna, italy   Tel +39 051 636 2598   Fax +39 051 636 2699   email alberta.cappelli@aosp.bo.i tAbstract:  A selective intra-arterial liver injection using yttrium-90-loaded microspheres as  sources for internal radiation therapy is a form of transarterial radioembolization (TARE).",Non-OADS,/arxiv_data1/oa_pdf/1c/79/jhc-1-163.PMC4918277.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/1c/79/jhc-1-163.PMC4918277.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1c/79/jhc-1-163.PMC4918277.pdf
"http://www.jnccn.org/content/7/4/350.lon g. Accessed September 9,  2014.",Non-OADS,/arxiv_data1/oa_pdf/1c/79/jhc-1-163.PMC4918277.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/fa/25/jhc-1-187.PMC4918278.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2014:1 187–193Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  187Original researCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JHC.S7160 2Chemoembolization with drug-eluting  microspheres (DeM-T aCe) for hepatocellular  carcinoma: single-center review of safety   and efficacy Vl Bishay1 K Maglione1 r Khanna2 KM lee1 aM Fischman1 ra lookstein1 e Kim1 1Department of radiology, icahn  school of Medicine at the Mount  sinai Hospital, new Y ork, nY, Usa;   2Department of radiology, Queens  Hospital Center, Jamaica, nY, Usa Correspondence: Vl Bishay   Department of radiology, icahn school   of Medicine at the Mount sinai Hospital,   Box 1234 One gustave levy Place,   new York, nY, Usa   Tel +1 212 241 1497   email vivian.bishay@mountsinai.or gPurpose:  This study examines the safety and efficacy of transarterial chemoembolization using  doxorubicin-loaded 30–60 µm QuadraSphere microspheres (DEM-TACE) for the treatment of  hepatocellular carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/fa/25/jhc-1-187.PMC4918278.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/fa/25/jhc-1-187.PMC4918278.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fa/25/jhc-1-187.PMC4918278.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9c/0d/jhc-2-003.PMC4918279.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 3–9Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  3ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S7382 8Untreated hepatocellular carcinoma   in Egypt: outcome and prognostic factors Ahmed Abdelmabood  Zeeneldin1 Salem Eid Salem1 Amira Diaa Darwish1 Mosaad Mahmoud  El-Gammal1 Marwa Mahmoud Hussein1 Mohamed Saadeldin2 1Medical Oncology/Hematology,   National Cancer Institute, Cairo  University, Cairo, Egypt;  2Medical  Oncology, Tanta Cancer Center,    Tanta, Egypt Correspondence: Salem Eid Salem   Medical Oncology/Hematology, National  Cancer Institute, Cairo University,   Kasr Al-Aini St, Fom El Khalig,   Cairo  11796, Egypt   Tel +20 2 2362 8411  Fax +20 2 2532 8286  Email salem.eid@nci.cu.edu.e g;  salemarwa2003@yahoo.co mBackground:  Hepatocellular carcinoma (HCC) is a common cancer worldwide as well as in  Egypt with hepatitis C and B, alcohol and aflatoxins being the commonest risk factors.",Non-OADS,/arxiv_data1/oa_pdf/9c/0d/jhc-2-003.PMC4918279.pdf
"Available from: http://globocan.iarc.f r. Accessed  October  16, 2014.",Non-OADS,/arxiv_data1/oa_pdf/9c/0d/jhc-2-003.PMC4918279.pdf
"Available from: http://www.emro.who.int/ncd/ pdf/cancer_registry_Egypt.pd f. Accessed October  16, 2014.",Non-OADS,/arxiv_data1/oa_pdf/9c/0d/jhc-2-003.PMC4918279.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/9c/0d/jhc-2-003.PMC4918279.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9c/0d/jhc-2-003.PMC4918279.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0f/38/jhc-2-019.PMC4918280.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 19–27Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  19Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4452 1A clinical perspective of the link between  metabolic syndrome and hepatocellular   carcinoma François Cauchy Jacques Belghiti HPB and Liver Transplantation Unit,   Hôpital Beaujon, Assistance Publique- Hôpitaux de Paris, Clichy, France Correspondence: Jacques Belghiti   HPB and Liver Transplantation Unit,  Hôpital Beaujon, HPB Surgery,   Hôpital Beaujon, 100 Boulevard Général  Leclerc, 92110 Clichy, France   Tel +33 1 4087 5895   Fax +33 1 4087 1724   email jacques.belghiti@bjn.aphp.f rAbstract:  Metabolic syndrome (MS), which is defined as a constellation of clinico-biological  features closely related to insulin-resistance has reached epidemic levels in Western Europe  and Northern America.",Non-OADS,/arxiv_data1/oa_pdf/0f/38/jhc-2-019.PMC4918280.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/0f/38/jhc-2-019.PMC4918280.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/0f/38/jhc-2-019.PMC4918280.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/32/63/jhc-2-011.PMC4918281.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 11–17Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  11Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4451 5emerging role of T oll-like receptor  4   in hepatocellular carcinoma Jing Yang1 Min Li2 Qi Chang Zheng2 1Department of First General Surgery,   Gansu Provincial Hospital, Lanzhou,   2Department of Hepatobiliary  Surgery, Union Hospital, Tongji  Medical College, Huazhong University  of Science and T echnology, wuhan,   People’s Republic of China Correspondence: Qi Chang Zheng   Department of Hepatobiliary Surgery,  Union Hospital, Tongji Medical College,  Huazhong University of Science and  Technology,  1277# Jiefang Avenue,  wuhan  430022, People’s Republic   of China   Tel +86 27 8535 1623  Fax +86 27 8535 1676  email qc_zheng@hust.edu.c nAbstract:  Toll-like receptor (TLR) signaling has been implicated in inflammatory-related  cancers.",Non-OADS,/arxiv_data1/oa_pdf/32/63/jhc-2-011.PMC4918281.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/32/63/jhc-2-011.PMC4918281.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/32/63/jhc-2-011.PMC4918281.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f6/f4/jhc-2-029.PMC4918282.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 29–38Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  29Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S7703 8c-MeT receptor tyrosine kinase as a molecular  target in advanced hepatocellular carcinoma Alessandro Granito1 elena Guidetti1 Laura Gramantieri2,3 1Dipartimento di Scienze Mediche e  Chirurgiche Università di Bologna,  Bologna, italy;  2Dipartimento  dell’Apparato Digerente, Azienda  Ospedaliero-Universitaria di Bologna,  Bologna, italy;  3Centro di Ricerca  Biomedica Applicata (CRBA), Azienda  Ospedaliero-Universitaria Policlinico  S Orsola-Malpighi e Università di  Bologna, Bologna, italy Correspondence: Laura Gramantieri   Azienda Ospedaliero-Universitaria   di Bologna, via Albertoni,    15, 40138, Bologna, italy   email laura.gramantieri@aosp.bo.i tAbstract:  c-MET is the membrane receptor for hepatocyte growth factor (HGF), also known  as scatter factor or tumor cytotoxic factor, a mitogenic growth factor for hepatocytes.",Non-OADS,/arxiv_data1/oa_pdf/f6/f4/jhc-2-029.PMC4918282.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/f6/f4/jhc-2-029.PMC4918282.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f6/f4/jhc-2-029.PMC4918282.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/71/4f/jhc-2-039.PMC4918283.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 39–47Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  39Original researCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JHC.S7935 3early α-fetoprotein response predicts survival   in patients with advanced hepatocellular  carcinoma treated with sorafenib sangheun lee1,* Beom Kyung Kim2–5,* seung Up Kim2–5 Jun Y ong Park2–5 Do Y oung Kim2–5 sang Hoon ahn2–6 Kwang-Hyub Han2–6 1Department of internal Medicine,   international st Mary’s Hospital,   Catholic Kwandong University,   incheon Metropolitan City,   republic of Korea;  2Department  of internal Medicine,  3institute of  gastroenterology,  4liver Cancer  special Clinic, Y onsei University  College of Medicine, seoul, republic  of Korea;  5liver Cirrhosis Clinical  research Center, seoul, republic of  Korea;  6Brain Korea  21 Project for  Medical science, seoul, republic of  Korea *These authors contributed equally   to this work Correspondence: seung Up Kim   Department of internal Medicine,   Yonsei University College of Medicine,   50 Yonsei-ro, sodaemun-gu,   seoul 120-752, republic of Korea   Tel +82 2 2228 1982  Fax +82 2 393 6884  email ksukorea@yuhs.a cBackground:  It is not clear whether tumor marker responses can predict survival during  sorafenib treatment in hepatocellular carcinoma (HCC).",Non-OADS,/arxiv_data1/oa_pdf/71/4f/jhc-2-039.PMC4918283.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/71/4f/jhc-2-039.PMC4918283.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/71/4f/jhc-2-039.PMC4918283.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f7/87/jhc-2-049.PMC4918284.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 49–55Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  49Editorialopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/JHC.S8394 1Hepatocellular carcinoma ablation and possible  immunity in the age of nanosecond pulsed   electric fields Stephen J Beebe Frank reidy research Center   for Bioelectrics, old dominion  University, Norfolk, V a, USa Correspondence: Stephen J Beebe   Frank reidy research Center for  Bioelectrics, old dominion University   4211 Monarch Way, Suite  300, Norfolk,  Va, 23508, USa   Email sbeebe@odu.ed uThe liver, the largest internal organ in the body, is stationed between us and everything  that enters our gastrointestinal tract.",Non-OADS,/arxiv_data1/oa_pdf/f7/87/jhc-2-049.PMC4918284.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/f7/87/jhc-2-049.PMC4918284.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f7/87/jhc-2-049.PMC4918284.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/10/10/jhc-2-057.PMC4918285.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 57–68Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  57Original researCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JHC.S8075 6Hapten-enhanced overall survival time in  advanced hepatocellular carcinoma by ultro- minimum incision personalized intratumoral  chemoimmunotherapy Feng gao2 Peng Jing2 Jian liu2 Yuanfei lu1 Peicheng Zhang2 Wei Han1 guoliang liu1 ning ru2 guanghui Cui2 Chenglin sun1 Yebing Che1 Huaming Zhang1 Qnglong Hu3 Huan-Y ou Wang4 Yingli Wu2 Changjiang guan2 Qiang Fu1 Zhenlu Ma2 Baofa Yu1–3 1Jinan Baofa Cancer Hospital, Jinan,  People’s republic of China;  2TaiMei  Baofa Cancer Hospital, Dongping,  People’s republic of China;   3Beijing Baofa Cancer Hospital,  Beijing, People’s republic of China;   4Department of Pathology, UC sD  school of Medicine, la Jolla, Ca, Usa Correspondence: Baofa Yu   no.",Non-OADS,/arxiv_data1/oa_pdf/10/10/jhc-2-057.PMC4918285.pdf
Available from: http://www.cancer.org/ Research/CancerFacts Figure s/CancerFacts Figure s/2013-cancer-facts- and-figure s.pdf.,Non-OADS,/arxiv_data1/oa_pdf/10/10/jhc-2-057.PMC4918285.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/10/10/jhc-2-057.PMC4918285.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/10/10/jhc-2-057.PMC4918285.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a7/3a/jhc-2-069.PMC4918286.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 69–78Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  69Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4850 5emerging role of Hpo signaling and YAP in  hepatocellular carcinoma vicente valero iii1 Timothy M Pawlik1 Robert A Anders2 1Department of Surgery, Division   of Surgical Oncology, 2Department  of Pathology, Sidney Kimmel Cancer  Center, Johns Hopkins University  School of Medicine, Baltimore,   MD, USA Correspondence: Robert A Anders   Department of Pathology, Division   of Gi/Liver Pathology, The Johns Hopkins  University School of Medicine, 1550  Orleans Street, Cancer Research Building  ii, Room 346, Baltimore, MD 21231, USA   Tel +1 410 955 3511   email rander54@jhmi.ed uAbstract:  Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third  most common cause of cancer-related mortality worldwide.",Non-OADS,/arxiv_data1/oa_pdf/a7/3a/jhc-2-069.PMC4918286.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/a7/3a/jhc-2-069.PMC4918286.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a7/3a/jhc-2-069.PMC4918286.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/37/46/jhc-2-079.PMC4918287.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 79–89Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  79Original researCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JHC.S6086 4ambovex® as a novel immunological modulator  drug for the treatment of hepatocellular carcinoma  (HCC) in the liver: a Phase ii clinical trial Hosny salama1 Hassan ahmad2 ismail elchagea2 abdel rahman Zekri2,3 eman Medhat1 abeer Bahnassy3 Michael lange4 Mohammed rabbat4 andrew n de la T orre4 Pravin Punamiya2 1Hepatology Department, Cairo  University, Cairo, egypt;  2aMK s Time  release llC, Montclair, nJ, Usa;   3national Cancer institute, Cairo  University, Cairo, egypt;  4saint Joseph  Hospital, Paterson, nJ, Usa Correspondence: Hosny salama   18 el rashidy str, Kasr el aini,    11441 Cairo, egypt   Tel +20 020 1222 1614 88  Fax +20 022 368 8805  email hsalama888@yahoo.co mAbstract:  Hepatocellular carcinoma (HCC) is a global public health problem, based on it being  the fifth most common cancer and third leading cause of cancer-related mortality worldwide.",Non-OADS,/arxiv_data1/oa_pdf/37/46/jhc-2-079.PMC4918287.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/37/46/jhc-2-079.PMC4918287.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/37/46/jhc-2-079.PMC4918287.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/92/ea/jhc-2-091.PMC4918288.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 91–99Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  91Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4895 6The androgen receptor as an emerging target   in hepatocellular carcinoma Tatsuo Kanda Osamu Y okosuka Department of Gastroenterology  and Nephrology, Chiba University,   Graduate School of Medicine,    Chiba, Japan Correspondence: Tatsuo Kanda   Department of Gastroenterology and  Nephrology, Chiba University, Graduate  School of Medicine, 1-8-1 inohana,  Chuo-ku, Chiba 260-8670, Japan   Tel +81 43 226 2086   Fax +81 43 226 2088   email kanda2t@yahoo.co.j pAbstract:  Hepatocellular carcinoma (HCC) is one of the male-dominant liver diseases with  poor prognosis, although treatments for HCC have been progressing in the past decades.",Non-OADS,/arxiv_data1/oa_pdf/92/ea/jhc-2-091.PMC4918288.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/92/ea/jhc-2-091.PMC4918288.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/92/ea/jhc-2-091.PMC4918288.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4e/70/jhc-2-101.PMC4918289.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 101–117Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  101Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S8520 1State-of-the-art cross-sectional liver imaging:  beyond lesion detection and characterization Gustavo Felipe Luersen Priya Bhosale Janio Szklaruk Department of Diagnostic Radiology,   The University of Texas MD Anderson  Cancer Center, Houston, TX, USA Correspondence: Janio Szklaruk   Department of Diagnostic Radiology,  The University of Texas MD Anderson  Cancer Center,  1515 Holcombe Blvd,  Unit 1473, Houston, TX  77030, USA   Tel +1 713 745 3230  Fax +1 713 745 4426Abstract:  Cross-sectional imaging with computed tomography or magnetic resonance imaging  is routinely used to detect and diagnose liver lesions; however, these examinations can provide  additional important information.",Non-OADS,/arxiv_data1/oa_pdf/4e/70/jhc-2-101.PMC4918289.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/4e/70/jhc-2-101.PMC4918289.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4e/70/jhc-2-101.PMC4918289.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d4/9c/jhc-2-119.PMC4918290.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 119–121Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  119Editorialopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/JHC.S9166 7Whither α-FP in the diagnosis of hepatocellular  carcinoma?,Non-OADS,/arxiv_data1/oa_pdf/d4/9c/jhc-2-119.PMC4918290.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/d4/9c/jhc-2-119.PMC4918290.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d4/9c/jhc-2-119.PMC4918290.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/90/d9/jhc-2-123.PMC4918291.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 123–129Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  123Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S4438 0Transarterial chemoembolization for  hepatocellular carcinoma: an evidence-based  review of its place in therapy Ji Hye Jang Jin-w oo Lee Ji Taek Hong Y oung-Joo Jin Division of Gastroenterology and  Hepatology, inha University School  of Medicine and Hospital, incheon,   Republic of Korea Correspondence: Jin-woo Lee   Division of Gastroenterology   and Hepatology, inha University   School of Medicine and Hospital,   27 inhang-ro, Jung-Gu, incheon   400-711, Republic of Korea   Tel +82 32 890 2548   Fax +82 32 882 6578   email jin@inha.ac.k rAbstract:  Transarterial chemoembolization (TACE) is the standard treatment for patients  with Barcelona Clinic Liver Cancer-intermediate stage hepatocellular carcinoma (HCC).",Non-OADS,/arxiv_data1/oa_pdf/90/d9/jhc-2-123.PMC4918291.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/90/d9/jhc-2-123.PMC4918291.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/90/d9/jhc-2-123.PMC4918291.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d9/94/jhc-2-001.PMC4918292.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 1–2Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  1Editorialopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/JHC.S6064 7Welcome to Journal of Hepatocellular Carcinoma ahmed o Kaseb department of Gastrointestinal  Medical oncology, the University   of texas M d anderson Cancer   Center, Houston, tX, USa Correspondence: ahmed o Kaseb   department of Gastrointestinal Medical  oncology, Unit  426, the University of  texas Md anderson Cancer Center,   1515 Holcombe Boulevard, Houston,   tX 77030, USa   tel +1713 792 2828  Fax +1713 745 1163  Email akaseb@mdanderson.or gHepatocellular carcinoma (HCC) develops as a consequence of underlying chronic  liver disease, most commonly cirrhosis.",Non-OADS,/arxiv_data1/oa_pdf/d9/94/jhc-2-001.PMC4918292.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/d9/94/jhc-2-001.PMC4918292.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d9/94/jhc-2-001.PMC4918292.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/19/12/jhc-2-131.PMC4918293.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 131–142Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  131Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S8130 9Type i insulin-like growth factor as a liver reserve  assessment tool in hepatocellular carcinoma Reham Abdel-w ahab1,2 Samir Shehata2 Manal M Hassan1 Mouhammed A Habra3 Ghazaleh eskandari4 Peggy T Tinkey5 Jennifer Mitchell5 Ju-Seog Lee6 Hesham M Amin4,7 Ahmed O Kaseb1 1Department of Gastrointestinal  Medical Oncology, The University of  T exas MD Anderson Cancer Center,   Houston, TX, USA; 2Department of  Clinical Oncology, Assiut University  Hospital, Assiut, egypt; 3Department  of endocrinology, 4Department of  Hematopathology, 5Department of  veterinary Medicine and Surgery,   6Department of Systems Biology, The  University of Texas MD Anderson  Cancer Center, 7Graduate School of  Biomedical Sciences, Houston, TX,   USA Correspondence: Ahmed O Kaseb   Department of Gastrointestinal Medical  Oncology, Unit 426, The University of  Texas MD Anderson Cancer Center,  1515 Holcombe Blvd, Houston, TX  77030, USA   Tel +1 713 792 2828   Fax +1 713 745 1163   email akaseb@mdanderson.or gAbstract:  Chronic liver diseases (CLDs) encompass a wide range of illnesses, including   nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis.",Non-OADS,/arxiv_data1/oa_pdf/19/12/jhc-2-131.PMC4918293.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/19/12/jhc-2-131.PMC4918293.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/19/12/jhc-2-131.PMC4918293.pdf
http://www.nccn.org/professionals/physician_ gls/pdf/hepatobiliary.pd f. 2015 version 2.,Non-OADS,/arxiv_data1/oa_pdf/19/12/jhc-2-131.PMC4918293.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d6/76/jhc-2-143.PMC4918294.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 143–149Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  143Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S6086 8Role of endoscopic ultrasound in diagnosis and  management of hepatocellular carcinoma Pramoda Koduru1 Rei Suzuki2 Sundeep Lakhtakia3 Mohan Ramchandani3 Dadang Makmun4 Manoop S Bhutani1 1Department of Gastroenterology,   Hepatology and Nutrition, University  of T exas MD Anderson Cancer Center,   Houston, TX, USA;  2Department of  Gastroenterology and Rheumatology,   Fukushima University School of  Medicine, Fukushima, Japan;  3Asian  institute of Gastroenterology,   Hyderabad, india;  4University of  indonesia/Cipto Mangunkusumo  Hospital, Jakarta, indonesia Correspondence: Manoop S Bhutani   Department of Gastroenterology,  Hepatology and Nutrition Unit  1466,   UT MD Anderson Cancer Center,   1515 Holcombe Blvd, Houston,   TX 77030-4009, USA   Tel +1 713 794 5073  Fax +1 713 563 4398  email manoop.bhutani@mdanderson.or gAbstract:  Hepatocellular carcinoma (HCC) is an aggressive tumor and a leading cause of  cancer-related deaths globally.",Non-OADS,/arxiv_data1/oa_pdf/d6/76/jhc-2-143.PMC4918294.pdf
Available from: http://globocan.iarc.,Non-OADS,/arxiv_data1/oa_pdf/d6/76/jhc-2-143.PMC4918294.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/d6/76/jhc-2-143.PMC4918294.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/76/jhc-2-143.PMC4918294.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8c/73/jhc-2-151.PMC4918295.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Hepatocellular Carcinoma 2015:2 151–157Journal of Hepatocellular Carcinoma Dove press submit your manuscript | www.dovepress.co m Dove press  151Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S7515 3Fibrolamellar hepatocellular carcinoma: current  clinical perspectives Kelly J Lafaro1 Timothy M Pawlik2 1Center for Pancreatic Cancer  Research, Memorial Sloan Kettering  Cancer Center, New Y ork, NY,   2Department of Surgery, The Johns  Hopkins University School of  Medicine, Baltimore, MD, USA Correspondence: Timothy M Pawlik   Division of Surgical Oncology,  Department of Surgery, Johns Hopkins  Hospital, 600 North wolfe Street,  Blalock 688, Baltimore, MD 21287, USA   Tel +1 410 502 2387   Fax +1 410 502 2388   email tpawlik1@jhmi.ed uAbstract:  Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC),  which comprises ∼1%–9% of all HCCs.",Non-OADS,/arxiv_data1/oa_pdf/8c/73/jhc-2-151.PMC4918295.pdf
Available from:  http://www.seer.cancer.go v. 2.,Non-OADS,/arxiv_data1/oa_pdf/8c/73/jhc-2-151.PMC4918295.pdf
"Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journa lThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina - tion and study of clinical, translational and basic research findings in  this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/8c/73/jhc-2-151.PMC4918295.pdf
Visit http://www.dovepress.com/testimonialsph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8c/73/jhc-2-151.PMC4918295.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/71/69/ov-2-047.PMC4918354.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2013:2 47–56Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  47ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S3662 3Cell carriers for oncolytic viruses: current  challenges and future directions Dominic G Roy1,2 John C Bell1–3 1Centre for innovative Cancer  Therapeutics, Ottawa Hospital  Research institute, 2Department  of Biochemistry, immunology and  Microbiology, 3Department of  Medicine, University of Ottawa,   Ottawa, ON, Canada Correspondence: John C Bell   Ottawa Hospital Research institute,   501 Smyth Road, Ottawa,   ON K1H 8L6, Canada   email jbell@ohri.c aAbstract:  The optimal route for clinical delivery of oncolytic viruses is thought to be systemic  intravenous injection; however, the immune system is armed with several highly efficient mecha - nisms to remove pathogens from the circulatory system.",Non-OADS,/arxiv_data1/oa_pdf/71/69/ov-2-047.PMC4918354.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/71/69/ov-2-047.PMC4918354.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/71/69/ov-2-047.PMC4918354.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2013:2 57–74Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  57ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S5260 1Oncolytic herpes viruses, chemotherapeutics,   and other cancer drugs Lynne Braidwood1 Sheila V Graham2 Alex Graham1 Joe Conner1 1Virttu Biologics Ltd, Department  of Neurology, Southern General  Hospital, Glasgow, UK; 2MRC- University of Glasgow Centre for  Virus Research, institute of infection,  immunity and inflammation, College  of Medical, Veterinary and Life  Sciences, Jarrett Building, University  of Glasgow, Glasgow, UK Correspondence: Lynne Braidwood   Virttu Biologics Ltd, Department of   Neurology, Southern General Hospital,   1345 Govan Road, Glasgow G51 4TF, UK   T el +44 141 445 1716   Fax +44 141 445 1715   email l ynne.",Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
Available from: http://clinicaltrials.gov/ show/NCT0174029 7.,Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
Available from: http://clinicaltrials.gov/show/NCT0093193 1.,Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
Available from: http://clinicaltrials.gov/show/NCT0172101 8.,Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
Available from: http://clinicaltrials.gov/ show/NCT0107194 1.,Non-OADS,/arxiv_data1/oa_pdf/29/d3/ov-2-057.PMC4918355.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5a/53/ov-3-001.PMC4918358.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2014:3 1–9Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  1ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S3670 3Arming viruses in multi-mechanistic oncolytic  viral therapy: current research and future  developments, with emphasis on poxviruses Padma Sampath Steve H Thorne Department of Surgery, University of  Pittsburgh Cancer institute, University  of Pittsburgh, Pittsburgh, PA, USA Correspondence: Steve Thorne   University of Pittsburgh,   1.46e Hillman Cancer Center,   5117 Centre Avenue, Pittsburgh,   PA-15238, USA   Tel +1 412 623 4896   Fax +1 412 623 7709   email t horne sh@upmc .eduAbstract:  The field of oncolytic virology has made great strides in recent years.",Non-OADS,/arxiv_data1/oa_pdf/5a/53/ov-3-001.PMC4918358.pdf
Available from: http://clinicaltrials.gov/show/NCT01171651.,Non-OADS,/arxiv_data1/oa_pdf/5a/53/ov-3-001.PMC4918358.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/5a/53/ov-3-001.PMC4918358.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/53/ov-3-001.PMC4918358.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bb/38/ov-3-011.PMC4918360.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2014:3 11–20Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  11ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S3670 1Critical analysis of an oncolytic herpesvirus  encoding granulocyte-macrophage colony  stimulating factor for the treatment of malignant  melanoma Tasha Hughes1 Robert S Coffin2 Caroline e Lilley2 Rafael Ponce2 Howard L Kaufman1 1Departments of General Surgery and  immunology and Microbiology, Rush  University Medical Center, Chicago  iL, 2BioVex, inc, a subsidiary of Amgen,   inc, Sherman Oaks, CA, USA Correspondence: Howard L Kaufman   Rush University Medical Center,   1725 w Harrison Street, Room 845,   Chicago, iL 60612, USA   Tel +1 312 942 0600   Fax +1 312 942 0601   email h oward_kaufman@rush.ed uAbstract:  Oncolytic viruses that selectively lyse tumor cells with minimal damage to normal  cells are a new area of therapeutic development in oncology.",Non-OADS,/arxiv_data1/oa_pdf/bb/38/ov-3-011.PMC4918360.pdf
Available from: http://clinicaltrials.gov/show/ NCT01740297.,Non-OADS,/arxiv_data1/oa_pdf/bb/38/ov-3-011.PMC4918360.pdf
Available from: http://clinicaltrials.gov/show/ NCT00402025.,Non-OADS,/arxiv_data1/oa_pdf/bb/38/ov-3-011.PMC4918360.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/bb/38/ov-3-011.PMC4918360.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/bb/38/ov-3-011.PMC4918360.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2a/80/ov-3-035.PMC4918362.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2014:3 35–46Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  35ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/OV.S5385 8Oncolytic viral therapy for pancreatic cancer:   current research and future directions Justin w Ady Jacqueline Heffner elizabeth Klein Yuman Fong Department of Surgery, Memorial   Sloan-Kettering Cancer Center,    New Y ork, NY, USA Correspondence: Yuman Fong   Department of Surgery, Murray F   Brennan Chair in Surgery, Memorial   Sloan-Kettering Cancer Center,   1275 York Avenue, New York,   NY 10065, USA   email fongy@mskcc.or gAbstract:  The development of targeted agents and chemotherapies for pancreatic cancer has  only modestly affected clinical outcome and not changed 5-year survival.",Non-OADS,/arxiv_data1/oa_pdf/2a/80/ov-3-035.PMC4918362.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/2a/80/ov-3-035.PMC4918362.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2a/80/ov-3-035.PMC4918362.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c7/44/ov-3-047.PMC4918364.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2014:3 47–55Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  47ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S5632 2Applications of coxsackievirus A21 in oncology Stephen Bradley1 Adam D Jakes1 Kevin Harrington2 Hardev Pandha3 Alan Melcher1 Fiona errington-Mais1 1Leeds institute of Cancer and  Pathology, Cancer Research UK  and experimental Cancer Medicine  Centre, St James’ University Hospital,   Leeds, UK; 2Division of Cancer  Biology, The institute of Cancer  Research, London, UK; 3Oncology  Department, Faculty of Health and  Medical Sciences, University of Surrey,   Guildford, UK Correspondence: Fiona errington-Mais  Leeds institute of Cancer and   Pathology, Leeds institute of Cancer and  Pathology (LiCAP), wellcome   Trust Brenner Building (level 5), St  James’s University Hospital, Beckett  Street, Leeds LS9 7TF, UK   email f.errington@leeds.ac.u kAbstract:  The clinical management of cancer continues to be dominated by macroscopic  surgical resection, radiotherapy, and cytotoxic drugs.",Non-OADS,/arxiv_data1/oa_pdf/c7/44/ov-3-047.PMC4918364.pdf
References 1. http://www.who.int/en/[homepage on the Internet].,Non-OADS,/arxiv_data1/oa_pdf/c7/44/ov-3-047.PMC4918364.pdf
http://www.viralytics.com/clinical-trial-information/investigator- information.,Non-OADS,/arxiv_data1/oa_pdf/c7/44/ov-3-047.PMC4918364.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/c7/44/ov-3-047.PMC4918364.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c7/44/ov-3-047.PMC4918364.pdf
Available from: http://www.viralytics.com/media/ presentations/130618%20ONCO%20Meeting%20CA V ATAK%20 and%20Bladder%20Cancer%20Pandha.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/44/ov-3-047.PMC4918364.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/90/b4/ov-3-057.PMC4918365.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2014:3 57–68Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  57Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OV.S5903 7live attenuated measles virus vaccine therapy   for locally established malignant glioblastoma   tumor cells ahmed M al-shammari1 Farah e ismaeel2 shahlaa M salih2 nahi Y Yaseen1 1experimental Therapy Department,  iraqi center for cancer and Medical  genetic researches, Mustansiriya  University,  2Departments of  Biotechnology, college of science,  al-n ahrain University, Baghdad, iraq correspondence: ahmed M al-shammari   Department of experimental Therapy,  iraqi center for cancer and Medical  genetic research, PO Box 15007,  Al-Yarmook Post Office, Baghdad, Iraq   Tel +964 780 914 3825  email ahmed.alshammari@iccmgr.or gAbstract:  Glioblastoma multiforme is the most aggressive malignant primary brain tumor  in humans, with poor prognosis.",Non-OADS,/arxiv_data1/oa_pdf/90/b4/ov-3-057.PMC4918365.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/90/b4/ov-3-057.PMC4918365.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/90/b4/ov-3-057.PMC4918365.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncolytic Virotherapy 2014:3 69–82Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  69ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S5132 1Reovirus in cancer therapy: an evidence-   based review Derek Clements1,* erin Helson2,* Shashi A Gujar2,3 Patrick wK Lee1,2 1Department of Pathology,   2Department of Microbiology and  immunology, Dalhousie University,   3Strategy and Organizational  Performance, iwK Health Center,   Halifax, Nova Scotia, Canada *These authors contributed equally to  this work, and are joint first authors Correspondence: Patrick wK Lee   Department of Microbiology and   immunology, Dalhousie University,   7P Charles Tupper Building,   5850 College Street, Halifax,   Nova Scotia B3H  1X5, Canada   email patrick.lee@dal.c aAbstract:  Reovirus, a double-stranded ribonucleic acid virus and benign human pathogen,  preferentially infects and kills cancer cells in its unmodified form, and is one of the leading  oncolytic viruses currently undergoing clinical trials internationally.",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.oncolyticsbiotech.com/English/ news/press-release-details/2012/Oncolytics-Biotech-Inc-Enters-into- Sponsorship-Agreement-with-NCIC-CTG-for-Randomized-Phase-II- Study-in-Prostate-Cancer.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available  from: http://www.oncolyticsbiotech.com/English/news/press-release- details/2002/Oncolytics-Biotech-Announces-Positive-Interim-Safety- Results-from-REOL YSIN-Phase-I-Malignant-Glioma-Study.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.gov/ct2/show/NCT0075303 8?term=reolysin&rank =13.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.oncolyticsbiotech.com/English/news/ press-release-details/2013/Oncolytics-Biotech-Inc-Announces-Positive- Top-Line-Data-from-REO-018-Randomized-Study-of-REOL YSIN-in- Head-and-Neck-Cancers.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.gov/ct2/show/NCT0116654 2?term=reolysin&rank =3.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://oncolytics.s3.amazonaws.com/data/46/original.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from:  http://www.oncolyticsbiotech.com/English/news/press-release- details/2010/Oncolytics-Biotech-Inc-Announces-Start-of-Enrollment- in-Randomized -Phase-II-Ovarian-Cancer-Study.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.oncolyticsbiotech.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available  from: http://www.oncolyticsbiotech.com/English/news/press-release- details/2009/Oncolytics-Biotech-Inc-Announces-Positive-Results-of- UK-Phase-II-REOL YSIN-and-Radiation-Combination-Clinical-Trial.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from:  http://www.oncolyticsbiotech.com/news/press-release-details/2012/ Oncolytics-Biotech-Inc-Completes-Patient-Enrollment-in-UK-Phase- I-Clinical-Trial-Investigating-REOL YSIN-in-Combination-with- Cyclophosphamide-in-Patients-with-Advanced-Malignances/default.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.gov/ct2/show/NCT0099832 2?term=reolysin&rank =10.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT0 0998192?term =reolysin&rank =12.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from:  http://www.clinicaltrials.gov/ct2/show/NCT00984464?term =reolys in&rank=11.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.oncolyticsbiotech.com/English/ news/press-release-details/2010/Oncolytics-Biotech-Inc-Announces- Phase-I-Study-in-Pediatric-Patients-with-Relapsed-or- Refractory - Solid-Tumors-to-be-Conducted-by-the-Childrens- Oncology -Group- and-Sponsored-by-the-National-Cancer-Institute.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.oncolyticsbiotech.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.oncolyticsbiotech.com/English/ news/press-release-details/2012/Oncolytics-Biotech-Inc-Enters- into-Sponsorship-Agreement-with-NCIC-CTG-for- Randomized - Phase-II-Study-in-Colorectal-Cancer.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.gov/ ct2/show/NCT01622543?term =reolysin&rank =9.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.oncolyticsbiotech.com/ English/news/press-release-details/2012/Oncolytics-Biotech-Inc- Enters-into-Sponsorship-Agreement-with-NCIC-CTG-for-Random - ized-Phase-II-Study-in-Non-Small-Cell-Lung-Cancer.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Available from: http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b5/cc/ov-3-069.PMC4918368.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/88/1d/ov-4-001.PMC4918372.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 1–11Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  1Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OV.S7237 2Myxoma virus attenuates expression of activating  transcription factor 4 (a TF4) which has  implications for the treatment of proteasome  inhibitor–resistant multiple myeloma Katherine M Dunlap Mee Y Bartee eric Bartee Department of Microbiology and  immunology, Medical University of  south carolina, charleston, sc, Usa correspondence: eric Bartee   Department of Microbiology   and immunology, Medical University   of south carolina, 175 ashley ave,   charleston, sc 29425, Usa   Tel +1 843 876 2775   Fax +1 843 792 4882   email bartee@musc.ed uAbstract:  The recent development of chemotherapeutic proteasome inhibitors, such as bort - ezomib, has improved the outcomes of patients suffering from the plasma cell malignancy  multiple myeloma.",Non-OADS,/arxiv_data1/oa_pdf/88/1d/ov-4-001.PMC4918372.pdf
Available from: http://www.llscanada.org/#/ diseaseinformation/myeloma /.,Non-OADS,/arxiv_data1/oa_pdf/88/1d/ov-4-001.PMC4918372.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/88/1d/ov-4-001.PMC4918372.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/88/1d/ov-4-001.PMC4918372.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f9/4d/ov-4-013.PMC4918373.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 13–23Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  13ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S4552 5The ex vivo purge of cancer cells using oncolytic  viruses: recent advances and clinical implications Jovian J Tsang1,2 Harold L Atkins2,3 1Department of Biochemistry,   University of Ottawa, 2Cancer  Therapeutics, Ottawa Hospital  Research institute, 3Blood and  Marrow Transplant Program, The  Ottawa Hospital, Ottawa, ON,    Canada Correspondence: Harold L Atkins   Blood and Marrow Transplant Program,  The Ottawa Hospital, 501 Smyth Road,   Box 926, Ottawa, ON, K1H 8L6, Canada   Tel +1 613 737 7700 ext 70341   Fax +1 613 737 8768   email hatkins@ohri.c aAbstract:  Hematological malignancies are treated with intensive high-dose chemotherapy, with  or without radiation.",Non-OADS,/arxiv_data1/oa_pdf/f9/4d/ov-4-013.PMC4918373.pdf
"Available from  http://www.cibmtr.org/referencecenter/slidesreports/summaryslides/ pages/index.asp x. Accessed August 10, 2014.",Non-OADS,/arxiv_data1/oa_pdf/f9/4d/ov-4-013.PMC4918373.pdf
"November 26, 2010, Available from: http://online.wsj.com/news/arti - cles/SB10001424052748704693104575639520875125424 /.",Non-OADS,/arxiv_data1/oa_pdf/f9/4d/ov-4-013.PMC4918373.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/f9/4d/ov-4-013.PMC4918373.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f9/4d/ov-4-013.PMC4918373.pdf
"Available from: http://www.bt.cdc.gov/ agent/smallpox/vaccination/faq.as p. Accessed July 23, 2014.",Non-OADS,/arxiv_data1/oa_pdf/f9/4d/ov-4-013.PMC4918373.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/74/a3/ov-4-025.PMC4918374.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 25–31Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  25ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S5964 0The emerging therapeutic potential of the  oncolytic immunotherapeutic Pexa-Vec (JX-594) Caroline J Breitbach1 John C Bell2,3 Tae-Ho Hwang1 David H Kirn1 James Burke1 1SillaJen inc, Seoul, South Korea;   2Department of Biochemistry,   Microbiology and immunology,   University of Ottawa, Ottawa,   ON, Canada;  3Centre for Cancer  Therapeutics, Ottawa   Hospital Research institute,    Ottawa, ON, Canada Correspondence: James Burke   16th floor,  450 Sansome St   San Francisco, CA, USA   Tel +1 406 850 8160  Fax +1 415 598 2600  email jburke@jennerex.co mAbstract:  Oncolytic immunotherapeutics (OIs) are viruses designed to preferentially replicate  in and lyse cancer cells, thereby triggering antitumor immunity.",Non-OADS,/arxiv_data1/oa_pdf/74/a3/ov-4-025.PMC4918374.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/74/a3/ov-4-025.PMC4918374.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/74/a3/ov-4-025.PMC4918374.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2f/45/ov-4-033.PMC4918376.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 33–38Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  33Case repO rtopen access to scientific and medical research Open access Full text article http: //dx.doi.org/10.2147/OV.S6246 1extended disease-free interval of  6 years   in a recurrent glioblastoma multiforme patient   treated with G207 oncolytic viral therapy thomas r Whisenhunt Jr Kiran F rajneesh James r Hackney James M Markert Department of Neurosurgery,   University of alabama at Birmingham,   Birmingham, aL, Usa Correspondence: James M Markert   510 20th street south, Birmingham,   aL 35294-3410, Usa   tel +1 205 934 7171  email jmarkert@uabmc.ed uBackground:  Glioblastoma multiforme (GBM) is a relentless primary central nervous system  malignancy that remains resistant to conventional therapy despite major advances in clinical  neurooncology.",Non-OADS,/arxiv_data1/oa_pdf/2f/45/ov-4-033.PMC4918376.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/2f/45/ov-4-033.PMC4918376.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2f/45/ov-4-033.PMC4918376.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 39–48Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  39ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S5478 0Chemovirotherapy: combining chemotherapeutic  treatment with onco lytic virotherapy eike Binz Ulrich M Lauer Department of internal  Medicine, Division of Hepatology,   Gastroenterology, infectiology,   Medical University Hospital,   T uebingen, Germany Correspondence: Ulrich M Lauer   University Hospital Tuebingen,  Department of internal Medicine,  Division of Hepatology,  Gastroenterology, infectiology,   Otfried-Mueller-Str  10, D-72076  Tuebingen, Germany   Tel +49 7071 29 83190   Fax +49 7071 29 4686  email ulrich.lauer@uni-tuebingen.d eAbstract:  Oncolytic virotherapy has made significant progress in recent years, however,  widespread approval of viro therapeutics is still limited.",Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
"Oncolytic Virotherapy 2015:4submit your manuscript | www.dovepress.co m Dove press Dove press 42Binz and Lauer Table  1 Phase  1 clinical trials of chemovirotherapy, sorted by virus family Virus family Vector Modifications Tumor Route Combination Study sites Status (NCT/PMID  reference) Adenovirus VCN-01 Ad5  E1A( -)Pancreatic cancer iT Gem Multicenter Spain Recruiting, NCT02045589 PH20   hyaluronidase+Diverse types of cancer iV Gem Multicenter Spain Recruiting, NCT02045602 DNX2401 ( Δ-24-RGD-4C) Ad5  E1A( -)Glioblastoma intraparenchymal TMZ Monocenter Spain Recruiting, NCT01956734 ColoAd1 Ad3/11p Ovarian cancer IP PTX Multicenter UK Recruiting, NCT02028117* ONYX-015 (dl1520) E1B-55k( -)   E3B( -)Pancreatic cancer IT (EUS) Gem Multicenter US Completed, PMID:  12576418*,7 Gi tumors IA (HAI) 5-FU + LV Multicenter US Completed, PMID:  118950006 Sarcoma iT MAP Monocenter US Completed, PMID:  15647767*,8 Herpes simplex   virusNV1020 ICP34.5( -) CRC with liver metastasis IA (HAI) Second-line CTX Multicenter US Completed, PMID: 20486770*,16 CRC with liver metastasis IA (HAI) FUdR, CPT-11/   OXAMonocenter US Completed, PMID:  1901825417 Talimogene laherparepvec  (OncoVEX)GM-CSF+   ICP34.5( -)  ICP47( -)Head and neck cancer iT CDDP +   radiation + NDTwo center UK Completed, PMID: 20670951*,20 Us11 ↑ Melanoma iT ipilimumab Multicenter US Recruiting, NCT01740297* Reovirus Reolysin – Diverse types of cancer iV CBCDA + PTX Multicenter UK Completed, PMID:  22316603*,3 Diverse types of cancer iV Gem Multicenter UK Completed, PMID: 2110672834 Diverse types of cancer iV DTX Multicenter UK Completed, PMID:  2092640035 Colorectal cancer iV FOLFiRi +   BevacizumabMulticenter US Recruiting, NCT01274624 Vaccinia (Lister  strain)GLV-1h68 (GL-ONC1) ruc-gfp+   β-gal+, β-gluc+   F14.5L( -), HA( -)  TK(-)Head and neck cancer iV CDDP +   radiationMonocenter US Recruiting, NCT01584284 Vaccinia   (Wyeth strain)JX-594 (Pexa-Vec) GM-CSF+, TK( -) Colorectal cancer iV CPT-11 Multicenter US,   France, CanadaActive, not recruiting,  NCT01394939* Notes:  A search for ongoing and published clinical trials was carried out on the clinical trial database http://clinicaltrials.gov/  and http://www.ncbi.nlm.nih.gov/pubmed/ .",Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
"Oncolytic Virotherapy 2015:4submit your manuscript | www.dovepress.co m Dove press Dove press 43Review on chemovirotherapyTable  2 Phase II clinical trials of chemovirotherapy, sorted by tumor entity Tumor Stage Virus family Name Modifications Route Combination Study sites Status (NCT/PMID reference) Diverse types of cancer incurable or recurrent Adenovirus H101 E1B-55k( -)  E3(-)iT Standard CTX Monocenter People’s  Republic of ChinaCompleted, PMID:  1553492013 Breast cancer Advanced or metastatic Reovirus Reolysin – iV PTX Multicenter Canada Recruiting, NCT01656538 Colorectal cancer CRC with liver   metastasisHSV NV1020 ICP34.5( -) IA (HAI) Second-line CTX Multicenter US Completed, PMID:  20486770*,16 Gi tumors with liver   metastasisAdenovirus ONYX-015   (dl1520)E1B-55k( -)   E3B( -)IA (HAI) 5-FU + LV Multicenter US Completed, PMID:  124146319 Metastatic Reovirus Reolysin – iV FOLFOX6 +  BevacizumabMulticenter Canada Recruiting, NCT01622543 Metastatic Vaccinia   (Wyeth strain)JX-594   (Pexa-Vec)GM-CSF+   TK(-)iV CPT-11 Multicenter US,   France, CanadaActive, not recruiting, NCT01394939* Head and neck cancer Recurrent Adenovirus ONYX-015   (dl1520)E1B-55k( -)  E3B( -)iT CDDP + 5-FU Multicenter US,   UK, CanadaCompleted, PMID:  1093222410 Advanced or metastatic HSV Talimogene  laherparepvec  (OncoVEX)GM-CSF+   ICP34.5( -)  ICP47( -)  Us11 ↑iT CDDP +   radiation + NDTwo center UK Completed, PMID:  20670951*,20 incurable or metastatic Reovirus Reolysin – iV CBCDA + PTX Multicenter UK Completed, PMID:  22316603*,3 HCC Unresec table Vaccinia   (Wyeth strain)JX-594   (Pexa-Vec)GM-CSF+   TK(-)iT + iV Sorafenib Multicenter Korea Active, not recruiting, NCT01171651 Lung cancer Recurrent or metastatic Reovirus Reolysin – iV CBCDA + PTX Multicenter US Active, not recruiting, NCT00861627 Recurrent or metastatic Reovirus Reolysin – iV CBCDA + PTX Multicenter US Active, not recruiting, NCT00998192 Melanoma Metastatic HSV Talimogene   laherparepvec   (OncoVEX)GM-CSF+   ICP34.5( -)  ICP47( -)  Us11 ↑iT ipilimumab Multicenter US Recruiting, NCT01740297* Metastatic Reovirus Reolysin – iV CBCDA + PTX Monocenter US Completed, NCT00984464 Pancreatic cancer Advanced or metastatic Adenovirus ONYX-015  (dl1520)E1B-55k( -)   E3B( -)IT (EUS) Gem Multicenter US Completed, PMID:  12576418*,7 Recurrent or metastatic Reovirus Reolysin – iV CBCDA + PTX Multicenter US Active, not recruiting, NCT01280058 Metastatic Reovirus Reolysin – iV Gem Multicenter US Unknown, NCT00998322 Reproductive tract tumors Recurrent Reovirus Reolysin – iV PTX Multicenter US Active, not recruiting, NCT01199263 Ovarian cancer Recurrent Adenovirus ColoAd1 Ad3/11p IP PTX Multicenter UK Recruiting, NCT02028117* Sarcoma Metastatic Adenovirus ONYX-015   (dl1520)E1B-55k( -)   E3B( -)iT MAP Monocenter US Completed, PMID:  15647767*,8 Notes:  A search for ongoing and published clinical trials was carried out on the clinical trial database http://clinicaltrials.gov/  and http://www.ncbi.nlm.nih.gov/pubmed/ .",Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
"Reovirus-based   chemo   viro therapeutic regimens Reolysin (recently reviewed by Clements et al)22 con - tains a naturally occurring, ubiquitous, non-enveloped  human reovirus strain which replicates in KRAS-mutant  cells resulting in profound tumor cell lysis.23 In a recent  Phase  I dose escalation study, a standard FOLFIRI  (folinic acid (leucovorin) + 5-fluorouracil + irinotecan)  chemotherapy regimen was administered parallel with  escalating Reolysin doses in patients with KRAS-mutant  mCRC.24 As a result, the chemovirotherapeutic combina - tion of FOLFIRI and Reolysin was found to be safe and  resulted in disease control in the majority of patients,  including those who previously progressed on irinotecan.24  Due to these encouraging results, additional studies are  planned.Table  3 Current Phase III clinical trials of chemovirotherapy Name Tumor Patients Combination Route Sequence Study sites Status (NCT/ PMID reference) ReO 018  (Reolysin)Head and  neck cancerRecurrent/metastatic  platinum refractory  squamous cell carcinoma Patient subgroup  1:   locoregional tumors   with or without  metastases (n =118) Patient subgroup  2:  only measured distal  metastases (n =47)CBCDA + PTX iV Day 1: PTX  3 h,  CBCDA  0.5 h Days 1–5:   Reolysin daily 1 h   (21 days per cycle)   Control arm:   CTX + iV placebo   (no virus)Multicenter US, Russia,   UK, Spain, Hungary,   Canada, Italy, Poland,   Belgium, France, Germany,  Greece, SloveniaCompleted,  NCT01166542 Notes:  A search for ongoing and published clinical trials was carried out on the clinical trial database http://clinicaltrials.gov/  and http://www.ncbi.nlm.nih.gov/pubmed/ .",Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
Further data on the study design of the ReO  018 trial are from Oncolytics Biotech ( http://www.oncolyticsbiotech.com/english/clinical-trials/clinical-trials-news/clinical-trials- details/2013/ReO-018/ ).,Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
Available from: http://www.oncolyticsbiotech.com/ news/press-release-details/2014/Oncolytics-Biotech-Inc-Announces- Additional-Data-from-REO-018-Randomized-Study-of-REOL YSIN- in-Head-and-Neck-Cancers.,Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
Available from: http://www.amgen.com/media/media_pr_detail.,Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
Strasbourg: Transgene;  Available from: http://www.transgene.fr/?option =com_content&view = article&id =82&Itemid =76.,Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
Available from: http://www.oncolyticsbiotech.com/ news/press-release-details/2013/Oncolytics-Biotech-Inc-Announces-   Positive-Top-Line-Data-from-REO-018-Randomized-Study-of-   REOL YSIN-in-Head-and-Neck-Cancers .,Non-OADS,/arxiv_data1/oa_pdf/60/a2/ov-4-039.PMC4918378.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/59/f3/ov-4-049.PMC4918379.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 49–62Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  49ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S7860 0Therapeutic potential of oncolytic Newcastle  disease virus: a critical review Shay Tayeb1,2 Zichria Zakay-Rones2 Amos Panet2 1Department of Biotechnology,  Hadassah Academic College,   Jerusalem, israel;  2Department of  Biochemistry and Molecular Biology,  The Chanock Center for Virology,  institute of Medical Research israel- Canada, The Hebrew University- Hadassah Medical School, Jerusalem,  israel Correspondence: Zichria Zakay-Rones   Department of Biochemistry and  Molecular Biology, The Chanock Center   for Virology, institute of Medical  Research israel-Canada, The Hebrew  University-Hadassah Medical School,  Jerusalem  91120, israel   Tel +972 2 675 8556  email zichriar@ekmd.huji.ac.i lAbstract:  Newcastle disease virus (NDV) features a natural preference for replication in many  tumor cells compared with normal cells.",Non-OADS,/arxiv_data1/oa_pdf/59/f3/ov-4-049.PMC4918379.pdf
"Oncolytic Virotherapy 2015:4submit your manuscript | www.dovepress.co m Dove press Dove press 58Tayeb et al Table  1 Selected clinical trials using Newcastle disease virus NDV strain Tumor type Treatment mode Phase Reference PV701 Solid cancers intravenous i 21,55 NDV-HUJ Glioblastoma intravenous i–ii 25 NDV-MTH-68/H Various advanced cancer Uncontrolled clinical   experiments (ii)19 Ulster Melanoma ATV-NDV ii/iii 86 Ulster Ovarian cancer   Stomach cancer   Pancreatic cancer   GlioblastomaATV-NDV ii 47 Ulster Colorectal cancer with metastases ATV-NDV iii 87 Ulster Glioblastoma ATV-NDV ii 88 Ulster Metastatic colorectal cancer ATV-NDV ii 89,90 Ulster Ovarian ATV-NDV ii 91 Ulster Advanced colorectal cancer ATV-NDV ii 92 Ulster Metastatic renal cell carcinoma ATV-NDV ii 93 Ulster Various advanced tumors ATV-NDV ii 94 LaSota Colorectal cancer ATV-NDV iii 95 LaSota Advanced gastrointestinal tumors ATV-NDV ii 95 Note:  Table  indicates the Newcastle disease virus strain, treatment modality, and clinical phase, and is summarized from the National Cancer institute ( http://www.cancer.gov ).84 Abbreviation:  ATV-NDV, autologous virus modified tumor vaccine using Newcastle disease virus.",Non-OADS,/arxiv_data1/oa_pdf/59/f3/ov-4-049.PMC4918379.pdf
Available from:  http://www.cancer.gov/cancertopics/pdq/cam/NDV/ HealthP rofessio nal/ page 5.,Non-OADS,/arxiv_data1/oa_pdf/59/f3/ov-4-049.PMC4918379.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/59/f3/ov-4-049.PMC4918379.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/59/f3/ov-4-049.PMC4918379.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cc/03/ov-4-063.PMC4918380.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 63–73Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  63ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6304 5Promising oncolytic agents for metastatic   breast cancer treatment James J Cody1 Douglas R Hurst2 1imQuest BioSciences, Frederick,   MD, 2Department of Pathology,   University of Alabama at Birmingham,   Birmingham, AL, USA Correspondence: James J Cody   imQuest BioSciences,  7340 executive  way, Suite R, Frederick, MD  21704, USA   Tel +1 301 696 0274  Fax +1 301 696 0381  email jcody@imquestbio.co m    Douglas R Hurst   1720,  2nd Avenue South, University of  Alabama at Birmingham, Birmingham,   AL 35294-0019, USA   Tel +1 205 934 2951  Fax +1 205 975 1126  email dhurst@uab.ed uAbstract:  New therapies for metastatic breast cancer patients are urgently needed.",Non-OADS,/arxiv_data1/oa_pdf/cc/03/ov-4-063.PMC4918380.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/cc/03/ov-4-063.PMC4918380.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/cc/03/ov-4-063.PMC4918380.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/92/86/ov-4-075.PMC4918382.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 75–82Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  75ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S5473 8Novel therapeutic strategies in human malignancy:  combining immunotherapy and oncolytic  virotherapy Padma Sampath Steve H Thorne Department of Surgery, University of  Pittsburgh Cancer institute, University  of Pittsburgh, Pittsburgh, PA, USA Correspondence: Steve H Thorne   Department of Surgery, University of   Pittsburgh Cancer institute, University   of Pittsburgh, 1.46e HCC, 5117 Centre  Avenue, Pittsburgh, PA 15213, USA   Tel +1 412 623 4896   email t horne sh@upmc .eduAbstract:  Results from randomized clinical trials over the last several years have finally  begun to demonstrate the potential of oncolytic viral therapies to treat a variety of cancers.",Non-OADS,/arxiv_data1/oa_pdf/92/86/ov-4-075.PMC4918382.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/92/86/ov-4-075.PMC4918382.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/92/86/ov-4-075.PMC4918382.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/48/30/ov-4-083.PMC4918384.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 83–93Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  83ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S5450 3Oncolytic virotherapy for head and neck cancer:  current research and future developments Akshiv Malhotra1 Arun Sendilnathan1 Matthew O Old2 Trisha M wise-Draper1 1Division of Hematology-Oncology,   Department of internal Medicine,   University of Cincinnati, Cincinnati,   2Department of Otolaryngology- Head and Neck Surgery, Ohio State  University, Columbus, OH, USA Correspondence: Trisha wise-Draper   Division of Hematology-Oncology,  Department of internal Medicine,  University of Cincinnati, Vontz Center  for Molecular Studies,  3125 eden   Avenue, ML  0562, Cincinnati,   OH 45267-0562, USA   Tel +1 513 558 2826   Fax +1 513 558 6703   email wiseth@ucmail.uc.ed uAbstract:  Head and neck cancer (HNC) is the sixth most common malignancy worldwide.",Non-OADS,/arxiv_data1/oa_pdf/48/30/ov-4-083.PMC4918384.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/48/30/ov-4-083.PMC4918384.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/48/30/ov-4-083.PMC4918384.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/44/d5/ov-4-095.PMC4918385.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 95–107Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  95ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6635 8On the potential of oncolytic virotherapy for the  treatment of canine cancers Amy L MacNeill Department of Microbiology,   immunology, and Pathology, College of  Veterinary Medicine and Biomedical  Sciences, Colorado State University,   Fort Collins, CO, USA Correspondence: Amy L MacNeill   Department of Microbiology,  immunology, and Pathology, College  of Veterinary Medicine and Biomedical  Sciences, Colorado State University,   300 w Drake Rd, Fort Collins,   CO 80523-1644, USA   Tel +1 970 297 5112   Fax +1 970 297 4441   email amy.macneill@colostate.ed uAbstract:  Over 6 million dogs are diagnosed with cancer in the USA each year.",Non-OADS,/arxiv_data1/oa_pdf/44/d5/ov-4-095.PMC4918385.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/44/d5/ov-4-095.PMC4918385.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/44/d5/ov-4-095.PMC4918385.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8e/2f/ov-4-133.PMC4918388.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 133–140Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  133ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6609 1Oncolytic virotherapy for human malignant  mesothelioma: recent advances Nicolas Boisgerault1–3 Carole Achard1–3 Tiphaine Delaunay1–3  Laurent Cellerin4 Frédéric Tangy5 Marc Grégoire1–3 Jean-François Fonteneau1–3 1iNSeRM, UMR892, 2CNRS, UMR6299,   Health Research institute of the  University of Nantes, 3University  of Nantes, 4Nantes CHU Hospital,   Department of Thoracic and Digestive  Oncology, 5Viral Genomics and  Vaccination Unit, institut Pasteur,   Paris, CNRS UMR-3569, France Correspondence: Nicolas Boisgerault   iNSeRM, UMR892 - CNRS UMR6299,  institut de Recherche Thérapeutique de  l’Université de Nantes, 8 quai Moncousu,  BP70721, 44007 Nantes Cedex 1, France   Tel +33 2 2808 0236   Fax +33 2 2808 0204   email nicolas.boisgerault@inserm.f rAbstract:  Cancer virotherapy is an attractive alternative to conventional treatments because it  offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are  now available and 2) their multifaceted activities against both tumor cells and tumor vessels,  in addition to their ability to induce antitumor immune responses.",Non-OADS,/arxiv_data1/oa_pdf/8e/2f/ov-4-133.PMC4918388.pdf
"This could be of great value when monitoring  tumors in patients treated by virotherapy.Table  1 Completed and ongoing clinical trials of virotherapy for malignant mesothelioma treatment Virus Phase Patients Treatment modalities Results Reference Adenovirus Ad.HSV tk i 21 MPM No previous therapy   intrapleural injection   ($1.5×1013 particles)   + systemic ganciclovirwell tolerated   Antitumor antibodies   2 long-term survivors    (.6.5 years)55 Ad.hiFN-β  (BG00001)i 7 MPM   3 metastatic pleural effusions   (ovary, lung, MPM)No previous therapy   Single intrapleural injection   (9×1011–3×1012 particles)Antitumor immune   response in 7/10 patients   Clinical response (SD) in   4/10 patients35 Ad.hiFN-β  (BG00001)i 10 epithelioid MPM   7 metastatic pleural effusions   (ovary, lung, breast)2 intrapleural injections   (7-day interval)   (3×1011–1×1012 particles)well tolerated   Antibody responses against   tumor antigens   1 PR, 2 SD, 7 with   survival .18 months36 Ad.hiFN-α2b  (SCH 721015)Pilot 9 MPM 2 intrapleural injections   (3-day interval)   (3×1011–1×1012 particles)well tolerated   Neutralizing antibodies   1 PR and 2 SD34 Ad.hiFN-α2b  (SCH 721015)i/ii MPM 2 intrapleural injections   + 4–6 cycles of chemotherapyOngoing NCT01119664a Ad.hiFN-α2b  (SCH 721015)i MPM 2 intrapleural injections   (3-day interval)Ongoing NCT01212367a Ad5-D24-GMCSF Unspecified 2 MPM After chemotherapy   Single intrapleural injection   (2.5×1011–3×1011 particles)well tolerated   Tumor-specific and virus-   specific immunity   1 SD and 1 PD54 Ad5/3-D24-GMCSF   (ONCOS-102)i 1 MPM After chemo-/radiotherapy   4 intratumoral injections   (3×1011 particles)   + cyclophosphamide (daily)T CD8+ tumor infiltration   Th1 polarization65 Poxvirus VV-iL2 6 MPM intratumoral injection well tolerated   No tumor regression21 JX-594   (pexastimogene   devacirepvec)i 1 metastatic MPM After chemotherapy   Single intravenous injection   (1.5×107 particles)PR over 10 weeks 16 GL-ONC1 i Malignant pleural effusions   (primary, metastases, and   MPM)intrapleural injection Ongoing NCT01766739a Reovirus Reolysin i 1 MPM Pretreatment with docetaxel   intravenous injection   (1×109–3×1010 TCiD50)  Up to 8 cycles (every 21 days)   of 5 daily injectionsMinor response   23% size decrease for   1 invaded lymph node48 Measles virus MV-NiS i MPM intrapleural injections   Up to 6 cycles (every 28 days)Ongoing NCT01503177a Herpesvirus HSV-1716 i/iia MPM Single/multiple intrapleural   injectionsOngoing NCT01721018a Note:  aNCT references can be viewed at https://clinicaltrials.gov / Abbreviations:  Ad, adenovirus; GM-CSF, granulocyte-macrophage colony-stimulating factor; iL2, interleukin-2; MPM, malignant pleural mesothelioma; PD, progressive  disease; PR, partial remission; SD, s table disease; VV, vaccinia virus; TCiD, tissue culture infective dose.",Non-OADS,/arxiv_data1/oa_pdf/8e/2f/ov-4-133.PMC4918388.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/8e/2f/ov-4-133.PMC4918388.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8e/2f/ov-4-133.PMC4918388.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/57/63/ov-4-141.PMC4918391.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 141–147Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  141ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6641 9Oncolytic Sendai virus-based virotherapy for  cancer: recent advances Kotaro Saga Yasufumi Kaneda Division of Gene Therapy Science,   Graduate School of Medicine, Osaka  University, Osaka, Japan Correspondence: Kotaro Saga   Division of Gene Therapy Science,   Graduate School of Medicine,  Osaka  University, 2 -2 Yamada-oka, Suita, Osaka   565-0871, Japan   Tel +81 6 6879 3901  Fax +81 6 6879 3909  email saga@gts.med.osaka-u.ac.j pAbstract:  Many drugs have been developed and optimized for the treatment of cancer; however,  it is difficult to completely cure cancer with anticancer drugs alone.",Non-OADS,/arxiv_data1/oa_pdf/57/63/ov-4-141.PMC4918391.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/57/63/ov-4-141.PMC4918391.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/57/63/ov-4-141.PMC4918391.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/76/b5/ov-4-149.PMC4918392.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 149–155Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  149ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6601 0Patient-derived mesenchymal stem cells   as delivery vehicles for oncolytic virotherapy:   novel state-of-the-art technology Manuel Ramírez1 Javier García-Castro2 Gustavo J Melen1 África González-Murillo1 Lidia Franco-Luzón1 1Oncohematología, Hospital  Universitario Niño Jesús, 2Unidad de  Biotecnología Celular, instituto de  Salud Carlos iii, Madrid, Spain Correspondence: Manuel Ramírez   Oncohematología, Hospital Universitario  Niño Jesús, Avenida Menéndez Pelayo,   65, 28009 Madrid, Spain   Tel +34 91 503 5938   Fax +34 91 503 5902   email manuel.ramirez@salud.madrid.or gAbstract:  Oncolytic virotherapy is gaining interest in the clinic as a new weapon against  cancer.",Non-OADS,/arxiv_data1/oa_pdf/76/b5/ov-4-149.PMC4918392.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/76/b5/ov-4-149.PMC4918392.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/76/b5/ov-4-149.PMC4918392.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/83/a8/ov-4-157.PMC4918393.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 157–167Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  157ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6607 9Mechanistic insights into the oncolytic activity   of vesicular stomatitis virus in cancer  immunotherapy Boris Simovic Scott R walsh Y onghong wan Department of Pathology and  Molecular Medicine, McMaster  immunology Research Centre,   Faculty of Health Sciences, McMaster  University, Hamilton, ON, Canada Correspondence: Yonghong wan   Department of Pathology and Molecular  Medicine, McMaster immunology  Research Centre, Faculty of Health  Sciences, McMaster University,   1280 Main Street west, Hamilton,   ON L8S 4K1, Canada   email wanyong@mcmaster.c aAbstract:  Immunotherapy and oncolytic virotherapy have both shown anticancer efficacy  in the clinic as monotherapies but the greatest promise lies in therapies that combine these  approaches.",Non-OADS,/arxiv_data1/oa_pdf/83/a8/ov-4-157.PMC4918393.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/83/a8/ov-4-157.PMC4918393.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/83/a8/ov-4-157.PMC4918393.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3c/25/ov-4-169.PMC4918394.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 169–181Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  169ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6604 5Targeting tumor vasculature through oncolytic  virotherapy: recent advances Marcela T oro Bejarano Jaime R Merchan Division of Hematology–Oncology,   Department of Medicine, University  of Miami Miller School of Medicine,   Sylvester Comprehensive Cancer  Center, Miami, FL, USA Correspondence: Jaime R Merchan   Division of Hematology–Oncology,  Department of Medicine, University   of Miami Miller School of Medicine,  Sylvester Comprehensive Cancer Center,   1475 Nw  12th Avenue, Suite  3300,   Miami, FL  33136, USA   email jmerchan2@med.miami.ed uAbstract:  The oncolytic virotherapy field has made significant advances in the last decade,  with a rapidly increasing number of early- and late-stage clinical trials, some of them showing  safety and promising therapeutic efficacy.",Non-OADS,/arxiv_data1/oa_pdf/3c/25/ov-4-169.PMC4918394.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/3c/25/ov-4-169.PMC4918394.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3c/25/ov-4-169.PMC4918394.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e9/31/ov-4-109.PMC4918395.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 109–118Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  109ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6607 8Advances in the design and development of  oncolytic measles viruses Brian Hutzen1 Corey Raffel2 Adam w Studebaker1 1Center for Childhood Cancer  and Blood Diseases, The Research  institute at Nationwide Children’s  Hospital, Columbus, OH, USA;   2Department of Neurological  Surgery and Pediatrics, University  of California, San Francisco, San  Francisco, CA, USA Correspondence: Adam w Studebaker   Center for Childhood Cancer and  Blood Diseases, The Research institute  at Nationwide Children’s Hospital,  700 Children’s Drive, Columbus,  OH 43205, USA   Tel +1 614 355 2699   Fax +1 614 722 5895   email adam.studebaker@ nationwidechildrens.or gAbstract:  A successful oncolytic virus is one that selectively propagates and destroys cancerous  tissue without causing excessive damage to the normal surrounding tissue.",Non-OADS,/arxiv_data1/oa_pdf/e9/31/ov-4-109.PMC4918395.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/e9/31/ov-4-109.PMC4918395.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e9/31/ov-4-109.PMC4918395.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/dc/05/ov-4-207.PMC4918397.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 207–219Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  207ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6608 6Oncolytic virotherapy using herpes simplex virus:  how far have we come?,Non-OADS,/arxiv_data1/oa_pdf/dc/05/ov-4-207.PMC4918397.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/dc/05/ov-4-207.PMC4918397.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/dc/05/ov-4-207.PMC4918397.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/60/95/ov-4-183.PMC4918398.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 183–191Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  183ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S6608 1Combining HDAC inhibitors with oncolytic  virotherapy for cancer therapy Hiroshi Nakashima Tran Nguyen ennio Antonio Chiocca Department of Neurosurgery,   Brigham and women’s Hospital,   Boston, MA, USA Correspondence: eA Chiocca   Department of Neurosurgery, Brigham  and women’s Hospital, 75 Francis Street,  Boston, MA 02115, USA   Tel +1 617 732 6939   email eachiocca@partners.or gAbstract:  Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regula - tion of cellular functions and signaling pathways in many cancers.",Non-OADS,/arxiv_data1/oa_pdf/60/95/ov-4-183.PMC4918398.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/60/95/ov-4-183.PMC4918398.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/60/95/ov-4-183.PMC4918398.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c0/72/ov-4-193.PMC4918399.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncolytic Virotherapy 2015:4 193–205Oncolytic Virotherapy Dove press submit your manuscript | www.dovepress.co m Dove press  193ReViewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OV.S66097Ultrasound-mediated oncolytic virus delivery   and uptake for increased therapeutic efficacy:  state of art Rounak Nande1 Candace M Howard2 Pier Paolo Claudio3,4 1Department of Biochemistry and  Microbiology, Marshall University  School of Medicine, Huntington, wV,   2Department of Radiology, University  of Mississippi Medical Center, Jackson,   MS, 3Department of BioMolecular  Sciences and National Center for  Natural Products Research, School of  Pharmacy, University of Mississippi,   MS, 4Department of Radiation  Oncology, University of Mississippi  Medical Center, Jackson, MS, USA Correspondence: Pier Paolo Claudio   Department of Radiation Oncology,  University of Mississippi Medical Center,   350 west woodrow wilson Drive, Suite   1600, Jackson, MS  39213, USA   email pclaudio@olemiss.ed uAbstract:  The field of ultrasound (US) has changed significantly from medical imaging and  diagnosis to treatment strategies.",Non-OADS,/arxiv_data1/oa_pdf/c0/72/ov-4-193.PMC4918399.pdf
"Oncolytic Virotherapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncolytic-virotherapy-journa lOncolytic Virotherapy is an international, peer-reviewed, open access online journal  publishing original research, study protocols, reviews, editorials and commentaries  on all aspects of oncolytic virology, namely the application of oncolytic viruses for  the treatment of cancer.",Non-OADS,/arxiv_data1/oa_pdf/c0/72/ov-4-193.PMC4918399.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/72/ov-4-193.PMC4918399.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9c/70/rjw117.PMC4918405.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www.nature.com/ismej)Thermal sensitivity impact on population dynamics Z Yang et al 1778 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/f6/34/ismej2015225a.PMC4918433.pdf
Temperature data compiled from the LTER climate database (http://www.mcmlter.org).,OADS,/arxiv_data1/oa_pdf/70/4c/ismej2015239a.PMC4918446.pdf
Sequences were compared against the GenBankdatabase using the BLASTn (http://blast.ncbi.nlm.,OADS,/arxiv_data1/oa_pdf/70/4c/ismej2015239a.PMC4918446.pdf
nih.gov/Blast.cgi) algorithm and Classifier tool ofRDPII (http://pyro.cme.msu.edu/) for identification of isolates.,OADS,/arxiv_data1/oa_pdf/70/4c/ismej2015239a.PMC4918446.pdf
"All sequences were aligned using ClustalX (http:// www.clustal.org/clustal2) and trimmed to the samelength (170 bp), and a maximum likelihood phylo- genetic tree (bootstrap value 500) was constructed in MEGA6.06 (http://www.megasoftware.net/).",OADS,/arxiv_data1/oa_pdf/70/4c/ismej2015239a.PMC4918446.pdf
"To view a copyof this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www.nature.com/ismej)Cold-arid limits of life in the upper dry valleys J Goordial et al 1624 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/70/4c/ismej2015239a.PMC4918446.pdf
"Identifying sequence-discrete populations Metagenomic reads were mapped to the recon- structed genomes using BBmap (https://sourceforge.net/projects/bbmap/), with minimum alignment identity cutoff of 0.60.",OADS,/arxiv_data1/oa_pdf/92/a6/ismej2015241a.PMC4918448.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on The I SME Journal website (http:/ /www.nature.",Non-OADS,/arxiv_data1/oa_pdf/92/a6/ismej2015241a.PMC4918448.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/66/a1/rjw112.PMC4918459.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/22/d7/rjw116.PMC4918473.pdf
Alignment of patient sequences  was performed using the Short Oligonucleotide Analysis  Package ( SOAP) aligner (soap2.21; http://soap.genomics.,OADS,/arxiv_data1/oa_pdf/72/6f/mmr-14-01-0649.PMC4918543.pdf
ncbi.nlm.nih.gov /) and YanHuang project ( http://yh.genomics.,Non-OADS,/arxiv_data1/oa_pdf/72/6f/mmr-14-01-0649.PMC4918543.pdf
"Sorting intolerant from tolerant prediction  (http://sift.jcvi.org /) was performed to evaluate whether amino  acid substitutions, amino acid indels and frameshifting indels  could affect protein function ( 16).",OADS,/arxiv_data1/oa_pdf/72/6f/mmr-14-01-0649.PMC4918543.pdf
Gene expression  data of AML samples were downloaded from the European  Bioinformatics Institute (EBI; http://www.ebi.ac.uk ) (8).,OADS,/arxiv_data1/oa_pdf/fa/7c/mmr-14-01-0089.PMC4918602.pdf
Ensembl Variant Effect Predictor: Available online:  http://asia.ensembl.org /info/docs/tools /vep/index.html (accessed  on 15 March 2015).,OADS,/arxiv_data1/oa_pdf/98/1a/mmr-14-01-0151.PMC4918605.pdf
The Human Gene Mutation Database: Available online:  http://www.hgmd.cf.ac.uk (accessed on 15 March 2015).,OADS,/arxiv_data1/oa_pdf/98/1a/mmr-14-01-0151.PMC4918605.pdf
Available online:  http://genetics.bwh.harvard.edu /ggi/pph2 /a914c296bdbd9ce - b1e8afb68bef4854ebc5f1c2b /2976072.html (accessed on 15 June  2015).,Non-OADS,/arxiv_data1/oa_pdf/98/1a/mmr-14-01-0151.PMC4918605.pdf
"Differentially expressed proteins were investigated using  Gene Ontology ( http://www.geneontology.org ) for molecular  function, biological processes and cellular components.",OADS,/arxiv_data1/oa_pdf/09/7e/mmr-14-01-0681.PMC4918607.pdf
"In silico analyses were performed using  the prediction algorithms of SIFT ( http://sift.jcvi.org ), MUpro  (http://www.ics.uci.edu/~baldig/mutation ), and PolyPhen2  (http://genetics.bwh.harvard.edu/pph2/ ).",OADS,/arxiv_data1/oa_pdf/0a/ab/mmr-14-01-0033.PMC4918608.pdf
"Disease -associated genes were then submitted to Agilent  Literature Search software, version 2.82 ( http://www.agilent.",OADS,/arxiv_data1/oa_pdf/8b/60/mmr-14-01-0661.PMC4918609.pdf
Cytoscape software version  2.71  (http://www.cytoscape.org/) was used for visualization of  disease -associated networks and analysis of the network  properties.,OADS,/arxiv_data1/oa_pdf/8b/60/mmr-14-01-0661.PMC4918609.pdf
"MOLECULAR MEDICINE REPORTS  14:  630-636,  2016 632 genotypes were tested for Hardy -Weinberg equilibrium (HWE)  using web -based software (http://scienceprimer.com/hardy- weinberg-equilibrium-calculator).",OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
"Individuals heterozygous for this  mutation, i.e., those with the G:A genotype, are usually not  affected unless carrying the H63D mutation simultane - ously  (http://browser.1000genomes.org/Homo_sapiens/   Variation/Population?db=core;r=6: 26092641-26093641;v=rs1 800562;vdb=variation;vf=1229831) (Table  VI).",Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
Allele --------------------------------------------------------------- Population A G Global 1% 99% European 4% 96% Greek 2% 98% The data for the global and European populations were obtained from  a previous study (http://browser.1000genomes.org/Homo_sapiens/ Variation/Population?db=core;r=6: 26092641-26093641;v=rs1800562 ;vdb=variation;vf=1229831).,Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
% Genotype ---------------------------------------------------------------------------------- Population G:G G:A  A:A Global 97.6 2.4 0.1 European 91.7 8.2 0.2 Greek 97.0 2.0 1.0 The data for the global and European populations were obtained from  a previously published data (http://browser.1000genomes.org/Homo_ sapiens/Variation/Population?db=core;r=6: 26092641-26093641;v=rs 1800562;vdb=variation;vf=1229831).Table VII.,Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
Allele ---------------------------------------------------------------- Population G C Global 7% 93% European 17% 83% Greek 9% 91% The data for the global and European populations were obtained from  a previously published data (http://browser.1000genomes.org/Homo_ sapiens/Variation/Population?v=rs1799945;%20vdb=variation).,Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
"org/Homo_sapiens/Variation/Population?v=rs1799945;%20vdb=   variation, http://browser.1000genomes.org/Homo_sapiens/ Variation/Population?r=6:26090685 -26091685;v=rs1800730;vdb=   variation;vf=1229981).",OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
% Genotype ---------------------------------------------------------------------------------- Population C:C C:G G:G Global 86.6 12.2 1.2 European 69.2 27.2 3.6 Greek 74.4 23.4 2.2 The data for the global and European populations were obtained from  a previously published data (http://browser.1000genomes.org/Homo_ sapiens/Variation/Population?v=rs1799945;%20vdb=variation).,Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
% Genotype ---------------------------------------------------------------------------------- Population A:A A:T  T:T Global 99.2   0.7 <1% European 97.0   2.8 0.2 Greek 98.1 10.5 0.4 The data for the global and European populations were obtained  from a previously published data (http://browser.1000genomes.org/ Homo_sapiens/Variation/Population?r=6:26090685-26091685;v=rs18 00730;vdb=variation;vf=1229981).Table IX.,Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
Allele -------------------------------------------------------------------- Population T A Global  <1% 100.0% European 2.0%   98.0% Greek 0.8%   99.2% The data for the global and European populations were obtained  from a previously published data (http://browser.1000genomes.org/ Homo_sapiens/Variation/Population?r=6:26090685-26091685;v=rs18 00730;vdb=variation;vf=1229981).,Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
"MOLECULAR MEDICINE REPORTS  14:  630-636,  2016 636 population  (http://www.irondisorders.org/hemochromatosis).",OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
"It seems to stabilize the situa - tion and contribute to the prevention of the progression to  cirrhosis, which adversely affects the long -term survival of  patients  (http://www.snpedia.com/index.php/Rs1800730).",Non-OADS,/arxiv_data1/oa_pdf/2f/ae/mmr-14-01-0630.PMC4918619.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/65/c0/dddt-10-1987.PMC4918732.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 1987–1993Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1987Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S9775 6 Double-blind, randomized, double-dummy  clinical trial comparing the efficacy of ketorolac  trometamol and naproxen for acute low back pain Pérola grinberg Plapler1 Morton aaron scheinberg2 christina da cunha  ecclissato3 Monalisa Fernanda Bocchi  de Oliveira3 roberto Bleuel amazonas3 1Orthopedic and Traumatology  institute of clinical hospital,   University of são Paulo, 2clinical  research center hospital aacD, são  Paulo, 3nc group Medical affairs,   hortolândia, são Paulo, BrazilBackground:  Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common type of  medication used in the treatment of acute pain.",Non-OADS,/arxiv_data1/oa_pdf/65/c0/dddt-10-1987.PMC4918732.pdf
"However, cumulative trauma  must also be considered in the etiology, such as occupational overuse injury.2,3 The best approach to treat LBP appears to be a combination of pharmacological  and nonpharmacological strategies.4 There is a great variability, possibly genetically  related, in the individual response to painkillers.5 Nonsteroidal anti-inflammatory correspondence: roberto Bleuel  amazonas nc group Medical affairs, rod Jornalista  Francisco aguirre Proença, Km 08,  Bairro chácara assay, hortolândia  ceP 13186-901, são Paulo, Brazil Tel +55 19 3887 9545 email rbleuel@uol.com.b r Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Plapler et al Running head recto: Ketorolac trometamol for acute low back pain DOI: http://dx.doi.org/10.2147/DDDT.S97756",Non-OADS,/arxiv_data1/oa_pdf/65/c0/dddt-10-1987.PMC4918732.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/65/c0/dddt-10-1987.PMC4918732.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/65/c0/dddt-10-1987.PMC4918732.pdf
"Available from: http://emedicine.medscape.com/ article/310353-followu p. Accessed May 13, 2016.",Non-OADS,/arxiv_data1/oa_pdf/65/c0/dddt-10-1987.PMC4918732.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/1a/a6/rmhp-9-129.PMC4918733.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/1a/a6/rmhp-9-129.PMC4918733.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Risk Management and Healthcare Policy Risk Management and Healthcare Policy 2016:9 129–133Dove press submit your manuscript | www.dovepress.co m Dove press  ORiginal ReseaRcHopen access to scientific and medical research Open access Full T ext article 129 http: //dx.doi.org/10.2147/RMHP .S9600 5are doctors risk takers?",Non-OADS,/arxiv_data1/oa_pdf/1a/a6/rmhp-9-129.PMC4918733.pdf
"Risk Management and Healthcare Policy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/risk-management-and-healthcare-policy-journa lRisk Management and Healthcare Policy is an international, peer- reviewed, open access journal focusing on all aspects of public health,  policy, and preventative measures to promote good health and improve  morbidity and mortality in the population.",Non-OADS,/arxiv_data1/oa_pdf/1a/a6/rmhp-9-129.PMC4918733.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1a/a6/rmhp-9-129.PMC4918733.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2016:9 135–142Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 135 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S91691 Biosimilars: potential implications for clinicians Misty G Eleryan1  Sophia Akhiyat2  Monica Rengifo-Pardo1  Alison Ehrlich1,2 1Department of Dermatology, The  George Washington Medical Faculty  Associates, 2George Washington  University School of Medicine & Health Sciences, Washington, DC, USAAbstract:  With the expiration of patent protection for several biologics looming, the produc- tion of highly similar therapeutic agents has begun to emerge on the pharmaceutical market.",Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
"5 The multifaceted development, manufacturing, and regulation associ- ated with creating a biologic are the factors that cause the drug to have a significant Correspondence: Alison Ehrlich   Department of Dermatology, The  George Washington University Medical Faculty Associates, 2150 Pennsylvania Avenue NW, Suite 2B-430, Washington, DC 20037, USA Tel +1 202 741 2625   Email aehrlich@mfa.gwu.eduJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Eleryan et alRunning head recto: BiosimilarsDOI: http://dx.doi.org/10.2147/CCID.S91691",Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: http://online.wsj.com/article/SB10001424127887323864304578318111144984632.html.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: https://securingalpha.files.wordpress.com/2014/01/biotechnology-2013.pdf.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: http://www.citationmachine.net/bibliographies/59804304?new=true.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: http://www.pacificresearch.org/fileadmin/documents/Studies/PDFs/2013-2015/PhamaPricingF .pdf.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsare DevelopedandApproved/ApprovalApplications/TherapeuticBiologic Applications/Biosimilars/default.htm.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
"Clinical, Cosmetic and Investigational Dermatology 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 142 Eleryan et al  14.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegu-latoryInformation/Guidances/UCM459987.pdf.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEU-TICS_FOR_WEB_22APRIL2010.pdf.,OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
Available from: http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medica-tions-and-substitution-of-biosimilars.aspx.,Non-OADS,/arxiv_data1/oa_pdf/61/ad/ccid-9-135.PMC4918734.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a9/81/ott-9-3603.PMC4918735.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3603–3612OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3603Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10410 8 XuefuZhuyu Tang  exerts antitumor effects by  inhibiting glioma cell metastasis and invasion via  regulating tumor microenvironment Jianmin liu1 Ji Zhang2 liangwen huang1 Xuhong Zhu1 Wei chen1 Peng hu1 1Department of n eurosurgery,   The First affiliated hospital of  guangzhou University of Traditional  chinese Medicine, 2Department of  neurosurgery, sun Yat-sen University  cancer center, guangzhou, People’s  republic of chinaBackground:  XuefuZhuyu Tang (XZT)  is a traditional Chinese herb used for destagnation and  is currently being used for oncotherapy.",Non-OADS,/arxiv_data1/oa_pdf/a9/81/ott-9-3603.PMC4918735.pdf
"The presence of blood–brain barrier, which prevents macromolecules from entering correspondence: Jianmin liu Department of neurosurgery,  The First Affiliated Hospital of  guangzhou University of Traditional  chinese Medicine, 16 Jichang road,  Baiyun District, guangzhou 510405,  People’s republic of china Tel +86 20 3659 1396 Fax +86 20 3659 1595 email jml_liu@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Liu et al Running head recto: XuefuZhuyu  Tang  against glioma by regulating tumor microenvironment DOI: http://dx.doi.org/10.2147/OTT.S104108",Non-OADS,/arxiv_data1/oa_pdf/a9/81/ott-9-3603.PMC4918735.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/a9/81/ott-9-3603.PMC4918735.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a9/81/ott-9-3603.PMC4918735.pdf
"The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cf/0e/ceg-9-131.PMC4918736.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Efficacy of the low FODMAP diet for treating  irritable bowel syndrome: the evidence to date Wathsala S Nanayakkara1 Paula ML Skidmore1 Leigh O’Brien2 Tim J Wilkinson3 Richard B Gearry3 1Department of Human Nutrition,   University of Otago, Dunedin,   New Zealand; 2Dietary Specialists,   Christchurch, New Zealand;   3Department of Medicine, University  of Otago, Christchurch, New Zealand Correspondence: Richard B Gearry   Department of Medicine, University of  Otago, 2 Riccarton Avenue, Christchurch  8140, New Zealand   T el +64 3 364 1567   Fax +63 3 364 0920   Email Richard.Gearry@cdhb.health.n zAbstract:  This review summarizes the published clinical studies concerning the management of  irritable bowel syndrome (IBS) using restriction of Fermentable Oligosaccharide,  Disaccharide,  Monosaccharide, and Polyols in the diet (low FODMAP diet).",Non-OADS,/arxiv_data1/oa_pdf/cf/0e/ceg-9-131.PMC4918736.pdf
Available at: http://www.med.monash.edu/cecs/gastro/fodmap /.,Non-OADS,/arxiv_data1/oa_pdf/cf/0e/ceg-9-131.PMC4918736.pdf
Available at: http://www.med.monash.edu/cecs/gastro/fodmap /.,Non-OADS,/arxiv_data1/oa_pdf/cf/0e/ceg-9-131.PMC4918736.pdf
"Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-and-experimental-gastroenterology-journa lClinical and Experimental Gastroenterology is an international, peer- reviewed, open access journal, publishing all aspects of gastroenterology  in the clinic and laboratory, including: Pathology, pathophysiology  of gastrointestinal disease; Investigation and treatment of gastointes - tinal disease; Pharmacology of drugs used in the alimentary tract; Immunology/genetics/genomics related to gastrointestinal disease.",Non-OADS,/arxiv_data1/oa_pdf/cf/0e/ceg-9-131.PMC4918736.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/cf/0e/ceg-9-131.PMC4918736.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cc/0f/dddt-10-1995.PMC4918737.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 1995–2002Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1995Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10725 6 MarT -10, a newly synthesized vitamin D analog,  represses metastatic potential of head and neck  squamous carcinoma cells shih-Wei Yang1,* chi-Ying Tsai2,* Yi-chun Pan3 chun-n an Yeh4 Jong-hwei s Pang5 Masashi Takano6 atsushi Kittaka6 horng-heng Juang7 Tai c chen8 Kun-chun chiang4,9 1Department of Otolaryngology  –  head and neck surgery, chang  gung Memorial hospital, Keelung,   2Department of Oral and Maxillofacial  surgery, chang gung Memorial  hospital, Taoyuan, 3Department of  general Dentistry, chang gung  Memorial hospital, chang gung  University, Keelung, 4general surgery  Department, chang gung Memorial  hospital, Keelung, 5graduate institute  of clinical Medical sciences, college  of Medicine, chang gung University,   Taoyuan, Taiwan, republic of china;   6Faculty of Pharmaceutical sciences,   T eikyo University, T okyo, Japan;   7Department of anatomy, college  of Medicine, chang gung University,   Taoyuan, Taiwan, republic of china;   8endocrine core laboratory, Boston  University school of Medicine, Boston,   Ma, Usa; 9Zebrafish center, chang  gung  Memorial hospital, Keelung,   Taiwan, republic of china *These authors contributed equally  to this workAbstract:  Even with multidisciplinary treatment, the prognosis and quality of life of patients  diagnosed with head and neck squamous cell carcinoma (HNSCC) are still not satisfactory.",Non-OADS,/arxiv_data1/oa_pdf/cc/0f/dddt-10-1995.PMC4918737.pdf
"1 α,25(OH)2D3, the active  form of vitamin D, has been widely studied in anticancer research category due to  the prodifferentiation, proapoptosis, antiangiogenesis, and antiproliferation effects  of 1α,25(OH)2D3 noted in the past decades.3,4 To exert its hormone-like functions,  1α,25(OH)2D3 needs to bind with vitamin D receptor (VDR), which has been shown  to exist in a variety of tissues in humans, indicating that 1 α,25(OH)2D3 is able to affect correspondence: Kun-chun chiang general surgery Department, chang  gung Memorial hospital, chang gung  University, 222 Mai-chin road, Keelung  204, Taiwan, republic of china email robertviolet6292@yahoo.com.t w Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Y ang et al Running head recto: MART-10 suppresses HNSCC cell metastasis DOI: http://dx.doi.org/10.2147/DDDT.S107256",Non-OADS,/arxiv_data1/oa_pdf/cc/0f/dddt-10-1995.PMC4918737.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/cc/0f/dddt-10-1995.PMC4918737.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cc/0f/dddt-10-1995.PMC4918737.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/67/f0/cia-11-801.PMC4918738.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 801–805Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  801OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S10547 2 lifestyle and lifestyle-related comorbidities  independently associated with colorectal adenoma  recurrence in elderly Chinese people Adake saiken Fang gu Department of gastroenterology,   Peking University Third hospital,   Beijing, People’s republic of ChinaObjective:  The purpose of this study was to determine the lifestyle and lifestyle-related  comorbidities independently associated with colorectal adenoma (CRA) recurrence in elderly  Chinese people.",Non-OADS,/arxiv_data1/oa_pdf/67/f0/cia-11-801.PMC4918738.pdf
"Keywords:  elderly Chinese, colorectal adenoma recurrence, lifestyle, lifestyle-related  comorbidities Introduction Colorectal cancer (CRC) is a common lethal malignancy in the People’s Republic  of China and other countries.1,2 Mortality caused by CRC in the West is declining,  but there is a rapidly rising trend in the People’s Republic of China.3 In view of  the adenoma–carcinoma sequence, colorectal adenomas (CRAs) are the precursor  lesions of CRC, and CRA recurrence serves as an informative end point for colorectal  carcinogenesis because it shares common etiopathogenesis with CRC.4 Colonoscopic  removal of CRAs not only reduces the prevalence of CRC but also decreases deaths  from  CRC, and identifying the possible factors associated with CRA recurrence has Correspondence: Fang gu Department of gastroenterology,  Peking University Third hospital,  no 49 north garden street,  haidian District, Beijing 100191,  People’s republic of China Tel +86 10 8226 6928   email gf0515@sina.co m Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Saiken and Gu Running head recto: Lifestyle and comorbidities associated with CRA recurrence in elderly DOI: http://dx.doi.org/10.2147/CIA.S105472",Non-OADS,/arxiv_data1/oa_pdf/67/f0/cia-11-801.PMC4918738.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/67/f0/cia-11-801.PMC4918738.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/67/f0/cia-11-801.PMC4918738.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/de/6a/opth-10-1131.PMC4918739.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1131–1138Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1131Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10609 6 effect of prophylactic timolol 0.1% gel on  intraocular pressure after an intravitreal injection  of ranibizumab: a randomized study alfredo Pece1 Davide allegrini1 giovanni Montesano2 andrea Fabio  Dimastrogiovanni1 1eye Clinic, Melegnano hospital,   Vizzolo Predabissi, 2eye Clinic, san  Paolo hospital, Università di Milano,   Milano, italyPurpose:  The purpose of this study is to make a prospective evaluation of the effect of timolol  0.1% eye gel on short-term intraocular pressure (IOP) after an intravitreal injection (IVI) of  ranibizumab.",Non-OADS,/arxiv_data1/oa_pdf/de/6a/opth-10-1131.PMC4918739.pdf
"The most frequent complications of IVIs are subconjunctival and vitreal hemorrhages,  corneal edema, conjunctival scars, retinal tears and detachment, lens damage, develop - ment of cataracts, choroidal rupture, ocular hypertension, and endophthalmitis.4,5 The  injection of anti-VEGF fluid into the vitreous cavity is expected to increase the intraocular Correspondence: Davide allegrini eye Clinic, Melegnano hospital, Via  Pandina 1, 20070 Vizzolo Predabissi,  Milano, italy Tel +39 028 184 4301 Fax +39 025 032 3150 email davideallegrini@yahoo.i t Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Pece et al Running head recto: Prophylactic timolol 0.1% gel after intravitreal injection DOI: http://dx.doi.org/10.2147/OPTH.S106096",Non-OADS,/arxiv_data1/oa_pdf/de/6a/opth-10-1131.PMC4918739.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/de/6a/opth-10-1131.PMC4918739.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/de/6a/opth-10-1131.PMC4918739.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/55/c9/opth-10-1123.PMC4918740.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1123–1129Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1123Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10772 6 The impact of a preloaded intraocular lens  delivery system on operating room efficiency  in routine cataract surgery Jason J Jones1 Jeffrey Chu2 Jacob graham2 serge Zaluski3 guillermo rocha4 1Jones eye Clinic, sioux City, ia,   2Quorum Consulting inc., san  Francisco, C a, Usa; 3Visis, Perpignan,   France; 4Ocular Microsurgery & laser  Centre, Brandon, MB, CanadaPurpose:  The aim of this study was to evaluate the operational impact of using preloaded  intraocular lens (IOL) delivery systems compared with manually loaded IOL delivery processes  during routine cataract surgeries.",Non-OADS,/arxiv_data1/oa_pdf/55/c9/opth-10-1123.PMC4918740.pdf
"In this Correspondence: Jason J Jones Jones eye Clinic, 4405 hamilton  Boulevard, sioux City, ia 51104, Usa Tel +1 712 239 3937 Fax +1 712 239 1305 email jasonjonesmd@mac.co mJournal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Jones et al Running head recto: Preloaded lens delivery system for routine cataract surgery DOI: http://dx.doi.org/10.2147/OPTH.S107726",Non-OADS,/arxiv_data1/oa_pdf/55/c9/opth-10-1123.PMC4918740.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/55/c9/opth-10-1123.PMC4918740.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/55/c9/opth-10-1123.PMC4918740.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/29/37/dddt-10-2003.PMC4918741.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2003–2013Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2003Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10790 9 The aqueous extract of chinese medicinal herb  Brucea javanica  suppresses the growth of human  liver cancer and the derived stem-like cells by  apoptosis Jian-he chen* seung-hun Kim* Po-Wei Fan chun-Yen liu chang-hung hsieh Kang Fang Department of life science, national  Taiwan normal University, Taipei,   Taiwan *These authors contributed equally  to this workAbstract:  Being effective and relatively safe, the traditional Chinese medicinal herb Brucea  javanica  (BJ) has been valuable in curing patients in East Asia and its nearby regions for years.",Non-OADS,/arxiv_data1/oa_pdf/29/37/dddt-10-2003.PMC4918741.pdf
"To address this topic, this study reported that low concentrations correspondence: Kang Fang Department of life science, national  Taiwan normal University, 88 Ting-chou  road, sector 4, Taipei 116, Taiwan  Tel +886 2 7734 6293 Fax +886 2 2931 2904 email kangfang@ntnu.edu.t w Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Chen et al Running head recto: Brucea javanica  suppresses growth of human liver cancer cells DOI: http://dx.doi.org/10.2147/DDDT.S107909",Non-OADS,/arxiv_data1/oa_pdf/29/37/dddt-10-2003.PMC4918741.pdf
The quantitation of visualized TUNEL was per - formed by ImageJ software ( http://rsbweb.nih.gov /).,OADS,/arxiv_data1/oa_pdf/29/37/dddt-10-2003.PMC4918741.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/29/37/dddt-10-2003.PMC4918741.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/29/37/dddt-10-2003.PMC4918741.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/2b/1e/nss-8-189.PMC4918802.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/2b/1e/nss-8-189.PMC4918802.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Nature and Science of Sleep 2016:8 189–196Nature and Science of Sleep Dovepress submit your manuscript | www.dovepress.com Dovepress  189 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NSS.S104383Sex-specific sleep patterns among university  students in Lebanon: impact on depression and  academic performance Colette S Kabrita1  Theresa A Hajjar-Muça2 1Department of Sciences,   2Department of Mathematics and  Statistics, Faculty of Natural and  Applied Sciences, Notre Dame University – Louaize, Zouk Mosbeh,  LebanonAbstract: Good sleep quality and quantity are fundamental to the maintenance of normal physi- ological processes.",Non-OADS,/arxiv_data1/oa_pdf/2b/1e/nss-8-189.PMC4918802.pdf
"5,6 Correspondence: Colette S Kabrita   Department of Sciences, Faculty of  Natural and Applied Sciences, Notre Dame University – Louaize, PO Box 72, Zouk Mikael, Zouk Mosbeh, Lebanon   Tel +961 9 20 8728   Fax +961 9 21 8771   Email ckabrita@ndu.edu.lbJournal name: Nature and Science of Sleep Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 8Running head verso: Kabrita and Hajjar-MuçaRunning head recto: Sex-specific sleep patterns, depression, and academic performanceDOI: http://dx.doi.org/10.2147/NSS.S104383",Non-OADS,/arxiv_data1/oa_pdf/2b/1e/nss-8-189.PMC4918802.pdf
"Nature and Science of Sleep 2016:8submit your manuscript | www.dovepress.com Dovepress Dovepress Nature and Science of Sleep Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/nature-and-science-of-sleep-journalNature and Science of Sleep is an international, peer-reviewed, open  access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep.",Non-OADS,/arxiv_data1/oa_pdf/2b/1e/nss-8-189.PMC4918802.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/42/87/ndt-12-1425.PMC4918803.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1425–1434Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1425Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S10790 5 The causes of new-onset epilepsy and seizures in   the elderly Shasha Liu1 weihua Yu2 Yang Lü1 1Department of Geriatrics, The First  Affiliated Hospital of Chongqing  Medical University, 2Department of  Anatomy, institute of Neuroscience,   Chongqing Medical University,   Chongqing, People’s Republic of ChinaAbstract:  With increasing age, the prevalence and incidence of epilepsy and seizures increases  correspondingly.",Non-OADS,/arxiv_data1/oa_pdf/42/87/ndt-12-1425.PMC4918803.pdf
"However,  new-onset epilepsy in the elderly is mainly the consequence of accumulated injuries  to the brain and other secondary factors.12,13 The most common acquired etiologies Correspondence: Yang Lü Department of Geriatrics, The First  Affiliated Hospital of Chongqing Medical  University, No 1 Youyi Road, Yuzhong  District, Chongqing 400016, People’s  Republic of China Tel +86 23 8901 1622 Fax +86 23 6881 1487 email lyu_yang@126.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Liu et al Running head recto: Causes of new-onset epilepsy and seizures in the elderly DOI: http://dx.doi.org/10.2147/NDT.S107905",Non-OADS,/arxiv_data1/oa_pdf/42/87/ndt-12-1425.PMC4918803.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/42/87/ndt-12-1425.PMC4918803.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/42/87/ndt-12-1425.PMC4918803.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7b/ed/ndt-12-1445.PMC4918804.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1445–1456Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1445OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S9826 0 altered lower leg muscle activation patterns in  patients with cerebral palsy during cycling on an  ergometer ana alves-Pinto1,* T obias Blumenstein1,* Varvara T urova1 renée lampe1,2 1research Unit of the Buhl- strohmaier  Foundation for cerebral Palsy and  Paediatric Neuroorthopaedics,   Orthopaedic Department, Klinikum  rechts der isar, 2Markus Würth  Professorship, Technical University  of Munich, Munich, germany *These authors contributed equally  to this workObjective:  Cycling on a recumbent ergometer constitutes one of the most popular rehabilitation  exercises in cerebral palsy (CP).",Non-OADS,/arxiv_data1/oa_pdf/7b/ed/ndt-12-1445.PMC4918804.pdf
"These signs are correspondence: renée lampe research Unit of the Buhl-strohmaier  Foundation for cerebral Palsy and  Paediatric Neuroorthopaedics,  Orthopaedic Department, Klinikum  rechts der isar, Technical University  of Munich, ismaninger straße 22,  81675 Munich, germany Tel +49 89 4140 6360 Fax +49 89 4140 4849 email renee.lampe@tum.d e Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Alves-Pinto et al Running head recto: Muscular activity during cycling in patients with cerebral palsy DOI: http://dx.doi.org/10.2147/NDT.S98260",Non-OADS,/arxiv_data1/oa_pdf/7b/ed/ndt-12-1445.PMC4918804.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/7b/ed/ndt-12-1445.PMC4918804.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/7b/ed/ndt-12-1445.PMC4918804.pdf
"aThe information provided in Table 1 is limited and a more comprehensive dataset relating to cannabinoid-based medications, their therapeutic indication(s), dose regi- men, clinical trials, ﬁrst-in-man case studies, and relevant publications can be found using the following web resources available free of charge or through subscription: http://www.fda.gov/Drugs/default.htm (US Food and Drug Administration)http://www.ema.europa.eu/ema/ (European Medicines Agency) http://www.medicines.org.uk/emc/ (U.K. Electronic Medicines Compendium) https://www.medicinescomplete.com/mc/ (Royal Pharmaceutical Society)http://apps.who.int/trialsearch/Default.aspx (WHO International Clinical Trials Registry Platform)https://www.clinicaltrials.gov/ (Clinical trials registry service of U.S. National Institutes of Health) https://www.clinicaltrialsregister.eu/ctr-search/search (E.U.",Non-OADS,/arxiv_data1/oa_pdf/dc/c9/CPT-97-553.PMC4918805.pdf
"Clinical Trials Register) http://www.ncbi.nlm.nih.gov/pubmed (Reference databases of U.S. National Library of Medicine)http://www.cochranelibrary.com/ (Cochrane Central Register of Controlled Trials, Wiley Online Library)http://thomsonreuters.com/cortellis-clinical-trials-intelligence/ (Cortellis-Thomson Reuters) http://www.isrctn.com/ (ISRCTN registry - Springer Science)TRANSLATION CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 97 NUMBER 6 | JUNE 2015 557",Non-OADS,/arxiv_data1/oa_pdf/dc/c9/CPT-97-553.PMC4918805.pdf
"This is an Open Access article distributed under the terms of the Creative CommonsAttribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0e/76/jiw129.PMC4918824.pdf
Aug 22; Avail - able from:  https://www.aamc.org/download/313228/data/2012physi - cianspecialtydatabook.pdf  2.,OADS,/arxiv_data1/oa_pdf/2a/7a/yjbm_89_2_131.PMC4918861.pdf
Available from: https://www.aamc.org/data/448474/resi - dentsreport.html  4.,OADS,/arxiv_data1/oa_pdf/2a/7a/yjbm_89_2_131.PMC4918861.pdf
Available from:  http://www.medscape.com/viewarticle/732197  5.,Non-OADS,/arxiv_data1/oa_pdf/2a/7a/yjbm_89_2_131.PMC4918861.pdf
Available from:  https://www.census.gov/geo/reference/gtc/gtc_census_di - vreg.html.,OADS,/arxiv_data1/oa_pdf/2a/7a/yjbm_89_2_131.PMC4918861.pdf
Available  from: http://www.cdc.gov/nchs/data/hus/hus11.pdf.,OADS,/arxiv_data1/oa_pdf/46/a8/yjbm_89_2_227.PMC4918863.pdf
Available from:  http://www.who.int/substance_abuse/facts/cannabis/en/  2.,Non-OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
Available from:  http://www.pewresearch.org/fact-tank/2013/06/03/more-  than-a-third-of-adults-say-theyve-tried-pot-but-not-recently/  3.,Non-OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
Available  from: http://www.gallup.com/poll/163835/tried-marijuana-  little-changed-80s.aspx English.,Non-OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
Available from:  http://www.samhsa.gov/data  5.,OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
Available from:  http://www.samhsa.gov/data/sites/default/files/NSDUHre - sultsPDFwHTML2013/web/NSDUHresults2013.pdf  6.,OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
Avail - able from:  http://babel.hathitrust.org/cgi/pt?id=pur1.32754078039595;v  iew=1up;seq=1  17.,Non-OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
"PubChem  Compound Database; CiD=5311501 (wiN 55,212-2),  https://pubchem.ncbi.nlm.nih.gov/compound/5311501 (ac - cessed May 3, 2016).",OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
"PubChem  Compound Database; CiD=104850 (Rimonabant),  https://pubchem.ncbi.nlm.nih.gov/compound/104850 (ac - cessed May 3, 2016).",OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
"PubChem  Compound Database; CiD=8955 (Pregnenolone),  https://pubchem.ncbi.nlm.nih.gov/compound/8955 (ac - cessed May 3, 2016).",OADS,/arxiv_data1/oa_pdf/e8/f6/yjbm_89_2_175.PMC4918871.pdf
Available from:  http://www.who.int/healthinfo/global_burden_disease/GBD  _report_2004update_full.pdf.,Non-OADS,/arxiv_data1/oa_pdf/17/99/yjbm_89_2_123.PMC4918874.pdf
Available from: http://www.iom.edu/reports/2011/the-health-of-lesbian-gay- bisexual-and-transgender-people/report-brief.aspx?page=2  10.,Non-OADS,/arxiv_data1/oa_pdf/ac/8a/yjbm_89_2_247.PMC4918875.pdf
"Available from: http://www.nimh.nih.gov/health/topics/depression/men-and- depression/index.shtml , accessed May 10, 2016.",Non-OADS,/arxiv_data1/oa_pdf/ac/8a/yjbm_89_2_247.PMC4918875.pdf
Available from: http://www.hhs.gov/ocr/privacy.,Non-OADS,/arxiv_data1/oa_pdf/ac/8a/yjbm_89_2_247.PMC4918875.pdf
Available from: http://www.aidsetc.org/sites/default/files/re - sources_files/CCGW_lowres.pdf.,OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/Adultan - dAdolescentGL.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available from: http://www.cdc.gov/nchh - stp/newsroom/2012/Continuum-of-Care-Graphics.html.200 Meyer et al: Gender-Responsive HIV Care for Women,Non-OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available from: http://www.apa.org/pi/lgbt/resources/sexu - ality-definitions.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available from:  http://stacks.cdc.gov/view/cdc/23109: 2014.,OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available  from: http://www.ncbi.nlm.nih.gov/books/NBK294008/.36.,Non-OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available from: http://www.cdc.gov/std/stats/.,OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available from: http://www.aidsinfo.nih.gov.,Non-OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
2010  Available from: https://www.aids.gov/federal-resources/na - tional-hiv-aids-strategy/overview/.,Non-OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
Available from: http://aidsinfo.nih.gov/con - tentfiles/lvguidelines/PerinatalGL.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b8/dc/yjbm_89_2_193.PMC4918880.pdf
"Retrieved November 5, 2015, from http://www.huffington - post.com/2014/11/10/chocolate-craving-pms-men-vegeta - bles_n_6102714.html.",Non-OADS,/arxiv_data1/oa_pdf/b8/bc/yjbm_89_2_161.PMC4918881.pdf
"[Internet] Retrieved November 5, 2015, from  http://www.who.int/mediacentre/factsheets/fs311/en/v.",Non-OADS,/arxiv_data1/oa_pdf/b8/bc/yjbm_89_2_161.PMC4918881.pdf
Avail - able from:  http://www.un.org/womenwatch/daw/cedaw/cedaw.htm  2.,Non-OADS,/arxiv_data1/oa_pdf/90/25/yjbm_89_2_153.PMC4918882.pdf
Available from: http://www.cdc.gov/vi - olenceprevention/sexualviolence/datasources.html  6.,Non-OADS,/arxiv_data1/oa_pdf/90/25/yjbm_89_2_153.PMC4918882.pdf
Available  from:  http://www.who.int/topics/reproductive_health/en/  18.,Non-OADS,/arxiv_data1/oa_pdf/90/25/yjbm_89_2_153.PMC4918882.pdf
Available  from: http://www.ncbi.nlm.nih.gov/books/NBK97297/  34.,Non-OADS,/arxiv_data1/oa_pdf/90/25/yjbm_89_2_153.PMC4918882.pdf
Available from: http://www.cdc.gov/in - jury/wisqars/leadingcauses.html.,OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://www.cdc.gov/healthyyouth/yrbs/pdf/trends/us_sui- cide_trend_yrbs.pdf 3.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Avail- able from: http://actionallianceforsuicideprevention.org/NSSP.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://williamsinstitute.law.ucla.edu/wp- content/uploads/AFSP-Williams-Suicide-Report-Final.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://www.samhsa.gov/nrepp.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://www.glsen.org/article/2013- national-school-climate-survey  18.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://apps.who.int/iris/bit- stream/10665/75166/1/9789241503570_eng.pdf 37.,OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available  from: http://www.sprc.org/training-institute/r2p- webinars/advances-suicide-prevention-research-practice- and-policy-implication  38.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://www.cdc.gov/violencepreven - tion/overview/social-ecologicalmodel.html 40.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://www.thetrevorproject.org/pages/lgbtq-on-campus-for- faculty-and-staff 58.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://grants.nih.gov/grants/guide/pa-files/PA-15-261.html  63.,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://www.who.int/violence_injury_prevention/violence/wo  rld_report/chapters/en/213 Marshall: Suicide Prevention Interventions for SGM Youth,Non-OADS,/arxiv_data1/oa_pdf/f5/60/yjbm_89_2_205.PMC4918883.pdf
Available from: http://www.cdc.gov/motorvehicle - safety/teen_drivers/teendrivers_factsheet.html.,Non-OADS,/arxiv_data1/oa_pdf/c5/ce/yjbm_89_2_261.PMC4918884.pdf
Available from: http://www.census.gov/newsroom/releases/archives/popula - tion/cb12-243.html  18.,OADS,/arxiv_data1/oa_pdf/c5/ce/yjbm_89_2_261.PMC4918884.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/12/2d/ijgm-9-207.PMC4918889.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/12/2d/ijgm-9-207.PMC4918889.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of General Medicine 2016:9 207–212International Journal of General Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress 207 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJGM.S104628The clinicopathological features of sinonasal  angiomatous polyps Yuan-Yun Tam1,*  Chia-Chen Wu2,*  Ta-Jen Lee2  Yang-Yu Lin3  Tai-Di Chen4  Chi-Che Huang2 1Department of Otorhinolaryngology –  Head and Neck Surgery, Lotung  Poh-Ai Hospital, Yilan County,   2Department of Otorhinolaryngology –  Head and Neck Surgery, 3Department  of Medical Imaging and Intervention,   4Department of Pathology, Linkou  Chang Gung Memorial Hospital,  Chang Gung University, Taoyuan County, Taiwan *These authors contributed equally to  this workBackground: Sinonasal angiomatous polyp (SAP) is a rare subtype of sinonasal polyp that  might be misdiagnosed as a malignant lesion due to its clinical symptoms.",Non-OADS,/arxiv_data1/oa_pdf/12/2d/ijgm-9-207.PMC4918889.pdf
"We enrolled 13 patients who were Correspondence: Chi-Che Huang   Department of Otorhinolaryngology –  Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Chang Gung University, Number 5, Fu Hsing Street, Kwei-Shan, Taoyuan County 333, TaiwanTel +886 3 328 1200 ext8466   Fax +886 3 327 1244   Email hcc3110@adm.cgmh.org.twJournal name: International Journal of General Medicine Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Tam et alRunning head recto: Sinonasal angiomatous polyps mimicking neoplasmsDOI: http://dx.doi.org/10.2147/IJGM.S104628",Non-OADS,/arxiv_data1/oa_pdf/12/2d/ijgm-9-207.PMC4918889.pdf
"International Journal of General Medicine 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of General Medicine Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-general-medicine-journalThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/12/2d/ijgm-9-207.PMC4918889.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 212 Tam et al On MR imaging, slight hyperintensity on T1WI5 and a  hypointense peripheral rim around the mass on T2WI,  indicative of old hemorrhage, are more specific to the correct diagnosis of SAP .",Non-OADS,/arxiv_data1/oa_pdf/12/2d/ijgm-9-207.PMC4918889.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/2f/e7/jpr-9-437.PMC4918890.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/2f/e7/jpr-9-437.PMC4918890.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 437–444Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  437 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S85183Neuromuscular blockade in the elderly patient Luis A Lee Vassilis Athanassoglou Jaideep J Pandit Nuffield Department of Anaesthetics,   Oxford University Hospitals NHS Foundation Trust, Oxford, UKAbstract: Neuromuscular blockade is a desirable or even essential component of general  anesthesia for major surgical operations.",Non-OADS,/arxiv_data1/oa_pdf/2f/e7/jpr-9-437.PMC4918890.pdf
"4,5Correspondence: Jaideep J Pandit Nuffield Department of Anaesthetics, Oxford University Hospitals NHS Trust, Oxford OX3 9DU, UKTel +44 01865 222 590Fax +44 01865 220 017Email jaideep.pandit@dpag.ox.ac.ukJournal name: Journal of Pain Research  Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Lee et alRunning head recto: Neuromuscular blockade in the elderlyDOI: http://dx.doi.org/10.2147/JPR.S85183",Non-OADS,/arxiv_data1/oa_pdf/2f/e7/jpr-9-437.PMC4918890.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/2f/e7/jpr-9-437.PMC4918890.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 444 Lee et al 52.,Non-OADS,/arxiv_data1/oa_pdf/2f/e7/jpr-9-437.PMC4918890.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/6f/76/jpr-9-417.PMC4918891.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/6f/76/jpr-9-417.PMC4918891.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 417–420Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  417 CASE REPORT open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S108503Ketofol for monitored anesthesia care in shoulder  arthroscopy and labral repair: a case report Kevin C Lee1  Hanyuan Shi2  Brian C Lee3 1Columbia University College of  Dental Medicine, New Y ork, NY,   2Vanderbilt University School of  Medicine, Nashville, TN, 3Department  of Anesthesiology, Columbia  University Medical Center, New Y ork,  NY, USAAbstract:  A 21-year-old male (body mass index: 28.3) with a history of asthma and reactive  airway disease since childhood underwent left shoulder arthroscopy and labral repair surgery  under monitored anesthesia care.",Non-OADS,/arxiv_data1/oa_pdf/6f/76/jpr-9-417.PMC4918891.pdf
"6 Both midazolam and propofol are used to prevent and  treat this terrifying phenomenon.Correspondence: Kevin C Lee   Columbia University College of Dental  Medicine, 630 West 168th Street,   New York, NY 10032, USA   Email kcl2136@cumc.columbia.eduJournal name: Journal of Pain Research  Article Designation: CASE REPORTY ear: 2016V olume: 9Running head verso: Lee et alRunning head recto: Ketofol for monitored anesthesia careDOI: http://dx.doi.org/10.2147/JPR.S108503",Non-OADS,/arxiv_data1/oa_pdf/6f/76/jpr-9-417.PMC4918891.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/6f/76/jpr-9-417.PMC4918891.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 420 Lee et al  18.,Non-OADS,/arxiv_data1/oa_pdf/6f/76/jpr-9-417.PMC4918891.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/01/64/jaa-9-109.PMC4918892.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/01/64/jaa-9-109.PMC4918892.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Asthma and Allergy 2016:9 109–115Journal of Asthma and Allergy Dovepress submit your manuscript | www.dovepress.com Dovepress 109 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JAA.S106567Training and administration of epinephrine   auto-injectors for anaphylaxis treatment in  US schools: results from the EpiPen4Schools®  pilot survey Susan L Hogue1 Diana Goss1 Kelly Hollis1 Suyapa Silvia2 Martha V White3 1Health Solutions, RTI International,   Research Triangle Park, NC,   2Education and Workforce  Development, RTI International,   Research Triangle Park, NC, 3Institute  for Asthma and Allergy, Wheaton, MD,  USABackground:  Anaphylaxis is a serious, potentially life-threatening condition.",Non-OADS,/arxiv_data1/oa_pdf/01/64/jaa-9-109.PMC4918892.pdf
"1 From 1997 to 2007, the preva- lence of reported food allergy in the US increased by 18% in children <18 years of age.2 Correspondence: Susan L Hogue RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USATel +1 919 541 6213Fax +1 919 541 1275Email shogue@rti.orgJournal name: Journal of Asthma and Allergy Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Hogue et alRunning head recto: Anaphylaxis recognition and management in schoolsDOI: http://dx.doi.org/10.2147/JAA.S106567",Non-OADS,/arxiv_data1/oa_pdf/01/64/jaa-9-109.PMC4918892.pdf
"Journal of Asthma and Allergy 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Asthma and Allergy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-asthma-and-allergy-journalThe Journal of Asthma and Allergy is an international, peer-reviewed  open access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physi-ology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies.",Non-OADS,/arxiv_data1/oa_pdf/01/64/jaa-9-109.PMC4918892.pdf
Available from: http://www.foodallergy.org/advocacy/epi-nephrine/map.,Non-OADS,/arxiv_data1/oa_pdf/01/64/jaa-9-109.PMC4918892.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/ca/55/jir-9-133.PMC4918894.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/ca/55/jir-9-133.PMC4918894.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Inflammation Research 2016:9 133–140Journal of Inflammation Research Dovepress submit your manuscript | www.dovepress.com Dovepress 133 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JIR.S101225 Association of tumor necrosis factor-α and - β  gene polymorphisms in inflammatory bowel  disease Ebtissam Saleh  Al-Meghaiseeb1 Abdulrahman AAl-Robayan 1 Mulfi Mubarak Al-Otaibi1 Misbahul Arfin2 Abdulrahman K Al-Asmari2 1Department of Gastroenterology,   2Research Centre, Prince Sultan  Military Medical City, Riyadh, Saudi  ArabiaAbstract:  Inflammatory bowel disease (IBD) is a complex, multifactorial, chronic inflam- matory disorder of the gastrointestinal tract in which immune dysregulation caused by  genetic and/or environmental factors plays an important role.",Non-OADS,/arxiv_data1/oa_pdf/ca/55/jir-9-133.PMC4918894.pdf
"2 IBD is a complex multifactorial disease in which immune dysregulation caused  by genetic and/or environmental factors plays an important role.3–7 It is believed to be Correspondence to: Abdulrahman K  Al-Asmari, Research Centre, Prince Sultan Military Medical City, PO Box 7897 , Riyadh  11159, Saudi ArabiaTel +966 11 477 7714 ext 25100Fax +966 11 477 7714 ext 23066Email abdulrahman.alasmari@gmail.comJournal name: Journal of Inflammation Research Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Al-Meghaiseeb et alRunning head recto: DOI: http://dx.doi.org/10.2147/JIR.S101225",Non-OADS,/arxiv_data1/oa_pdf/ca/55/jir-9-133.PMC4918894.pdf
"Statistical analysis Frequencies of various alleles and genotypes for each poly-morphism were compared between patients and controls and analyzed by Fisher’ s exact test using the CalcFisher software (http://www.jstatsoft.org/v08/i21/paper), and P -values≤ 0.05  were considered as significant.",OADS,/arxiv_data1/oa_pdf/ca/55/jir-9-133.PMC4918894.pdf
"Journal of Inflammation Research 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Inflammation Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journalThe Journal of Inflammation Research is an international, peer-reviewed  open access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis for - mation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflam-mation.",Non-OADS,/arxiv_data1/oa_pdf/ca/55/jir-9-133.PMC4918894.pdf
Visit http://www.dove   press.com/testimonials.php to read real quotes from published authors.Dovepress 140 Al-Meghaiseeb et al 47.,Non-OADS,/arxiv_data1/oa_pdf/ca/55/jir-9-133.PMC4918894.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/25/a9/jpr-9-425.PMC4918895.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/25/a9/jpr-9-425.PMC4918895.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 425–435Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  425 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S86579Challenges of pain control and the role of the  ambulatory pain specialist in the outpatient  surgery setting Nalini Vadivelu1 Alice M Kai2 Vijay Kodumudi3 Jack M Berger4 1Department of Anesthesiology, Yale  University School of Medicine, New  Haven, CT, 2Stony Brook University  School of Medicine, Stony Brook,  NY,  3Department of Molecular and  Cell Biology, College of Liberal Arts and Sciences, University of Connecticut, Storrs, CT,  4Department  of Anesthesiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USAAbstract: Ambulatory surgery is on the rise, with an unmet need for optimum pain control in  ambulatory surgery centers worldwide.",Non-OADS,/arxiv_data1/oa_pdf/25/a9/jpr-9-425.PMC4918895.pdf
"Uncontrolled pain Correspondence: Nalini Vadivelu Department of Anesthesiology, Yale University School of Medicine,   TMP 3, 333 Cedar Street, New Haven, CT 06519, USATel +1 203 785 2802Fax +1 203 785 6664Email Nalini.vadivelu@yale.eduJournal name: Journal of Pain Research  Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Vadivelu et alRunning head recto: Pain control in ambulatory surgeryDOI: http://dx.doi.org/10.2147/JPR.S86579",Non-OADS,/arxiv_data1/oa_pdf/25/a9/jpr-9-425.PMC4918895.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/25/a9/jpr-9-425.PMC4918895.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 435 Pain control in ambulatory surgery 26.,Non-OADS,/arxiv_data1/oa_pdf/25/a9/jpr-9-425.PMC4918895.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cc/61/ijn-11-2839.PMC4918896.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 2839–2854International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2839OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10450 5 reinjury risk of nano-calcium oxalate monohydrate  and calcium oxalate dihydrate crystals on injured  renal epithelial cells: aggravation of crystal adhesion  and aggregation Qiong-Zhi gan1,2 Xin-Yuan sun1,2 Poonam Bhadja1,2 Xiu-Qiong Yao1,2 Jian-Ming Ouyang1,2 1Department of chemistry, Jinan  University, guangzhou, People’s  republic of china; 2Institute of  Biomineralization and lithiasis  research, Jinan University, guangzhou,   People’s republic of chinaBackground:  Renal epithelial cell injury facilitates crystal adhesion to cell surface and serves  as a key step in renal stone formation.",Non-OADS,/arxiv_data1/oa_pdf/cc/61/ijn-11-2839.PMC4918896.pdf
"Keywords:  nano-calcium oxalate crystals, cell injury, crystal adhesion, kidney stones Introduction Crystal formation and retention lead to kidney stone development.1 Crystal retention  can be caused by the adherence of crystals to renal tubular epithelial cells.2 Thus, stone  development occurs when crystals bind to the epithelial cell surface.3 Epithelial cell  injury induces crystals to attach to the site of injury.4,5 Cell injury is also required for  crystal–cell adhesion.6–8correspondence: Jian-Ming Ouyang Department of chemistry, Jinan  University, 601 huangpu avenue West,  guangzhou 510632, People’s republic  of china Tel +86 20 8522 3353 email toyjm@jnu.edu.c n Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Gan et al Running head recto: Reinjury risk of calcium oxalate on injured cells DOI: http://dx.doi.org/10.2147/IJN.S104505",Non-OADS,/arxiv_data1/oa_pdf/cc/61/ijn-11-2839.PMC4918896.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/cc/61/ijn-11-2839.PMC4918896.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/cc/61/ijn-11-2839.PMC4918896.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/f9/94/imcrj-9-149.PMC4918898.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/f9/94/imcrj-9-149.PMC4918898.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Medical Case Reports Journal 2016:9 149–153International Medical Case Reports Journal Dovepress submit your manuscript | www.dovepress.com Dovepress 149 CASE SERIES open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IMCRJ.S106382Retropupillary iris-claw intraocular lens in ectopia  lentis in Marfan syndrome Mun Yueh Faria1 Nuno Ferreira2 Eliana Neto1 1Vitreo Retinal Department,   2Ophthalmology Department, Santa  Maria Hospital, Lisbon, PortugalObjective: To report visual outcomes, complication rate, and safety of retropupillary iris-claw  intraocular lens (ICIOL) in ectopia lentis in Marfan syndrome (MFS).",Non-OADS,/arxiv_data1/oa_pdf/f9/94/imcrj-9-149.PMC4918898.pdf
"Considering the age of patients with MFS, the expected life span, and eye grow- ing modification, careful observations and surgical timing are required.2 In significant Correspondence: Mun Yueh Faria Vitreo Retinal Department, Santa Maria Hospital, Rua Prof Egas Moniz, 1649-035 Lisbon, PortugalEmail munfaria1@gmail.comJournal name: International Medical Case Reports Journal Article Designation: CASE SERIESY ear: 2016V olume: 9Running head verso: Faria et alRunning head recto: Retropupillary iris-claw IOL in ectopia lentis in Marfan syndromeDOI: http://dx.doi.org/10.2147/IMCRJ.S106382 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/f9/94/imcrj-9-149.PMC4918898.pdf
Or use: http://youtu.be/bfHueqQqgqc,Non-OADS,/arxiv_data1/oa_pdf/f9/94/imcrj-9-149.PMC4918898.pdf
"International Medical Case Reports Journal 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/international-medical-case-reports-journal-journalThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/f9/94/imcrj-9-149.PMC4918898.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 153 Retropupillary iris-claw IOL in ectopia lentis in Marfan syndrome,Non-OADS,/arxiv_data1/oa_pdf/f9/94/imcrj-9-149.PMC4918898.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 421–423Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  421 PERSPECTIVES open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S110675Unraveling the confusion behind hyaluronic acid  efficacy in the treatment of symptomatic knee  osteoarthritis Larry E Miller1  Roy D Altman2  Louis F McIntyre3 1Miller Scientific Consulting, Inc.,   Asheville, NC, 2Department of  Rheumatology, University of California  Los Angeles, Los Angeles, CA,   3Northwell Physician Partners, Sleepy  Hollow, NY, USAAbstract:  Hyaluronic acid (HA) is a commonly prescribed treatment for knee pain resulting  from osteoarthritis (OA).",Non-OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
"7 A number of meta-analyses on the safety and efficacy of HA for knee OA have been  recently published, each using different methodology leading to different conclusions.8–16  Meta-analysis is a useful tool that involves systematic evaluation and analysis of published Correspondence: Larry E Miller   Miller Scientific Consulting, Inc., 1854  Hendersonville Road, #231, Asheville, NC 28803, USA Tel +1 828 450 1895   Email larry@millerscientific.comJournal name: Journal of Pain Research  Article Designation: PERSPECTIVESY ear: 2016V olume: 9Running head verso: Miller et alRunning head recto: Unraveling the confusion behind hyaluronic acid efficacyDOI: http://dx.doi.org/10.2147/JPR.S110675",Non-OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 423 Unraveling the confusion behind hyaluronic acid efficacy  6.,Non-OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
Available from: http://www.aaos.org/research/guidelines/Treat-mentofOsteoarthritisoftheKneeGuideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
Available from: http://www.aaos.org/uploadedFiles/PreProduction/Quality/Guide-lines_and_Reviews/Osteoarthritis%20of%20the%20Knee%20-%20non-arthroplasty.pdf.,Non-OADS,/arxiv_data1/oa_pdf/92/17/jpr-9-421.PMC4918943.pdf
"Copyright © 2016 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6 http://e-eht.org/ Introduction  With advancements in science and technology, chemicals are  not only used for convenience in daily life, but also are used as  necessary fuel and basic material in industries, such as those re - lated to semi-conductors, electronics, cars, aerospace technolo -gy, information technology, biotechnology, and nanotechnolo - gy.",Non-OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"On the other hand,  only less than 10% of 45000 domestically distributed chemicals Risk assessment of di(2-ethylhexyl) phthalate in  the workplace Hyeon-Y eong Kim  Occupational Safety and Health Research Institute, Korea Occupational Safety and Health Agency, Daejeon, Korea• Original ArticleOpen Access Environmental Health and Toxicology Volume: 31, Article ID: e2016011, 6 pages http://dx.doi.org/10.5620/eht.e2016011 eISSN: 2233-6567  Objectives  A hazard assessment of di(2-ethylhexyl) phthalate (DEHP), a commonly  used workplace chemical, was conducted in order to protect the occupational health of  workers.",Non-OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"Keywords  Di(2-ethylhexyl) phthalate, Risk assessment, Dose-responseCorrespondence:  Hyeon-Yeong Kim  60 Expo-ro 339beon-gil, Yuseong-gu,  Daejeon 34122, Korea   Tel: +82-10-3530-3843 Fax: +82-42-869-8693 E-mail: 1989135@kosha.or.kr  Received:  March 21, 2016 Accepted:  April 18, 2016 Published:  May 13, 2016 This article is available from: http://e-eht.org/",Non-OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"http://e-eht.org/ Page 2 of 6Environmental Health and Toxicology    2016;31:e2016011 have been studied for their potential risk, including chronic tox - icity [1].",Non-OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"http://e-eht.org/ Page 3 of 6Hyeon-Yeong Kim  | Working environment and risk assessment of DEHP tion, one of the tools used in hazard and risk assessment.",Non-OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"http://e-eht.org/ Page 4 of 6Environmental Health and Toxicology    2016;31:e2016011 (W-6-2011) “T oxicity and risk assessment guideline of chemi - cal substance” , the reference concentration for carcinogenicity  risk, reference concentration in workplace (RfC work) was deter - mined.",OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"http://e-eht.org/ Page 5 of 6Hyeon-Yeong Kim  | Working environment and risk assessment of DEHP Determination of Exposure Level  In order to determine the exposure level of DEHP , the work - ing environments of 12 workers in DEHP manufacturing work - places and 21 workers in DEHP handling workplaces were  measured.",OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"http://e-eht.org/ Page 6 of 6Environmental Health and Toxicology    2016;31:e2016011 conclusive results, genotoxicity testing indicated the possibility  of genetic effects based on in vitro  exposure to DEHP [11].",Non-OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
ORCID Hyeon-Y eong Kim http://orcid.org/0000-0002-3343-3799  References   1.,Non-OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
Available from:  http://www.cdc.gov/niosh/docs/90-110/ pdfs/90-110.pdf.,OADS,/arxiv_data1/oa_pdf/86/33/eht-31-e2016011.PMC4919054.pdf
"Copyright © 2016 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 2 http://e-eht.org/ The humidifier disinfectant scandal in South Korea is the first  of its kind in the world and represents the most deaths caused  by a home supply item.",Non-OADS,/arxiv_data1/oa_pdf/70/81/eht-31-e2016012.PMC4919055.pdf
"Ensure that not a single victim is excluded from receiving appropri - ate relief measures and compensation due to limitations of modern The humidifier disinfectant scandal: the need for  vigorous government oversight of chemicals and  household products to secure public safety • Editorial Open Access Environmental Health and Toxicology Volume: 31, Article ID: e2016012, 2 pages http://dx.doi.org/10.5620/eht.e2016012 eISSN: 2233-6567",Non-OADS,/arxiv_data1/oa_pdf/70/81/eht-31-e2016012.PMC4919055.pdf
http://e-eht.org/ Page 2 of 2Environmental Health and Toxicology    2016;31:e2016012 science or administrative difficulties.,Non-OADS,/arxiv_data1/oa_pdf/70/81/eht-31-e2016012.PMC4919055.pdf
"Copyright © 2016 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5 http://e-eht.org/ Introduction Melanin is a group of natural pigment striking dark color  found in organisms like human and animal to protect their skins  from ultraviolet (UV) radiation of sun.",Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
"If  the lysosomal membrane proteins are associated with treatment  of melanin directly, they will be identified and the revealed pro - teins play important roles to use as a prescription, medical ther - apy and cosmetics to protect UV radiation.Analysis of lysosomal membrane proteins exposed  to melanin in HeLa cells Seung Hyuck Bang1, Dong Jun Park1, Yang-Hoon Kim2, Jiho Min1 1Department of Bioprocess Engineering, Chonbuk National University, Jeonju; 2Department of Microbiology, Chungbuk  National University, Cheongju, Korea • Original ArticleOpen Access Environmental Health and Toxicology Volume: 31, Article ID: e2016009, 5 pages http://dx.doi.org/10.5620/eht.e2016009 eISSN: 2233-6567  Objectives  There have been developed to use targeting ability for antimicrobial, antican - cerous, gene therapy and cosmetics through analysis of various membrane proteins  isolated from cell organelles.",Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
"Keywords  Lysosome, Lysosomal membrane proteins, HeLa cell, Melanin, 2-Dimension - al electrophoresisCorrespondence:  Jiho Min  567 Baekje-daero, Deokjin-gu, Jeonju  54896, Korea  Tel: +82-63-270-2436 Fax: +82-63-270-2306 E-mail: jihomin@jbnu.ac.kr Received:  March 23, 2016 Accepted:  April 25, 2016 Published:  May 4, 2016 This article is available from: http://e-eht.org/",Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
"http://e-eht.org/Page 2 of 5Environmental Health and Toxicology    2016;31:e2016009 Materials and Methods Cell Cultures and T reatment HeLa cells were cultured in Dulbecco’s modified Eagle’s medi - um which added 5% newborn calf serum, 1% penicillin strepto - mycin at 37oC with medium under 5% carbon dioxide.",Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
"http://e-eht.org/ Page 3 of 5Seung Hyuck Bang, et al.",Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
http://e-eht.org/Page 4 of 5Environmental Health and Toxicology    2016;31:e2016009 tein concentration and then we could gain high level resolution  them separated.,Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
Conflict of Interest The authors have no conflicts of interest associated with mate - rial presented in this paper ORCID Seung Hyuck Bang http://orcid.org/0000-0002-9023-6812  Dong Jun Park http://orcid.org/0000-0002-4209-0302 Yang-Hoon Kim http://orcid.org/0000-0002-3406-4868 Jiho Min http://orcid.org/0000-0001-6025-7746   References 1.,Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
"http://e-eht.org/ Page 5 of 5Seung Hyuck Bang, et al.",Non-OADS,/arxiv_data1/oa_pdf/ea/78/eht-31-e2016009.PMC4919056.pdf
"Several surveys of the nosological characteristics of  Stickler syndrome have evaluated mutations in the COL2A1  Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> Received 5 December 2015 | Accepted 21 June 2016 | Published 23 June 2016© 2016 Molecular Vision 697Mutation survey and genotype-phenotype analysis of COL2A1  and  COL11A1  genes in 16 Chinese patients with Stickler syndrome Xun Wang, Xiaoyun Jia, Xueshan Xiao, Shiqiang Li, Jie Li, Yadi Li, Yantao Wei, Xiaoling Liang, Xiangming  Guo State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China Purpose:  To identify mutations in COL2A1  and COL11A1  genes and to examine the genotype-phenotype correlation in  a cohort of Chinese patients with Stickler syndrome.",Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> © 2016 Molecular Vision  698and COL11A1  genes.,Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
"Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> © 2016 Molecular Vision  699c.3356delG, c.3401delG), and two were previously reported  (c.1693C>T, c.2710C>T) [ 5,17,18].",Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> © 2016 Molecular Vision  700 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> © 2016 Molecular Vision  701without tenderness.,Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> © 2016 Molecular Vision  702mutation in the helix was the glycine substitution in Gly-X-Y  repeating motifs of COL2A1  in Caucasians [ 20].,Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> © 2016 Molecular Vision  703and COL11A1 .,Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
Molecular Vision  2016; 22:697-704 <http://www.molvis.org/molvis/v 22/697> © 2016 Molecular Vision  70416.,Non-OADS,/arxiv_data1/oa_pdf/5d/43/mv-v22-697.PMC4919091.pdf
"When carried by male mice, along with  a target allele, Pou4f2Cre efficiently targets recombination in Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> Received 5 August 2015 | Accepted 21 June 2016 | Published 23 June 2016© 2016 Molecular Vision 705Pou4f2  knock-in Cre mouse: A multifaceted genetic tool for vision  researchers Aaron B. Simmons,1 Samuel J. Bloomsburg,1 Samuel A. Billingslea,1 Morgan M. Merrill,1 Shuai Li,1 Marshall  W. Thomas,2 Peter G. Fuerst1,3 1Department of Biological Sciences, University of Idaho, Moscow, ID; 2Department of Biology, Brigham Young University— Idaho, Rexburg, ID; 3WWAMI Medical Education Program, University of Washington School of Medicine, Moscow, ID Purpose : A transgenic mouse that expresses Cre recombinase under control of the Pou4f2-promoter (also referred to  as Brn-3b  and Brn-3.2 ) was characterized.",Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  706the germline.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
"Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  70730 min at room temperature, and the retina was dissected  from the eyecup.",Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  708 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  709Cre activity was determined by visualization of RFP  in cryosections and tissue biopsies of mouse tissues (Figure  2C–E).,OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  710 Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  711 Figure 4.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
"Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  712DISCUSSION This study characterized a Pou4f2Cre transgenic mouse line,  in which Cre recombinase is driven by the Pou4f2  promoter.",Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  713 Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  714 Figure 6.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  715 Figure 7.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
"Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  716was observed only in RGCs, ACs, and HCs, consistent with  activity of the Thy1  promoter.",Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
Molecular Vision  2016; 22:705-717 <http://www.molvis.org/molvis/v 22/705> © 2016 Molecular Vision  71714.,Non-OADS,/arxiv_data1/oa_pdf/d6/be/mv-v22-705.PMC4919092.pdf
"Third, RS1 Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> Received 11 March 2016 | Accepted 22 June 2016 | Published 24 June 2016© 2016 Molecular Vision 718An ex vivo gene therapy approach in X-linked retinoschisis Abu E. Bashar, Andrew L. Metcalfe, Ishaq A. Viringipurampeer, Anat Yanai, Cheryl Y. Gregory-Evans, Kevin  Gregory-Evans Department of Ophthalmology, University of British Columbia, Vancouver BC, Canada Purpose:  X-linked retinoschisis (XLRS) is juvenile-onset macular degeneration caused by haploinsufficiency of the  extracellular cell adhesion protein retinoschisin (RS1).",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  719is a secreted, extracellular protein, so it can be replaced in the  retinal extracellular space by secretion from other cell types  (e.g., mesenchymal stem cells [MSCs]).",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  720bovine serum and 1% penicillin/streptomycin (both from Life  Technologies).,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  721Electroretinography:  Mice were dark-adapted overnight, then  anesthetized with an intraperitoneal injection of xylazine  (16 mg/kg) and ketamine (120  mg/kg), and maintained on  a heating pad.",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  722statistically significant.,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  723 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  724eyes treated with inducible MSCs was significantly higher  than that for all the other groups (p<0.01).,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  725could be induced to express RS1 by exposure to doxycy - cline.,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  726mind, for example, ease of harvest, low immunogenicity [ 36],  and safety for human clinical use, which is currently being  explored in 389 clinical trials (including four studies in retinal  degeneration) [ https://clinicaltrials.gov/ ].",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  727In this study, cells delivered intravitreally were able to reach  the INL where RS1 is normally expressed, thus negating the  need for sub-retinal delivery.",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  728found to have higher levels of RS1 expression, although the  level did not reach statistical significance.",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  729a rhodopsin promoter resulted in better in vivo functional  responses compared to using a Müller cell–specific promoter  [45].,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  730This proof-of-principle suggests that this inducible ex  vivo approach can also be applied to other similar ocular  disorders where deficiency of a functional, extracellular  protein is the major cause of the disease.",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  73117.,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  73240.,Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"Molecular Vision  2016; 22:718-733 <http://www.molvis.org/molvis/v 22/718> © 2016 Molecular Vision  733Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R.",Non-OADS,/arxiv_data1/oa_pdf/1e/d7/mv-v22-718.PMC4919093.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/82/de/40120_2015_Article_39.PMC4919129.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.Neurol Ther (2016) 5:1–25 19",Non-OADS,/arxiv_data1/oa_pdf/63/9c/40120_2016_Article_40.PMC4919130.pdf
2011http://www.ema.europa.e u/docs/en_GB/document_ library/EPAR_-_Product_Information/human/ 002294/WC500117862.pdf .,Non-OADS,/arxiv_data1/oa_pdf/63/9c/40120_2016_Article_40.PMC4919130.pdf
Eisai Ltd. http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/01/96/40120_2016_Article_41.PMC4919131.pdf
